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Abstract Regulatory T cells (Tregs) are a distinct subset of CD4+ T cells that play a vital role in maintaining immune homeostasis and peripheral tolerance, thereby preventing autoimmunity. Tregs are generally categorised into two main subsets; natural and induced Tregs. In cancer, Tregs are found extremely enriched in the tumour microenvironment and contribute to the inhibition of anti-tumour response and tumour progression. The origin of tumour-infiltrating Tregs (whether it is nTregs or iTregs) is still enigmatic, since there are no distinct biomarkers which can differentiate between the two subsets. Therefore, the aim of this study is to identify cell surface biomarkers that can differentiate phenotypic features of iTregs from nTregs in the context of cancer. With this aim, an in vitro murine model was successfully developed to generate CD4+CD25++Foxp3+ iTregs from purely sorted naïve CD4+CD25-Foxp3- T cells in the presence of TGF-β1. The induction of iTregs was assessed using flow cytometry. Methylation status of Foxp3-TSDR and Foxp3 stability was assessed. Naïve CD4+CD25-Foxp3- T cells and CD4+CD25+Foxp3+ nTregs were purely sorted using cell sorting. Five biologically different subsets of CD4+ cells including naïve CD4+CD25-Foxp3- T cells, activated CD4+CD25-Foxp3- T cells, naïve CD4+CD25+Foxp3+ nTregs, activated CD4+CD25+Foxp3+ nTregs and CD4+CD25++Foxp3+ iTregs were subjected to quantitative proteomic profiling using SWATH-MS. Subcellular fractionation methods were employed to isolate membrane and  cytoplasmic proteins from each of the subsets. Quantitative proteomic data were analysed using artificial neural networks. The results revealed that 4 distinct membrane biomarkers (PLP2, ITIH4, HEM6 and MAVS) were differentially up-regulated in iTregs compared to other subsets. EPHX1 (HYEP) was identified upregulated only in naïve nTregs and downregulated in iTregs and other subsets. The biomarkers were further tested. Pathway enrichment analysis of iTregs showed a distinct metabolic pathway enrichment in iTregs indicating a mechanistic insight into the iTreg development. Once validated in humans these proteins could be used as a biomarker for iTreg or as a drug target for the selective depletion for better immunotherapeutic outcome in cancer patients.    
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Chapter 1.  
General introduction 
1.1. Cancer – A brief overview 
Cancer is the second most common cause of death worldwide. In 2018, 9.6 million deaths have been reported due to cancer, which is about 1 in 6 deaths worldwide 
(WHO, 2018, www.who.com, Accessed on 20 Oct 2019). In UK, cancer incidence has 
been estimated about 363,000 new cancer cases in 2016; 178,000 (545 per 
100,000) cases are female and 185,000 (664 per 100,000) cases are male. Moreover, 53% of all new cases have been diagnosed with breast, prostate, lung and bowel 
cancer. In 2017, 28% of all deaths in UK have been reported due to cancer (Cancer 
Research UK, www.cancerresearchuk.org, Accessed on 20 Oct 2019).           Cancer is a group of diseases defined by uncontrolled cell growth through which cells acquire the ability to invade adjacent tissues and then disseminate (metastasise) from the primary site of origin to other sites in the body. More than 
100 types of cancer have been identified which are characterised based on the tissue of origin where tumour develops (Knowles and Selby 2005). For instance, cancers derived from epithelial tissue are categorised as “carcinomas” and constitute around 
85% of cancers. This include cancers come from glandular epithelial tissues which are called “adenocarcinomas”. Whereas cancers developed in mesoderm tissues (bone, muscle and connective tissues) are called “sarcomas”(Pecorino 2012). Several external and lifestyle factors can contribute to the development of cancer including smoking, infection, obesity, alcohol consumption, ionising and ultraviolet radiation and chemical reagents (Hesketh 2013). There is a broad consensus that cancer is a genetic disease in which accumulation of molecular lesions in the genetic material of somatic cells (DeVita 2015). In normal circumstances these molecular aberrations are corrected by our own DNA repair machinery or eliminated along with mutation bearing cells by the immune system (Bernstein, et al. 2013). Once the 
mutation/s evaded the repair/immune system favours the bearing cell proliferative and oncogenic advantage resulting in malignancy (Messerschmidt, Prendergast and 
Messerschmidt 2016).        
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1.2. The immune system – A brief overview The main function of the immune system is to protect multicellular organisms from pathogens. The immune system generates an enormous array of cells and molecules which act together in a dynamic network to recognise and eliminate foreign invaders. The immune system can protect the body by two related activities; recognition and response. Immune recognition is characterised by the ability to discriminate foreign invaders from self-components. It can even perceive slight chemical differences that differentiate one foreign pathogen from another (Janeway, 
et al. 1996). In addition, the immune system can also recognise host cells that are abnormally transformed or on their way to become cancerous cells. Recognition of a pathogen by the immune system induces an effector response that eliminates or overcomes the invader. Each immune cell has a different pattern of response and is specialised to eliminate or neutralise a particular type of pathogen. Some exposures trigger a memory response that is characterised by a more rapid and powerful immune reaction upon later attack. This type of response is a remarkable feature of the mammalian immune system which protects the body from catching certain diseases a second time (Kindt, et al. 2007). In general, immunity is divided into two main categories; “innate” and “adaptive” immunity which both collaborate to protect the body. The innate immune system is known as the first line of defence which can effectively eliminate pathogens within hours of encounter with innate immune cells. The adaptive immunity provides a second, comprehensive line of defence in which adaptive immune cells recognise, eliminate and memorise the invading pathogens that evade the innate response 
(Roitt, Brostoff and Male 2001).  Innate and adaptive immune cells are generated by a highly regulated process called “haematopoiesis” which takes place in the bone marrow. This process involves the production and development of red and white blood cells and starts when self-renewing haematopoietic stem cells give rise to lymphoid and myeloid progenitors. Lymphoid progenitors give rise to T-cell progenitors, B-cell progenitors, dendritic cells and natural killer (NK) cells, whereas myeloid progenitor give rise to granulocyte-monocyte progenitor, eosinophil progenitor, basophil progenitor, 
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megakaryocyte and erythroid progenitor (figure 1.2) (Kindt, et al. 2007)   (Taniuchi 
2018)                                           
Figure 1.1. Schematic representation of haematopoiesis process by which red and white blood cells are produced in the bone marrow. The left panel shows innate immune cells that are developed from lineage committed progenitors derived from myeloid-lineage progenitors. The right panel shows adaptive immune cells that are developed from lineage committed progenitors derived from lymphoid-lineage progenitors. This figure was adaptive from (Kindt, 
et al. 2007).  
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1.2.1. Innate immunity The innate immunity provides the first primitive type of defence mechanism which is ready for immediate activation prior to invasion by a pathogen. The innate immune system consists of three different types of barriers to protect the body, including physical, chemical and cellular barriers. The key physical barriers are skin and mucous membranes which prevent the entry of invading pathogens into the body. Chemical barriers involve the acidity of the stomach contents and specialised soluble molecules such as lysozyme that have antimicrobial activities (Tosi 2005). Once a pathogen breaches these primary barriers, it will encounter the cellular barrier which consists of various types of cells that can initiate a rapid response within minutes of invasion (Gallo and Nizet 2008).     As shown in figure 1.1, innate immune cells develop from myeloid progenitor in the bone marrow and are broadly grouped int two main classes. Mononuclear phagocytes include dendritic cells (DCs), monocytes and macrophages. polymorphonuclear phagocytes include neutrophils, basophils and eosinophils based on the shape of their nucleus (De Kleer, et al. 2014). Innate immune cells generally express pattern recognition receptors (PRRs) and Toll-like receptors (TLRs). PRRs allow innate cells to specifically recognise broad structural motifs (pathogen-associated molecular patterns (PAMPs)) that highly conserved within pathogens but are completely absent from the host. TLRs are a 
family of 11 versatile receptors, each reacts with a specific microbial product, allowing innate cells to detect different types of pathogens (Mogensen 2009). Innate immune responses are mediated by the participation of various cells. The 
major functional innate cells are neutrophils, macrophages, dendritic cells and NK cells (Beutler 2004). Neutrophils are the first cells to travel from the blood into the site of inflammation (pathogen invasion) where they kill and eliminate pathogen by phagocytosis (Kobayashi and DeLeo 2009). They are also important for the innate defence against bacteria and fungi. Neutrophils express several TLRs on their surfaces. The two key receptors are TLR2 and TLR4 which enables neutrophils to recognise the peptidoglycans of Gram-positive bacteria and the lipopolysaccharide 
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(LPS) expressed on the wall of Gram-negative microbes, respectively (Sabroe, et al. 2003).  Macrophages and dendritic cells are professional antigen presenting (Ito, et al. 
2013) cells that link innate and adaptive responses via antigen presentation on MHC molecules. Macrophages are generated in the bone marrow as immature monocytes that circulate in the blood to become mature monocytes. Mature monocytes further differentiate into macrophages once they enter peripheral tissues (Mosser and 
Edwards 2008). Interaction between PRRs expressed on macrophages and pathogen components (PAMPs) activates macrophages which induce phagocytosis. Activated macrophages then secrete proinflammatory cytokines such as interleukin-1 (IL-1), IL-6 and tumour necrosis alpha (TNF-α) which induce and support inflammatory responses (Arango Duque and Descoteaux 2014).  DCs act as a bridge between innate and adaptive immunity as they can interact with T helper (Th) and T cytotoxic (Tc) cells. Immature DCs as innate cells recognise pathogens via PRRs and TLRs (Steinman 2006). This recognition induces maturation of DCs that results in the upregulation of MHC class II on their surfaces. In addition, as nucleated cells, DCs also express MHC class I (Dalod, et al. 2014). Upon maturation, DCs internalise pathogens components and then migrate to the lymphoid tissue (e.g. lymph nodes) where they introduce antigen (pathogens components) to MHC class II-dependent Th cells and MHC class I-dependent Tc cells. DCs can also produce IL-12, IL-6 and TNF-α (Guermonprez, et al. 2002). 
NK cells play an important role in the innate immunity by their ability to kill virus-infected cells and pre-malignant transformed cells. NK cells lack membrane molecules and antigen-specific receptors (Hamerman, Ogasawara and Lanier 2005). 
Instead, NK cells express specific receptors which allow them to distinguish defects such as a reduction in the expression of MHC class I molecules, the unusual phenotypes expressed by tumour cells and cells infected by some viruses. NK cells have an essential role in the regulation of both innate and adaptive immunity (Brilot, 
Strowig and Munz 2008, Bellora, et al. 2010). They produce Interferon gamma (IFN-
γ) which activates macrophages and enhances their phagocytic and anti-microbial activities. IFN-γ produced by NK cells can also affect the Th1 versus Th2 lineage by 
6  
inhibition Th2 expansion and stimulation development of Th1 in the presence of IL-
12 derived from macrophages and DCs (Mailliard, et al. 2003). One of the hallmarks of innate immunity is the lack of antigenic specificity and immunogenic memory. Therefore, if there is a recognised antigenic challenge to the pathogen which may exceed the ability of innate immune cells during inflammation, adaptive immunity will be initiated to respond to the challenge with a high degree of specificity and immunologic memory (Kindt, et al. 2007). However, a recent evidence has revealed that NK cells develop antigenic specificity and immunological memory against viruses although they are involved in the innate immunity (Peng and Tian 2017).   
1.2.2. Adaptive immunity   The adaptive immunity has four different features including antigenic specificity, diversity, immunologic memory and self-nonself recognition. The antigenic specificity allows adaptive immune system to discriminate finer differences among antigens. The adaptive system can produce tremendous highly-diverse receptors which can recognise many of unique structures with minor genetic variations of foreign antigens (Bonilla and Oettgen 2010). The adaptive system can also memorise the eliminated antigens by generating memory cells that specifically react to the same antigens for future exposure, conferring lifelong immunity to many pathogens after an initial exposure. Finally, the adaptive system is educated to distinguish between self and non-self molecules and initiate immune response against non-self molecules only. Failure of this ability leads to autoimmune diseases and can be fatal (Kurtz 2004). Adaptive immune responses are mediated by specialised cells including B and T cells in addition to other specialised antigen-presenting cells (macrophages and DCs). B cells are generated and mature in the bone marrow and express unique antigen-binding receptor (B-cell receptor (BCR)) which is a membrane-bound antibody molecule. B cells are responsible for mediating humoral immune response (LeBien 
and Tedder 2008). Upon antigen binding to BCR, B cells undergo activation and differentiation into effector B cells (plasma cells) and memory B cells. A single plasma cell can secrete hundreds to thousands of antibodies per second. Secreted 
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antibodies are considered as key effector molecules of humoral immunity (LeBien 
and Tedder 2008). Unlike B cells, T cells are generated in the bone marrow as progenitor T cells that migrate to thymus where they become mature. T cell maturation includes rearrangements of the germ line TCR genes and the expression of various 
membrane markers such as CD3, CD4, CD25 and CD8 (Koch and Radtke 2011). Developing T cells in the thymus are defined as thymocytes that undergo a highly regulated selection process, called thymic selection. Positive thymic selection allows only T cells with TCRs that can recognise self-MHC molecules to continue as mature self-MHC-restricted T cells. T cells that react too strongly with self-peptide mounted on MHC molecules are eliminated by negative selection (Klein, et al. 2014a). Negative selection is responsible for the creation of primary T cells that are self-tolerant (Takaba and Takayanagi 2017). Mature T cells are grouped into two main subpopulations; Th and Tc cells. Th cells express CD4, a membrane glycoprotein receptor that recognises antigens bound to MHC class II molecules. Tc cells express 
CD8 that recognises antigens bound to MHC class I molecules (Murphy and Weaver 
2016).  The key event in the development of cell-mediated immune responses is the activation and clonal expansion of T cells. T cell activation is triggered by interaction of the TCR-CD3 complex with a processed antigenic peptide bound to either MHC 
class I (CD8+ T cells) or class II (CD4+ T cells) molecule expressed on the surface of antigen-presenting cells (APCs) (Smith-Garvin, Koretzky and Jordan 2009). However, this interaction is not sufficient to fully activate naïve T cells. For subsequent proliferation into effector cells, naïve T cells receive two essential activation signals. The first signal is initiated by interaction of an antigenic peptide with the TCR-CD3 complex. The second signal is a consecutive antigen-nonspecific 
costimulatory signal provided by interactions between CD28 on T cells and 
receptors of the B7 family expressed on the surface of APCs; B7-1 (CD80) and B7-2 
(CD86) (figure 1.2) (Chen and Flies 2013). B7 receptors are mainly expressed on dendritic cells and induced on activated macrophages and B cells (Mbongue, et al. 
2017). Costimulatory signals derived by CD28 are regulated by CTLA-4 (CD152), a 
glycoprotein which is structurally similar to CD28. CD152 provides inhibitory 
8  
signals that down-regulate the activation of T cells (Rudd, Taylor and Schneider 
2009). Activation of T cells by the interaction of TCR-CD3 with an antigenic peptide 
in the absence of CD28 costimulatory signalling leads to T cell anergy, which a state of nonresponsive characterised by failure of T cells to proliferate (Schwartz 2003). This confirms the importance of both signals in the activation of T cells. However, the strength of activation signals can also affect the function of T cells. It is found that persistent antigen-derived TCR activation signals lead to T cell exhaustion which is a state when T cells lose their functional ability as effector cells following prolonged antigen stimulation (Wherry 2011).                       
Figure 1.2. Signals of T cells activation and inactivation mediated by CD80/86 receptors expressed on APC. Signa1 is generated by the interaction of antigenic peptide attached with MHC molecule. Signal 2 is a costimulatory signal derived by the interaction of B7 receptors family (CD80/CD80) with CD28 expressed on the surface of T cells. Costimulatory signal is regulated by CTLA-4 which induce inhibitory signals to deactivate T cells. This figure was adapted from (Sharma, 
et al. 2019). Copyright permission was obtained from the publisher (Elsevier, license number 4855390275342, license date on 24 Jun 2020 by Copyright Clearance Center).       
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Upon activation, naïve T cells differentiate into effector T cells. Naïve CD8+ T cells 
differentiate into CD8+ effector T cells with cytotoxic killing activity and memory 
CD8+ T cells. Naïve CD4+ T cells differentiate into several subpopulations based on secreted cytokines in the local microenvironment. Figure 1.3 shows differentiation of naive CD4+ T cells in the presence of cytokines that are required for lineage commitment of each subsets of CD4+ T cells.                       
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Figure 1.3. Differentiation of naïve CD4+ T cells (Th0) upon activation by antigenic peptides represented by MHC class II molecule expressed on the surface of an antigen-presenting cell (APC) in the presence of other required cytokines. Th1 cells are differentiated in the presence of IL-12 cytokines and secrete IFN-γ and IL-2 after differentiation. The 
differentiation of Th1 is regulated by the transcription factor T-bet that maintains their lineage-specific development. The differentiation of Th2 cells is regulated by the transcription factor Gata-3 and induced in the presence of IL-4. Th2 cells are characterised by the secretion of various interleukins such as IL-4, IL-10, IL-5 and IL-13. Th17 cells are differentiated in the presence of TGF-β and IL-6, and their differentiation is controlled by the transcription factor RoRγt. Upon differentiation, Th17 cells secrete IL-17, IL-22 and TNF-α. Tregs are characterised by the expression of the transcription factor Foxp3 and differentiated in the presence of IL-2 and TGF-β. Tregs secrete TGF-β and IL-10 immunosuppressive cytokines. Th9 cells are characterised by the expression of PU.1 
transcription factor and differentiated by the effect of TGFβ and IL-4. Th9 cells are found to secrete IL-9 and IL-10 to mediate their function. TfH (T follicular helper) cells are defined by the expression of Bcl-6 transcription factor and differentiated in the presence of IL-6. TfH cells produce high level of IL-21. This figure was adapted from (Russ, et al. 2013).           
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Th1 cells secrete several cytokines including IL-2, IFN-γ and TNF-α/β which can induce cell-mediated immune response by activating CD8+ T cytotoxic cells against invading pathogens or altered host cells. Production of IL-4 by Th2 can effectively induce humoral immune response by activating B cells to produce antibodies against pathogens (Zhang, et al. 2014). The function of other subsets of CD4+ T cells 
(Th17 and Th9 cells) is mentioned in the section (1.5.1.3). The innate and adaptive immune cells play pivotal role in the recognition and elimination host transformed-malignant cells. However, another evidence confirms that some of these immune cells contribute to the progression of tumour (Vesely, et al. 2011). The cellular interactions between immune and tumour cells which result in tumour escape from immune response will be discussed in the next section.  
1.3. Cancer and immune system The interaction between immune system and cancer is widely acknowledged in the literature. Inflammation in the context of cancer plays a significant role in the progression of cancer. Inflammation is a complex physiological process triggered by various immune cells in response to infection or tissue injury, thereby providing a full protection against dangerous pathogens (Barton 2008).  This highly regulated response can be detrimental if it becomes dysregulated which results in pathological consequences including chronic inflammatory diseases, autoimmunity, systemic sepsis, tissue damage and fibrosis, neoplasia (Medzhitov 2008). In cancer, it has been reported that inflammation is an essential process at different stages of tumour growth and progression as it can promote tumorigenesis by altering the host immune response to tumour (Grivennikov, Greten and Karin 2010). For instance, chronic Helicobacter pylori inflammation can lead to gastric cancer and mucosa-associated lymphoid tissue lymphoma, whereas persistent infection with hepatitis B and C viruses is associated with hepatocellular carcinoma  (Kew 2013, Correa and 
Piazuelo 2011, J. B. Park and Koo 2014). In cancer-related inflammation, at the initial stage of tumorigenesis, the tumour microenvironment contains various immune cells which recognise tumour-expressed antigens and produce inflammatory and potentially protective anti-tumour responses. However, the subversion of these responses by tumour cells enables the establishment of a persistent inflammatory 
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microenvironment (low grade chronic inflammation) which further promote tumour development (Grivennikov, et al. 2010). A wide array of immune cells infiltrating with the tumour microenvironment, which include macrophages, neutrophils, mast cells, myeloid-derived suppressor cells (MDSCs), dendritic cells (DCs), natural killer (NK) cells, T and B lymphocytes (Mantovani, et al. 2008). The inflammatory tumour microenvironment can also be regulated by certain oncogenes such as MYC and RAS which can recruit leukocytes, lymphocytes, and maintaining a proinflammatory microenvironment tumour, thus remodelling the tumour microenvironment (Soucek, et al. 2007). Accumulating evidence confirms that there is a dynamic cellular communication between tumours and immune cells which can regulate tumour growth and progression. This evidence has been translated into a concept of “cancer immunoediting” which postulated that the host’s immune system can inhibit cancer growth and promote cancer progression simultaneously. Cancer immunoediting consists of three different phases including elimination, equilibrium and escape (Dunn, Old and Schreiber 2004). The concept of immunoediting which is characterised by three distinct phases is discussed in detail in the following sections. 
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Figure 1.4. Schematic representation showing the stages of cancer immunoediting. In the first phase (elimination), innate (NK, macrophages, DCs) and adaptive immune cells (CD4+ 
and CD8+ and γδ T cells) recognise pre-malignant lesions (newly transformed cells and kill growing tumours by producing several cytokines, thus maintaining protection against cancer. In the second phase (equilibrium), poorly-immunogenic tumour cells are thought to be specifically selected by the tumour to maintain its progression by avoiding the intensive, constant attack from the immune cells  (CD4+ and CD8+, NK cells ) that still have potential to eliminate the newly growing cells. In the third phase (escape), tumour cells that have gained the competency to evade immune recognition and destruction sprout progressively by creating immunosuppressive tumour microenvironment through recruiting Tregs, MDSCs 
that can inhibit the function of CD8+ T cells and NK cells and several other immune evasion mechanisms. This graph was adapted from (Schreiber, Old and Smyth 2011). Copyright permission was obtained from the publisher (The American Association for the Advancement of Science, license number 4855370109321, License date on 24 Jun 2020 by Copyright Clearance Center).    
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1.3.1. The phase of tumour elimination (Cancer 
immunosurveillance) The elimination phase (which is also known as “immunosurveillance”) starts when the innate and adaptive immune cells recognise pre-malignant lesions (newly transformed cells and kill growing tumours, thus maintaining protection against cancer (Shankaran, et al. 2001). It has been proposed that the initial anti-tumour immune response is induced by innate immune cells triggered due to the local tissue disruption. The tissue disruption occurs as a results of angiogenesis or tissue-invasive growth (Carmeliet and Jain 2000, Hanahan and Weinberg 2000). These two processes are believed to promote the tissue-stromal remodelling which produces proinflammatory molecules that direct the innate immune cells to the site of tissue damage. These proinflammatory molecules include interleukin (IL-1), TNF-α (tumour necrosis factor alpha), type 1 IFNs (interferon), GM-CSF (granulocyte-macrophage colony-stimulating factor) and IL-15 (Smyth, Dunn and Schreiber 2006). These proinflammatory molecules mediate the differentiation and function of DCs which have a direct cellular communication with NK cells and T cells (Blanco, 
et al. 2008). DCs are thought to serve as sentinel cells that monitor tissue stress, damage and transformation, secretion of proinflammatory molecules derived from extracellular matrix breakdown, and secretion of heat-shock proteins (HSPs) as a result of tumour cell necrosis and damage (Hanke, et al. 2013). Several cells have been proposed to participate in the phase of cancer 
immunosurveillance. NK cells, macrophages, NKT cells, CD4+ and CD8+ T cells and 
γδ+ T cells are thought to be recruited to the site of pre-malignant transformed tissue in which they become fully activated and exert their protective response (Chow, 
Möller and Smyth 2012) (figure 1.4). NK cells are thought to be activated through their activating receptor NKG2D (natural killer group 2, member D) which can bind to the stress ligands expressed by the developing tumour cells, infected, stressed or transformed cells (Waldhauer and Steinle 2008). These stress ligands include MHC-
class І-polypeptide-related sequence A (MICA) and MICB. Upon activation, NK cells 
secrete perforin and various granzymes which can permeabilise the plasma membrane of tumour cells and initiate cascades of apoptosis (Zitvogel, Tesniere and 
Kroemer 2006). Secretion or expression of tumour necrosis factor (TNF)-related 
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apoptosis-inducing ligand (TRAIL) by NK cells can kill tumour cells which express the corresponding  receptor “TRAIL receptor” (Falschlehner, et al. 2009).  The 
developing tumours can also be recognised by T cells and NKT cells via the cellular interaction between T-cell receptors (TCRs) and MHC-tumour associated peptide complexes and glycolipid-CD1 complexes which are expressed by the growing 
tumour cells. Upon activation, cytotoxic effector cells, mainly CD8+ T cells and NKT cells, exert their cytotoxic mechanisms to eliminate tumour or premalignant-transformed cells by secreting various types of IFNs including type І IFNs (IFN-α and IFN-β) and type ІІ IFN (IFN-γ) (Krijgsman, Hokland and Kuppen 2018). The production of IFNs, mainly IFN-γ, can mediate the recruitment of other innate immune cells to the site of growing tumour. The production of IFN-γ inhibits angiogenesis mediated by tumour cells and induce proapoptotic mechanisms within tumour cells which inhibit the growth of tumour cells (Sun, et al. 2014).  Apoptotic or lysed tumour cells release intracellular molecules and antigens that recruit adaptive immune cells (DCs, macrophages, CD4+ and CD8+ T cells) and initiate the development of tumour-specific adaptive immune responses. Signals derived from tumour infiltrating innate immune cells can also induce the recruitment and activation of adaptive immune cells (Topfer, et al. 2011). For instance, immature DCs can be recruited to the site of growing tumour and activated by the cytokine milieu of innate immunity (Palucka, et al. 2011). Upon activation, immature DCs encounter and present tumour antigens on their cell surface in two different ways either directly by ingesting tumour cell apoptotic bodies or indirectly when tumour antigens become bound and chaperoned with heat shock proteins which are taken up by DCs (McDonnell, Robinson and Currie 2010, Murshid, Gong 
and Calderwood 2012). After antigen internalisation, DCs acquire a highly activated-mature phenotype by which they can activate naïve tumour-specific T helper 1 
(Th1) CD4+ T cells via MHC (major histocompatibility complex) class ІІ signalling. 
Th1 mediate the activation of naïve tumour-specific CD8+ T cells induced through cross-presentation of antigenic tumour  peptides on DC-MHC class І complexes 
(Sánchez-Paulete, et al. 2017). The activation of tumour-specific adaptive immune response provides the host with a potential to effectively eliminate the growing tumour. At the site of developing 
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tumour, CD4+ T cells secrete IL-2 that maintains the function and viability of CD8+ T cells (Gajewski, Schreiber and Fu 2013). Production of IL-15 due to tissue-stromal remodelling can also maintain cytotoxic activity of tumour-specific CD8+ T cells which carefully recognise and attack antigen-positive tumour cells (Doedens, et al. 
2016). After interaction with tumour cells, tumour-specific CD8+ T cells can also secrete large amount of IFN-γ and thus kill tumour cell via IFN-γ-dependent mechanisms of apoptosis and angiogenesis inhibition (Bruno, et al. 2014). The contribution of tumour-specific adaptive immunity may vary among different tumours. Therefore, the elimination phase of cancer immunoediting is mainly based on the immunogenicity of antigens expressed by newly-growing tumour and must be repeated each time when new antigenically distinct tumour cells develop (Vesely 
and Schreiber 2013). 
1.3.2. The phase of equilibrium (cancer persistence) Tumour cells which have escaped the elimination phase can persist and resist the activated tumour-specific adaptive immune cells via expression of non-immunogenic antigens (Quezada, et al. 2011) (figure 1.4). These non-immunogenic tumour cells are thought to be specifically selected by the tumour to maintains its progression by avoiding the intensive, constant attack from the immune cells that still have potential to eliminate the newly growing cells. This process has been called “immunoselection” (Zitvogel, et al. 2006). The equilibrium phase (immunoselection) is a period of cancer persistence in which tumour cells are prevented from expanding by immune resistance. In this stage, tumour cells show a functional state of dormancy and may reprogram their intrinsic mechanisms which block antigen-processing machinery and therefore inhibit expression of immunogenic molecules that can be recognised by immune cells (Teng, et al. 2008). 
Loss of MHC class І molecules, TAP1 (transporter associated with antigen 
processing 1), LMP2 (low-molecular mass protein 2) and IFN-γR (IFN-γ receptor) helps tumour cells to avoid adaptive immune response which is mediated via a process called immune-mediated tumour dormancy (Starling 2017). The molecular mechanisms of immune-mediated tumour dormancy in the equilibrium phase are still not comprehensively explained due to the difficulties of developing a mouse model that can represent the equilibrium phase (Mittal, et al. 2014). An evidence 
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confirming the existence of equilibrium phase has been reported by Koebel et al. The authors have showed that immunocompetent mice failed to develop any palpable tumours after receiving low-dose carcinogen (3’-methylcholanthrene (MCA)) which induced occult cancer cells within mice. However, 50% of these mice rapidly developed tumours at the site of MCA injection when their immune system was inhibited by administrating monoclonal antibodies targeting T cells and IFN-γ 
(Koebel, et al. 2007). The authors have also demonstrated that adaptive immune cells, specifically CD4+, CD8+, IL-12-secreting and IFN-γ-secreting T cells, but not innate immune cells were responsible for preserving  occult tumour cells in a dormant state (Koebel, et al. 2007). Another study has also used the MCA-induced occult tumour mouse model to investigate the equilibrium phase of immunoediting 
(Teng, et al. 2012). The authors suggested that this specific phase could be the longest in cancer immunoediting as primary tumours were apparent within mice 
after 10-20 weeks of carcinogen inoculation, while occult tumour cells in a state of dormancy for 200 days before T-cell depletion which promoted the tumour progression (Teng, et al. 2012). The authors have also demonstrated that IL-12 and IL-13 cytokines might be the main regulators that coordinate the molecular mechanisms of immune-mediated tumour dormancy in the equilibrium phase. IL-23 has been shown to maintain tumour growth and persistence, whereas IL-12 was efficient to inhibit and control the outgrowth of occult primary tumour cells. Whereas, IL-4, IL-17A, TNF, and IFN-α and β cytokines were not shown to have any role in mediating the equilibrium phase (Teng, et al. 2012). Wu et al. have profiled immune cells enriched in the microenvironment of tumours at the equilibrium and 
escape phases. The authors have found that CD8+ T cells, NK cells and γδ+ T cells were predominantly enriched in tumours undergoing immune-equilibrium phase, 
whereas NKT cells, Tregs and MDCSs were present in very low percentages. However, the microenvironment of tumours in the immune-escape phase was heavily enriched with immunosuppressive cells, mainly T regulatory cells (Tregs) and MDSCs (Wu, et al. 2013). 
1.3.3. The phase of immune escape (cancer progression) Tumour cells that have gained the competency to evade immune recognition and destruction sprout progressively and therefore enter the escape phase,  which is the 
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last phase of cancer immunoediting (Kim, Emi and Tanabe 2007). Tumour escape is mediated through different mechanisms, including development of immunosuppressive tumour microenvironment by the recruitment and/or 
induction of immunosuppressive/immunoregulatory T cell populations, reduced immune recognition of T cells due to the absence of immunogenic antigens/MHCs expressed on tumour cells, overexpression of anti-apoptotic molecules by tumour cells  and immune exhaustion (Mittal, et al. 2014, Schreiber, Old and Smyth 2011) 
(figure 1.4). Understanding the molecular biology of these mechanisms has provided new insights for the development of immunotherapy against cancer 
(Beatty and Gladney 2015). These mechanisms will be discussed in more details in the next section.        
1.4. Immune escape mechanisms in the tumour 
microenvironment Accumulative evidence has suggested that immune evasion is mediated by tumour cell-mediated mechanisms and immune cell-mediated mechanisms; both of which contribute to resistance to cancer immunotherapies and promote tumour invasiveness, progression and metastasis (Bhutia, Mallick and Maiti 2010). 
1.4.1. Tumour cell-mediated mechanisms Several studies have reported that the cellular microenvironment may vary between tumours. Some tumours are heavily infiltrated by immune cells which have been called T-cell-inflamed tumours, while other that lack a baseline of  immune-cell infiltration are called non T cell-inflamed tumours in which T cells and other immune cells are precluded from the tumour microenvironment (Trujillo, et al. 
2018). It has been reported that tumour cells can employ several intrinsic mechanisms that mediate T cell exclusion (Trujillo, et al. 2018). 
1.4.1.1. WNT/β-catenin pathway  Tumour cell-intrinsic upregulation of the WNT/β-catenin pathway has been correlated with absence of T cell infiltration in the tumour microenvironment. Spranger et al. (2015) have found that genes related WNT/β-catenin pathway are significantly upregulated in non-T cell-inflamed metastatic melanoma tumours, 
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compared to T cell-inflamed tumours. By using inducible genetically engineered autochthonous mouse model, the authors have demonstrated that activation of 
WNT/β-catenin signalling due to gain-of-function mutations could inhibit the initial steps of T cell priming by tumour antigens. Moreover, the authors have revealed that 
tumours with active β-catenin failed to recruit and activate Batf3-encoded CD103+ DCs in the microenvironment, which was correlated with lacking T cell infiltration within the tumour microenvironment (Spranger, Bao and Gajewski 2015). Batf3 DCs are found to be indispensable mediators for priming and activation of CD8+ T cells in the tumour microenvironment via cross-presentation of tumour-associated antigens (Engelhardt, et al. 2012, Fuertes, et al. 2011, Hildner, et al. 2008). T cell 
exclusion due to activation of the WNT/β-catenin signalling has been found in the tumour microenvironment of other cancers including bladder cancer, head and neck and other types of cancer (Sweis, et al. 2016, Luke, et al. 2016). Abnormal activation 
of the WNT/β-catenin signalling has been found to suppress the expression of Eomesoderin (EOMES) which is the master regulator of the function of CD8+ T effector cells (Gattinoni, Ji and Restifo 2010). Activation of the WNT/β-catenin signalling due to functional mutations has found to affect the role of DCs and condition them to a regulatory state which inactivates anti-tumour immunity (Castañeda-Patlán, Fuentes-García and Robles-Flores 2018). Activation of β-catenin has also found to enhance the expression of the transcription repressor ATF3 that inhibits the transcription of CCL4. The insufficient production of CCL4 impairs the maturation and activation of Batf3-CD103+ DCs that are essential for CD8+ T cells priming and differentiation (Pai, et al. 2017). 
1.4.1.2. PTEN/PI3K pathway Another pathway found to mediate T cell exclusion within the microenvironment of non-T cell-inflamed tumours is loss of PTEN/PI3K activation pathway. PTEN (the phosphatase and tensin homologue) is a well-known tumour suppressor which 
negatively regulates the PI3K/Akt signalling pathway (Song, Salmena and Pandolfi 
2012). PI3K/Akt signalling pathway plays a pivotal role in maintaining cell growth and survival and has been found significantly upregulated in tumour cells, thereby maintaining the tumour progression (Porta, Paglino and Mosca 2014). In preclinical models of melanoma, loss of PTEN in tumour cells is found to promote the expression of immunosuppressive cytokines, suppress T cell-mediated anti-tumour 
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response and reduce T cell infiltration into the tumour microenvironment (Peng, et 
al. 2016). Loss of PTEN pathway in prostate tumour cells has also been found to induce immunosuppressive tumour microenvironment via downregulation of 
PTPN11/SHP2 which therefore maintains the activation of the JAK2/STAT3 pathway (Toso, et al. 2014). The activation of STAT3 has been found to prevent anti-tumour responses by blocking the activation of DCs, NK cells and T cells, thereby promoting tumour growth. Kortylewski et al. have demonstrated that blocking STAT3 signalling in haematopoietic cells could markedly activate and maintain the 
function of  DCs, T cells, NK cells and neutrophils, and suppress the tumour growth 
(Kortylewski, et al. 2005). Loss of functional PTEN pathway leads to persistent 
activation of PI3K/Akt signalling pathway which has been correlated with non T cell-inflamed tumours (Carnevalli, et al. 2018). In muscle-invasive bladder cancer, 
upregulation of PI3K signalling due to PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) mutations is found to be significantly 
correlated with the downregulation of 57 relevant immune genes, compared to unmutated-PIK3CA bearing tumours. Inhibiting PI3K signalling has been shown to promote T cell activation and trafficking within the tumour microenvironment of muscle-invasive bladder cancer (Borcoman, et al. 2019). In chronic myeloid 
leukaemia, activation of PI3K signalling is also found to inhibit the expression of 
NKG2D receptor on NK cells, thereby preventing NK cells activation within tumour microenvironment (Groh, et al. 2002, Boissel, et al. 2006). In melanoma, the PI3K signalling is found to promote the production of IL-10 following prolonged exposure to TGF-β through a crosstalk between Smad and PI3K/Akt signalling pathway. IL-10 
as an immunosuppressive cytokine could inhibit the activation and function of NK cells and DCs by reducing MICA expression on melanoma cell surface (Serrano, et al. 
2011). Loss of PTEN has been found to inhibit the maturation and activation of DCs 
and macrophages via blocking the expression of LC3І and LC3ІІ genes that regulate the process of autophagy (Peng, et al. 2016). Autophagy facilitates cross-presentation of tumour-derived antigens by antigen-presenting cells, and thus activate innate and adaptive immune response (Zhong, Sanchez-Lopez and Karin 
2016). 
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1.4.1.3. c-MYC signalling pathway                        c-MYC signalling as a tumour cell-intrinsic mechanism has also been found to affect anti-tumour immunity within the tumour microenvironment. c-MYC is one of three related proto-oncogenes that normally regulate cell cycle, cell growth and survival 
(Lin, et al. 2012). The expression of c-MYC is found significantly upregulated in many types of cancer and promote tumour initiation and maintenance (Gabay, Li and 
Felsher 2014). In leukaemia/lymphoma mouse model, inactivation of c-MYC 
signalling contributes to significantly reduction in the size of tumour in wide-type animals (Jain, et al. 2002), whereas, minimal reduction in the size of tumour with tumour recurrence has been noticed in immunocompromised mice, confirming the cellular link between c-MYC signalling and immune cells within the tumour milieu (Felsher 2010, Casey, Bellovin and Felsher 2013). For instance, Rakhra et al. have showed that CD4+ T cells, but not CD8+ T cells, are required for sustained tumour regression upon MYC inactivation. The authors have demonstrated that CD4+ T cells are found to be rapidly localised to the site of tumour after 4 days of MYC inactivation. The presence of CD4+ T cells is also found to significantly inhibit angiogenesis upon MYC inactivation via the expression of TSP-1 (thrombospondin-
1), a robust anti-angiogenic protein (Rakhra, et al. 2010). This study suggests that the activation of MYC by tumour cells may inhibit the activation and recruitment of innate immune cells to the site of tumour and prevents them activating adaptive immune cells, and therefore facilitate tumour progression (Rakhra, et al. 2010). 
MYC has also been found to regulate the expression of CD47 and PD-L1 (Casey, et al. 
2016). CD47 is found significantly expressed on the surface of tumour cells and acts as innate immune checkpoint which regulate immune response derived from innate immune cells such as macrophages and DCs (antigen-presenting cells (APCs)) 
(Jaiswal, et al. 2009). Upregulation CD47 by tumour cells inhibits the recruitment and activation of APCs and T cells into the site of tumour, thereby facilitating T cell exclusion within the tumour microenvironment through inhibition of tumour cells phagocytosis by APCs (McCracken, Cha and Weissman 2015). This finding is also 
supported by Kauder et al. The authors have demonstrated that blocking CD47 enhances tumour cells phagocytosis by macrophages and promotes the activation of DCs and adaptive immune cells, thereby boosting anti-tumour immunity (Kauder, 
et al. 2018). PD-L1 (programmed death-ligand 1) is also found to be significantly 
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expressed on the surface of tumour cells and mediates coinhibitory mechanism via binding to its receptor PD-1 expressed on T cells to inhibit the activation of T cells, leading to T cell exhaustion within the tumour microenvironment (Wang, et al. 
2016). Casey et al. have proved that the expression of both CD47 and PD-L1 is correlated with the expression of MYC oncogene. Using MYC-induced T cell acute lymphoblastic leukaemia (MYC T-ALL) transgenic mouse model, the authors have showed that MYC inactivation could significantly reduce the expression of CD47 and PD-L1 on tumour cells at the mRNA and protein level in vitro and in vivo. The authors 
have also confirmed that MYC could induce the expression of both CD47 and PD-L1 by binding directly to their gene promoters (Casey, et al. 2016). These finding have 
also been supported by Kim et al. The authors have confirmed the positive correlation between the expression of MYC and PD-L1 in non-small cell lung carcinoma (NSCLC). NSCLC tumours expressing both MYC and PD-L1 are significantly correlated with worse prognosis and decreased disease-free and overall survival rates, compared to MYCnegative PD-L1negative tumours (Kim, et al. 
2017). Another mechanism by which MYC controls anti-tumour immunity has been 
demonstrated by Kortlever et al. In this study, using KrasG12D-derive lung adenocarcinoma mouse model, MYC amplification could inhibit the infiltration of B, 
T and NK cells into the tumour microenvironment by inducing the production of IL-23 from tumour cells. The authors have also found that MYC amplification could increase the induction of CCL9 from adenoma epithelial compartment, which promotes stromal angiogenesis (Kortlever, et al. 2017). 
1.4.1.4. Loss of antigenicity                                                         Loss of antigenicity is also another tumour-cell intrinsic mechanism which is operated by tumour cells to avoid anti-tumour immune responses. Loss of antigenicity occurs when tumour cells fail to express immunogenic antigens that can be recognised by immune cells (Coulie, et al. 2014). Loss of antigenicity is either due to the selection of less immunogenic variants of tumour cell, down-regulation of Class I MHC molecule or defects in antigen processing machinery within tumour cells, which hinders cross-presentation of antigens by tumour cells. Loss of MHC class І expression is found to be one of main mechanisms by which malignant cells evade adaptive immune response (Schreiber, et al. 2011). Even if a tumour produces enough immunogenic antigens, immune recognition is based on the ability of 
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tumour cells to present antigen in the context of a peptide-MHC complex (Beatty and 
Gladney 2015). Loss of MHC class І expression is found in about 18-60% of common solid cancers including breast, head and neck squamous cell carcinoma, lung, colon, renal cell carcinoma, cervical cancer, bladder cancer, prostate and melanoma 
(Campoli and Ferrone 2008). Loss of MHC class І expression can be due to genetic alterations at the gene level or regulatory alteration at the transcriptional level. 
These alterations result in total loss of all class І molecules or selective downregulation of HLA class I alleles (Leone, et al. 2013). Mutations in the β2-microglobulin gene are found highly correlated with the total loss of MHC class I expression. In addition, aberrations in the components of antigen processing machinery which include low-molecular weight proteins (LMPs), transporter associated with antigen presentation (TAP) isoforms and tapasin (TPN) contribute to the loss of MHC class I expression on tumour cells (Thuring, et al. 2015). Hypermethylation of MHC gene promoters may also affect cross-presentation of MHC class I expression on tumour cells (Leone, et al. 2013). 
1.4.2. Immune cell-mediated mechanisms Tumour escape is not only mediated by tumour cells, immune cells infiltrating into the tumour microenvironment can facilitate tumour evasion and progression through establishing an immunosuppressive tumour microenvironment (Croci, et al. 
2007). Several immune cells are found to play an essential role in the development of immunosuppressive microenvironment which promotes tumour progression, including MDSCs, T regulatory cells (Tregs), tumour-associated macrophages 
(TAMs), DCs, T helper 17 (Th17), mast cells and B regulatory cells (Kitamura, Qian 
and Pollard 2015). 
1.4.2.1. Tumour-associated macrophages  Growing evidence has confirmed the role of tumour-associated macrophages (TAMs) in promoting the tumour microenvironment. TAMs are found to be the more abundant among the inflammatory cells within the tumour microenvironment 
(Vitale, et al. 2014). TAMs are generated from circulating monocytes that are recruited to the site of tumour via tumour-derived chemokine CCL2, or from tissue-resident macrophages (Sica, et al. 2007). Macrophages are conventionally classified into two main subsets including classical and alternative macrophages. “classical” 
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M1 macrophages are thought to boost anti-tumour response and regulate the 
functional activity of T helper 1 cells (Th1) by producing Th1-related cytokines such as IL-12 and TNF-α (Sica, et al. 2008). Whereas “alternative” macrophages, known as M2 macrophages, are involved in many mechanisms such as wound healing, tissue remodelling and angiogenesis, and secrete Th2-related cytokines such as TGF-β, IL-6, and IL-10 that regulate the function of  T helper 2 (Th2) cells (Solinas, 
et al. 2009). Many studies have confirmed that TAMs are unstable in tumour microenvironment in that they can switch their phenotypic signature from a M1 to a M2 phenotype, thus providing a favourable milieu for tumour growth (Sica, et al. 2006). This polarisation of M2-TAMs is favoured by other immune cells including Tregs and dendritic cells (DCs), and also by tumour-related factors such as colony-stimulating factor (CSF-1) and hypoxia-inducible factor 1 (HIF 1-α) (Noy and Pollard 
2014). Unlike classical macrophages, M2-TAMs are deficient in antigen-presenting capabilities and express PD-L1, and thus suppress anti-tumour immunity (Chanmee, 
et al. 2014). The immunosuppressive role of TAMs has been reported in many solid tumours including breast, hepatocellular and renal cell carcinomas, and thus several clinical trials have been designed for targeting TAMs for the treatment of cancer 
(Williams, Yeh and Soloff 2016, Shirabe, et al. 2012, Behnes, et al. 2014). 
1.4.2.2. Tumour-infiltrating dendritic cells Dendritic cells (DCs) also play an important role in mediating anti-tumour responses due to their functional ability as ‘professional’ antigen-presenting cells which have the capacity to activate adaptive immune cells (CD4+ and CD8+ T cells) (Moser 2003). However, a robust activation of anti-tumour responses requires only mature DCs which can cross-present antigens effectively. The maturation of DCs is regulated by several factors depending on the local milieu (Munz, Steinman and Fujii 2005). For instance, the majority of infiltrating DCs in the tumour microenvironment are immature or “paralyzed” DCs that have become tolerogenic due to many factors such as IL-10 and vascular endothelial growth factor (VEGF) secreted by TAMs (Suciu-Foca, Berloco and Cortesini 2009). Immature DCs can also secrete IL-10 and TGF-β and induce the expression of IDO, and thereby can promote the expansion of Tregs. Thus, immature DCs elicit an immunosuppressive role which can suppress the activation of effector T cells, induce T-cell anergy, and then promote tumour progression (Benencia, Muccioli and Alnaeeli 2014). The 
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immunosuppressive function of immature DCs can also be mediated by Tregs through cell-cell contact mechanisms involving cytotoxic T-lymphocyte antigen-4 (CTLA-4) expressed on Tregs, and CD80/CD86 expressed on DCs. This upregulates the expression of IDO in DCs, and thus promotes the immunosuppressive milieu 
(Hubert, et al. 2007). Furthermore, Tregs are thought to influence the maturation of DCs via IL-10 and TGF-β signalling and affect the ability for DCs to stimulate effector T cells via inhibition of co-stimulatory molecules expressed on DCs (Tran Janco, et 
al. 2015). 
1.4.2.3. Myeloid-derived suppressor cells (MDSCs)         MDSCs are a heterogenous subpopulation derived from myeloid progenitor and immature myeloid cells. MDSCs are highly immunosuppressive cells which act as negative  regulators of immune response in various pathological conditions such as chronic inflammation and cancer (Gabrilovich and Nagaraj 2009). MDSCs can be grouped into two main subsets; monocytic-MDSCs (M-MDSCs) and polymorphonuclear-MDSCs (PMN-MDSCs). MDSCs are found highly enriched in the tumour microenvironment. Many studies have studied molecular features by which MDSCs are recruited and regulated in the tumour bed and found that several factors could mediate the expansion and activation of MDSCs in the tumour milieu. These factors include granulocytes-macrophage colony-stimulating factor (GM-CSF), G-CSF, IL-6, prostaglandin-E2 (PGE2), VEGF and cyclooxygenase-2 (COX-2) 
(Obermajer, et al. 2011, Sinha, et al. 2007, Ostrand-Rosenberg, et al. 2012). Two main transcription factors are also found to play a significant role in the development and function of MDSCs including STAT transcription factors and 
C/EBP-β transcription factor, respectively (Qu, Wang and Lin 2016). The secretion of GM-CSF and G-CSF could regulate the development of MDSCs through downregulation of interferon-regulatory factor 8 (IRF-8) via STAT3 and STAT5- dependent pathways, confirming the role of IRF-8 as a negative regulator of MDSCs 
(Waight, et al. 2013). In addition, C/EBP-β transcription factor is also found to regulate the suppressive activity of tumour-induced MDSCs. Blocking C/EBP-β could significantly inhibit the activity of MDSCs, affect the differentiation of immature 
myeloid precursors and enhance the activity of CD8+ effector T cells (Marigo, et al. 
2010). The immunosuppressive activity of MDSCs is mediated by several factors including inducible nitric oxide synthase (iNOS), Cox-2, PGE-2, TGF-β and arginase-
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1 (Arg-1) (Li, et al. 2009, Bogdan 2010, Yang, et al. 2008, Parker, Beury and Ostrand-
Rosenberg 2015). In general, PMN-MDSCs are found more enriched in the tumour microenvironment than M-MDSCs, whereas the latter can elicit stronger immunosuppressive activity (Marvel and Gabrilovich 2015). The suppressive activity of M-MDSCs is linked with the metabolism of L-arginine which is used as a common substrate by Arg-1 and iNOS to produce urea or nitric oxide to inhibit proliferation and differentiation of T cells (Bogdan 2010). M-MDSCs are more plastic cells and found to have the potential to differentiate into tumour-associated macrophages (TAMs) within the tumour microenvironment. CCL2-CCR2 signalling pathway is found to mediate the recruitment of M-MDSCs into the tumour site where they can become TAMs (Tcyganov, et al. 2018). Unlike M-MDSCs, PMN-MDSCs can subdue anti-tumour immunity in an antigen-specific manner. These cells can take up and present antigens to antigen-specific T cells and then induce nitration of T cell receptors which makes T cells unresponsive to antigen stimulation (Dilek, et al. 
2012).  Reactive oxygen species (ROS) plays an essential role in PMN-MDSCs mediated immune suppression. The production of ROS by PMN-MDSCs is found tightly regulated by NADPH oxidase (NOX2). Therefore, inhibition of NOX2 could suppress PMN-MDSCs mediated immune suppression, confirming the pivotal role of ROS in the functional activity of PMN-MDSCs (Corzo, et al. 2009). The presence of both ROS and nitric oxide (NO) could induce the production of peroxynitrite which mediates 
the nitration of TCR and thus blocks CD8+ T cell response (Feng, et al. 2018).  MDSCs are also found to promote tumour progression by inducing Tregs expansion within the tumour microenvironment. The induction of Tregs by MDSCs is mediated via secretion of IL-10 and TGF-β (Nakamura and Ushigome 2018). The production of IFN-γ by activated T cells induces expression of immunoregulatory molecules PD-
L1 and CD40 on MDSCs (Lu, et al. 2016, Pan, et al. 2010). Upregulation of CD40 by MDSCs is found to mediate the induction of Tregs within the tumour microenvironment (Pan, et al. 2010).  In addition, MDSCs are found to be implicated in the process of EMT (epithelial-to-mesenchymal transition) which mediates tumour invasiveness and metastasis. The production of NO and TGF-β by MDSCs could induce upregulation of COX-2 in 
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tumour cells and then activate β-catenin/TCF-4 pathway (Li, et al. 2015). This pathway is found to play a critical role in mediating the process of EMT (Chang, et 
al. 2015). Moreover, MDSCs play a vital role in regulating the process of angiogenesis which facilitates tumour progression. MDSCs express matrix metalloproteinase-9 (MMP-9) which can release VEGF stored in extracellular matrix, thereby promoting angiogenesis (Lee, et al. 2018). In addition, MDSCs produce VEGF and fibroblast growth factor (FGF) via STAT3-dependent mechanism which boosts angiogenesis within the tumour milieu (Kujawski, et al. 2008).                                                                                        
1.4.2.4. T regulatory cells (Tregs) Regulatory T cells (Tregs) are a distinct subset of CD4+ T cells that play a vital role in maintaining immune homeostasis and peripheral tolerance therby preventing autoimmunity (Fehervari and Sakaguchi 2004). Tregs are characterised by the expression of the transcription factor forkhead-box protein P3 (Foxp3) that is fundamental for their development and suppressive activity. In human, mutation of the foxp3 gene leads to develop a severe X-linked organ-specific autoimmune disease known as immune-dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) (Gambineri, Torgerson and Ochs 2003). A foxp3-mutant mouse strain called the Scurfy mouse is also found to show multi-organ autoimmunity (Le Bras and Geha 2006). Tregs are generally categorised into two main subsets according to their ontogeny including naturally thymus-derived Tregs (nTregs) and peripherally-derived or induced Tregs (p or iTregs) (de Lafaille, Maria A Curotto and 
Lafaille 2009). Both of these subsets of Tregs are phenotypically defined by the expression of CD4+CD25++Foxp3+CD127- and based on the methylation status of their Treg-specific demethylated region (TSDR) within the Foxp3 locus. The TSDR is found demethylated in nTregs, whereas it is methylated in i/pTregs (Floess, et al. 
2007).  nTregs are developed in the thymic medulla from immature CD4+ T cells in response to high-affinity interaction with a self-peptide: major histocompatibility (MHC) complex expressed on medullary thymic epithelial cells (mTECs) and dendritic cells (DCs) (Bettini and Vignali 2010). Whereas, peripheral or induced Tregs are developed extra-thymically from mature naïve CD4+ T cells circulating in the 
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periphery in response to sub-optimal TCR signalling in the presence of several cytokines such as IL-2 and TGF-β (Lee, Bautista and Hsieh 2011). iTregs are also found to be generated at sites of inflammation or in a tolerogenic environment and have been characterised to have a various recognition of antigens (Workman, et al. 
2009).  In cancer, Tregs are found extremely enriched in the tumour microenvironment and mediate several mechanisms that contribute to the inhibition of anti-tumour response and tumour progression (Facciabene, Motz and Coukos 2012). Several mechanisms are identified to mediate the recruitment of Tregs to the site of tumour. The production of CC-chemokines ligand 22 (CCL22) by tumour cells and macrophages can attract Tregs to the tumour bed via CC-chemokine receptor 4 (CCR4) expressed on the surface of Tregs (Gobert, et al. 2009). Upregulation of 
CCL17 by tumour cells is also found to regulate recruitment of Tregs via CCR4 
(Mizukami, et al. 2008). Moreover, the overexpression of CCL28 by hypoxic tumour cells is found to recruit Tregs to the tumour milieu via binding to the cognate 
receptor CCR10 expressed on Tregs. Hypoxia-inducible factor 1α (HIF-1α) secreted by tumour cells is found to mediate Tregs recruitment by regulating upregulation of 
CCL28 in tumour cells (Ren, et al. 2016). CCL5 is also found to mediate Tregs recruitment to the tumour microenvironment via its corresponding receptor CCR5 which is detected on the surface of Tregs. CCL5 can be expressed by macrophages, T lymphocytes, platelets, tubular epithelium and tumour cells (Aldinucci and 
Colombatti 2014). Tregs are also found to be recruited to the tumour microenvironment through CXCR3 (C-X-C motif chemokine receptor 3) expression 
which is a cognate receptor for CXCL9, CXCL10 and CXCL11. For instance, the expression of CXCL10 by tumour cells could recruit Tregs to the site of tumour in hepatocellular carcinoma (Li, et al. 2016).  Upon recruitment to the tumour microenvironment, Tregs exert their immunosuppressive activities via various mechanisms including: (1) secretion of soluble immunosuppressive cytokines, (2) modulation of dendritic cells, (3) metabolic disruption and (4) suppression by direct cytolysis (Vignali, Collison and Workman 2008). Tregs are found to secret TGF-β cytokine which acts as a negative 
regulator for CD8+ T cells by affecting their proliferation and differentiation (Strauss, 
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et al. 2007). In addition, Tregs can also produce IL-10 which is an immunoregulatory cytokine and plays a pivotal role in the regulation of adaptive immunity by 
suppressing prolonged activation of CD8+ T cells (Ng, et al. 2013). Tregs can also inhibit anti-tumour response via production and secretion of IL-35 cytokine which is found to be required for Tregs to maintain their suppressive activity (Wei, et al. 
2017). IL-35 has showed the ability to arrest the proliferation of T helper 1 and 17 
cells at the G1 phase of cell division (Wirtz, et al. 2011). Another mechanism by which Tregs suppress anti-tumour immunity is via direct cytolysis of T effector cells. Although granzyme-mediated cytolysis has been widely considered the forte of NK 
cells and CD8+ T effector cells (Lieberman 2003), activated human Tregs are shown 
to express granzyme A and perforin which directly kill the target cells via the 
adhesion of CD18 (Grossman, et al. 2004). Furthermore, not only human Tregs, mouse Tregs are also found to mediate their functional suppression via upregulation 
of granzyme B expression (McHugh, et al. 2002, Herman, et al. 2004). Tregs derived 
from granzyme B-deficient mouse are found to be less suppressive in vitro, confirming the important role of granzyme B in the suppressive potential of Tregs. 
Tregs also shown to mediate cytolysis in a granzyme B-dependent and perforin-dependent and independent manners (Herman, et al. 2004, Cao, et al. 2007). Tregs can also mediate their cytolytic function to kill CD8+ T effector cells by inducing apoptosis via the TRAIL pathway, especifically TRAIL-death receptor 5 (TRAIL-DR5) (Ren, et al. 2007). Treg can also induce apoptosis on effector T cells through the expression of galetin-
1 which is highly upregulated in human and mouse Tregs. Galectin-1-defecient Tregs have shown a significant reduction in their suppressive activity in vitro, confirming the importance of galectin-1 signalling in mediating regulatory activity of Tregs (Garin, et al. 2007). Tregs can also attenuate proliferation of CD8+ T effector cells metabolically. It has been suggested that Tregs can inhibit proliferation of effector T cells by depleting local IL-2 via the expression of CD25. Depleting IL-2 induces cellular starvation and therefore apoptosis (Pandiyan, et al. 2007). However, IL-2 depletion alone is found not required for Tregs to inhibit effector T cells (Oberle, 
et al. 2007). Coordinated expression of CD39 and CD73 is shown to maintain 
suppressive activity of Tregs. These ectoenzymes allow Tregs to hydrolyse ATP (adenosine triphosphate) to adenosine which suppresses functional activity of CD8+ 
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T effector cells (Deaglio, et al. 2007). Exogenous ATP is hydrolysed to ADP (adenosine diphosphate) and 5’AMP (adenosine monophosphate), while CD73 hydrolyses 5’AMP to adenosine (Bynoe and Viret 2008). Adenosine is shown to suppress T effector cells through stimulation A2A (adenosine 2A) receptor. Upon stimulation, A2A receptor signalling could inhibit production of proinflammatory cytokine IL-6 and enhance production of TGF-β which in turn promote the induction of induced Tregs (Zarek, et al. 2008).   Tregs are also shown to inhibit T effector cells indirectly by modulating the maturation and function of DCs which act as robust activators of effector T cells 
(Whiteside 2012). It has been reported that Tregs can control the maturation and function of DCs through interaction between the inhibitory receptor “cytotoxic T-lymphocyte antigen-4 (CTLA-4) and the co-stimulatory receptors “CD80/CD86” which is constitutively expressed by Tregs and CDs, respectively. This interaction could inhibit the expression of co-stimulatory receptors of DCs, thereby reducing their ability to activate T effector cells (Tadokoro, et al. 2006, Read, Malmstrom and Powrie 2000, Oderup, et al. 2006). Moreover, the interaction between CTLA-4 and 
CD80/CD86 could induce DCs to produce IDO (indoleamine 2,3-dioxygenase) which is a potent regulatory molecule that inhibit proliferation of T cells (Fallarino, et al. 2003).   IDO is one of three different heme-containing enzymes that catalyse the first rate-limiting step of tryptophan breakdown into immune suppressive kynurenines 
(Prendergast 2008). IDO can activate the GCN2 stress-response kinase, which inhibits the proliferation of T cells and mediates the differentiation of naïve CD4+ T cells into Tregs cells. Also, IDO produces soluble factors, such as kynurenines, which bind the aryl hydrocarbon receptor (AhR) to induce Treg differentiation (Nguyen, et 
al. 2014).  Tregs can also affect the function of DCs through lymphocyte-activation gene-3 (LAG-3) which is found expressed on Tregs, activated T effector cells and NK cells 
(Liang, et al. 2008). LAG-3 is homologous to CD4 and has high affinity to bind MHC 
class ІІ complexes. LAG-3 is required to maintain immunosuppressive activity of Tregs. Upon binding to MHC class ІІ expressed on immature DCs, LAG-3 initiates an immunoreceptor tyrosine-based activation motif (ITAM) which mediates an 
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inhibitory pathway to constrain DC maturation and their immunostimulatory ability 
(Huang, et al. 2004, Liang, et al. 2008). Consistence with this, it has been found that 
human MHC class ІІ-expressing Tregs are more suppressive than MHC class ІІ-
negative Tregs, supporting the notion that MHC class ІІ-positive Tregs might inhibit activated T cells by ligating LAG-3 expressed on them (Baecher-Allan, Wolf and Hafler 2006). It has also been reported that Tregs could modulate the function of DCs via neuropilin-1 which is found differentially expressed on Tregs (Sarris, et al. 2008).                                                                                                
1.4.2.5. T helper 17 (Th17) cells 
Th17 cells are highly plastic cells differentiated independently from a CD4+ T cell 
lineage distinct from Th1, Th2 and Tregs (Harrington, et al. 2005). Development of 
Th17 from naïve CD4+ T cells is mediated by several cytokines including IL-1β, IL-6 and TGF-β. In addition to IL-21 and IL-23 cytokines that maintain the developed 
Th17 cells for long-term (Stritesky, Yeh and Kaplan 2008). Th17 cells are identified by their ability to secrete IL-17A, IL-17F, IL-21, IL-22 and CCL20 (Liang, et al. 2006, 
Chang and Dong 2007, Dong 2008). Th17 cells have shown the capability to 
transdifferentiate mainly into Th1 or Tregs, and occasionally into Th2, T follicular 
helper (TFH) cells and type 1 regulatory (Tr1) cells based on the presence of cytokines and chemokines secreted in the local microenvironment (Guéry and 
Hugues 2015). For instance, the enrichment of proinflammatory cytokines including IL-1β, IL-23,  IL-6 and IL-12 could mediate the conversion of Th17 into Th1 which 
promotes activation of CD8+ T cells in the local milieu, whereas Th17 cells could be converted into Tregs in the presence of TGF-β, but in the absence of IL-6 (Bailey, et 
al. 2014).  
In cancer, Th17 are found to play a paradoxical role in tumour immunity as they can boost tumour progression by acquiring and initiating immunosuppressive activities and induce anti-tumour immune responses by secreting proinflammatory cytokines 
which can enhance the function of CD8+ T cells and NK cells. Th17 cells are found to have no direct cytotoxic effect on tumour cells as they do not produce perforin and 
granzymes (Kryczek, et al. 2009, Yen, et al. 2009). Instead, Th17 cells can mediate anti-tumour responses indirectly by mediating recruitment of other immune cells into the tumour site. For instance, by secreting IL-17, Th17 cells can induce tumour 
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cells to upregulate CXCL9 and CXCL10 chemokines which in turn recruit effector T cells into the tumour microenvironment (Kryczek, et al. 2009). IL-17 can also stimulate macrophages to produce IL-12 which mediates the expension of CD8+ cytotoxic T cells and boots their functional activities (Markiewicz, et al. 2009). 
However, Th17 cells can promote tumour progression by inhibiting anti-tumour responses. IL-17 secreted by TH17 is found to induce angiogenesis in tumour context by stimulating stromal cells (myeloid cells and fibroblasts) and epithelial cells to produce VEGF and angiogenin-2 (Chung, et al. 2013). IL-17 is found also to provoke tumour-related fibroblasts to generate G-CSF which triggers myeloid cells to generate MMP-9, prokineticin-2/Bv8 and proinflammatory S100A8/9 molecules to mediate angiogenesis (Chung, et al. 2013). The interaction between IL-17 and stromal cells-related cytokines is found to be correlated with the increased levels of TGF-β (Jeon, et al. 2007). It has been reported that Th17 cells can upregulate CD39 
and CD73 on their surface in the presence of TGF-β, and therefore acquire the ability 
to hydrolyse ATP to adenosine which suppresses CD8+ T cells proliferation (Bailey, 
et al. 2014), thereby exerting its regulatory activity. IL-17 is also found to stimulate 
upregulation of CCL17 and CCL22 by DCs which in turn recruits Tregs to the tumour site (Halim, et al. 2017). IL-17 mediates the migration of MDSCs into the tumour milieu. Injection of IL-17 has significantly increased in the number and suppressive activity of MDSCs within the tumour microenvironment in IL-17R-/- tumour -bearing mice (He, et al. 2010). IL-17 has shown to trigger tumour cells to activate the COX-
2/PGE2 pathway which mediate the differentiation of M2 macrophages that promotes tumour progression (Li, et al. 2014). IL-17 has also been found to trigger hepatocellular tumour cells to upregulate expression of MMP-2 and MMP-9 via NF-kB pathway which promotes tumour invasiveness and metastasis (Li, et al. 2011). 
1.4.2.6. Mast cells  Mast cells are generated in the bone marrow as precursor cells that migrate to peripheral tissues where they become fully mature. Mast cells belong to granulated innate immune cells and express various receptors such as Toll-like receptors (TLRs), Nod-like receptors (NLRs), Fc receptors and complement receptors. These receptors allow mast cells to mediate several immunological responses including pro-inflammatory and anti-inflammatory immune responses (Galli, Nakae and Tsai 
2005, Gurish and Austen 2001). Mast cells have been found dramatically enriched 
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within tumour microenvironment and correlated with worse prognosis and reduced survival in many types of human cancer including B-cell chronic lymphocytic leukaemia (Molica, et al. 2003), Hodgkin lymphoma (Glimelius, et al. 2005), melanoma (Ribatti, et al. 2003), prostate (Nonomura, et al. 2007), pancreatic adenocarcinoma (Strouch, et al. 2010) and oesophageal-squamous cell carcinoma 
(Elpek, et al. 2001). It has been reported that tumour-derived stem cell factor (SCF) mediates migration and activation of mast cells into tumour bed by binding to 
CD117 (KIT receptor) which is highly expressed on mast cells. Activation SCF/Kit pathway in mast cells mediates tumour progression (Huang, et al. 2008). Mast cells are found to mediate angiogenesis by releasing several angiogenic molecules including TGF-β, VEGF, fibroblast growth factor-2 (FGF-2), angiopoietin-1, IL-8, tryptase and chymase (Ribatti and Crivellato 2012). Mast cells are also found to produce IL-10 which can inhibit anti-tumour immune response (Galli, 
Grimbaldeston and Tsai 2008). Recently, it has been reported that tumour-derived TNF-α stimulates tumour-infiltrating mast cells to upregulate expression of PD-L1 via activation NF-kB pathway, and contribute to immune suppression and tumour progression in gastric cancer (Lv, et al. 2019). 
1.4.2.7. B regulatory cells (Bregs) Bregs are a unique subset of B cells and found to play a pivotal role in regulating and balancing immune responses in inflammatory diseases, autoimmune diseases and cancer (Berthelot, et al. 2013). Several subpopulations of Bregs have been identified in human and mouse models including IL-10-producting Bregs, TNF-α-secreting Bregs, Fas-ligand (Fas-L+) Bregs, granzyme-B+ Bregs, TGF-β-producing Bregs, GITR+ Bregs and STAT+ Bregs (Zhang, Gallastegui and Rosenblatt 2015). In pancreatic cancer, it is found that increased levels of IL-18 produced by tumour cells mediate the induction and immunosuppression of Bregs in vitro and in vivo. IL-18-induced Bregs have shown to upregulate expression of PD-L1 and  produce IL-10 which both maintain their immunosuppressive activity (Zhao, et al. 2017). In gastric cancer, it is found that IL-35-secreting Bregs are significantly enriched in the peripheral blood of patients with advanced gastric cancer. Also, the accumulation of IL-35-secreting Bregs is found to be positively correlated with high frequencies of Tregs and MDSCs, confirming the potential role of Bregs in tumour progression (Wang, Liu and Li 
2018). Bregs are also found to significantly enriched in the peripheral blood of 
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patients with lung and oesophageal cancer, compared to healthy individuals (Zhou, et al. 2014, Shi, et al. 2014). In 4T1 breast cancer mouse model, Bregs are detected significantly enriched in axillary and inguinal lymph nodes, spleen and blood. The accumulation of Bregs is found to promote lung metastasis in tumour-bearing mice. Also, Bregs are shown to produce high levels of TGF-β and therefore mediate the induction of Tregs from naïve CD4+CD25- T cells (Olkhanud, et al. 2011). It has been reported that IL-21 can mediate the induction of Bregs in the microenvironment of several human tumour types including prostate, colorectal, breast and cervical carcinoma. IL-21-drived Bregs are found to express high levels of granzyme-B, along with IL-10, CD25 and IDO which inhibit T cell proliferation and function. These 
granzyme-B positive Bregs have also been found existed adjacent to IL-21-secreting Tregs, suggesting that Tregs may mediate the induction of Bregs through IL-21 expression (Lindner, et al. 2013).   According to what discussed above, it seems that TGF-β is a multifunctional master cytokine which contributes for the promotion of immunosuppressive tumour microenvironment through molecular interactions with different immunosuppressive T cells. The role of TGF-β in the biology of T cells and cancer will be discussed in the next section.  
1.5. TGF-β cytokine 
Transforming growth factor β (TGF-β) is a multifunctional cytokine that belongs to a family consisting of three distinct isoforms including TGF-β1, TGF-β2 and TGF-β3, while TGF-β1 is the prevalent isoform expressed in the immune system (Chin, et al. 2004). TGF-β is a pleiotropic cytokine that regulates a variety of essential cellular events including cell development, proliferation, differentiation, homeostasis and apoptosis. TGF-β is initially translated as a precursor form “pre-pro-TGF-β”, which consists of pre-region signal peptide, pro-region latency-associated peptide (LAP) (N terminal peptide) and mature TGF-β peptide (C terminal peptide). The pre-pro-TGF-β resides within the endoplasmic reticulum where it undergoes post-translational modifications that result in the removal of signal peptide from LAP and the cleavage of the mature TGF-β peptide from LAP by a furin convertase (Annes, Munger and Rifkin 2003). To preserve TGF-β activity, the homodimeric LAP binds 
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and wraps the homodimeric mature TGF-β by noncovalent bonds, forming a soluble small latent complex (SLC) (Lawrence 2001) (Figure 1.5).  The SLC is then released from the cell to the extracellular matrix (ECM) where it can associate with milieu molecules such as LTBPs (latent TGF-β binding proteins) and LRRC32 (leucin rich repeat containing 32, which is also known as glycoprotein A repetitions predominant (GARP)). LTBP attaches the SLC by covalent bonds to form a large latent complex (LLC). LTBP facilitates the deposition of the LLC to the ECM 
(figure 1.6). The SLC can also bind the LRRC32/GARP to form a membrane-latent TGF-β (mLTGF-β). The LRRC32/GARP acts as a cognate receptor for the SLC (Unsold, 
et al. 2001, Wang, et al. 2012) . Therefore, TGF-β can be identified in three different forms; soluble SLC (small form), LLC (large form) and mLTGF-β (membrane form). These three forms represent the latent “inactive” state of TGF-β which is unable to bind its receptors and, therefore, requires activation to free the TGF-β as an active form to initiate TGF-β downstream signalling pathways (Tran 2011). Activation of TGF-β is mediated by several mechanisms that involve acidification, matrix metalloproteases, thrombospondin-1, plasmin, αv-integrins and proteases 
(Henderson, et al. 2013, Murphy-Ullrich and Poczatek 2000, Jenkins 2008, 
Hyytiäinen, Penttinen and Keski-Oja 2004). Once being exposed to these activator, the latent form of TGF-β undergoes proteolytic cleavage and structural modifications that result in conformational changes to the LAP structure and liberation of the bioactive TGF-β (Kubiczkova, et al. 2012).   
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Figure 1.5. Mechanism of production of TGF-β. Initially, TGF-β is translated as a precursor form “pre-pro-TGF-β” which consists pre-signal peptide, pro-region latency associated peptide (LAP) and mature TGF-β. After 
dimerization, homodimeric pre-pro-TGF-β is released to the endoplasmic reticulum where it undergoes post-translational modifications that leads to the removal of pre-signal peptide. Then TGF-β is cleaved from pro-LAP peptide by Furin at cleavage site. Then, pro-LAP attaches to the free TGF-β to prevent its activity in the cytoplasm. Attachment pro-LAP to TGF-β initiates structural modifications that results in the generation of soluble small latent complex (SLC) which is inactive form of TGF-β.  
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                 The bioactive form of TGF-β initiates its biological activities by ligation to TGF-β type 
І (TGF-βRІ) and type ІІ (TGF-βRІІ) receptors which are serine/threonine kinases. The bioactive TGF-β has a high affinity binding to TGF-βRІІ (Shi and Massagué 2003). Upon binding, TGF-βRІІ undergoes autophosphorylation and triggers TGF-βRІ, forming a tetrameric receptor complex which comprises of two TGF-βRІІ and two TGF-βRІ molecules (figure 1.7). This activated tetrameric complex induces downstream signalling pathways. Two key mechanisms have been identified to mediate TGF-β-downstream signalling, including Smad-dependent and Smad-independent signalling pathways (Derynck and Zhang 2003). Smad-dependent 
pathway is triggered through phosphorylation and activation of Smad2/3 complex 
Figure 1.6. Mechanism of formation of large latent complex (LLC) from SLC. TGF-β is released from the cell as an inactive form “soluble SLC”. Free soluble SLC binds to latent TGF-β binding protein (LTBP) which is released from the extracellular matrix (ECM), forming large latent complex (LLC). LLC is deposited and stored in the ECM as inactive form of TGF-β.     
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by the activated TGF-β ligand-receptor tetrameric complex. Smad-2 and Smad-3 are receptor-regulated effector proteins which are also known as “R-Smads” (Shi and Massagué 2003). Transphosphorylation of TGF-βRІ mediates its binding to other specialised scaffold proteins called SARA (Smad anchor for receptor activation) and Hrs (hepatic growth factor-regulated tyrosine kinase substrate). This binding  induces phosphorylation of R-Smads at a C-terminal SSXS motif leading to activation of R-Smads (Chen 2009). The activated R-Smads can associate with Smad-4 (Co-Smad) in the cytoplasm forming a heterodimeric complex which is then transported to the nucleus where the complex attaches to the regulatory sequences of target genes in corporation with other transcriptional factors to regulate the expression of hundred genes (Massague, Seoane and Wotton 2005) (figure 1.7). The bioactive TGF-β can also induce several cell type-specific Smad-independent signalling 
pathways which are mediated by PI3K-Akt, mitogen-activated proteins kinase 
(MAKP), Rh0-like GTPases, protein phosphatase 2A (PP2A) and partition-defective 6 (Par6) signalling (Zhang 2017).              
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Figure 1.7. Schematic representation of Smad-dependent TGF-β pathway. Upon activation, free active TGF-β binds its receptor TGF-β type II (TGF-βRІІ). Upon binding, TGF-βRІІ undergoes autophosphorylation and stimulates TGF-βRІ to form a tetrameric receptor complex consisting of two TGF-βRІІ and two TGF-βRІ receptors. The activated tetrameric complex initiates downstream signalling cascade by mediating 
phosphorylation and activation of Smad2/3 complex (R-Smads) via SARA molecule which is a scaffold acting protein and functions to facilitate the phosphorylation process of R-Smads complex. The activated R-Smads complex phosphorylates and activates Smad4 to form a heterodimeric molecule which is directed to the nucleus where the heterodimeric binds to the regulatory sequences of targets genes.       
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1.5.1. The role of TGF-β in T cell biology TGF-β plays a fundamental role in T cell development, differentiation, homoeostasis and tolerance. TGF-β has a paradoxical regulatory function that mediates both suppressive and inflammatory immune responses based on the status of the local microenvironment. This context-dependent function has enabled TGF-β to be the master of all T cell decisions (Li, et al. 2006). 
1.5.1.1. TGF-β in the thymus  In the thymus, T precursor cells are subjected to a series of molecular and phenotypic modifications before they differentiate into mature T cells. The most critical stage in T cell differentiation is when immature CD4+CD8+ (double positive) T cells undergo thymic selection and lineage commitment. At this stage, TGF-β is found to play an important role in the differentiation of conventional CD8+ T cells that requires TCR engagement and expression of IL-7 receptor that are the main 
requirements for CD8+ T-cell lineage commitment (Park, et al. 2010). TGF-β is found to regulate the expression of IL-7 receptor α-chain (IL-7Rα) on the surface of 
developing CD8+ T cells by repressing the expression of Gfi-1 (growth factor 
independent 1), a well-known transcription repressor, that inhibits the expression of Il7Rα in CD8+ T cells (Ouyang, et al. 2013) (figure 1.8A). TGF-β also controls the development of regulatory and innate-like T cells during thymic selection, including thymus-derived nTregs, invariant NK T (iNKT) cells and 
CD8αα+ TCRαβ+ intraepithelial lymphocytes (IELs) (figure 1.8A). The development of these specific subsets is based on their interactions with MHC-presenting self-ligands (agonist ligands) in a high-affinity manner. TGF-β is found to mediate and promote these interactions (Stritesky, Jameson and Hogquist 2012). The development of intrathymic nTregs is based on a combination of rigorous TCR interactions, co-stimulation and cytokines signals. Early studies have reported that TGF-β signalling is not required for nTregs development in mice with T cell-specific 
Tgfbr2 (TGF-β receptor II) deletion as these mice have been shown to possess normal populations of  Foxp3+ thymocytes (Li, Sanjabi and Flavell 2006, Marie, Liggitt and Rudensky 2006). However, Liu et al. (2008) have confirmed the contribution of TGF-β signalling to the early development of intrathymic nTregs based on the finding that 3 to 5 day-old mice with T cell-specific Tgfbr1 (TGF-β 
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receptor I) deletion have shown a significant reduction in the frequency of Foxp3+ thymocytes (Liu, et al. 2008). Tone et al. have identified a conserved Smad3-binding sequence in the Foxp3 enhancer which maintains Foxp3 expression in intrathymic nTregs. Smad3 signalling is found to be required for activating the enhancer and thereby inducing Foxp3 expression, confirming the role of TGF-β in enhancer-related activation of Foxp3 expression in intrathymic nTregs (Tone, et al. 2008). However, Schlenner et al. have confirmed that the development of intrathymic nTregs is not regulated by TGF-β based on the finding that conserved Smad3-binding sequence-deficient mice have shown normal intrathymic Tregs development identical to wild-type mice (Schlenner, et al. 2012). Zheng et al. have also supported this finding and demonstrated that conserved noncoding sequence-
1 (CNS1), which includes the conserved Smad3-binding sequence, at the Foxp3 locus is dispensable for nTregs development within the thymus (Zheng, Josefowicz, 
Chaudhry, Peng, Forbush and Rudensky 2010a). However, although TGF-β signalling is dispensable for nTregs development and lineage commitment, it is found to be required for maintaining the nTregs survival and viability within the thymus. Intrathymic nTregs have been found to  express high levels of proapoptotic molecules and undergo negative selection-induced apoptosis in TGF-βRII-deficient mice compared to wild-type mice, confirming the role of TGF-β for promoting T cell survival by antagonising thymic negative selection (Ouyang, et al. 2010). 
iNKT cells are characterised by their ability to induce both innate and adaptive immune responses, and recognise lipids presented by the MHC Class I-like molecule 
CD1d. These cells develop from CD4+CD8+ thymocytes and, like intrathymic nTregs, are induced by high-affinity interactions with agonist ligands (figure 1.8A) (Brennan, 
Brigl and Brenner 2013). The finding that TGF-βRII-deficient mice have failed to 
develop thymic and peripheral iNKT cells has indicated the requirement of TGF-β 
signalling in iNKT cells development (Li, et al. 2006, Marie, et al. 2006, Doisne, et al. 
2009). TGF-β is found to maintain iNKT cells development by suppressing the apoptosis of their precursor cells (Doisne, et al. 2009). 
CD8αα+ TCRαβ+ IELs are innate-like T cells that have an essential role in intestinal homeostasis (Cheroutre, Lambolez and Mucida 2011) (figure 1.8A). These cells are thought to be developed and differentiated within and outside the thymus and 
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induced by high-affinity TCR interactions with their agonist ligands (Pobezinsky, et 
al. 2012). The importance of TGF-β signalling in the development of these cells has confirmed by the finding that deletion of TGF-βRI has led to a significant reduction 
in the frequency of  CD8αα+ TCRαβ+ IELs population and their thymic precursors 
(Konkel, et al. 2011). 
     
  
Figure 1.8. Regulation of T-cell biology by TGF-β. (A) In the thymus, TGF-β regulates the expression of IL-7R (IL-7 receptor) that is essential for the CD8+ T cells lineage commitment. TGF-β also maintain the survival of tTregs, CD8αα+ and iNKT cells which reacts with MHC-mounted self-ligand s (agonist ligands) with high-affinity by blocking apoptotic signals directed against tTregs, CD8αα+ and iNKT cells. (B) In the periphery, TGF-β maintains homeostasis of the low-affinity CD4+ and CD8+ T cells by maintaining the expression of IL-7, whereas (C) TGF-β inhibits the proliferation of CD4+/CD8+ T cells that react with high-affinity to self-molecules. (D) TGF-β blocks the differentiation of Th1/Th2 cells, while it promotes the differentiation of other subpopulations of CD4+ T cells in a cytokine-dependent context. In the presence of IL-2 and retinoic acid, TGF-β mediates the development of peripheral (induced) Tregs from naïve CD4+ T cells. TGF-β also mediates the development of Th17 and Th9 in the presence of IL-6 and IL-4, respectively. The differentiation of TFH (T follicular helper) cells is also mediated by TGF-β in the presence of both IL-21 and IL-23 cytokines. This figure was adapted from 
(Soyoung and Ming 2013).      
43  
1.5.1.2. TGF-β in peripheral homeostasis A competent immune system must produce and preserve a diverse naïve T cell pool within the confines of a relatively constant number of peripheral T cells. TGF-β is found to play a pivotal role in the maintenance of an efficient naïve T cell population by regulating T cell homeostasis, proliferation and repertoire diversity (McKarns 
and Schwartz 2005). During T-cell priming,  TGF-β can suppress T cell proliferation by blocking transcription of the Il-2 gene and thereby suppressing IL-2 production via Smad3-mdiated signalling (McKarns, Schwartz and Kaminski 2004). However, the capability of TGF-β in regulating T cell proliferation is based on the status of T cell proliferation and the presence of other co-stimulation signalling pathways involved in cell activation. For instance, TGF-β can suppress the proliferation of naïve T cells only, while it has no effect on activated T cells which reduce expression of TGF-βRII after activation (Cottrez and Groux 2001, Sanjabi, Mosaheb and Flavell 
2009). In addition, CD28 co-stimulatory signalling is found to challenge and abrogate inhibitory effect of TGF-β on naïve T cells once being engaged with CD28. This confirms that TGF-β is unable to suppress the ability of activated APCs (antigen-presenting cells) to prime naïve T cells (Sung, Lin and Gorham 2003). T cell proliferation must be properly controlled to maintain homeostasis under steady-state conditions and during immune challenges. Deletion or absence of TGF-
β signalling affects homeostasis of both CD4+ and CD8+ T cells (Li, et al. 2006). For instance, TGF-βRII-deficient mice have shown a dramatic decrease in the peripheral T cell population. In addition to its role in CD8+ T cell lineage commitment, TGF-β is found to mediate the homeostasis of peripheral CD4+ T cells by maintaining the expression of IL-7Rα during their development in the thymus, which enables naïve peripheral CD4+ T cells to recognise IL-7 for their survival in an IL-7-dependent manner (Ouyang, et al. 2013) (figure 1.8 B). Interestingly, TGF-β is found to specifically preserve the homeostasis of naïve peripheral CD4+ T cells expressing low-affinity TCR (low-affinity CD4+ T cells) (figure 1.8 B, C). TGF-βRII-deficient mice in which T cells are engineered to express TCR with high affinity, TGF-βRII-deficient T cells with high-affinity TCR have been shown to express high levels of IL-7Rα and thereby maintaining their homeostatic survival, whereas T cells with low-affinity TCR show impaired homeostatic survival in the absence of TGF-β (Robinson and 
Gorham 2007). These findings confirm that the strength of both TGF-β and TCR 
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signalling contribute to IL-7Rα expression. Therefore, loss of TGF-β signalling can affect TCR diversity and repertoire changes of naïve peripheral T cells resulting from selective loss of low-affinity T cells (Robinson and Gorham 2007). TGF-β is also found to regulate the homeostasis of peripheral CD8+ T cells by promoting IL-7Rα expression. Impaired TGF-β signalling has resulted in altered homeostasis and 
aberrant activation of CD8+ T cells with limited TCR diversity (Johnson and Jameson 
2012) (figure 1.8 C). 
1.5.1.3. TGF-β in T cell differentiation TGF-β generally suppresses T cell activation by interfering with TCR signalling. It 
also inhibits differentiation of specific T cells including T helper 1 (Th1) and Th2 cells (Chen, et al. 2003). TGF-β suppresses differentiation of Th1 cells by inhibiting the expression of transcription factors T-bet and Stat4 and thereby inhibiting production of IFN-γ via Smad2/3 signalling pathway (Gorelik, Constant and Flavell 2002, Lin, et al. 2005, Takimoto, et al. 2010) . TGF-β also inhibits Th2 differentiation by blocking the expression of GATA-3, a lineage-defining transcription factor that mediates Th2 differentiation (Gorelik, Fields and Flavell 2000). The inhibition of GATA-3 expression is mediated by Smad-signalling pathway which results in the induction of Sox-4, a transcription factor that binds and inhibits GATA-3 (Kuwahara, 
et al. 2012) (figure 1.8 D). TGF-β can also induce IL-9- and IL-10-secreting Th9 cells in co-operation with the Notch pathway and IL-4 signalling. Although Th9 cells produce abundant levels of IL-10, they act mainly as effector cells not regulatory cells (Dardalhon, et al. 2008). TGF-β is also found to promote the differentiation of T-follicular helper (Tfh) cells. Here, TGF-β acts as a pivotal co-factor in the presence of IL-12 and IL-23 which in turn induce Tfh cells (Schmitt, et al. 2014) (figure 1.8 D). TGF-β can also regulate the differentiation of Th17 cells that are characterised by the expression of retinoic acid receptor-related orphan receptor C (RORC) in humans and retinoic acid receptor-related orphan receptor-γ t (RORγt) in mice 
(Gutcher, et al. 2011). TGF-β, in the presence of IL-6, induces the expression of  
RORγt/RORC that promotes the differentiation of Th17 in a Smad2-dependent and -independent manner (Ivanov, et al. 2006, Takimoto, et al. 2010, Martinez, et al. 
2010). In addition, TGF-β mediates Th17 differentiation by suppressing the 
45  
expression of STAT4, GATA-3, GFi-1 and Eomesodermin, thus curbing Th1- and Th2-cell differentiation (Das, et al. 2009, Ichiyama, et al. 2011, Zhu, et al. 2009) . Therefore, TGF-β enhances the differentiation of Th17 cells both directly and indirectly by blocking T-cell differentiation into other cell lineages. It is well-known 
that Th17 are highly plastic cells which function paradoxically as immunoregulatory or inflammatory cells based on cumulative signalling pathways mediated by different cytokines within the local microenvironment (Sharma, Kaveri and Bayry 
2013). The presence of TGF-β within the local milieu affects the cellular decision of 
Th17 to act as immunoregulatory or inflammatory. The absence of TGF- β, but in the presence of IL-6, IL-1β and IL-23 induces differentiation of Th17 (Ghoreschi, et al. 
2010), whereas the presence of TGF-β, IL-6 and IL-1β mediates the induction of 
regulatory Th17 (McGeachy, et al. 2007) (figure 1.8D), therefore suggesting its strong role in the developing regulatory T cells. 
Differentiation of Th17 cells can be interfered with by the differentiation of peripheral or induced Tregs based on the concentration of TGF-β in the local microenvironment. At low concentrations, TGF-β can cooperate with IL-6 and IL-21 to induce the expression of IL-23 receptor, thus promoting the differentiation of 
regulatory Th17 cells. However, at high concentrations, TGF-β inhibits the expression of IL-23 receptor and induces iTregs or pTregs differentiation 
(Knochelmann, et al. 2018, Sanjabi, Oh and Li 2017). The divergent effects of TGF-β 
on pTregs versus Th17 cell-fate indicate the context-dependent function of this versatile cytokine. Beside of nTregs that are generated in the thymus, naïve T cells can gain Foxp3 expression and differentiate into induced Tregs  (iTregs) cells in peripheral tissue (Abul 2003). Peripherally induced Tregs constitute 20-40% of the fully-mature Treg-cell pool in naïve steady-state mice and act in a cooperation with nTregs to maintain immune tolerance (Petzold, et al. 2014). Activated CD4+CD25- or CD4+Foxp3- T cells can be converted into CD4+CD25+Foxp3+ iTregs in vitro in the presence of TGF-β which maintain their immunosuppressive activities (Huber and Schramm 2006). The induction of Foxp3 expression in iTregs is mediated by Smad3 which can be recruited to bind to the conserved Smad3-binding sequence in the 
Foxp3 enhancer CNS1 region which activates the induction of Foxp3 expression 
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(Tone, et al. 2008). In addition to TGF-β, other factors are found to essential for the induction of iTregs, including TCR activation-derived signals and the presence of IL-2. IL-2 is found to stimulate the transcription factor STAT5 which binds to the Foxp3 promoter, thus inducing Foxp3 expression (Burchill, et al. 2007). Suboptimal TCR 
signals with decreased CD28 signalling can also promote Foxp3 induction and iTregs generation in the presence of IL-2 and TGF-β (Josefowicz, Lu and Rudensky 
2012). iTregs can also be developed in the gut-associated lymphoid tissue (GALT). GALT-
related CD103+ DCs are found enriched at the mucosal site and implicated in the generation of iTregs there (Kushwah and Hu 2011). CD103+ DCs mediate the 
recruitment of T cells to the gut by inducing the expression of α4β integrin and CCR9 (homing receptors) on T cells (Del Rio, et al. 2010). In addition, CD103+ DCs are found to expressed high levels of retinal dehydrogenase which is an enzyme that 
converts vitamin A into retinoic acid (RA). RA is redundantly required for CD103+ DCs to upregulate gut-homing receptors on T cell (Iwata, et al. 2004). CD103+ DCs 
are found to preferentially express αvβ8 integrin which support their ability to activate TGF-β, thus promoting induction of iTregs (Boucard-Jourdin, et al. 2016). 
The generation of iTregs by DC103+ DCs is found to be mediated by RA and TGF-β-dependent manners (Coombes, et al. 2007). Moreover, CD103+ DCs are also found to express TGF-βR1 which has a pivotal, cell-intrinsic role in the development of these cells, suggesting that 103+ DCs may require TGF-β to maintain their maturation and in turn mediate the induction of iTregs (Bain, et al. 2017). 
1.5.1.4. TGF-β in T cell tolerance The immune system has two main mechanisms to prevent autoimmunity. Central tolerance is an essential process in which self-reactive T cells are carefully removed in the thymus. Peripheral tolerance is developed to monitor autoreactive T cells that have escaped central tolerance and released to the periphery (Mueller 2010, Hogquist, Baldwin and Jameson 2005). The fatal inflammatory disorders that have occurred in mice with deficiency or total loss of  TGF-β signalling reflect the crucial role of TGF-β in immune tolerance (Marie, et al. 2006, Li, et al. 2006). Loss of tolerance that emerges in the absence of TGF-β is not only caused by impaired activity of Tregs as the adoptive transfer of Tregs to TGF-β-deficient mice fails to 
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completely manage inflammatory disorder (Marie, et al. 2006). These findings indicate that peripheral tolerance is regulated directly and indirectly by TGF-β signalling. TGF-β can directly regulate peripheral tolerance by maintaining homeostatic survival of low-affinity CD4+ T cells which maintain a unique regulatory population of CD4+ T cells, called “deletor” T cells. These deletor cells control TCR repertoire and diversity of T cells and restrict the frequency of antigen-specific T cells that are highly reactive to the same antigen in the peripheral T cell pool (Singh, Bando and Schwartz 2012). Loss of TGF-β signalling in the developing T cells may contribute to establishment a lymphopenic environment which lacks low-affinity T cells and is preferentially enriched with high-affinity autoreactive T cells in humans 
(Singh, et al. 2012). TGF-β is also found to curb tissue damage by converting pathogenic, autoreactive CD4+ T cells to a non-pathogenic phenotype (Reis, et al. 
2013). In a transgenic diabetes mouse model,  the absence of TGF-β signalling leads to activation of pathogenic CD4+ T cells that promote disease progression by destroying pancreatic islets by autoreactive CD4+ T cells (Ishigame, et al. 2013). TGF-β can also control peripheral tolerance in an indirect way by promoting the development of peripheral iTregs that inhibit activation and proliferation of highly-autoreactive T cells thereby preventing the development of autoimmune diseases 
(Oh and Li 2013). The role of TGF-β in the generation of iTregs in peripheral tissues 
has been mentioned in the previous section (1.6.1.3).  
1.5.2. TGF-β in cancer  TGF-β, as a pleiotropic cytokine, is found to have two conflicting roles in cancer development and progression. In initial stages of cancer, TGF-β serves as a tumour suppressor by promoting inhibition of cell proliferation and induction of apoptosis. However, in advanced stages of cancer, TGF-β acts as a tumour promoter which enhances cell motility, invasion, metastasis and maintenance of cancer stem cells. This opposite switch in the function of TGF-β is defined as “TGF-β paradox” (Wendt, 
Tian and Schiemann 2012).         TGF-β-mediated growth inhibition is mediated by the suppression of cyclin-
dependent kinases (CDKs) and the down-regulation of MYC. TGF-β exerts its 
inhibitory activity during the G1 phase of cell cycle where TGF-β inhibits the 
activation of several CDKs including cyclin D-CDK4, cyclin D-CDK6, cyclin E-CDK2 
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and A-CDK2 via several mechanisms which results in dephosphorylation of retinoblastoma protein (pRb) and thereby cell cycle arrest (Zhang, Alexander and 
Wang 2017). Inhibition of the MYC gene by TGF-β is mediated via Smad3/Smad4 signalling pathway in which Smads complex is recruited to the nucleus to bind to a transcriptional inhibitory element on the MYC promoter and thus curb MYC expression. TGF-β can also induce cell apoptosis by promoting expression of several pro-apoptotic genes via Smad-dependent pathway. These genes include the TGF-β-inducible early-response gene (TIEG1), the death-associated protein kinase and the SH2 domain-containing inositol-5-phosphatase (Drabsch and Ten Dijke 2012). This antimitogenic capacity of TGF-β is usually overwhelmed by the potent mitogenic cancer cells that can mutate both TGF-β receptors and Smads thereby switching the role of TGF-β to enhance cell growth, motility and invasion. This mis-regulation of TGF-β signalling contribute to the cancer progression and metastasis 
(Massagué 2008). Biallelic inactivation of TGF-βRII by mutations is found in many types of cancer including colon, gastric, biliary, ovarian, oesophageal and head and neck cancer (Levy and Hill 2006). TGF-βRII mutations are also highly associated with microsatellite instability and promote cancer progression through altered TGF-
β signalling pathway (Levy and Hill 2006). TGF-βRI is also found mutated in ovarian and head and neck cancers (Chen, et al. 2001b, Chen, et al. 2001a) . In addition to mutation in the coding region of TGF-βRII and TGF-βRI, loss of expression of both receptors is also another type of TGF-β signalling alterations found frequently in cancer. Loss of expression of TGF-βRII is frequently detected and associated with poor prognosis in non-small cell lung carcinomas (NSCLCs), bladder cancers, head and neck squamous cell carcinomas (HNSCC), ovarian carcinomas, oesophageal carcinomas,  prostate and breast cancers (Malkoski, et al. 2012, J. Bian, et al. 2013, 
Weber, et al. 2008, Roane, Arend and Birrer 2019, Fukai, et al. 2003, Tu, et al. 2003, 
Busch, et al. 2015). Although mutations in TGF-βRI are somewhat rare, loss of expression of TGF-βRI is more frequently found (Levy and Hill 2006). It is very commonly identified in HNSCC and bladder carcinomas (Fukai, et al. 2003, 
Tokunaga, et al. 1999).                         Smad proteins, as key components of TGF-β signalling pathway, have been found mutated within certain cancers. Smad2 protein is found mutated at very low 
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frequency in 8% of cervical cancers, 8% in colorectal cancer, 3% in hepatocellular carcinoma (HCC) and 2% in NSCLC. Loss of Smad2 expression contribute to the 
delay in P15 upregulation and failure to inhibit c-MYC by TGF-β, thereby promoting tumour-cell growth (Samanta and Datta 2012). Loss of the expression of Smad3 is also found in some of gastric cancers and is associated with increased tumorigenesis. In choriocarcinoma, a subtype of uterine cancers, loss of Smad3 expression is found to be correlated with down-regulation of TIMP-1 (tissue inhibitor of metalloprotease-1 and thus promotes the activity of matrix metalloproteinases for supporting tumour invasion (Xu, Chakraborty and Lala 2003). Loss of Smad4 expression is also found and correlated with metastasis and poor prognosis in certain cancers including breast (Liu, et al. 2015), pancreas (Shugang, et al. 2016), colon(Yan, et al. 2016) and lung (Bian, et al. 2015).  TGF-β is found to mediate tumour progression by a process called epithelial-mesenchymal transition (EMT) in which tumour cells lose epithelial phenotype and acquire mesenchymal phenotype thereby promoting their migratory and invasive properties. This dynamic process is normally occurred during embryonic development, wound healing, tissue regeneration and fibrosis (Moustakas and de 
Herreros 2017). However, EMT is exploited by tumour cells to maintain cancer progression and metastasis. The essential features of EMT include interruption of cell-cell adhesion and cellular polarity, remodelling of the cytoskeleton and defects in cell-matrix adhesion (Guarino, Rubino and Ballabio 2007). TGF- β signalling is found to downregulate the expression of epithelial markers; E-cadherin, zona occludins-1 (ZO1), B4-integrin, α- and γ-catenin that maintain architecture of epithelial tissues. Whereas, upregulation of mesenchymal markers; vimentin, fibronectin, N-cadherin, smooth-muscle actin and Twist, is enhanced in response to TGF-β signalling to mediate tumour cell survival, migration and invasion (Drabsch 
and Ten Dijke 2012).                 
1.6. TGF-β enriched tumours  Overexpression of TGF-β and increased its plasma level has been correlated with advance tumour progression and metastasis in certain types of cancer.  
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In breast cancer, increased TGF-β1 serum levels in the blood of patients  have been  correlated with advanced stages of the disease (Sheen-Chen, et al. 2001). Also, TGF-
β1 is found to be highly expressed in breast cancer tissues and is corelated with poor prognosis and shorter disease-free survival (Desruisseau, et al. 2006). In addition, high expression of TGF-β1 in breast tumours has been associated with increased lymph node metastasis (De Kruijf, et al. 2012). In triple negative breast cancer (TNBC), which is the most aggressive subtype of breast cancer, high expression of TGF-β1 is found to be significantly correlated with advanced tumour histological grade, axillary lymph node metastasis and shorter 5-year disease-free survival rate 
(Ding, et al. 2016).  In colorectal cancer, the expression of TGF-β1 is found to be higher in both tissue and plasma of patients with metastatic disease compared to those with non-metastatic disease. Even in patients with non-metastatic colorectal cancer, the expression of TGF-β1is found significantly correlated with lymph node involvement 
(Langenskiöld, et al. 2008). Xiong et al. have also found that patients with stage 3 and 4 of metastatic colorectal cancer show higher serum levels of TGF-β1 than those 
with stage 1 and 2 of non-metastatic tumours (Xiong, et al. 2002). In prostate cancer, Reis et al. have found that TGF-β1 is highly overexpressed in 33% of prostate tumour tissues and is correlated with poor prognosis, confirming the importance role of TGF-β1 as a prognostic biomarker for prostate cancer (Reis, et al. 
2011). Wu et al. have also found that elevated TGF-β1 expression is found highly correlated with aggressive advanced stages of prostate cancer and with accumulation of Tregs within tumour tissues (Wu, et al. 2015). The same author has also found that increased expression of TGF-β1 is significantly correlated with tumour-cell resistance to radiation therapy in patients with prostate cancer (Wu, et al. 2015). In pancreatic cancer, Zhao et al. have demonstrated that high serum levels of TGF-
β1 are dramatically correlated with reduced survival rate, advanced stages of disease and lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC) (Zhao, et al. 2016). Park et al. have found that serum level of TGF-β1 could be used as prognostic biomarkers at the diagnosis of unresectable pancreatic cancer patients. The authors have demonstrated that patients with high 
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serum levels of soluble TGF-β at the time of diagnosis have shown shorter overall survival rate compared to patients having low serum levels of TGF-β1 at the time of diagnosis (Park, et al. 2018). Javle et al. have also supported these findings. The authors have found that high expression of TGF-β1 in PDAC tumour tissues and high serum levels of TGF-β1 are significantly correlated with reduced overall survival rate in patients with advanced PDAC (Javle, et al. 2014). In lung cancer, Li et al. have confirmed that high expression of TGF-β correlates positively with worse prognosis in patients with lung cancer (Li, et al. 2019). Luo et al. have found that lung cancer patients who have high serum levels of TGF-β1 following radiotherapy show unresponsive progressive disease than those with low levels of TGF-β1. The authors have also found that high serum levels of TGF-β1 are significantly correlated with CD4+ T cells and CD8+ T cells percentages, suggesting the impact of TGF-β1 on circulating T cells for promoting disease progression (Luo, 
et al. 2018). Kim et al. have also found that high serum levels of VEGF, IL-1β and TGF-
β1 in patients with advanced non-small cell lung carcinoma are significantly correlated with shorter overall survival rate. The authors also found that high serum levels of these cytokines are significantly correlated with increased number of leukocytes (Kim, et al. 2013). Moreover, Xie et al. have demonstrated that tumours with positive expression of TGF-β1 have been correlated with late stages, lymph node involvement and reduced overall survival rate in patients with lung adenocarcinoma (Xie, He and Wei 2015). 
In hepatocellular carcinoma (HCC), Kohla et al. have found that increased serum levels of TGF-β1 are associated with disease aggressiveness and shorter overall survival rate in patients with HCC (Kohla, et al. 2016). Lin et al. have also found that elevated serum levels of TGF-β1 are significantly correlated with advanced stage of disease and reduced progression-free survival and overall survival rates in patients with HCC. The high levels of TGF-β1 are also found associated with increased resistance to sorafenib, a multikinase inhibitor (Lin, et al. 2015). An et al. have also confirmed that high serum levels of TGF-β are significantly correlated with high percentage of TGF-β-expressing Tregs in the blood of patients with HCC, and both TGF-β serum levels and TGF-β-expressing Tregs percentage are correlate with  reduced 5-year overall survival rate (An, et al. 2018). 
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In oesophageal cancer, Von Rahden et al. have found that TGF-β1 is found significantly overexpressed in tissues derived from patients with primary oesophageal adenocarcinoma and its overexpression is significantly associated with advanced stages of disease, poor prognosis and low cumulative survival rate (von Rahden, et al. 2006). Sun et al. have also noticed that  elevated serum levels of TGF-
β1 in patients with oesophageal carcinoma following radiotherapy are significantly correlated with advanced unresponsive disease and very shorter overall survival, compared to patients who have low serum levels of TGF-β1 (Sun, et al. 2007). According to the results of studies discussed above, it seems that the expression of TGF-β1 could be used as a prognostic and predictive biomarker for cancers in which TGF-β1 is significantly enriched within tumour tissue or in the peripheral blood. In addition, some of studies have shown that the expression of TGF-β1 is significantly correlated with increased percentage of Tregs in the blood of patients, confirming the clinical importance of this correlation as prognostic biomarkers for TGF-β1-enriched cancers. The clinical importance of Tregs in cancer will be discussed in the next section.              
1.7. The clinical importance of Tregs in cancer In cancer, immunosuppressive T regulatory cells (Tregs) are found to inhibit immune responses directed against tumour cells and promote immune evasion and cancer progression (Elkord, et al. 2010). Many studies have confirmed that tumour-infiltrating Tregs are associated with a worse prognosis in various types of cancer, including breast cancer, ovarian cancer, lung cancer, hepatocellular carcinoma, glioblastoma, pancreatic ductal adenocarcinoma, renal carcinoma, non-Hodgkin’s lymphomas, melanoma and other malignancies (Zhang, et al. 2017, Curiel, et al. 2004, 
Tao, et al. 2012, Sun, et al. 2017, Sayour, et al. 2015, Tang, et al. 2014, Yang, et al. 
2014, Yang, et al. 2006, Li, et al. 2010, Gerber, et al. 2014, Shang, et al. 2015a). In breast cancer, Merlo et al. have found that increased Foxp3 expression within tumour microenvironment is significantly associated with poor overall survival rate. The authors have also found that Foxp3-positive tumours is significantly associated with lymph node metastasis, distant relapse and shorter distant-metastasis (DM) free survival rate (Merlo, et al. 2009). Sun et al. have confirmed that increased frequency of Foxp3+ Tregs and PD-1+ immune cells in breast cancer patients is 
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significantly correlated with reduced survival rate (Sun, et al. 2014). Kim et al. have also found that increased frequency of  Foxp3+ Tregs within the tumour stroma derived from breast cancer patients is significantly correlated with decreased 
infiltration of CD8+ T cells and reduced 5-year disease free survival rate (Kim, et al. 
2014). Zhou et al. have also found that high Foxp3+ Tregs infiltration with the tumour microenvironment is correlated with high histological grade, HER2+ tumours and reduced recurrence-free survival rate in breast cancer patients (Zhou, et al. 2017). Li et al. have also found that high expression of PD-L1 is significantly correlated tumour-infiltrating Foxp3+ Tregs and both are correlated with reduced overall and recurrence-free survival rates in patients with breast cancer (Li, et al. 
2010).  In lung cancer, Liu et al. have demonstrated that Tregs are significantly enriched in the blood of patients with NSCLC at first relapse following radiotherapy. The authors have also found that the accumulation of Tregs in the peripheral blood is significantly correlated with reduced progression-free survival rate (Liu, et al. 
2017b). Tao et al. have also demonstrated that increased tumour-infiltrating Tregs within the tumour tissue derived from patients with NSCLC is significantly associated with shorter overall and relapse-free survival rate (Tao, et al. 2012). 
Kotsakis et al. have also confirmed that the frequency of circulating Tregs is significantly elevated in the peripheral blood derived from untreated NSCLC patients compared to healthy individual. Increased circulating Tregs is found significantly correlated with reduced progression-free and overall survival rate 
(Kotsakis, et al. 2016). Hanagiri et al. have also found that increased proportions of Tregs in the regional lymph node lymphocytes in patients with NSCLC following surgery is significantly correlated with lymph node metastasis and shorter overall survival rate (Hanagiri, et al. 2013). In ovarian cancer, Sato et al. have demonstrated that high Tregs frequency relative to total T cells or CD8+ T cells is significantly associated with reduced overall survival rate in patients with ovarian compared to low Tregs frequency group of patients (Sato, et al. 2005). Curiel et al. have also found that enrichment of tumour-infiltrating Tregs is correlated with advanced stages of ovarian cancer. Increased infiltration of Tregs within the tumour tissue is also significantly correlated with 
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reduced overall survival rate in patients with ovarian cancer from stage 1 to 4. In addition, patients with ovarian cancer stage 4 have shown more significant reduction in the overall survival rate than those at stages 1 to 3, confirming the role of Tregs in the progression of ovarian cancer (Curiel, et al. 2004). In pancreatic cancer, Hwang et al. have found that increased frequency of  tumour-infiltrating Foxp3+ Tregs within the microenvironment is significantly correlated 
with low frequency of granzyme B+ CD8 T cells and reduced overall survival rate in patients with PDAC (Pancreatic ductal adenocarcinoma) following distal pancreatectomy (Hwang, et al. 2016). Liu et al. have also confirmed that elevated percentages of circulating Tregs in the peripheral blood of patients with unresectable PDAC prior to chemotherapy is significantly correlated with reduced overall survival rate. The author have also found that high percentage of circulating Tregs following chemotherapy treatment is significantly correlated with decreased 
ratio of circulating CD8+ T cells and reduced overall survival rate in patients with unresectable PDAC (Liu, et al. 2017a). Tang et al. have also demonstrated that Foxp3+ Tregs are significantly enriched in the juxtatumoural stroma immediately beside tumour epithelial cells in patients with PDAC and their enrichment is 
significantly correlated with reduced frequency of CD8+ T cells and reduced overall rate. The enrichment of Foxp3+ Tregs in the tumour stroma is also found highly correlated with undifferentiated tumour cells and high histological grades (Tang, et 
al. 2014). In hepatocellular carcinoma (HCC), Sun et al. have performed a comprehensive meta-analysis on 3854 patients with HCC collected from 27 cohort studies. The authors have found that high frequency of Foxp3+ Tregs in the tumour tissues and peripheral blood derived from HCC patients is significantly correlated with advanced disease stages, high histological grades with poorly undifferentiated tumour cells and reduced overall and disease-free survival rate (Sun, et al. 2017). In gastric cancer, similar findings have been found by Lee et al. The authors have confirmed that elevated expression of Foxp3+ Tregs is significantly correlated with 
poor prognosis and reduced overall survival rate in 2941 patients with gastric cancer (Zheng, et al. 2017).  
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In brain cancer, Yue et al. have demonstrated that elevated infiltration of Foxp3+ Tregs within the tumour tissue derived from patients with glioblastoma (GBM) is significantly corelated with reduced overall and progression-free survival rat, compared to patients with low Tregs infiltration (Yue, et al. 2014). Taken together, the presence and infiltration of Foxp3+ Tregs within the tumour microenvironment contributes to the tumour progression and poor prognosis in the most common types of cancer as mentioned above. Therefore, inhibiting their role within tumour milieu will improve the treatment outcomes of cancer therapy, especially cancer immunotherapy (Shitara and Nishikawa 2018).      Several approaches have been followed for targeting tumour-infiltrating Tregs which represent a major obstacle for effective anti-tumour immunotherapy. These approaches including: (1) nonspecific depletion or modulation of Tregs using conventional anticancer drugs such as cyclophosphamide, sunitinib, sorafenib and imatinib (Galluzzi, et al. 2012, Ge, et al. 2012, Adotevi, et al. 2010, Desar, et al. 2011),  
(2) specific depletion of Tregs using Daclizumab (anti-CD25 monoclonal antibody) and Denileukin Diftitox which is an engineered protein combining IL-2 and Diphtheria toxin (Rech, et al. 2012, Attia, et al. 2005), (3) targeting mechanisms 
mediating Tregs recruitment into tumours using Mogamulizumab ( anti-CCR4 monoclonal antibody) (Kurose, et al. 2015), (4) depletion of Tregs using checkpoint inhibitors such as Ipilimumab (anti-CTLA-4 monoclonal antibody) and Nivolumab (anti-PD-1 monoclonal antibody) (Hellmann, et al. 2018, Larkin, et al. 2015). However, these therapies are designed to deplete Tregs systemically and have found to induce severe autoimmune problems (Bakacs, Mehrishi and Moss 2012, Kurose, 
et al. 2015, Larkin, et al. 2015). Therefore, therapeutic agents that can selectively deplete tumour-infiltrating Tregs are still required. However, developing such agents requires an in-depth understanding of the difference between tumour-infiltrating Tregs and other circulating Tregs at normal tissue sites, in addition to identification additional markers that can selectively distinguish tumour-infiltrating Tregs from other circulating Tregs (Liu, Workman and Vignali 2016a, Togashi, 
Shitara and Nishikawa 2019).  The origin of tumour-infiltrating Tregs is still controversial. Studies have found that most of Tregs within tumour are induced Tregs (iTregs) developed from naïve CD4+ 
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T cells in the presence of tumour-drived TGF-β and other co-stimulatory cytokines secreted by DCs and tumour-infiltrating macrophages (Valzasina, et al. 2006, Liu, et 
al. 2007, Ghiringhelli, et al. 2005). Other studies have reported that natural Tregs (nTregs) are also enriched within the tumour nest and contribute to tumour immunosuppressive. Moreover, several studies have assessed the crucial role of chemokines receptors in the recruitment of both naïve CD4+ T cells and circulating Tregs into the tumour microenvironment (Gobert, et al. 2009, Mizukami, et al. 2008, 
Facciabene, et al. 2011). However, it is difficult to identify the origin of tumour-infiltrating Tregs without finding a distinct biomarker that can discriminate iTregs from nTregs since both subsets rise from CD4+ T cells and share many features.     
1.8. Aims and objectives The main aim of this study is to identify cell surface biomarkers that can differentiate phenotypic features of peripherally-induced Tregs (iTregs) from thymic-drived natural Tregs (nTregs) in the blood and tissue of cancer patients. The identification of such biomarkers will enable us to further delineate the origin of tumour-infiltrating Tregs and circulating Tregs in the tissue and blood of cancer patients, respectively by understanding their biology in detail. This will also facilitate development of therapeutic agents that can selectively target iTregs without inhibiting the function of nTregs, thereby enhancing the efficacy of immunotherapy in combination with other conventional anti-cancer therapies for better treatment outcomes and minimising the chance of development autoimmune diseases. Identification of such biomarkers will also help to predict the prognosis of cancer patients at the time of diagnosis based on their immunological profiling.  To achieve the main aim, objectives are as follows: 
1- Establishment of mice model for generating CD4+CD25+Foxp3+ induced Tregs from purely sorted naïve CD4+CD25- T cells in the presence and absence of tumour cells in vitro. 2- Isolation of a pure population of naïve natural Tregs, in vitro-induced Tregs, naïve CD4+CD25- T cells using cell sorting. 
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3- Optimisation of a quantitative proteomics approach to profile iTregs and nTregs populations 4- Verification and validation of any discovered biomarker/s.   The reasons of establishing a mice model instead of human model are that; first, establishing a successful mice model will help in validating the discovered biomarkers pre-clinically and will be required as a routine step of any clinical trial for biomarker validation. Second, based on the main aim of this project, finding healthy individuals living in a pathogen-free environment and who have not exposed to any infection during their lives is impossible. Therefore, isolation and sorting Tregs from healthy donors’ blood based on the expression of CD25 and Foxp3 will not give a clue whether the sorted Tregs are natural or induced Tregs. Thus, studying phenotypic features and discrepancies between nTregs and iTregs will be very difficult.     
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Chapter 2.    
Development of an in vitro murine model to study 
induced T regulatory cells 
2.1. Introduction 
The most critical trait of immune system is the ability of maintaining homeostasis in the periphery. Based on this feature, immune system prevents the development of autoimmunity. Regulatory T cells (Tregs) are specialised subsets of CD4+ T cells and function to maintain immune homeostasis and tolerance in the periphery. Tregs can be divided into two main subpopulations: thymic-derived natural Tregs (nTregs) and peripherally-derived Tregs or induced Tregs (p/i Tregs). nTregs are developed within the thymus during medullary thymic selection and function to maintain immune tolerance against auto-antigens, thus preventing autoimmunity. Induced or peripheral Tregs are developed in the peripheral tissues, mainly the intestine, to maintain immune tolerance against innocuous antigens expressed by commensal microflora. The early process of the development of both nTregs and p/i Tregs that occurs in the thymus where all T-cell populations develop and mature will be discussed in the introduction of this chapter.       
2.1.1. Thymopoiesis Thymopoiesis is defined as the process by which thymocytes differentiate into mature T-lymphocytes in the thymus. It is a highly regulated process which involves migration of the earliest T-lineage progenitors (ETPs) from bone marrow niches to the thymus where further development and differentiation of mature T cells occurs 
(Schwarz and Bhandoola 2006). The thymus is a specialised lymphoepithelial organ and consists of  two main compartments: the cortex and the medulla, each of which contains particular populations of thymic epithelial cells, dendritic cells and endothelial cells, thus furnishing an exceptional microenvironment for the optimal production of a diverse T cell repertoire (Gordon and Manley 2011). The origin of the ETPs settled in the thymus is thought to be unknown. However, to be qualified as a T-lineage progenitor, a bone marrow progenitor must achieve two 
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key requirements. First, it must show the ability to effectively generate T cells in the thymus. Second, it must have the potential to migrate from the bone marrow to the thymus (Witt and Robey 2005). Several bone marrow progenitors are found to have the potential of T-lineage progenitors, including pluripotent self-renewing haematopoietic stem cells (HSCs), committed myeloid-lymphoid progenitors (MLPs) that lack the potential for erythroid and megakaryocyte lineage, and common committed lymphoid progenitors (CLPs) (Wu 2006). Although the definite identity of the bone marrow cell precursors that generate T cells is still debated, the origin of the ETPs has been proposed to be derived from HSCs that can self-
differentiate into LSK progenitors that show a phenotype Lineagenegative Sca-1hi c-
Kithi (LSK) (figure 2.1). The LSK progenitors have the potential to differentiate into two main subpopulations; CD62L+ IL-7Rα- LSK progenitors and CD62L- IL-7Rα- LSK progenitors that are also called early lymphoid progenitors (ELPs) (Wu 2006). The CD62L+ LSK and  ELP progenitors are thought to be released from the bone marrow into the bloodstream where they may migrate to thymus via the expression of CD62L (L-selectin) which is function as a cell adhesion molecule (Wu 2006). The migration of ELPs to the thymus is through to be via the expression of P-selectin, however this is still enigmatic. In the thymus, CD62L+ LSK progenitors undergo further differentiation to become ETPs which is mediated by Notch-1 signalling (Wu 2006) (figure 2.1). 
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2.1.2. Ontogeny of T cells After arriving the thymus, T-cell precursors (ETPs) face Notch-1 ligands that are amply expressed by the thymic epithelium. Notch-1 signalling is considered as a key mediator of T cell-lineage commitment and regulates the early decision between whether to become a T or B lymphocytes (Deftos and Bevan 2000). After interaction with with Notch-1 ligands, T-cell precursors migrate to the outer thymic cortex where they start to develop their T-cell receptors. The primitive T cell precursors 
lack the expression of CD4 and CD8 and therefore recognised as double negative 
(DN) cells. These DN cells can be further classified into four subsets, DN1 – DN4, based on certain cell surface antigens including c-Kit (CD117), CD44 and CD25 (Germain 2002). T-cell precursors at the stage DN1 of development show 
phenotypic features of CD117++CD44+CD25- on their surface, and then after being cross-linked with Notch-1 ligands for T-cell lineage commitment, they travel to the cortex where they acquire the expression of CD25, becoming DN2 thymocytes 
(CD117++CD44+CD25+). At this critical stage of development, the rearrangement for 
genes of the T cell receptors β, γ, and δ occur. At the end of DN2 stage, thymocytes or T cell precursors are entirely committed to the T-cell lineage (Wu 2006). During 
DN3 stage, thymocytes begin to reduce their expression of CD117 and CD44 and can 
Figure 2.1. A proposed representation for initial stages of early T cell progenitors (ETPs) development from the bone marrow to the thymus. HSC: haematopoietic stem cell, LSK: Lineage Sca-1 c-Kit phenotype, ELP: early lymphoid progenitor, ETP: early T-lineage progenitor, DN: double negative. This figure is modified from (Wu 2006). 
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be identified as (CD117+/-CD44-CD25+) thymocytes. DN3 cells then progress to develop their TCR-γ, -δ, and –β chains, and have the potential to make the first critical decision in T-cell development to become TCR- γδ or TCR-αβ T-cell lineage 
via a process called β-selection (Germain 2002). This process includes a glycoprotein called the pre-Tα chain that is specifically expressed at this stage. The pre-Tα plays as a surrogate for the actual TCR-α which has not been rearranged yet and binds to the successfully rearranged β chains and CD3 complex. This Immature 
TCR/CD3 complex is called the pre-T cell receptor (pre-TCR) (Spits 2002). At DN4 stage, DN4 thymocytes that have successfully developed their pre-TCR begin to lose the expression of CD25 and CD117 to become CD117-/lowCD44-CD25- thymocytes and mature directly to CD4+CD8+ double positive (DP) thymocytes after completing TCR-α chain locus rearrangement. CD4+CD8+ DP thymocytes express mature TCR-
αβ on their cell surface (Harrington 2019). 
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2.1.3. Thymic selection of the T-cell repertoire The random rearrangement of TCRs genomic loci during thymocytes development leads to generate a diverse TCR repertoire with different recognition specificities in the newly developed CD4+CD8+ DP thymocytes. At this stage, unlike mature CD4+ 
and CD8+, the DP thymocytes lack a well-programmed affinity for foreign antigen 
Figure 2.2. Schematic representation showing developmental stages of T cells in the murine thymic outer cortex. Upon arrival the thymus, ETPs migrate to the outer cortex where they 
differentiate into DN1 thymocytes (c-Kit+CD44+) that lack the expression of CD4 and CD8. DN1 thymocytes acquire CD25 expression during their development to become DN2 (c-
Kit+CD44+CD25+). During DN2 developmental stage, the rearrangement for genes of the T cell 
receptors β, γ, and δ occur. At DN3 stage, DN3 thymocytes lose the expression of c-Kit and CD44 and develop their TCR-β, -γ, and -δ. DN3 thymocytes undergo β-selection process by which they give rise to either γδ T cell or αβ T cell lineage. At DN4 stage, DN4 thymocytes develop expression of pre-αβ TCR  and mature to CD4+CD8+ DP thymocytes after losing the expression of CD25. ETP: early T-lineage progenitor, DN: double negative, DP: double positive. This figure is modified from    (Germain 2002). 
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plus a self-MHC (major histocompatibility complex) molecule; in theory they should have the potential to recognise soluble antigens either foreign or self, self-MHC molecules or antigen bound with a non-self MHC molecule (Singer, Adoro and Park 
2008). However, to be qualified as a mature functional T cell, the T cell must recognise only foreign antigen attached with self-MHC molecules before leaving the thymus to peripheral tissues. To reach this level, DP thymocytes undergo two selection processes: positive selection that ensures MHC restriction, and negative selection that confirms self-tolerance (Starr, Jameson and Hogquist 2003) (figure 2.3). Positive selection is for DP thymocytes expressing receptors that can bind self-MHC molecules either class I or class II which are expressed by cortical thymic epithelial cells (cTECs). Cells that do not interact with MHC molecules will die by apoptosis (Takahama 2006). Then, positively selected thymocytes travel to the thymic medulla where they encounter with a variety of antigen-presenting cells including haematopoietic dendritic cells (DCs) and medullary thymic epithelial cells (mTECs). mTECs are found to produce a wide range of self-proteins, tissue specific self-molecules and display the majority of self-antigens, providing the thymocytes a test environment for negative selection (figure 2.3). Negative selection is a process of elimination thymocytes expressing receptors with high-affinity for self-MHC molecules or self-antigen presented by self-MHC (Klein, et al. 2014b, Sprent and 
Kishimoto 2002). The successful thymocytes that pass the negative selection will then leave the medulla as self-tolerant, mature naïve CD4+ and CD8+ T cells to the periphery (figure 2.3). A small subpopulation of thymocytes with high-affinity for self-MHC can survive the elimination of negative selection and are destined to become T regulatory cells (Tregs) (Sakaguchi, et al. 2008).      
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Figure 2.3. Schematic representation showing positive and negative thymic selection of the T-cell repertoire. After maturation, DP thymocytes migrate to the thymic inner cortex where they undergo positive selection that ensures MHC restriction. During this selection, DP thymocytes are exposed to self-MHC molecules expressed by cTECs. DP thymocytes that recognise self-MHC class II pass the selection to become CD4-commited DP thymocytes, whereas those recongise self-MHC class I 
become CD8-committed DP thymocytes. DP thymocytes that do not recognise self-MHC molecules are eliminated by apoptosis. Positively-selected CD4-commited and CD8-commited DP thymocytes migrate to the thymic medulla where they undergo negative selection that ensures self-tolerance. During this selection, both CD4-commited and CD8-commited DP thymocytes are exposed to self-MHC molecules attached with self-antigens that are expressed by mTEC and H-DC. CD4-commited DP thymocytes that recognise self-MHC class II with high affinity are eliminated by apoptosis, whereas those recognise self-MHC class II with low affinity are selected to become mature CD4+ T 
cells. CD8-commited DP thymocytes that interact with self-MHC class I with low affinity are selected 
to become mature CD8+ T cells, while those interact with high affinity are eliminated by apoptosis. Both mature CD4+ and CD8+ T cells are then released into the periphery. cTEC: cortical thymic epithelial cell, DP: double positive, mTEC: medullary thymic epithelial cell, H-DC: Haematopoietic dendritic cell, MHC: major histocompatibility complex. This graph is modified from (Germain 2002).   
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2.1.4. The role of thymic medulla microenvironment in Thymic 
tolerance  
The negative selection imposed by the thymic medulla ensures that αβ-T cells leaving the thymus can recognise the self-MHC proteins and are tolerant to self -antigens simultaneously. The specialised mTECs and DCs, by expressing most of self-antigens enforce CD4+ and CD8+ single-positive (SP) thymocytes to undergo negative selection if they show high-affinity recognition for self-antigens. Thus, this clonal deletion is programmed to eliminate most of the self-reactive thymocytes 
(Klein, et al. 2014b). However, thymic tolerance machineries do not ensure the elimination of all autoreactive thymocytes, while efficiently prune the frequency of self-reactive cells leaving the thymus to the periphery through a process that may 
bypass the presence of flaws in the αβTCR repertoire. To compensate for the chaotic inefficiencies in negative selection, the medulla also distorts a subpopulation of CD4+ SP thymocytes into the Foxp3+ Tregs lineage (Kakugawa, et al. 2017). When migrated to the periphery, these cells are highly efficient in inhibiting autoreactive responses introduced by self-reactive T cells that evade thymic tolerance (Fan, et al. 
2018).  Although, the precise mechanisms by which the mTECs select T cell repertoire is not fully elucidated, it is believed  that the mTECs and thymic DCs are thought to act as key regulators for the development of Foxp3+ Tregs, thereby confirming the important role of the thymic medulla in that process (Cowan, et al. 2013, Perry, et 
al. 2014). The complex heterogeneity of mTECs and DCs allows the medulla to manage the maturation of diverse T cells populations including conventional SP T cells and CD4+Foxp3+ Tregs (Takahama, et al. 2017).  In the murine thymus, mTECs are generally stratified into two distinct mTECslow (MHC-ІІlowCD80low) and mTECshigh (MHC-ІІhighCD80high) subpopulations. The mTECslow have been proposed to function as precursors for mature mTECshigh as they both share a linear developmental progress (Rossi, et al. 2007). Of note, the conversion of mTECslow to mTECshigh can be regulated by certain TNF receptor 
superfamily (TNFRSF) signals such as RANK and CD40, the upregulation of the autoimmune regulator (Aire), and the expression of different peripheral tissue 
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antigens (PTAs) including insulin-2 and salivary protein-1 (Rossi, et al. 2007), (Anderson, et al. 2002), (Irla, et al. 2008, Hikosaka, et al. 2008, Akiyama, et al. 2008). The murine thymic DCs contain many subpopulations that are different in their developmental origins, and perhaps in their functional contributions to thymic tolerance. The thymus is thought to involve thymic conventional DCs (cDCs) that can 
be classified into cDC1 cells (CD8α+ Sirpα- CD11b-) and cDC2 (CD8α- Sirpα+ CD11b+) cells, and plasmacytoid DCs (pDCs) that are characterised by the expression of PDCA-1  (Liu and Nussenzweig 2010). cDCs arise from pre-cDC precursors that evolve within the bone marrow and egress into the periphery before developing into 
cDC1 and cDC2 cells (Liu, et al. 2009). Whereas pDCs are generated directly from the common DC progenitor within the bone marrow. Both cDCs and pDCs have the 
expression of CD11c on their surfaces. After maturation in the peripheral tissues, cDC2 cells and pDCs are attracted to the thymus via the expression of CCR9 and 
CCR2 that bind to the chemokine ligands CCL25 and CCL8, respectively, which are produced by thymic stroma (Baba, Nakamoto and Mukaida 2009, Hadeiba, et al. 
2012). By contrast, unlike cDC2, cDC1 cells are developed within the thymus from migrant immature pre-cDC progenitors that express CCR7 and are recruited to the 
thymus via the secretion of CCL21 from the mTECs. Also, these intrathymic DCs can be regulated by mTECs via the chemokine XCL-1 that is produced in an Aire-dependent manner (Schlitzer, et al. 2015, Lei, et al. 2011). Migration of cDC2 cells, pDCs and pre-cDC progenitors to the thymus must be tightly balanced as it may be essential for efficient thymic tolerance. It has been proposed that the exact location of DCs within the thymic medulla plays a crucial role in tolerance mechanisms. A study has confirmed that in both Aire-deficient and XCL-1 deficient mice intrathymic 
cDC1 cells were displaced and unsettled in the thymic medulla that lack the expression of Aire and XCL-1. This DC mispositioning was also followed by deficient self-tolerance and insufficient induction of Tregs. These findings suggest that mTECs via the expression of Aire and XCL-1 can direct cDC1 cells to migrate to the relevant medullary areas for optimal thymic tolerance and sufficient development of Tregs 
(Lei, et al. 2011).    
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2.1.5. The development of intra-thymic natural T regulatory cells 
(nTregs) Despite the crucial role of the thymic medulla in the development of Foxp3+ Tregs, the initial mechanisms that control commitment to the thymic Treg lineage remain controversial. However, two main subpopulations of CD4+ SP thymocytes have been proposed to act as direct precursors of mouse CD4+CD25+Foxp3+ Tregs, including CD25+Foxp3- and CD25-Foxp3+CD4+ SP thymocytes (Lio and Hsieh 2008, Tai, et al. 
2013) (figure 2.4). CD25+Foxp3-CD4+ thymocytes were found to induce CD25+Foxp3+ Tregs after being transferred intrathymically (Lio and Hsieh 2008). Whereas CD25-Foxp3+CD4+ thymocytes were found to give rise to CD25+Foxp3+CD4+ Tregs following intrathymic adoptive transfer (Tai, et al. 2013). These findings suggest that both subsets may act as Tregs precursors intrathymically. However how both subsets contribute to the newly developed intrathymic Tregs is still enigmatic, especially when two separate development pathways are involved in the process. However, a recent mouse model (Nr4a3-Tocky) has been developed by Bending et al. to study the dynamics of Tregs development and differentiation via TCR signalling within the thymus using a fluorescent timer protein. In this model, TCR signalling generates unstable chromophore that spontaneously shifts its emission from blue fluorescence to red fluorescence when it becomes maturely stable. Thus, upon receiving a TCR trigger cells emit only blue fluorescence and become blue+ red-. Then, with persistent TCR engagement cells shift the emission to become blue+ red+, whereas they express red fluorescence only (blue- red+) when TCR signals are disrupted. This model has shown that CD25+Foxp3-CD4+ SP thymocytes were mainly blue+ red-, while both CD25+Foxp3+ Tregs and CD25-Foxp3+ thymocytes were mostly blue+ red+. These findings suggested that CD25+Foxp3-CD4+ SP thymocyte could act as main precursors for thymic Treg lineage as they received persistent TCR signals to generate CD25+Foxp3+ Tregs, compared to CD25-Foxp3+ thymocytes that found to be enriched with mature Foxp3+ cells that have received less TCR signals. These findings confirm the important role of persistent TCR signals for generating intrathymic Tregs (Bending, et al. 2018). However, another mouse model (Rag2GFP) has reported that CD25-Foxp3+CD4+ SP thymocytes might have the potential to play as precursors for intrathymic Tregs development (Cowan, McCarthy and Anderson 
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2016). Both mouse models support the hypothesis that intrathymic Tregs development may rise from two distinct precursor subsets.  
Figure 2.4. The development and recirculation of Foxp3+ nTregs in the murine thymus. The thymic medulla provides a suitable microenvironment for the commitment and development of CD4+CD25+Foxp3+ intrathymic Tregs from newly selected CD4+ SP thymocytes. These CD4+ SP thymocytes are found to give rise to CD25+Foxp3- and CD25-Foxp3+ thymocytes which function as precursors for the development of de novo CD4+CD25+Foxp3+ intrathymic Tregs. De novo Tregs have been reported to be a heterogeneous population containing Triplehi (CD25hi PD1hi GITRhi), Triplelo (CD25lo 
PD1lo GITRlo) and central Tregs (CD62L+ CD44-). De novo Tregs depart the thymus as RTE Tregs to the periphery where they join the mature peripheral Treg pool. Mature peripheral Tregs are found to acquire the expression of CCR6+ during their maturation in the periphery, which enables them to re-enter the thymus again in response to the production of CCL20 from Aire+ mTEC. SP: single positive, RTE: recent thymic emigrants, mTEC: medulla thymic epithelial cell. This figure is modified from (Inglesfield, et al. 
2019).      
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The presence of two different precursors for intrathymic Treg-lineage commitment may highlight the ability of the thymic medulla of producing heterogeneous Treg subsets that are phenotypically and functionally distinct. Indeed, mature Tregs that are exported to peripheral tissues show distinct function with diverse phenotypic features especially in the expression of chemokine receptors and adhesion molecules. This phenotypic heterogeneity may boost their ability to maintain various immune responses across different body organs (Smigiel, et al. 2014, Wyss, 
et al. 2016). However, whether this heterogeneity is formed intrathymically during Tregs development or after leaving the thymus is obscure. Accordingly, two Foxp3+ Treg populations have been identified in mice including central Tregs (cTregs) and effector Tregs (eTregs) that are CD44-CD62L+ and CD44+CD62L-, respectively.  By using the Rag2GFP mouse model, cTregs have been found to be phenotypically similar to the newly developed intrathymic Tregs, proposing that cTregs might be initially developed in the thymus before travelling to peripheral tissues where they mature to eTregs (figure 2.4) (Wyss, et al. 2016). Similar results have been shown using adoptive transfer of sorted cTregs which displayed CD44+CD62L-, the phenotype of eTregs, following transfer in mice (Smigiel, et al. 2014). By contrast, another study has found two distinct subsets of intrathymic Tregs including triple high cells (CD25hi PD-1hi GITRhi) and triple low cells (CD25lo PD-1lo GITRlo), and both subsets have shown to involve newly developed intrathymic Tregs in Rag2GFP mice, supporting the hypothesis of the heterogeneity of Tregs development within the thymus (figure 2.4). Moreover, this study has shown that both triple high and low cells express different sequenced TCR repertoire and have different affinity for self-
antigens, based on the strength of TCR signals using Nur77-GFP reporter expression. Triple high cells have shown higher expression of Nur77-GFP than triple low cells, confirming that they might receive stronger TCR signals than triple low cells. Also, triple cells have shown higher affinity for self-antigens than triple low, suggesting that the heterogeneity of Tregs development in the thymus might be based on the affinity of their TCR for self-antigens (Wyss, et al. 2016). It has also been proposed that the heterogeneity of the de novo Tregs in the thymus may due to the presence of mature recirculated Tregs that have been found alongside their newly developed Tregs in the thymic medulla (figure 2.4). This has been widely demonstrated using Rag2GFP mice where thymocytes undergoing 
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intrathymic development can be characterised as GFP+, whereas fully mature T cells are GFP-. In these mice, the newly developed intrathymic Tregs are found to be densely contaminated by GFP- Tregs, suggesting that GFP- Tregs might recirculate back to the thymus or be recruited to the thymus from the periphery (Cowan, et al. 
2016, E. Yang, et al. 2014, Thiault, et al. 2015). Studies have been carried out to understand the mechanisms that regulate the process of thymic recirculation and its possible effect on thymus function. A study by Thiault et al. has shown that the migration of mature peripheral Tregs to the thymus might be mediated by the expression of CXCR4 that is expressed by GFP- Tregs in the thymus. Also, the number of Tregs homing to the thymus is reduced about 50% following injection of Tregs into mice treated with a CXCR4 inhibitor (Thiault, et al. 2015). However, another study has disproved this finding by using Cd4cre/Cxcr4floxed mice where the number of intrathymic Tregs is not affected (Lucas, et al. 2017). A recent study has shown that the intrathymic recirculating Tregs are decreased in Ccr6-/-Rag2GFP mice compared to wild-type controls. Also, it is found that the newly developed intrathymic Tregs are CCR6-CCR7+GFP+, whereas mature Tregs show CCR6+CCR7-GFP-, proposing that mature thymic Tregs acquire the expression of CCR6 in the periphery, which is a key regulator for Tregs recirculation to thymus. These findings highlight the possibility of involvement of the thymic medulla in Tregs recirculation mechanism as CCR6+ Tregs may be attracted to the thymus via the secretion of CCL20 by mTECs. Relevant to this, it has been found that mTECs from Aire-/- mice show a significant reduction in the expression of CCL20 compared to the wild-type controls, and then a reduction in the GFP- recirculating Tregs, proposing the role of AIRE-derived mTECs in the process of thymic Tregs recirculation via CCR6-CCL20 signalling (Cowan, et al. 2018) (figure 2.4). This finding also supports the role of AIRE-derived mTECs in controlling and directing the thymic DCs within the medulla via XCL-1 signalling as mentioned above (Lei, et al. 2011). Recirculating Tregs have been found to inhibit the development of intrathymic Tregs, particularly when mice become old; as older mice show a reduction in thymic Treg pool and an increase in the number of mature recirculating Tregs within the thymus compared to younger (Thiault, et al. 2015). However, other experiments on osteoprotegerin (OPG)-deficient mice where recirculating Tregs are increased has not shown any reduction in the development of intrathymic Tregs compared to 
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wild-types controls (McCarthy, et al. 2015). Taken together, there are still many unanswered questions such as to what extent does the thymus need recirculating Tregs? Do thymus recirculating Tregs need to travel back to the periphery again? How do recirculating Tregs mediate their function in the thymus? Which peripheral tissues do recirculating Tregs come from?. 
2.1.6. The development of peripherally-induced T regulatory cells  In addition to natural or intrathymically derived Tregs, another population of regulatory cells has been identified to maintain immune homeostasis in the periphery. Unlike natural Tregs, peripherally-induced T regulatory cells (iTregs) are immunosuppressive cells that differentiate from naïve CD4+ T cells in peripheral tissues following exposing to antigen stimulation in the presence of certain cytokines including interleukin-2 (IL-2), transforming growth factor (TGF-β1) and interleukin-10 (IL-10) (Abul 2003). Different abbreviations have been used to describe induced Tregs including “iTreg” when cells are generated in vitro, or “pTregs” or adaptive Tregs when generated in vivo. Despite pTregs constituting only a small percentage of Tregs as a whole, these populations are found highly enriched in particular organs including maternal placenta and the gut (Mizrahi and Ilan 
2009). Therefore, pTregs are thought to sustain immune tolerance against commensal bacteria, foods, allergens and the fetus in the uterine (Samstein, et al. 
2012, Luu, Steinhoff and Visekruna 2017). In humans, the development of pTregs is found to occur mainly in the intestine where mucosal DCs and commensal bacteria are enriched. Mucosal DCs, particularly 
CD103+ lamina propria DCs, can secrete TGF-β1 that is known as a master regulator of pTregs, and retinoic acid (RA) that shows a potential of induction of pTregs from naïve CD4+ T cells (Darrasse-Jeze, et al. 2009, Yamazaki, et al. 2007). Also, commensal bacteria including Bacteroides fragilis and Clostridia are found to promote the production of pTregs in the gut in a process to protect the host against inflammatory bowel diseases such as ulcerative colitis. B. Fragilis have shown to directly induce pTregs by triggering Toll-like receptor 2 (TLR2) that is expressed on activated T cells via the expression of capsular polysaccharide A of B. Fragilis. B. 
Fragilis – induced Tregs are found to secrete IL-10, an anti-inflammatory cytokine, and protect the host against colitis (Round and Mazmanian 2010). A specific 
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pathogen-free (SPF) mice model has been proposed by Atarashi et al. to study the impact of indigenous Clostridium species on intestinal CD4+ T cells. Clostridium bacteria, especially cluster XIVa and IV, are found predominantly enriched in the colonic mucosa and work to maintain immune homeostasis by secreting antigens which attract intraepithelial lymphocytes and IgA+ cells. These antigens are directly 
presented by CD103+ DCs which then activate naïve CD4+ T cells to become either pTregs or effector CD4+ T cells based on the physiological condition (Atarashi, et al. 
2011) . CD103+ DCs play an essential role in manipulating the immune responses, for examples during steady state, DCs produce TGF-β1 and RA regulatory molecules to induce pTregs, whereas during inflammatory conditions DCs secrete inflammatory molecules such as IL-23 to initiate the inflammation response by promoting differentiation of effector CD4+ T cells (Lathrop, et al. 2011). 
The development of pTregs/iTregs is mainly mediated by TGF-β1 signalling that promotes the induction of Foxp3 expression. The main signalling pathway initiated by TGF-β1 is the activation and phosphorylation of its downstream transcription 
factors “Smads”; mainly Smad2 and Smad3. Smad2/3 are key mediators for the 
induction of Foxp3. Once activated, Smad2/3 are recruited into the conserved non-
coding sequence 1 (CNS1) region in the Foxp3 gene locus (Xu, Kitani and Strober 
2010). IL-2 is also found to be an essential factor for the induction of Foxp3 expression, which stimulates transcription factor STAT5 to bind the Foxp3 promoter and CNS2 region which is the major Treg-specific demethylated region (TSDR) (Kanamori, et al. 2016). pTregs are thought to have a different TCR repertoire compared to nTregs as they develop in various conditions in the periphery. pTregs, unlike nTregs, are found to be more specific for foreign or non-self antigens, given that they are differentiated from naïve conventional T cells (Haribhai, et al. 2011). Although both pTregs and nTregs are biased for different TCR-antigen affinities, it has been found that both subsets share minimal overlap between their TCR repertoire, suggesting that this shared overlap may be required for both subsets in the resolution of autoimmune diseases as the combination shows a more diverse TCR repertoire (Schmitt and 
Williams 2013). Moreover, another study has shown that pTregs derived from the intestinal mucosa had a distinct TCR repertoire compared with Tregs from other 
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location, confirming that pTregs are originally developed outside the thymus 
(Lathrop, et al. 2011). In the periphery, various types of antigen-presenting cells could generate different peptide-MHC complexes by processing and displaying tissue-derived proteins/peptides, and then trigger TCR on T cells. These interactions have been found to induce Foxp3+ T cells with a broader TCR repertoire that could recognise a diverse pool of antigens (Yadav, Bluestone and Stephan 
2013). By contrast, other studies on TCR repertoire have demonstrated that the generation of pTregs in non-mucosal tissues such as the central nervous system and the pancreas might be restricted as both T conventional cells and Tregs found to share a minimal overlap in TCR repertoire, suggesting that Tregs could be recruited to rather than induced at these locations (Liu, et al. 2009, Wong, Mathis and Benoist 
2007). These findings imply that tumours developed in mucosal cells may be more enriched with peripheral or induced Tregs.  
2.1.7. Aim of this study The aim of this chapter is to establish a mice model for generating CD4+CD25+Foxp3+ induced Tregs from purely sorted naïve CD4+CD25- Foxp3- T cells in the presence and absence of tumour cells in vitro. The objectives of this chapter are: 
1- Selection of an appropriate model to generate and study iTregs. 2- Purification of naïve CD4+CD25-Foxp3- T cells and CD4+CD25+Foxp3+ nTregs using beads and cell sorting based technology. 3- Optimisation of Tregs induction parameters including CD3/28 TCR activation signal, the concentration of TGF-β1 and the duration of induction. 4- Validation of the induction of Tregs from naïve CD4+CD25- T cells using flow cytometry, Foxp3-TSDR methylation status and functional assay. 5- Scaling up the model for obtaining sufficient cell number for MS-based profiling.    
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2.2. Materials and Methods 
2.2.1. Mice and Cell lines 
Female naïve BALB/c and C57 mice, 8-12 week of age, were brought from Charles Rivers laboratories (UK) and maintained in pathogen-free environment at the animal unit of the John van Geest Cancer Research Centre in accordance with established guidelines of the Animal Care and Use of Nottingham Trent University. 
4T1 cells (ATCC® CRL-2539™), a highly metastatic epithelial breast cancer cell line derived from BALB/c mice, were cultured in complete 4T1 cell medium (RPMI 1640 
medium supplemented with 10% FCS, 10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate and 2250 mg/500 mL glucose).  
2.2.2. Isolation of CD4+CD25+ and CD4+CD25- T cells and Cell 
sorting CD4+CD25+ T cells were purified from mouse spleens using a mouse CD4+CD25+ T 
Regulatory Cell Isolation Kit (Miltenyi Biotec, Cat no: 130-091-041) according to the manufacturer’s instructions.  CD4+CD25- T cells were purified from mouse spleens using two different ways. First, by using the mouse CD4+CD25+ T Regulatory Cell Isolation Kit (mentioned above), CD4+CD25- T cells were obtained from the flow-through tube during positive selection of CD4+CD25+ cells by MS columns. Second, naïve CD4+ T cells were purified using Dynabeads™ Untouched™ Mouse CD4 Cells Kit (Invitrogen, Thermo 
Fisher Scientific, Cat no: 11415D) according to manufacturer’s instructions. The isolated CD4+ T cells were stained with mouse anti-CD4 monoclonal antibody 
(eFluor 450, Clone GK1.5, eBioscience™, Thermo Fisher Scientific, Cat no: 48-0041-
82) and mouse anti-CD25 monoclonal antibody (PE, Clone PC61.5, eBioscience™, Thermo Fisher Scientific, Cat no: 12-0251-82). The stained cells were then sorted using a Beckman Coulter MoFlo XDP cell sorter (sorting mode: purify, the purity of sorting was ≥ 98%). The strategy for sorting a pure population of naïve CD4+CD25-Foxp3- T cells and naïve CD4+CD25+Foxp3+ nTregs is discussed in detail in the chapter 3 (section 3.2.2.1). 
 
75  
2.2.3. Flow Cytometry Single-cell suspensions of splenocytes, purified, sorted and cultured T-cells were prepared using 40µm cell strainers (Greiner Bio-one). Red blood cells were lysed 
using RBC lysis buffer 1X (BD Pharm LyseTM, BD Biosciences, Cat no: 555899). Cell counting and viability were assessed following staining with solution 18 
(Chemometec, Cat no: 910-3018), which contains Acridine Orange (AO, 80 µg/mL) for staining total living and dead cells, and 4′,6-diamidino-2-phenylindole (DAPI, 40 
µg/mL) for counterstaining only dead cells, using NucleoCounter cell counter (NucleoCounter® NC-250™, Chemometec). For flow cytometry, cells were washed twice with DPBS buffer, centrifuged at 350 x g for 5 min at room temperature and stained with Fluorochrome-conjugated monoclonal antibodies (mAbs) (table 2.1) 
and analysed using a flow cytometer (Gallios, 10 channels, Beckman Coulter). Details about the Gallios flow cytometer are summarised in table 2.2. To prevent non-specific binding, mouse FCR blocking reagent (purified anti-mouse CD16/32 
antibody, BioLegend, Cat no: 101302) was used before staining with Fluorochrome-conjugated antibodies. LIVE/DEAD™ Fixable Yellow Dead Cell Stain Kit (405 nm excitation, Thermo Fisher Scientific) was used to detect the viability of cells prior to intracellular staining. 
Table 2.1: List of antibodies that were used for flow cytometry analysis.  
Channel mAbs Fluorochrome Clone Company Cat no. 
FL1 CD73 FITC TY/11.8 BioLegend 127219 
FL2 CD25 PE PC61.5 ThermoFisher 12-0251-82 
FL3 Tim-3 PE/Dazzle B8.2C12 BioLegend 134013 
FL3 CTLA-4 PE/Dazzle UC10-4B9 BioLegend 106317 
FL5 CD39 PE/Cy7 Duha59 BioLegend 143806 
FL5 LAG-3 PE/Cy7 C9B7W BioLegend 125225 
FL5 GITR PE/Cy7 DTA-1 BioLegend 126317 
FL6 FOXP3 eFluor 660 FJK-16s ThermoFisher 50-5773-82 
FL8 CD127 APC-eFluor 780 A7R34 ThermoFisher 47-1271-80 
FL9 CD4 eFluor 450 GK1.5 ThermoFisher 48-0041-82 
FL10 DEAD/LIVE Yellow 405  ThermoFisher L34959  
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Table 2.2: List of lasers and filter that are available on the Gallios flow cytometer.  Laser Channel Filters Fluorochromes   Blue Laser  
488nm 
FL-1 525/40 FITC FL-2 575/30 PE FL-3 620/30 ECD, PE Tx Red, PE/Dazzle FL-4 695/30 PerCP-Cy5.5 FL-5 755LP PE-Cy7  Red Laser  
638nm 
FL-6 660/20 EFluor 660, APC FL-7 725/20 Alexa-Fluor 700 FL-8 755LP APC-eFluor 780, APC-Cy7 
Violet Laser 405nm FL-9 450/40 Pacific Blue FL-10 550/40 Krome Orange    
2.2.4. Generation of induced T regulatory cells in vitro Naïve CD4+CD25- T cells were purified and sorted (as mentioned in section 2.2.2) 
and rested overnight in complete T cell medium (RPMI 1640 supplemented with 
10% FCS, 1% penicillin/streptomycin, 20 mM HEPES buffer, 50 µM β-mercaptoethanol, 2 mM L-glutamine) at 37⁰C, 5% CO2. Then, a 24-well culture plate 
was prepared by adding 900 µL of complete T cell medium in each well. Hanging cell culture inserts for 24 well plate, PET (polyethylene terephthalate) membrane 
bottom, transparent, pore size 0.4 µm (SARSTEDT, Cat no: 83.3932.041) were placed in each well of the 24-well plate. After that, 2.5x105 of sorted naïve CD4+CD25- T cells resuspended in 200 µL of complete T cell medium were transferred into each of hanging cell culture inserts. Then, cells were activated using Dynabeads™ Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activation Kit 
(Invitrogen, Thermo Fisher Scientific, Cat no: 11452D) according to the 
manufacturer’s instruction at ratio 1:1 (naïve CD4+CD25- T cells: CD3/38 beads). The cells were grown in the presence of IL-2 (30 U/mL) (Recombinant Murine IL-2, 
PeproTech, Cat no: 212-12), and TGF-β1 (5 ng/mL) (Mouse TGF beta 1 Recombinant 
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Protein, Thermo Fisher Scientific, Cat no: 14-8342-80) for 5 days at 37⁰C, 5% CO2. The overall steps of the iTregs genertion in vitro are shown in figure 2.5.   
  
2.2.5. Generation of induced T regulatory cells in vitro in the 
presence of tumour cells (contactless co-culture) 
Murine breast cancer tumour cells (4T1) resuspended in 900 µL of the complete 4T1 
cell medium (mentioned in section 2.2.1) were seeded in a 24-well plate and 
incubated overnight at 37⁰C, 5% CO2. Hanging cell culture inserts were placed over 
Figure 2.5. A diagrammatic representation showing the process of iTregs generation in vitro. 
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already seeded tumour cells. Subsequently, 2.5x105 of sorted naïve CD4+CD25- T cells resuspended in 200 µL of complete T cell medium were transferred into hanging inserts to be separately co-cultured with tumour cells at ratio 1:20 (tumour cells: CD4+CD25- T cells). The sorted naïve CD4+CD25- T cells were activated using 
CD3/28 beads and cultured in the presence of IL-2 (30 U/mL) and TGF-β1 (5 
ng/mL) for 5 days at 37⁰C, 5% CO2. 
2.2.6. Intracellular (nuclear) staining of Foxp3 For intracellular nuclear and cytoplasmic staining, eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set (Thermo Fisher Scientific, Cat no: 00-5523-00) was used. For nuclear staining, Fixation/Permeabilisation (F/P) solution was 
prepared by mixing one part of F/P concentrate with three parts of F/P diluent. 
Then, 1x solution of Permeabilisation buffer (PB) was prepared by mixing one part 
of 10x PB with nine parts of nano-pure distilled water. After staining with cell 
surface antibodies and live/dead stain, cells were fixed by F/P solution (1 mL for 
1x106 cells) in the dark at room temperature for 40 min. After the incubation, the cells were washed by DPBS (2 mL for 1x106) and centrifuged at 350 x g for 5 min. The cells were resuspended in 200 µL of PB buffer and stained with Foxp3 mAb for 30 min in the dark at room temperature. For intracellular cytoplasmic staining, the same protocol of nuclear staining was followed. However, cells were fixed by F/P 
concentrate only (500 µL/1x106 cells) without mixing with F/P diluent. 
2.2.7. Establishment of functional assay Induced T regulatory cells were generated as shown in figure 2.5. At day 5 of iTregs generation, naïve CD8+ T cells were purified using Dynabeads™ Untouched™ Mouse 
CD8 Cells Kit (InvitrogenTM, Thermo Fisher Scientific, Cat no: 11417D) according to 
the manufacturer’s instructions from the spleen. The purified CD8+ T cells were washed twice with DPBS and stained with anti-mouse CD8 mAb (Alexa Fluor® 700, clone: 53-6.7, BioLegend, Cat no: 100730) for cell sorting using purify mode as 
mentioned above. Sorted CD8+ T cells were rested for 4 h and stained again with 
CD8 mAb to assess the purity of cell sorting which was ≥ 98% using the flow cytometer. Then induced CD4+CD25- T cells were harvested, washed and stained with CD4, CD25 and Foxp3 mAbs to assess the percentage of induction of Foxp3 after 
5 days of culture using flow cytometer. After that, sorted CD8+ T cells were 
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resuspended in DPBS supplemented with 0.1% BSA (1 mL/1x106 CD8+ T cells). 
While vortexing, 1 µL of 5 µM CFSE (carboxyfluorescein succinimidyl ester) dye was 
added into the cell suspension at (1:1000) dilution using CellTrace™ CFSE Cell Proliferation Kit, for flow cytometry (InvitrogenTM, Thermo Fisher Scientific, Cat no: 
C34554). Then cells were incubated for 10 min in the dark at 37°C. after that, while 
vortexing, cells were washed by adding 10 mL of pre-warmed complete T cell medium and incubated for 5 min in the dark at room temperature. After incubation 
cells were centrifuged at 350 x g for 8 min at room temperature. Washing step was repeated twice to ensure removing extra CFSE dye in the solution. Then cells were centrifuged, counted and seeded into a 96-well plate, rounded bottom. After that, CFSE-stained CD8+ T cells were activated using Dynabeads™ Mouse T-Activator 
CD3/CD28 for T-Cell Expansion and Activation Kit in the presence of IL-2 (30 U/mL). Then, induced CD4+CD25+Foxp3+ T cells (iTregs) were co-cultured with CFSE-stained CD8+ T cells at six different ratios including 1:2, 1:1, 2:1, 4:1, 8:1, 16:1 (CD8+ 
T cells : iTregs), in addition to controls that contain CD8+ T cells cultured without 
iTregs,  for 4 days at 37°C, 5% CO2. Cells were co-cultured in 96-well plate in 200 µL of complete T cells medium as a total volume.  At day 4, co-cultured cells were 
harvested, washed twice. CD3/28 beads were magnetically removed. Then cells 
were stained with Dead/Live stain and CD8 mAb, and then analysed on flow cytometer for assessing the proliferation of CD8+ T cells in the presence and absence of iTregs. The steps of establishment the functional assay are shown in figure 2.6. 
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2.2.8. The stability of Foxp3 expression of induced Tregs Induced Tregs were generated as shown in figure 2.5 for 5 days. At day 5, total CD4+ Cells, which contain both activated CD4+CD25- T cells and CD4+CD25+Foxp3+ iTregs, were harvested and washed twice with DPBS. CD3/28 beads were magnetically removed. The Cells were centrifuged at 350 x g for 5 min and then resuspended in a fresh complete T cell medium. The cells were counted and 1x106 of cells were stained with Live/Dead dye, anti-CD4, -CD25 and -Foxp3 mAbs to assess the percentage of induction of Foxp3 expression. After that, the remaining cells were cultured again in a fresh T cell medium in the presence of IL-2 (30 U/mL) for another 
5 days at 37°C, 5% CO2. The expression of Foxp3 of iTregs was assessed at day 3 
(day 8 of Fox3 induction) and day 5 (day 10 of Foxp3 induction) of the second culture period. 
Figure 2.6. A diagramatic representation showing the steps of establishment of functional assay for assessing the suppressive activity of iTregs. 
81  
2.2.9. Foxp3-TSDR methylation assay The methylation status of Foxp3-TSDR region was assessed in 6 different subpopulation of CD4+ T cells including naïve CD4+CD25- T cells, activated CD4+CD25- T cells, TGF-β1-drived CD4+CD25+Foxp3+ iTregs, TGF-β1/4T1-drived CD4+CD25+Foxp3+ iTregs, naïve CD4+CD25+Foxp3+ nTregs and activated CD4+CD25+Foxp3+ nTregs. Naïve CD4+CD25- T cells were purely sorted as 
mentioned in section 2.2.2. The cells were activated using CD3/CD28 beads at ratio 
1:1 (naïve CD4+CD25- T cells: CD3/28 beads) in the presence of IL-2 (30 U/mL) for 
5 days at 37°C, 5% CO2. TGF-β1-drived CD4+CD25+Foxp3+ iTregs were generated as mentioned in section 2.2.4. TGF-β1/4T1-drived CD4+CD25+Foxp3+ iTregs were generated as mentioned in section 2.2.5. naïve CD4+CD25+Foxp3+ nTregs were purely sorted using the cell sorter as mentioned in section 2.2.2. The sorted naïve 
nTregs were then activated using CD3/28 beads as mentioned above. The generated iTregs were purely sorted following the sorting strategy that is mentioned in the chapter 3 (section 3.2.2.1). 1x106 cells from each of the 6 subpopulations were carefully washed twice with DPBS, centrifuged at 350 x g for 5 min. a cell pellet from 
each of the subpopulations was freezed at -80°C and shipped to EpigenDX company (MA, USA) for assessing the methylation status of Foxp3-TSDR.  
The mouse Foxp3 methylation assay (Assay ID: ADS568-FS2) was carried out by EpigenDX, MA, USA. This assay was optimised to assess the methylation status of 4 different CpGs within TSDR region, intron 1, location (-2238 to -2207) from ATG, 
and +4442 to +4473) from TSS. Table 2.3 shows the list of CpG regions that were assessed during the assay.  
Table 2.3: List of CpG regions that were examined to assess the methylation status of mouse 
Foxp3 interon1-TSDR region. Assay ID ADS568-FS2 (Intron 1-TSDR Region, Foxp3, Mouse) CpG# CpG# -22 CpG# -21 CpG# -20 CpG# -19 From ATG -2238 -2219 -2215 -2205 From TSS +4442 +4461 +4465 +4473 
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2.3. Results 
2.3.1. Establishment of a murine model to generate induced T 
regulatory cells from naïve CD4+CD25-Foxp3- T cells To develop a representative murine model for studying the difference between nTregs and iTregs, two most appropriate mouse strains were selected based on the availability of commercial mouse tumour cell lines that are compatible with the mouse strain. The percentage of nTregs in the spleen of BALB/c and C57BL/6 mice was assessed. The results showed that the percentage of naïve CD4+CD25+Foxp3+ nTregs from total naïve CD4+ T cells was significantly higher in the spleen of BALB/c 
(mean=12%) than C57BL/6 mice (mean=2.7%) (Figure 2.7).            
Figure 2.7. The percentage of naive CD4+CD25+Foxp3+ nTregs from total naive CD4+ T cells in the spleens 
of BALB/c and C57BL/6 mice. (A) Flow cytometric density plots showing the expression of CD25+Foxp3+ (gate D) in naïve nTregs of both BALB/c and C57BL/6. These plots were gated on live CD4+ T cells. (B) Scatter plots showing the mean of the percentage of naïve CD4+CD25+Foxp3+ T cells in the spleens of 
BALB/c (12%) and C57BL/6 (2.7%). The results were statistically significant (p>0.0015). Three independent experiments were carried out, a spleen from each of mouse strains was analysed in each experiment, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.   Bars errors represent the standard error (SE) of the mean. Unpaired t test was used using GraphPad Prism 8.0.1 software. Kalusa software (version 1.3) was used for analysing flow cytometric data.  
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 According to the results shown in figure 2.7, the BALB/c mice strain was selected to develop the model.  Then it was decided to deplete naïve CD25+Foxp3+ Tregs within naïve CD4+ T cells population to obtain pure naïve CD4+CD25-Foxp3- T cells as a control population for the model. To achieve this, it was assessed whether all naïve CD25+ T cells express positively Foxp3; since depletion of nTregs based on the expression of Foxp3 was not suitable in this model; as Foxp3 is mainly expressed in the nucleus. Therefore, the depletion of CD4+CD25+Foxp3+ nTregs was based on the co-expression of CD4 and CD25 as both are surface markers. The mouse CD4+CD25+ T Regulatory Cell 
Isolation Kit (Miltenyi Biotec) was used as it could isolate both CD4+CD25+ T cells and CD4+CD25- T cells simultaneously. The results of isolation confirmed that 92% of CD25+ T cells were positive for Foxp3 expression, confirming that CD25 expression could be useful for depleting CD25+Foxp3+ T cells in this model (figure 
2.8). The results also confirmed the efficiency of that kit for isolating naïve nTregs from purified CD4+CD127- T cells.           
Figure 2.8. The percentage of Foxp3+ cells within the naïve CD4+CD25+ T cells population after isolating naïve CD4+CD25+ T cells from purified naïve CD4+ T cells using the Miltenyi kit. (A) Flow cytometric density plots showing the percentage of CD25+ T cells that positively express Foxp3. The plots also show the gating strategy for analysing flow cytometric data; Foxp3+CD25+ cells (gate D) were gated on CD4+CD127- cells (gate J) that were gated on singlets cells (gate G) of total stained cells. (B) Column bar graph displaying the effectiveness of the Miltenyi kit in isolating nTregs from purified CD4+ T cells; the isolation purity was ≥ 90%. Three independent experiments were carried out, a spleen from each of mouse strains was analysed in each experiment, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.   Bars errors represent the standard error (SE) of the mean. GraphPad Prism was used for drawing bar graph. Kalusa software (version 1.3) was used for analysing flow cytometric data. 
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The same kit was used to deplete CD4+CD25+ T cells nTregs for obtaining pure CD4+CD25-Foxp3- T cells as a control population to generate iTregs. Accordingly, naïve nTregs were depleted, and CD4+CD25- T cells were stained with CD4, CD25 
and Foxp3 mAbs as well as live/dead staining to assess the purity of depletion. Then CD4+CD25- T cells were cultured for 3 days in the presence and absence of IL-2 to confirm the purity of the control population in this model. Surprisingly, the results showed that CD4+CD25- T cells (control population) were positive for CD25 
expression (38%) after 3 days of culture, whereas they showed a negativity for CD25 expression (0%) on day 0 of culture after depletion in the absence of IL-2, confirming that the CD25+ T cells were not originally depleted. To confirm these results, the same experiment was repeated and a different conjugated anti-CD25 mAbs (PerCP-Cy5.5-conjugated) was used to assess the expression of CD25 after depletion; because PE-conjugated anti-CD25 antibody and anti-PE microbeads were included in the kit. The results of staining showed that CD25+ T cells were completely depleted following depletion using both CD25 mAbs, however after 3 days of culture 30-42% of CD25 depleted cells were positive for CD25 expression (figure 2.9). As the purity of depletion of CD25+ T cells using the Miltenyi kit was ~ 62%, it was suggested to use cell sorting for obtaining pure CD4+CD25- T cells. The results of cell sorting showed that CD4+CD25- T cells were 100% negative for the expression of CD25 following cell sorting at day 0 and after 5 days of culture (figure 2.10). As a result, cell sorting using purity mode was selected to be used in this model.            
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Figure 2.9. The percentage of CD25+ T cells following depletion of CD25 expressing cells using the Miltenyi kit. (A) Flow cytometric density plots showing the staining of CD25 (gate D) following depletion of CD25+ T cells ex-vivo at day 0 and after 3 days of culture in the presence and absence of IL-2. Gate D was gated on CD4+CD127- T cells (gate J) which was gated on live CD4+ T cells. (B) Column bar graph showing the percentage of CD25+ T cells after their depletion ex-vivo on day 0 and day 3 of culture in the presence and absence of IL-2 (30 U/mL). Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean.  Control: naïve CD4+CD25- T cells were cultured in the complete T cell medium in the absence of IL-2.   
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Figure 2.10. The percentage of CD25+ T cells before and after sorting of CD4+CD25- T cells from total purified CD4+ T cells. (A) Flow cytometric density plots showing the staining of CD25 expression (gate D) on total CD4+ T cells (pre-sorting) and sorted CD4+CD25- T cells (post-sorting) at day 0 and day 5 of culture. Gate D was gated on live CD4+ T cells (gate J.). (B) Column bar graph illustrating the percentage of CD25+Foxp3+ T cells within total CD4+ T cells (pre-sorting) and sorted CD4+CD25- T cells (post-sorting) at day 0 and day 5 of culture. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean.   
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2.3.2. Conversion of naïve CD4+CD25- T cells to CD4+CD25+Foxp3+ 
iTregs in vitro 
 Generation of iTregs with and without CD3/CD28 TCR activation 
signals It is known that TCR activation signals are essential for generating iTregs from naïve CD4+CD25- T cells. To assess whether 4T1 tumour cells could induce naïve CD4+CD25- T cells to iTregs without CD3/28 TCR activation in the presence and absence of TGF-β1 cytokine. The results showed that only 1.3% of naïve CD4+CD25- T cells were induced to iTregs in the presence of tumour cells, whereas 2.2% of 
iTregs were generated in the presence of both 4T1 cells and TGF-β1 (figure 
2.11).The results confirmed that 4T1 cells were able to generate iTregs even in a small percentage in contactless culture, suggesting that 4T1 cells might secrete molecules for mediating that induction independently of TCR activation despite the difference in the induction between both culture conditions was not statistically significant. Although iTregs could be generated without TCR activation in the presence of tumour cells and TGF-β1, the induction was in a very small percentage. 
To assess the effect of CD3/CD28 TCR activation signals on the differentiation of iTregs from naïve CD4+CD25- T cells, we repeated the same experiment. Naïve CD4+CD25- T cells were co-cultured with 4T1 cells in the presence of CD3/28 T cell activator beads and IL-2, and in the presence and absence of TGF-β1 for 5 days. The co-culture was contactless using hanging culture inserts. The results (figure 2.12) showed that only 2%-3% (mean = 2.6 %) of naïve CD4+CD25- T cells were induced 
to iTregs in the presence of 4T1 cells, IL-2 and CD3/28 beads, whereas the induction 
of iTregs was significantly increased in range from 58% to 67% (mean = 61.3%) in the presence of 4T1, IL-2, CD3/28 beads and TGF-β1 (figure 2.12). The results also confirmed that the induction of iTregs was mainly due to the presence of TGF-β1 
and CD3/28 beads as 4T1 cells alone could yield that much induction. However, comparing these results with the results shown in figure 2.11, it is clear that the 
induction of iTregs results from CD3/28 TCR activation signals and TGF-β1 as the 
induction was 2.6 % in the presence of 4T1 cells and TGF-β1 without CD3/28 beads, while it was significantly increased to 61.3 % in the presence of 4T1, TGF-β1 and 
CD3/28 beads.  
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Figure 2.11. The percentage of induction of iTregs from naïve CD4+CD25- T cells that were co-cultured 
with 4T1 tumour in a contactless system using hanging culture inserts in the presence and absence TGF-
β1 (5 ng/mL) without TCR CD3/CD28 activation. IL-2 (30 U/mL) was added into all culture conditions. 
Culture ratio of 4T1 cells to naïve CD4+CD25- T cells was 1 : 5, respectively. Cells were cultured for 5 days. Control cells were cultured alone in the presence of IL-2 only. (A) Flow cytometric density plots displaying the percentage of CD25+Foxp3+ iTregs (gate D) differentiated from naïve CD4+CD25- T cells (gate J’). (B) Column bar graph illustrating the percentage of iTregs raised from naïve CD4+CD25- T cells cultured in different conditions as mentioned above. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. Control: naïve CD4+CD25-Foxp3- T cells were cultured in the complete T cell medium in the presence of IL-2 only.   
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Figure 2.12. The percentage of induction of iTregs from naïve CD4+CD25- T cells that were co-cultured 
with 4T1 cells (contactless co-culture) and CD3/CD28 beads in the presence and absence of TGF-β1 
(5 ng/mL) for 5 days. Culture ratio of 4T1 cells to naiveCD4+CD25- T cells was 1 : 5, respectively. IL-2 
(30 U/mL) was added into all cultures. Control cells (naïve CD4+CD25-) were cultured alone in the presence of IL-2 and CD3/28 beads. (A) Flow cytometric density plots illustrating the percentage of induction of iTregs (gate D) from live CD4+CD25- T cells (gate J’). (B) Column bar graph showing the percentage of CD25+Foxp3+ iTregs generated from naïve CD4+CD25- T cells cultured with 4T1 tumour cells in the presence and absence of TGF-β. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. Control: naïve CD4+CD25-Foxp3- T cells were cultured in the complete T cell medium in the presence of IL-2 only. (p ≤ 0.0001). Ordinary one-way ANOVA test was 
used for analysis using GraphPad Prism 8.0.1.     
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 Generation of iTregs using contact and contactless co-culture models To define the contribution of 4T1 cells in the induction of iTregs. Then, naïve CD4+CD25- T cells were cultured in the presence of IL-2, CD3/28 beads and TGF-β1 
in the presence and absence of 4T1 cells using hanging culture inserts (contactless co-culture), in addition to the control where naïve CD4+CD25- T cells were cultured in the presence of IL-2 and CD3/28 beads only. The results (figure 2.13) showed that the percentage of induction of iTregs by adding TGF-β1 was 50.7%, whereas it was 
significantly increased to 61.3 % by adding TGF-β1 in the presence of 4T1 tumour 
cells, although 4T1 cells contributed to only 2.5 % of induction in the absence of TGF-β1 (figure 2.13). These results suggested that TGF-β1 might direct 4T1 cells to contribute to the induction of iTregs.   
To assess whether the presence of 4T1 cells in a cell-cell contact with naïve CD4+CD25- T cells could affect the percentage of iTregs induction. Naïve CD4+CD25- T cells were co-cultured with 4T1 cells in a contact co-culture without using hanging inserts in the presence and absence of TGF-β1. The results of this experiment 
showed (figure 2.14) that cell-cell contact co-culture between 4T1 tumour cells and naïve CD4+CD25- T cells yielded 62.7 % of iTregs induction, while contactless co-
culture showed 61.3 % (figure 2.13), confirming that 4T1 secretome (4T1-conditioned media) was enough for mediating the induction of iTregs in the presence of TGF-β1. This shows that naïve CD4+CD25- T cells do not require cell-cell contact with tumour cells to be differentiated to iTregs. Therefore, the contactless co-culture system was used in this model.         
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Figure 2.13. The percentage of induction of iTregs from naïve CD4+CD25- T cells that were cultured in different conditions for 5 days in vitro. Here the co-culture of naïve CD4+CD25- T cells and 4T1 cells was contactless. IL-2 (30 U/mL) was added into all cultures. TGF-β1 (5 ng/mL) was added into the relevant cultures (+TGF-β). Culture ratio of 4T1 cells to naiveCD4+CD25- T cells was 1 : 5, respectively.  Control cells (naïve CD4+CD25-) were cultured alone in the presence of IL-2 and CD3/28 beads. (A) Flow cytometric density plots illustrating the percentage of induction of iTregs (gate D) from live CD4+CD25- T cells (gate J’). (B) Column bar graph showing the percentage of CD25+Foxp3+ iTregs generated from naïve CD4+CD25- T cells as mentioned above. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. Control: naïve CD4+CD25-Foxp3- T cells were cultured in the complete T cell medium in the presence of IL-2 only. (p 
≤ 0.0001 (****), p ≤ 0.01 (*)). Ordinary one-way ANOVA test was used for analysis using GraphPad 
Prism 8.0.1.  
92  
                
 
Figure 2.14. The percentage of induction of iTregs from naïve CD4+CD25- T cells that were cultured in different conditions for 5 days in vitro. Here the co-culture of naïve CD4+CD25- T cells and 4T1 cells was 
cell-cell contact. IL-2 (30 U/mL) was added into all cultures. TGF-β1 (5 ng/mL) was added into the relevant cultures (+TGF-β). Culture ratio of 4T1 cells to naiveCD4+CD25- T cells was 1 : 5, respectively. Control cells (naïve CD4+CD25-) were cultured alone in the presence of IL-2 and CD3/28 beads. (A) Flow cytometric density plots illustrating the percentage of induction of iTregs (gate D) from live CD4+CD25- T cells (gate J’). (B) Column bar graph showing the percentage of CD25+Foxp3+ iTregs generated from naïve CD4+CD25- T cells as mentioned above. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. Control: naïve CD4+CD25-Foxp3- T cells were cultured in the complete T cell medium in the presence of IL-2 only. (p ≤ 0.0001 (****), p ≤ 0.01 (*)). Ordinary one-way ANOVA test was used for analysis using GraphPad Prism 8.0.1.    
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 The presence of TGF-β1 is essential during CD3/28 TCR activation 
signals for optimal induction of iTregs 
As both CD3/28 TCR activation and TGF-β1 were required for inducing iTregs from naïve CD4+CD25- T cells in vitro. Next, it was assessed whether the initiation of 
CD3/28 TCR activation signals simultaneously in the presence of TGF-β1 is required for iTregs differentiation from naïve CD4+CD25- T cells. To achieve that, naïve CD4+CD25- T cells were activated with CD3/28 beads in the presence of IL-2, then TGF-β1 was added into cultures at different time points: immediately following 
adding CD3/28 beads (0 h), 2 hours after adding CD3/28 beads (2 h), 5 hours after 
adding CD3/28 beads (5 h) and 24 hours after adding CD3/28 beads (24 h). This experiment was done in the presence and absence of 4T1 tumour cells. Cultures 
were incubated for 5 days at 37oC, 5% CO2. The results showed that the presence of TGF-β1 immediately during CD3/28 TCR activation signals was substantial for generating iTregs (figure 2.15). The mean of the percentage of TGF-β1-derived 
iTregs induction was 54.3%, 43.6%, 38.8% and 11.6% at 0 h, 2hrs, 5 h and 24 h, respectively. These results showed that the induction of iTregs was significantly declined by increasing the period between CD3/28 TCR activation of naïve CD4+CD25- T cells and the addition of TGF-β1. Similarly, the mean of the percentage of TGF-β1/4T1-derived iTregs was significantly decreased from 66% at 0 h to 
15.06 % at 24 h of adding TGF-β1 into CD3/28 activated CD4+CD25- T cells in vitro 
(figure 2.15). Taken together, these results confirmed that the induction of iTregs is tightly dependent on the time when naïve CD4+CD25- T cells received TCR-activation signals and the availability of secreted TGF-β1 in the induction milieu. Moreover, these results suggest that naïve CD4+CD25- T cells might resist TGF-β1 
signalling after prolonged CD3/28 TCR activation and become differentiated to effector CD4+ T cells.       
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Figure 2.15. The percentage of induction of TGF-β1-derived iTregs and TGF-β1/4T1-derived iTregs from 
CD3/28-activated CD4+CD25- T cells following adding TGF-β1 (5 ng/mL) at different time points. Cells were cultured for 5 days in vitro. IL-2 (30 U/mL) was added into all cultures. Culture ratio of 4T1 cells to naïve CD4+CD25- T cells was 1 : 5, respectively. (A) Flow cytometric density plots illustrating the percentage of induction of TGF-β1-derived iTregs and TGF-β1/4T1-derived iTregs (gate D) that was gated on live CD4+CD25- T cells (gate L (not shown)). (B) Column bar graph showing the percentage of CD25+Foxp3+ TGF-
β1-derived iTregs and TGF-β1/4T1-derived iTregs generated from CD3/28-activated CD4+CD25- T cells. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. (p 
≤ 0.0001 (****), p ≤ 0.0007 (***), p ≤ 0.0020 (**)). Two-way ANOVA test was used for analysis using GraphPad 
Prism 8.0.1.   
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 Generation of iTregs using different concentrations of TGF-β1 Due to the crucial role of TGF-β1 for mediating the induction of iTregs from naïve CD4+CD25- T cells following CD3/28 TCR activation signals. Next, the induction of iTregs using different concentrations of TGF-β1 was assessed in vitro. Here, naïve CD4+CD25- T cells were activated with CD3/28 beads and cultured in the presence 
and absence of 4T1 cells. Then TGF-β1 was added into cultures at different 
concentrations including 5 ng/mL, 3 ng/mL, 1 ng/mL, 0.5 ng/mL, 0.05 ng/mL and 
0.005 ng/mL. The results (figure 2.16B) showed that the induction of iTregs was 
significantly decreased from 58.8% at concentration 5 ng/mL to 41.3% at 
concentration 0.5 ng/mL, 4.46% at concentration 0.05 ng/mL and 1% at 0.005 
ng/mL (figure 2.16B). Also, the results confirmed that the induction of iTregs was increased with the increase of TGF-β concentration. Although there were no 
significant differences between concentrations 5 ng/mL, 3 ng/mL and 1 ng/mL, the 
concentration 5 ng/mL yielded the highest induction of iTregs. These results also suggested that the concentration 0.05 ng/mL of TGF-β could be the minimum concentration required for inducing iTregs in vivo. Moreover, the induction of iTregs 
was significantly increased in the presence of 4T1 tumour cells with all concentrations of TGF-β, however the highly significant difference in the induction 
of iTregs in the presence and absence of 4T1 cells was at concentration 0.05 ng/mL of TGF-β (20.6% and 4.46%, respectively) (figure 2.16C). Accordingly, the concentration of 5 ng/mL was selected to be used for the next experiments.             
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Figure 2.16. The percentage of induction of TGF-β1-derived iTregs and TGF-β1/4T1-derived iTregs from 
CD3/28-activated CD4+CD25- T cells following adding TGF-β1 at different concentrations. Cells were cultured for 5 days in vitro. IL-2 (30 U/mL) was added into all cultures. Culture ratio of 4T1 cells to naïve CD4+CD25- T 
cells was 1 : 5, respectively. (A) Flow cytometric density plots illustrating the percentage of induction of TGF-
β1-derived iTregs and TGF-β1/4T1-derived iTregs (gate D) that was gated on live CD4+CD25- T cells (gate L (not shown)). (B) Column bar graph showing the percentage of CD25+Foxp3+ TGF-β1-derived iTregs and TGF-
β1/4T1-derived iTregs generated from CD3/28-activated CD4+CD25- T cells using different concentrations of TGF-β1. (C) Column bar graph illustrating the percentage of iTregs induction in the presence and absence of 
4T1 using different concentrations of TGF-β1. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. (p ≤ 0.0001 (****), p ≤ 0.0065 (**)). Two-way ANOVA test was 
used for analysis using GraphPad Prism 8.0.1.   
97  
 Optimising the duration of induction of iTregs in vitro As “5 days” period of culture was followed for all experiments mentioned above for generating iTregs in vitro. Next, the induction of iTregs was tracked over 6 days period of time to assess whether the induction of iTregs would increase with time 
in the presence of CD3/28 beads, IL-2 and TGF-β1. Here, naïve CD4+CD25- T cells 
were activated with CD3/28 beads and cultured in the presence of TGF-β1 and IL-2 
and in the presence and absence of 4T1 cells for 6 days at 37oC, 5% CO2. Then, the 
induction of iTregs was observed in each day of culture. The results (figure 2.17) showed that the percentage of induction of iTregs was significantly increased from 
day 1 (11.3%; with TGF-β, and 18.3%; with TGF-β1 and 4T1 cells) until day 6 (51%; with TGF-β1, and 63%% with TGF-β1 and 4T1 cells). However, although there were no significant differences in the induction of iTregs between day 4, day 5 and day 6, day 5 showed the highest percentage of iTregs induction (figure 2.17). As a result, 5 days period of culture was selected to be used in the model. These results also justify why 5 days period of culture was followed in the previous experiment.   
 Optimising the co-culture ratio of naïve CD4+CD25- T cells and 4T1 
tumour cells for generating iTregs in vitro 
As the induction of iTregs was significantly increased in the presence of 4T1 cells and TGF-β1, compared to cells cultured in the presence of TGF-β1 only. It was assessed whether iTregs induction could be affected by the number of tumour cells co-cultured with naïve CD4+CD25- T cells. Next, 4T1 cells were co-cultured with naïve CD4+CD25- T cells at different ratio in the presence of TGF-β1, IL-2 and 
CD3/28 TCR activation beads. The results (figure 2.18A,B) showed that the 
percentage of iTregs induction was significantly higher at ratio 1:2 (70%) and 1:3 
(69%), compared with the control (56.1%) where naïve CD4+CD25- T cells were cultured in the absence of 4T1 (figure 2.18A,B). Even in the presence of 4T1 cells, the induction of iTregs was significantly increased at ratio 1:4 (67%) and 1:5 (64.3%), compared with the control. There were no significant differences in the induction of iTregs between ratios 1:25 (61%), 1:50 (58.8%) and the control (figure 
18A,B). These results suggest that the number of naïve CD4+CD25- T cells infiltrating to the tumour microenvironment might contribute to increase the differentiation of 
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iTregs within tumour milieu, particularly if the infiltration ratio was 1:2 or 1:3 (tumour cells: naïve CD4 T cells). However, although the induction of iTregs was increased when naïve CD4+CD25- T cells were co-cultured with 4T1 cells in the presence of TGF-β1, it was noticed that the number of CD4+ T cells recovered after 5 days of culture was significantly reduced, compared to the control population where naïve CD4+CD25- T cells were 
cultured in the absence of tumour cells. The results (figure 2.18C) showed that an average of 6.4 x 106 total CD4+ T cells (which include activated CD4+CD25+Foxp3- and CD4+CD25+Foxp3+ iTregs) were proliferated from 1 x 106 CD4+CD25- T cells in 
the presence of CD3/28 beads, IL-2 and TGF-β1 for 5 days of culture, whereas the average number of  total CD4+ T cells proliferated from 1 x 106 in the presence of 
4T1 cells was in range between 1.52 x 106 cells (ratio 1:2) and 3.93 x 106 cells (ratio 
1:50) (figure 2.18C). This significant reduction in the cell recovery after 5 days in 
the presence of 4T1 suggest that: (1) 4T1 cells might secrete stress signals that could affect the proliferation of naïve CD4+CD25- T cells even in the presence of CD3/28 
TCR activation beads, or (2) iTregs that were induced in the presence of 4T1 might be more suppressive cells that could inhibit the proliferation of activated CD4+CD25+Foxp3- T cells than TGF-β1-derived iTregs. 
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Figure 2.17. The percentage of induction of TGF-β1-derived iTregs and TGF-β1/4T1-derived iTregs from 
CD3/28-activated CD4+CD25- T cells over 6 days of culture in vitro. The induction of iTregs was assessed in each day. IL-2 (30 U/mL) was added into all cultures. Culture ratio of 4T1 cells to naiveCD4+CD25- T 
cells was 1 : 5, respectively. (A) Flow cytometric density plots illustrating the percentage of induction of TGF-β1-derived iTregs and TGF-β1/4T1-derived iTregs (gate D) that was gated on live CD4+CD25- T cells (gate L (not shown)). (B) Column bar graph showing the percentage of CD25+Foxp3+ TGF-β1-derived iTregs and TGF-β1/4T1-derived iTregs generated from CD3/28-activated CD4+CD25- T cells in each day for 6 days period of culture. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. (p ≤ 0.0001 (****), p ≤ 0.0003 (***), p ≤ 0.0095 (**), p ≤ 
0.0118 (*)). Two-way ANOVA test was used for analysis using GraphPad Prism 8.0.1. 
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Figure 2.18. The percentage of induction of iTregs from CD3/28-activated CD4+CD25- T cells co-cultured with 
4T1 tumour cells at different culture ratios (4T1 cells : naïve CD4+CD25- T cells) in vitro for 5 days. IL-2 (30 
U/mL), TGF-β1 (5 ng/mL) were added into all cultures. (A) Flow cytometric density plots illustrating the percentage of induction of TGF-β1-derived iTregs and TGF-β1/4T1-derived iTregs (gate D) that was gated on live CD4+CD25- T cells (gate L (not shown)). (B) Column bar graph showing the percentage of TGF-β1/4T1-
derived iTregs generated from CD3/28-activated CD4+CD25- T cells co-cultured with 4T1 cells in different ratios. Ordinary one-way ANOVA test was used for analysis using GraphPad Prism 8.0.1. (C) Column bar graph illustrating the average of total number of CD4+ T cells that were proliferated from 1x106 of naïve CD4+CD25- T cells co-cultured with 4T1 cells at different ratios. Control population includes naïve CD4+CD25- T cells cultured without 4T1 cells. Ordinary one-way ANOVA test was used for analysis using GraphPad Prism 8.0.1. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. (p ≤ 
0.0001 (****), p ≤ 0.0003 (***), p ≤ 0.0035 (**)). Control: naïve CD4+CD25-Foxp3- T cells were cultured in the complete T cell medium in the presence of IL-2 and TGF-β1, in the absence of 4T1 tumour cells. 
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 Establishment of functional assay To assess whether iTregs generated in this model could function as immunosuppressive cells, a functional assay was developed by co-culturing the 
generated iTregs with purely sorted CD8+ T cells that were stained with CFSE dye 
for 4 days. To achieve this, first, the purity of CD8+ T cell sorting was assessed, and then the proliferation of naïve CD8+ T cells following CFSE staining in the presence of IL-2 and CD3/28 TCR activator beads (1:1 ratio (CD8+ cells:CD3/38 beads)) for 4 days was assessed in vitro. The results of the purity of cell sorting shown in figure 
2.19. After pure sorting, naïve CD8+ T cells were stained with CFSE (5µM), activated 
with CD3/28 beads and cultured in the presence of IL-2 (30 U/mL) for 4 days. The results of the proliferation of CFSE-stained CD8+ T cells showed that 8 generations 
of activated CD8+ T cells were proliferated from CD8+ paternal T cells after 4 days of culture. The results also showed that the staining of CFSE was nicely shifted from 
paternal cells with higher CFSE intensity to the 8th generation with lower CFSE intensity (figure 2.20).                      
Figure 2.19. Flow cytometric density plots showing the percentage of purity of CD8+ T cells 
sorting. CD8+ T cells (gate N) that were gated on singlets cells (gate O). 93% of CD8+ T cells were live after cell sorting. (n=4).    
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Figure 2.20. The percentage of proliferating CD8+ T cells from CFSE-stained paternal CD8+ T cells cultured 
in the presence of CD3/28 beads and IL-2 (30 U/mL) in vitro for 4 days. (A) Flow cytometric density plots showing the shift of CFSE-intensity of proliferating CD8+ T cells from higher intensity (right, log 103) to lower 
intensity (toward left, log 100), gate P (parental unstimulated CD8+ T cells), gate G1 (generation 1 of 
proliferating CD8+ T cells after CD3/28 TCR activation), gate G8 (generation 8 of proliferating CD8+ T cells). 
Kalusa software was used for analysing flow cytometric data. (B) Column bar graph illustrating the 
percentage of proliferating CD8+ T cells in each generation following staining with CFSE cell trace dye for 4 days of culture in vitro. GraphPad Prism 8.0.1 software was used for drawing the graph. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean.  
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As the trend of proliferation of CD8+ T cells in vitro was tracked and achieved in this model. Next, the functional activity of the generated iTregs was assessed by co-culturing them with sorted, CFSE-stained CD8+ T cells as mentioned above at 
different ratios. The results (figure 2.21) of the functional assay showed that the generated iTregs were highly immunosuppressive cells which could significantly 
inhibit the proliferation of CD8+ T cells even in the presence of CD3/28 TCR activator and IL-2. The results showed that the percentage of CD8+ T cells proliferation was 
only ~3% at 1:2 ratio (CD8+ cells:iTregs), compared to the control (100%) where 
CD8+ T cells were cultured without iTregs. Also, at ratio (1:1) the inhibition of CD8+ 
T cells proliferation was ~95% by TGF-β1-derived iTregs and ~97% by TGF-
β1/4T1-derived iTregs (figure 2.21). Even at ratio (16:1) the inhibition of CD8+ T 
cells proliferation was 18% by TGF-β1-derived iTregs and 22.8% by TGF-β1/4T1-derived iTregs, which was significant compared to the control. The results also showed that iTregs induced in the presence of 4T1 were slightly more suppressive than iTregs induced by TGF-β1 only at specific ratios including (1:1), (2:1), (4:1) and 
16:1), however these results were not statistically significant (figure 2.21). 
 The stability of Foxp3 expression of iTregs  As the generated iTregs were functionally immunosuppressive cells, it was assessed whether iTregs could maintain foxp3 expression after induction. The results showed (figure 2.22) both TGF-β1-derived iTregs and TGF-β1/4T1-derived iTregs lost about 5% of their Foxp3 expression after 5 days of removing TGF-β1 and CD3/28 TCR activator beads. Although there was a reduction in the expression of Foxp3 of iTregs, the reduction was not statistically significant (figure 2.22). These results suggest that the generation of iTregs might be based on the secretion of cytokines such as TGF-β1 with persistent TCR signals in vivo. 
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Figure 2.21. The percentage of proliferating CD8+ T cells from CFSE-stained parental CD8+ T cells cultured in the presence of TGF-β1/4T1-derived iTregs and TGF-β1-derived iTregs at different ratios for 4 days in vitro. 
CD3/28 beads (1:1 ratio (CD8:CD3/28 beads) and IL-2 (30 U/mL) were used for activating CD8+ T cells. (A) Flow cytometric density plots showing the percentage of proliferating CD8+ T cells (gate P) co-cultured with 
iTregs at different ratios (CD8 : iTregs). The proliferation of CD8+ T cells is illustrated by the change of CFSE 
staining intensity from higher intensity (right, log 103) to lower intensity (toward left, log 100). Kalusa software was used for analysing flow cytometric data. (B) Column bar graph illustrating the percentage of proliferating 
CD8+ T cells cultured in the presence of iTregs as mentioned above. By adding iTregs, the proliferation of CD8+ T cells was significantly reduced according to the culture ratio. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. Control: naïve purely sorted CD8+ T cells were cultured in the complete T cell medium in the presence of IL-2, in the absence of iTregs. (p ≤ 0.0001 (****), p ≤ 0.0010 (***), 
p ≤ 0.0099 (**), p ≤ 0.0301 (*). Two-way ANOVA test was used for statistical analysis using GraphPad Prism 8.0.1 software. 
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Figure 2.22. The percentage of Foxp3 expression of TGF-β1/4T1-derived iTregs and TGF-β1-derived iTregs after 3 and 5 days of removing TGF-β1 and CD3/28 TCR activator beads (which is 8 and 10 days of induction). iTregs were induced as mentioned above for 5 days. Then cells were cultured in a fresh complete T cell medium supplemented with IL-2 (30 U/mL) only. CD3/28 beads were removed magnetically. Then cells were cultured for another 5 days, and the expression of Foxp3 was assessed at day 3 and 5. (A) Flow cytometric density plots showing the percentage of Foxp3 expression of iTregs (gate D). gate D was gated on live CD4+ T cells (gate L (not 
shown)). Kalusa software was used for analysing flow cytometric data. (B) Column bar graph illustrating the percentage of the expression of Foxp3 in both TGF-β1/4T1-derived iTregs and TGF-β1-derived iTregs at day 5, 
8 and 10 of induction as mentioned above. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. Two-way ANOVA test was used for analysis using GraphPad Prism 
8.0.1 software.  
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 Foxp3-TSDR methylation status of the generated iTregs The methylation status of Foxp3-TSDR of iTregs generated in this model was assessed. The results (figure 2.23) showed that all CpG regions were significantly hypermethylated within the Foxp3-TSDR of naïve and activated CD4+CD25- T cells as the percentage of methylation was more than 90% for all CpGs compared to the percentage of methylation of the CpGs of naïve CD4+CD25+Foxp3+ nTregs, which 
was between 2.5% and 8.5%. However, the percentage of methylation of the CpGs of TGF-β1-drived iTreg, TGF-β1/4T1-drived iTregs was between 71% and 78 %, which was significantly lower than the methylation status of naïve and activated CD4+CD25- T cells (figure 2.23). However, the percentage of methylation of CpGs of iTregs was significantly higher than those of naïve nTregs. Surprisingly, the CpGs of 
activated nTregs were significantly hypermethylated (57-63%), compared to naïve nTregs (figure 2.23). Taken together, these results confirmed that the methylation status of 4 CpGs within Foxp3 TSDR was decreased in iTregs due to the presence of TGF-β1 mainly and the 4T1 cells, compared to naïve CD4+CD25- T cells and activated CD4+CD25- T cells. Although the generated iTregs were not as hypomethylated as naïve nTregs, they were slightly similar to activated nTregs.  
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Figure 2.23. The percentage of methylation of 4 different CpG regions within Foxp3-TSDR locus of naïve CD4+CD25- T cells that were cultured in different conditions, and naïve and activated CD4+CD25+Foxp3+ nTregs. 
Here, CD3/28 TCR activator beads were used to activate cells. IL-2 (30 U/mL) and TGF-β1 (5 ng/mL) were added into the relevant culture conditions as shown in the legend of the graph and heatmap. (A) Column bar graph showing the percentage of methylation of 4 different CpG regions within mouse Foxp3-TSDR gene. Two-
way ANOVA was used for statistical analysis using GraphPad Prism software 8.0.1. (p ≤ 0.0001 (****), p ≤ 0.0056 
(**)). (B) Heatmap showing the percentage of methylation of 4 different CpG regions within Foxp3-TSDR locus. 
Heatmap was drawn using GraphPad Prism software 8.0.1. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. 
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2.4. Discussion 
The immune tolerance is one of key features of the immune system, which recognises and eliminates autoreactive immune cells that induce immune reactions against self-tissue. The T regulatory cells (Tregs) are professional cells with suppressive activity and employed by the immune system to maintain the immune tolerance by inhibiting and eliminating autoreactive immune cells. There are two main population of Tregs: nTregs and iTregs. nTregs are found to develop within the thymus and function to govern central tolerance. Whereas iTregs are generated in the periphery and function to maintain peripheral tolerance. Both subpopulations share similar phenotypic features by the expression of Foxp3 and CD25, however, they differ in the origin of development and functional stability within the local microenvironment. nTregs are originally generated as immunosuppressive cells by the immune system, whereas iTregs are generated from niave CD4+ T cells in the periphery under certain conditions in the presence of cytokines such as TGF-β and IL-2. Therefore, in this study, a mouse model was developed to study the difference between nTregs and iTregs.   
To develop the mouse model, both mouse strains; BALB/c and C57BL/6 were analysed and compared to select the appropriate strain for generating and studying 
iTregs. The BALB/c mice strain was selected to establish the model since it had 
significantly more nTregs (12% of total CD4+ T cells) in the spleen, compared to 
C57BL/6 mice (~ 3% of total CD4+ T cells). Similar findings were also found by a study conducted by Chen et al. the authors demonstrated that the percentage of 
nTregs in the lymphoid organs of BALB/c mice was significantly higher than in 
C57BL/6 mice. Also, nTregs of BALB/c mice were more suppressive than those of 
C57BL/6 mice (Chen, Oppenheim and Howard 2005). Moreover, Volgelsang et al. 
have demonstrated that BALB/c mice shown to have significantly more nTregs and plasmacytoid dendritic cells (pDCs) in the blood and spleen than C57BL/6 
(Vogelsang, et al. 2009a). Another study also has reported that Foxp3+ Tregs of 
BALB/c mice were significantly more functional to suppress IL-9-driven mast cells 
than those of C57BL/6 (Blankenhaus, et al. 2014a). 
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In this model, the results showed that the induction of iTregs was significantly enhanced following TCR activation of naïve CD4+CD25- T cells in the presence of IL-2 and TGF-β1. However, there was no induction in the presence of IL-2 and TGF-β1 without TCR activation, highlighting the importance of TCR signals for initiating iTregs induction in the presence of TGF-β1 and IL-2. Vahl et al. have found that TCR signals are essential for the generation and activation of peripheral Tregs. Also, the authors have demonstrated that TCR-deficit Tregs were unable to supress T cells responses in vivo (Vahl, et al. 2014). Moreover, Vaeth et al. have found that suboptimal TCR signals were essential for the generation of iTregs from naïve CD4+CD25- T cells by promoting the expression of Foxp3 via NFAT (nuclear factor of activated T cells) pathway (Vaeth, et al. 2012). Also, Ruan et al. have confirmed the importance of TCR stimulation in inducing Foxp3 expression of iTregs via activation NF-kB pathway in which c-Rel could bind Foxp3 promoter and then initiate iTreg differentiation (Ruan, et al. 2009). Taken together, the TCR engagement seems to play a crucial role in the development and differentiation of iTregs in vitro and in vivo by mediating the downstream signals for inducing the expression of Foxp3. However, TCR signals alone were not sufficient for generating iTregs as the induction of iTregs following TCR activation in the presence of IL-2 did not occur.  Whereas the induction of iTregs was significantly increased following adding TGF-
β1, confirming the decisive role of TGF-β1 signalling in the development of iTregs. Li et al. have supported these findings. The authors demonstrated the critical role of TGF-β1 by modulating the expression of Foxp3 of iTregs, and how TGF-β1 
antagonised TCR signalling via p38 pathway for maintain the expression of Foxp3 of iTregs. The author also demonstrated the mutual effort of both TCR and TGF-β signalling in controlling the methylation of Foxp3 locus during iTregs generation. 
(Li, Ebert and Li 2013). Recently, a study has demonstrated that the importance of both TGF-β receptor and IL-2 receptor in mediating Foxp3 expression via CNS2-5-
azacytidine (5-aza-C) mechanisms (Freudenberg, et al. 2018). Another mechanism of TGF-β-induced Foxp3 expression was found to be mediated by the activation and 
recruitment of Smad2/3, a downstream transcription factor complex of TGF-β signalling, to a Foxp3 enhancer element which induces the expression of Foxp3 during iTregs development (Zheng, et al. 2010a, Tone, et al. 2008). 
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The results also showed that following receiving the same strength of TCR signals, the induction of iTregs from naïve CD4+CD25- T cells was significantly increased by increasing the concentration of TGF-β1, confirming that TGF-β signalling could predominantly antagonise TCR signalling and mediate the Foxp3 induction. Moreover, the induction of iTregs was significantly reduced following prolonged TCR activation in the absence of TGF-β. These results confirmed the dominant role of TGF-β for generating iTregs in the presence of strong TCR signals, and the dominant role of TCR signals for resisting iTregs induction in the presence of TGF-
β1 at lower concentrations. These finding also were supported by Li et al., as mentioned above (Li, et al. 2013). Another study has also found that CD3/28 co-stimulation could overcome TGF-β-mediated repression of the proliferation of activated T effector cells. This means that after persistent CD3/28 co-stimulation, effector activated T cells become more resistant to the influence of TGF-β signalling 
(Koehler, et al. 2007). These results have also been supported by the finding that 
activated T cells following CD28 engagement downregulate the expression of TGF-
β receptor II (TGF-βRII), thereby bypassing the effect of TGF-β signalling (Sanjabi, et al. 2017).    The results also revealed that the induction of iTregs was significantly increased in 
the presence of 4T1 tumours cells, compared to those induced in the presence of TGF-β1 only. However, 4T1 cells could convert only ~ 3% of naïve CD4+CD25- T cells to CD4+CD25+Foxp3+ iTregs in the absence of TGF-β1. These results suggested that 
4T1 cells might secrete insufficient amount of TGF-β1, so that could not induce 
iTregs or 4T1 cells might need a cellular interaction with other mediator cells such as dendritic cells and macrophages for inducing iTregs in vitro. Sun et al. have demonstrated the crosstalk between M2-macrophages and laryngeal squamous cancer cells for inducing iTregs. The authors have confirmed that cancer cell-activated M2-macrophages were able to induce iTregs from naïve CD4+CD25- T cells. Moreover, it was found that M2-marcrophages-derived iTregs were able to distort the differentiation of monocytes towards M2-macrophages, thereby establishing a positive-feedback cycle (Sun, et al. 2017). These findings have also been found within the tumour microenvironment of nasopharyngeal carcinoma where tumour cells predominantly could induce M2-macrophages from monocytes via TGF-β1 and 
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IL-10, which leaded to the development of M2-macrophages-derived iTregs (Wang, 
et al. 2017a).  The results in this chapter also demonstrated that the percentage of methylation of 4 CpGs within Foxp3-TSDR of iTregs was significantly lower than those of naïve and activated CD4+CD25- T cells. However, iTregs were significantly hypermethylated compared to naïve inactivated nTregs. These results were also found in a study conducted by Schmidt et al. where the authors assessed the methylation status of 15 different CpG regions within human Foxp3 gene locus and found that iTregs were significantly hypermethylated compared to unstimulated naïve nTregs. However, the iTregs and stimulated CD4+CD25- T cells were similar in the methylation status 
(Schmidt, et al. 2016). Compared to the results in this model, however, the generated iTregs were significantly less methylated compared to activated CD4+CD25- T cells. This also was demonstrated by the stability of the expression of Foxp3 of iTregs that 
were generated in this model. The results revealed that ~ 95% of the Foxp3 expression of iTregs was stable and maintained after 5 days of induction in the presence of IL-2 (30 U/mL) without re-activated with CD3/28 beads and TGF-β1. Although the demethylation status of Foxp3-TSDR is considered as a marker for the stability of Foxp3 expression, particularly in naïve nTregs, iTregs without TSDR demethylation could maintain their Foxp3 expression and suppressive activities 
(Hippen, et al. 2011, Lee, Lydon and Kim 2012, Gu, et al. 2014). Interestingly, the results showed that naïve nTregs lost their demethylation status and became significantly hypermethylated following TCR activation. These results were also supported by Zhang et al.; where the authors demonstrated that nTregs lost their Foxp3 expression after TCR engagement and experienced re-methylation 
of the CNS1 region within Foxp3 locus (Zhang, et al. 2017). These findings were also found in an earlier study by Bailey-Bucktrout et al. in 2013. There the authors found that nTregs underwent Foxp3 instability and secreted pro-inflammatory cytokines following self-antigen-driven activation during inflammation in the CNS (Bailey-
Bucktrout, et al. 2013). Taken together, it seems that both iTregs and nTregs can lose their stability in vivo after activation. This may stand with the idea that the immunosuppressive activity acquired by Tregs is induced upon the presence of stressful stimuli that promote prolonged acute or chronic inflammation, which can 
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make Tregs behaving with more flexibility based on the physiological condition in the milieu. 
In summary, the BALB/c mouse model was successfully developed to generate and study the iTregs. In this model, iTregs (CD4+CD25++Foxp3+) were generated in vitro from purely sorted CD4+CD25-Foxp3- T cells in the presence of TGF-β1 (5 ng/mL) and IL-2 (30 U/mL), and in the presence and absence of 4T1 tumour cells for 5 days. CD4+CD25-Foxp3- T cells were activated with CD3/CD28 TCR activation beads during the culture period for maintaining the induction of iTregs. The percentage of iTregs induction was 55-70% of total CD4+CD25-Foxp3- T cells after 5 days.  The induction of iTregs was enhanced in the presence of both TGF-β1 and 4T1 tumour cells, confirming the role of tumour cells in the induction of iTregs. The iTregs were successfully generated by different concentrations of TGF-β1, while 0.05 ng/mL of TGF-β1 was the lowest concentration required for inducing iTregs from naïve CD4+CD25- T cells. This study has also revealed that the generation of iTregs is based 
on a simultaneous synergy of TCR/CD28 and TGF-β1 signalling since activated CD4+C25- T cells were less responsive to the effect of TGF-β1. The generated iTregs showed potent immunosuppressive activities by inhibiting the proliferation of CD8+ T cells. In this model, the generated Tregs could maintain their Foxp3 expression for 5 days in the absence of TGF-β1, although their Foxp3-TSDR was hypermethylated compared to naïve nTregs. Finally, the percentage of iTregs induction and the percentage of nTregs in this mouse model was sufficient for profiling using mass spectrometry-based proteomics. Based on these results, optimisation for MS-based proteomic profiling of iTregs, nTregs and other subpopulation of naïve CD4+ T cells will be discussed in the next chapter.          
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Chapter 3.  
Optimisation of sample preparation for proteomic 
analysis 
3.1. Introduction  Advances in ‘omic’ technologies, which include genomics, transcriptomics, proteomics and metabolomics, have contributed to the discovery of biomarkers that are currently used in the clinic as screening, diagnostic, prognostic and predictive biomarkers. Also, these technologies are increasingly being used in drug discovery and evaluation of their potency and toxicity (Quezada, et al. 2017). The omic based high throughput platforms have enabled the scientists to understand the relationship between the genotype and the phenotype in a scale which was never possible few decades ago. However, each of the above-mentioned technologies has its own advantages and disadvantages which will be discussed in the following section. 
3.1.1. Profiling techniques used for biomarker identification 
3.1.1.1. Genomics Genomics is the comprehensive study of an organism’s genome that includes the total DNA and its genes. There are several levels at which genome information can be derived such as structural and numerical alterations of chromosomes and sequence alterations at genome level. Chromosomal abnormalities have found to contribute to the emergence of many developmental diseases and malignancies 
(Theisen and Shaffer 2010). Numerical chromosomal abnormalities are characterised by the gain or loss of a single chromosome (Russo, et al. 2015). Structural abnormalities occur when there is an alteration in the structure of the chromosome arms and involve deletions, duplications, translocations, amplifications and inversions (Grade, Difilippantonio and Camps 2015). Advances in genome-based techniques such as next-generation sequencing, single-nucleotide polymorphism array, fluorescence in situ hybridisation, microarray-based comparative genome hybridisation and spectral karyotyping have contributed to the detection of chromosomal aberrations and mutations that cause genetic 
114  
diseases and malignancies (da Silva, et al. 2017, Ratan, et al. 2017, Braun, et al. 2019, 
Aleksandrova, et al. 2016, Song, et al. 2017). These chromosomal aberrations and mutations have been used as diagnostic biomarkers for several types of cancer including breast cancer, multiple myeloma, bladder cancer, endometrial cancer, colorectal cancer, cervical cancer, prostate cancer, renal cell carcinoma and acute lymphoblastic leukaemia (Yap, et al. 2015, Vargas-Rondón, Villegas and Rondón-
Lagos 2017). 
3.1.1.2. Transcriptomics Transcriptomics is the global analysis of an organism’s transcriptome that consists of all RNA transcripts expressed within cells. The transcriptome is the initial product of gene expression and plays as a biological bridge between DNA and functional proteins, the final products of the genome (Horgan and Kenny 2011). Different techniques have been developed for analysing gene expression including serial analysis of gene expression (SAGE), cap analysis of gene expression (CAPE), gene expression microarrays and RNA-sequencing (RNA-Seq). RNA-Seq is the most recent technology developed which superseded conventional array-based platforms and now widely adapted for transcriptome profiling with better dynamic range and accuracy. (Lowe, et al. 2017).  Transcriptomic profiling has been extensively used for biomarker discovery in many diseases such as cardiovascular diseases, tuberculosis, autoimmune diseases and cancer (Pedrotty, Morley and Cappola 2012, Van Rensburg and Loxton 2015, 
Ostrowski, et al. 2018, Sager, et al. 2015). However, information derived from transcriptomic profiling reflects the level of RNAs abundance, not proteins. Therefore, the interpretation of transcriptomic data is difficult to predict the phenotypic feature of a cell or tissue (Misra, et al. 2018). This limitation has been solved by the integration of genomic and transcriptomic datasets with data generated from proteomics and metabolomics that provide information about epigenetic and phenotypic variations (Misra, et al. 2018). 
3.1.1.3. Proteomics Proteomics is the field of studying the “proteome” that is defined as the collection of all proteins expressed within a cell, tissue or organism. One of the key aims of proteomics is to characterise phenotypic signatures of a cell or tissue through 
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proteins pathways and networks and describe the structure and function of proteins on a global scale (Theodorescu and Mischak 2007, Petricoin, et al. 2002). Like the transcriptome, the proteome is also dynamic in nature and can be easily altered or modified according to the condition of the biological microenvironment surrounding the cell or tissue. Proteins are the primary targets of most approved drugs, confirming the importance of identifying proteins that may have the potential for drug-target (Bull and Doig 2015) and also act as the mean for the most FDA-approved tests in the clinic, particularly plasma protein targets that constitute 45% of FDA-approved tests (Anderson 2010). However, the complexity of the proteome renders various challenges for comprehensive analysis (Merrick, et al. 2011). Proteins are more complex in nature than nucleic acids as they undergo post-translational modifications that are required to maintain the bioactivity of proteins within a cell or tissue. These modifications are one of the major reasons for the increased complexity of the proteome in any organism (Seo and Lee 2004). These complexities have contributed to the development of various proteomic platforms that facilitate the quantification and identification of different types of proteins and its post-translational modifications with comprehensive data analysis. These 
platforms will be described later in the following section (3.1.2). 
3.1.1.4. Metabolomics Similar to the transcriptomic characterisation of cellular RNAs and the proteomic characterisation of entire proteins expressed at a given time, cells can also be analysed for detecting metabolites that are final-end products of complex biochemical pathways that link genotype to phenotype (Goodacre, et al. 2004). The study of total low-molecular-weight compounds (metabolites) within a cell or organism is called “metabolomics” (Kamburov, et al. 2011). Theoretically, metabolomics has more advantages over the other omics technologies. First, since metabolites are the final downstream products, changes in the level of metabolites expression are correlated with changes in the transcriptome and proteome. Second, the cellular metabolome reflects a functional signature of the cellular proteome 
(Urbanczyk‐Wochniak, et al. 2003, Fiehn 2002). The evolution of metabolomic technologies such as mass spectrometry (MS), high-resolution nuclear magnetic resonance spectroscopy (NMR), ultra-performance liquid chromatography (UPLC) and bioinformatics has enabled more comprehensive quantification of the 
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metabolome (Tsutsui, et al. 2011). Also advances in mass spectrometry have improved the accuracy, reliability and efficiency of metabolic profiling (Liang, Wang 
and Li 2015). Metabolomics-derived biomarkers can also be used as targets for clinical laboratory tests. For instance, recently, metabolic profiling using 1H NMR has been carried out to identify biomarkers that can predict renal failure in patients who received contrast medium before undergoing angiography. This analysis has identified a panel of six urinary metabolites that can predict renal damage including glutamic acid, uridine diphosphate, glutamine and tyrosine (Dalili, et al. 2019). Also, another study has analysed metabolomic changes in tissues derived from patients with adenocarcinoma lung cancer and squamous cell lung carcinoma. This study has 
identified 851 metabolites that were aberrated in lung cancer tissue compared to the normal tissues (Moreno, et al. 2018). Such studies have confirmed the importance of metabolomic profiling to identify robust biomarkers that can be used clinically for monitoring patients. However, metabolomics approach suffers from several challenges that make it more complex than other omics approaches. First, the cost of experiments and instrumentations as metabolomic profiling requires multiple analytical platforms to study the complexity of biochemical pathways 
(Wishart 2016, Pinu, et al. 2019). Second, metabolites are present with different molecular weights and lower concentrations and varied in their stability and turnover rates within cells, thereby measuring them using a single universal analysis method is difficult (Beale, et al. 2018, Fiehn, et al. 2007). Third, the accuracy and reproducibility of metabolite quantification is another challenge due to the variations of sample extraction and different instrumental standardisation steps 
(Broadhurst, et al. 2018). Finally, the validation of a metabolite fingerprint is also challenging due to the complexity of metabolites networks within cells (Zhang, et al. 
2015). 
3.1.2. Mass spectrometry-based proteomics In general, proteomics is used to link genotype to phenotype through a large-scale determination of gene and cellular function at the protein level. The complexity of the cellular proteomes and the presence of many low-abundant proteins require highly sensitive techniques for proteomic analysis (Tyers and Mann 2003). Mass spectrometry (MS) has been evolved for analysis of complex protein samples. MS-
117  
based proteomics has proven itself as a powerful technology to characterise the structure and function of proteins. To date, proteomic analyses such as protein primary sequencing, post-translational modifications, protein-proteins interactions and secretome (proteins that are secreted extracellularly) have been carried out using MS-based instruments (mass spectrometers) (Mishra 2010). In general, mass-spectrometers have three main parts (figure 3.1). The first is the ionisation source, which converts peptides or proteins mixture into positively and negatively charged ions based on the nature of a mixture. The second is the mass analyser, which sorts and separates ions based on their mass to charge (m/z) ratio. The third part is the 
detector, which detects the ions sorted by the mass analyser (Lemière 2001). The development of soft-ionisation methods such as MALDI (matrix assisted laser desorption ionisation) and ESI (electrospray ionisation) has enabled the proteomics field to accurately measure peptide masses and identify their sequences.              
Figure 3.1. Schematic representation of the basic structure of a mass spectrometer. Upon injection, samples (peptides) are directed to the ion source where they become ionised with positive and negative charge based on their nature. After ionisation, peptide ions are eluted to travel through a high-pressure atmosphere to reach the mass analyser which sorts and separates peptide ions based on their m/z ratios. The sorted ions continue flying in a speed based on their m/z ratios to finally hit the ion detector which produces a signal which represents the time of flight for each ions to hit the detector. The signals are then processed and recorded as peaks or mass spectra. 
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3.1.2.1. MALDI-TOF MS Instruments MALDI-TOF instruments represent the conventional MS technology which are generated to measure peptide masses. These instruments consist of the ionisation source “MALDI” and the mass analyser; time of flight (TOF). In the MALDI source, the sample of interest is mixed with matrix chemical compounds such as 2,5-
dihydroxybenzoic acid, 3,5-dimethoxy-4-hydroxycinnamic acid and α-cyano-4-hydroxycinnamic acid, in addition to acetonitrile and water (Liebler 2001). The admixture of sample and matrix compounds is then loaded as spots onto a target plate and allowed to dry in air. Once dried, spots usually look like a powdery deposit or crystal lattice into which the peptide or protein sample is combined. The target plate is then placed into the source equipped with a laser which produces a beam of light at the target (figure 3.2). Once spots of sample are introduced to the laser beam, matrix compounds become electronically excited and transfer this energy to the peptides or proteins in the sample which are then expelled from the target plate into the gas phase(El-Aneed, Cohen and Banoub 2009). Each peptide can pick up a single proton, and therefore most of peptide ions produced by MALDI are singly charged ions and defined as [M+H]+ ions; M is the actual mass of a peptide or protein and H is the proton (charge) bound to the peptide or proteins. Then the positive singly charged ions ([M+H]+ ions) are directed to the TOF mass analyser (Demeure, 
Gabelica and De Pauw 2010) (figure 3.2).  The mass analyser measures the time needed for the ions to fly from the beginning to the end of the analyser until they hit the detector. The speed of ions flying through the analyser is proportional to their m/z values. Ions with high m/z values strike the detector faster than those with low m/z values (Demeure, et al. 2010). TOF analyser operates in two different modes; linear and reflectron mode. Linear mode is where ions are produced from the source and fly through the analyser tube until reach the detector. However, TOF analysers with linear mode are not sensitive as the resolution of MS analysis is very poor. The resolution in MS is defined as the ability of the instrument to discriminate between ions that are slightly different in their 
m/z values. The poor resolution in linear-mode TOF is due to differences in the velocities of ions having the same m/z values as they fly, which leads to create peak broadening during analysis (Kinter and Sherman 2005, Demelbauer, et al. 2004). In contrast, a TOF analyser operating in reflectron mode shows better resolution 
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where the reflectron acts as a speed controller for ions flying through the analyser, and therefore ions of the same m/z values are focused by the reflectron to reach the detector at the same time. This leads to better resolution as sharp, narrow peaks will be produced from analysis (Demelbauer, et al. 2004). Given the development of MALDI-TOF instruments with different modes, they have some limitations. First, these instruments are designed to measure peptide masses, and this type of information is not useful in obtaining true sequence data for peptides or proteins. Second, MALDI-TOF instruments are not linked directly with separation systems such as HPLC (high performance liquid chromatography) which separate contaminants such as urea, glycol, and Tris, and therefore the resolution and sensitivity of the analysis will be very poor (Byrd and McEwen 2000, Müller, et al. 
2001, Liebler 2001), although offline chromatographic spotting/fractionation can overcome this it adds time and complexity to the analysis .     
     
   
Figure 3.2. Schematic representation showing the principle of MALDI ionisation method. The peptides samples are mixed with the matrix compounds. The mixture of peptides and matrix compounds is then loaded into the target plate as spots. The target plate is then introduced into the source of ionisation supplied with a laser. Upon activation, the laser produces a beam directly to the target plate which makes matrix spots become electronically excited by acquiring protons (H+). Excited matrix spots transfer protons to the peptides spots to produce positively-charged peptide ions ([M+H]+ ions). The [M+H]+ ions are then directed to the mass analyser for MS analysis.  
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3.1.2.2. ESI Tandem MS Instruments       ESI tandem MS or (ESI-MS-MS) instruments have been evolved to improve the sensitivity and reproducibility of proteomic analysis. ESI is electrospray ionisation, the source of ions production in the instrument. Tandem mass spectrometry (MS-MS) refers to mass analysers that are designed to carry out two- or multi-stage mass analyses of generated ions (Pitt 2009). The main principle of ESI method is the generation of multiple charged ions from a mixture of peptides or proteins. In this method, samples in liquid form are injected into the source via a flow stream that comes often from the HPLC linked with the source. Samples then enter a capillary, which has a shape of a cone, supplied with high electric voltages on its tip (figure 3.3). As the samples exit the capillary, they are sprayed out in a fine mist of droplets. The continuous application of electric voltages to the capillary’s tip leads to the formation of charged droplets. These droplets are in a state of solvation and contain peptides or proteins in addition to ingredients (e.g. water, acetonitrile and acetic acid) from the HPLC mobile phase. All these steps occur under an atmospheric pressure (Ho, et al. 2003). The charged droplets (solvated droplets) are then dispersed from the capillary cone to the mass analyser which is held in high vacuum region. Before entering the mass analyser, ions of peptides of proteins will be purified and separated from the HPLC solvents by the source in a process called “ion desolvation”. Ion desolvation can be achieved in different ways based on the type of the source. In some sources, the droplets pass through a heated capillary which assists evaporation the solvents (Banerjee and Mazumdar 2012). In other sources, a curtain of nitrogen gas cross through against the direction of the droplets’ flow, which facilitates evaporation of the solvents and reduction in the size of the droplets. In both ways, the peptides or proteins ions are released from the source into the mass analyser, whereas the solvents from the droplets are bumped away by the vacuum system (Janusson, et al. 2015) (figure 3.3).       
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 ESI-MS-MS instruments have been designed with different types of mass analysers including TOF, quadrupole, ion trap, Fourier transform mass spectrometry, Fourier transform-ion cyclotron resonance, orbitrap. Other instruments have hybrid mass analysers which are a combination of two or three mass analysers to obtain better 
performance. These instruments include triple/tandem quadrupole, quadrupole-TOF (Q-TOF), TOF-TOF, linear trap quadrupole-orbitrap (LTQ-orbitrap) and others. Each of these instruments has specific features for ions analysis, and therefore the  use of such instruments is based on the proteomic approach required to sequence and characterise proteins of interest (Matthiesen and Bunkenborg 2013). All these analysers are the best examples of MS-MS technology which is now indispensable for any kind of proteomic approaches. There are three primary steps in any MS-MS mass analysers. First, selection of precursor ions (desolvated ions) that are produced by the ESI source. This step is mostly called “ions scanning or filtration” in which ions with a specific m/z value will proceed to the next stage of analysis. This is usually achieved by quadrupole analysers, specifically Q1, and ion trap analysers. Second, fragmentation of the selected precursor ions to generate fragment or 
Figure 3.3. Schematic representation showing the principle of ESI ionisation method. The peptide samples are injected into the ionisation source via a flow-stream coming from the HPLC that is linked with the source. In the source, samples enter a capillary which has a shape of a cone supplied with high electric voltages on its tip where peptide ions become positively charged. The samples are then ejected from the tip in a fine mist of droplets with multiple charges. The multiple charged droplets contain peptides and other ingredients such as water and  acetonitrile. These 
charged droplets are directed into a heated, high pressure zone in a process called desolvation 
that results in a reduction the size of droplets and liberation of free positively-charged peptides ions. The peptide ions are then directed into the mass analyser for MS analysis.    
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product ions. This step is achieved by a process called “collision-induced dissociation (CID)”. This process occurs when the selected precursor ions are subjected to collide with “neutral collision gas”, which is usually helium, nitrogen or argon, in a region called collision cell (Dawson 2013). This region of the analyser is usually supplied with radiofrequency voltages that facilitate fragmentation of the selected precursor ions by applying kinetic energy which exceeds the internal energy of the precursor ions, leading to dissociation of precursor ions into small fragments (product ions). Third, these product or fragment ions are further analysed based on their m/z values to generate a spectrum for each product ions. This MS-MS spectrum is usually used to deduce the sequence of a peptide 
(Matthiesen and Bunkenborg 2013). 
3.1.2.3. Proteomic approaches for sequencing and characterisation of 
proteins Sequencing of proteins can be accomplished either by analysing proteins using their intact from or by digesting them. Although modern MS instruments are still able to measure the molecular weight of intact proteins, it is still very difficult to sequence them using their intact structure, especially high molecular weight and hydrophobic or complex  protein mixtures (Chait 2006). Also, the sensitivity of analysing intact proteins is not as high as sensitivity of analysing peptides. For this reason, proteomic analysis using digested proteins is more commonly carried out than using intact proteins (Feist and Hummon 2015). There are three main proteomic approaches to sequence and identify proteins, including bottom-up approach, top-down approach and middle-down approach. 
3.1.2.3.1. Bottom-up (BU) approach  BU approach is the most common technique used to identify proteins and their amino acid sequences by digesting proteins into small peptides prior to analysis using MS-based instruments. With regard to digestion, the proteins are either  
introduced to enzymatic proteolysis (e.g. Trypsin, Glu-C, Lys-C, Asp-N and Chymotrypsin) or chemical proteolysis (e.g. cyanogen bromide) (Kinter and 
Sherman 2005, Liebler 2001) . Each of these proteases can cleave proteins at specific amino acid residues. BU is a peptide-based approach for identification of a proteins, which means that complete digestion of proteins is ideally required to obtains 
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numerous fragments of peptides with length of ~ 7-20 amino acids, which is the ideal length for MS analysis. By this strategy, the identity of a protein is deduced by unequivocal detection of peptides that have unique sequences for that protein (Xie, 
Smith and Shen 2012). However, obtaining complete digestion of proteins is not straightforward as it depends on the complexity of the sample that will be analysed and the abundance of specific amino acid residues in the structure of proteins. For example, trypsin, which is the most common protease enzyme used for protein digestion in BU approach, cleaves proteins at the carboxyl side (C-terminal side) of the lysine and arginine amino acid residues. However, trypsin does not cleave proteins if the C-terminal of the lysine and arginine amino acids is followed by Proline residues (Olsen, Ong and Mann 2004). Therefore, the number of peptides fragments resulting from the digestion of a protein will be based on the number and site of lysine and arginine residues of that protein and whether the lysine and arginine are linked with Proline. (Tsiatsiani and Heck 2015). As a consequence, limited sequence coverage of proteins is a major obstacle in BU approach due to the incomplete digestion of proteins, which hampers detection of post-translational modifications and isoforms of proteins (Catherman, Skinner and Kelleher 2014). 
3.1.2.3.2. Top-down (TD) approach  The TD approach is referred to identification and sequencing of proteins using their intact structure without introducing to any kind of digestion. The TD approach has been found more useful for studying and detecting post-translational modifications and isoforms of proteins than BU approach (Savaryn, et al. 2013). However, applying MS-based proteomics is relatively limited using a TD approach, although trials have been done to develop a realistic method for sequencing and characterising proteins using MS-based TD analysis (Toby, Fornelli and Kelleher 2016). 
3.1.2.3.3. Middle-down (MD) approach  The MD approach is an emerging method for sequencing proteins by combining the principles of both BU and TD approaches. MD approach has been suggested and invented based on the advantages and disadvantages of BU and TD approaches 
(Garcia 2010). By MD strategy, digested proteins would be analysed instead of intact proteins by introducing them to enzymatic and chemical proteolysis as mentioned in BU approach. However, in MD approach, incomplete digestion of proteins is 
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typically required, compared with BU where complete digestion of proteins is needed. Therefore, the incomplete digestion would produce polypeptides fragments with length of ~20-100 amino acids, which are significantly longer than peptides resulted in BU approach (Cristobal, et al. 2017). Therefore, the number of peptides generated by MD approach would be fewer than the number of peptide produced by BU approach, which means that the complexity of the peptides mixture resulted in the MD approach would be significantly lower than the peptide mixture resulting from the BU approach (Pandeswari and Sabareesh 2019). Thus, the percentage of sequence coverage would be increased high enough to identify proteins and characterise their post-translational modifications (PMTs) and isoforms using  MD compared to the BU approach where detection and identification PMTs and isoforms of proteins is very limited (Pandeswari and Sabareesh 2019). 
3.1.2.4. Separation methods of peptides/proteins prior to MS analysis Due to the complexity of proteomic samples that include a complex mixture of peptides or intact proteins, several methods have been used to reduce the complexity of proteomic samples, which allow the MS instruments to analyse maximum number of peptides and generate useful information for identifying proteins, especially low-abundant proteins (Shi, et al. 2004, Fonslow and Yates Iii 
2009) . The separation methods can be classified into two main methods; gel-based and gel-free method. Gel-based methods include one-dimensional and two-dimensional gel electrophoresis that can separate proteins based on their isoelectric points and molecular weights, respectively (Baggerman, et al. 2005). Gel-free methods include liquid chromatography methods such as reverse phase high performance liquid chromatography (HPLC), ultra-high performance liquid chromatography (UHPLC) and multi-dimensional liquid chromatography (Mitulović and Mechtler 2006). In liquid chromatography, the degree of separation of peptides or intact proteins is based on the features of mobile phase (solvents) and the stationary phase (separation column). The mobile phase facilitates elution of analytes (peptides or proteins) that are attached to the stationary phase. The analyte’s elution by the mobile phase is correlated with the strength of interaction between the analytes and the stationary phase (Pandeswari and Sabareesh 2019). Thus, the selection of columns and solvents is highly important to achieve great separation of complex mixture of peptides or intact proteins. The HPLC method is 
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mostly used in proteomic studies, where the mobile phase or solvents are water, acetonitrile and methanol (Ali, et al. 2010). These solvents are compatible to ESI-MS-MS instruments, and for this reason the HPLC technology has been successfully linked with most of ESI-MS-MS instruments, which is denoted as LC-MS or LC-MS-MS proteomics (Arrivault, et al. 2009). Another method is also used for separation peptides or intact proteins, which is called capillary electrophoresis (CE) (Simpson and Smith 2005). CE can be classified either gel-based or gel-free methods based on 
several operation modes including capillary gel electrophoresis, capillary zone electrophoresis, capillary isoelectric focusing, capillary isotachophoresis and capillary affinity electrophoresis (Sun, et al. 2016, Storms, et al. 2004, Nesbitt, Zhang and Yeung 2008). 
3.1.2.5. Shotgun and targeted proteomics 
3.1.2.5.1. Shotgun proteomics Shotgun proteomics is a discovery-based method that is widely used in proteomic studies to acquire a broad overview of the proteins expressed in a sample that would be analysed (McDonald and Yates 2002). The shotgun method is broadly utilised as a high-throughput tool for biomarker discovery in which potent clinical validation may or may not be accomplished. Although the shotgun method is highly efficient in identifying hundreds or thousands of proteins in any biological samples, it is rarely used to analyse specific molecules within a cell or tissue at different conditions. This means that shotgun method is not suitable for hypothesising or answering a specific question (Faria, et al. 2017). Rather, the shotgun method has already been designed to provide complex answers for somewhat non-specific questions. For example, identifying a significant number of proteins that are upregulated and downregulated in various experimental conditions can be achieved using the shotgun method, however, knowing the main cause for the up- and down-regulation of the proteins will be very limited (Martins-de-Souza, et al. 2010, Castagnola, et al. 2012) . Also, shotgun proteomics has a very limited potential of identifying low-abundant proteins because it is based on the analysis of fragmented peptides that are usually identified relative to the abundance of each protein in a sample, thus only the highly enriched proteins will be identified (Wang, et al. 2017b). However, this does not mean that the shotgun approach is irrelevant or time-consuming in nature. 
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This approach has opened the doors for other methodologies such targeted proteomics that can investigate the proteome in a selective way (Faria, et al. 2017). 
3.1.2.5.2. Targeted proteomics Targeted proteomics is a question-based or hypothesis-based method that is widely used in proteomic studies to answer specific questions more quickly and more accurately than classic shotgun approach (Marx 2013). Targeted approach is mainly used to monitor or analyse a selection of proteins that are already known beforehand. Therefore, by using a targeted approach, it is compulsory to select proteotypic peptides (PTPs) that have unique amino acid sequences which constantly determine a specific protein in a given proteome investigated by MS 
(Domon and Gallien 2015). There PTPs play as a marker or signature for the selected protein of interest and are tracked throughout the experimental run on MS. Thus, the selection of PTPs is the most critical step in the targeted approach, which requires in-depth knowledge about the protein of interest (Gallien, Duriez and 
Domon 2011). There are two main strategies used in targeted proteomics including selection reaction monitoring (SRM) or multiple reaction monitoring (MRM) and parallel reaction monitoring (PRM). In SRM, a panel of peptides is selected to quantify the protein of interest and analysed on a mass spectrometer, usually triple quadrupole mass analysers in which the first mass analyser is used a mass filter with a narrow isolation window to isolate a specific peptide precursor ion generated from the selected peptide (Ebhardt 2014). Then the isolated precursor ion is further fragmented to generated small fragment ions, and one of the generated fragment ions is monitored by the next mass analyser which is set to filter a specific m/z value 
(Picotti and Aebersold 2012a). The double selection of the peptide precursor ion and fragment ion by the tandem mass analysers is called a transition process. This transition is highly specific and produces highly sensitive measurements for proteins of interest. In contrast, PRM method (such as from a Q-TOF instrument) operates in a different way where all fragments ions generated from the pre-selected peptide precursor ion are analysed simultaneously (Borràs and Sabidó 
2017). In PRM method, a peptide precursor ion of interest is filtered and selected by a narrow isolation window setting of the first mass analyser. The selected peptide precursor ion is then fragmented, and the resulting fragment ions are together analysed by the next mass analyser set to screening mode (Bourmaud, Gallien and 
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Domon 2016). Then chromatographic peaks resulted from fragment ions are analysed to determine the best fragment ions for peptide identification and quantification. Therefore, PRM is more flexible method than SRM because it can analyse a broad range of fragment ions  instead of monitoring only one fragment ion, and generate highly sensitive and specific data with dynamic range for peptide and protein quantification (Rauniyar 2015, Borràs and Sabidó 2017) . Thus, the PRM method can be specifically used for monitoring low-abundant proteins (Faria, et al. 
2017). However, the limitation of using targeted proteomics in the clinic is the requirement of extremely sensitive and specific biomarkers for targeted analysis (Faria, et al. 2017). 
3.1.2.6. Methods of quantifying proteins There are two main methods commonly used for protein quantification in MS-based proteomics, including label-based and label-free methods. 
3.1.2.6.1.  Label-based method  Label-based method is a comparison analysis of proteins quantification between samples that are labelled with different mass tags which allow detection of proteins based on specific change in mass. These tags share the same chemical structure and are different in their isotopic affinity (Domon and Aebersold 2010). There are three 
different types of labelling, including metabolic, chemical and enzymatic labelling 
(Zhang, et al. 2010).  
3.1.2.6.1.1. Metabolic labelling  Metabolic labelling is one of the most favoured method of labelling because samples of interest are labelled at the early stage of sample preparation, which leads to decrease experimental variabilities between samples (Bantscheff, et al. 2007). By metabolic labelling, different samples are introduced to an isotopically defined medium containing distinct labels that can incorporate with the proteome of samples during the process of protein metabolism. The samples are then equally pooled together and analysed on MS (Iliuk, Galan and Tao 2009). This generates two forms of each peptide with different isotopic structure, but with identical reaction to sample preparation and MS analysis, thus allowing quantification of proteins of the labelled samples without affecting their biochemical features (Geiger, et al. 
2011). Initially 15N-modified media was used for labelling, in which all 14N 
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(nitrogen) isotopes were replaced by 15N isotopes (Oda, et al. 1999). However, using this media showed several limitations including partial or inadequate labelling of samples and difficulties in data analysis as well as higher costs (Anand, et al. 2017). A more effective labelling technique known as SILAC (stable isotope labelling of amino acids in cell culture) was developed by Ong et al. (Ong, et al. 2002). SILAC is a non-selective method of labelling proteins where heavy isotopes of specific amino acids are used as labels. By this technique, two different medium are used to grow two different populations of cells in vitro; one medium contains normal (light) amino acids and the second contains isotopically-labelled heavy amino acids (Chen, 
et al. 2015). This labelling is achieved by replacing the natural atoms of H, 14N and 
12C to 2H, 15N and 13C, respectively. Leucine, lysine, methionine and arginine are the most suitable amino acids have been used for effective isotopic labelling (Mann 2006). The labelled amino acids can then integrate into the newly synthesised proteins of the labelled sample. Then samples are mixed and prepared to be analysed by MS. The MS analysis can distinguish between samples by the molecular weight of the heavy and light isotopes of the specific amino acids that were used during cell culture (Harsha, Molina and Pandey 2008). There are key advantages of using SILAC including an effective labelling due to the high integration rate of labelled amino acids into the proteome of interest, efficient labelling without any chemical manipulation to the samples, and reducing experimental variabilities as the samples are labelled in the early steps (Ong, et al. 2006). SILAC has been broadly 
used to study PTMs, protein signalling pathways and enzyme substrates, as well as identification of cancer-related biomarkers (Chen, et al. 2015). A major limitation of using SILAC is that the number of heavy forms of amino acids used for labelling is very limited, so that only 5 different biological states can be analysed within a single experiment (Anand, et al. 2017). 
3.1.2.6.1.2. Chemical labelling Chemical labelling is also another labelling technique which is mostly used for protein quantification. It is a flexible labelling technique as the isotopic labels can be selectively introduced into any of desired position in a peptide or a protein of interest (Chahrour, Cobice and Malone 2015). Chemical labelling is relatively similar to metabolic labelling except that isotopic labels of a peptide or a protein are mediated by chemical reactions (Kainosho, et al. 2006). Isotope-coded affinity 
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tagging (ICAT) is of the earliest chemical labelling methods, which has been introduced by Gygi et al. (Gygi, et al. 1999). ICAT reagent consists of thiol-reactive iodoacetamide group that labels cysteinyl thiols residues in proteins, a linker region that contains heavy or light deuterium atoms and biotin tag used for affinity purification (Smolka, et al. 2001). The limitation of  ICAT is that the rate of peptide recovery during purification  is very low due to the presence of deuterium atoms in the linker region (Zhang, et al. 2001). There are other techniques of chemical labelling including tandem mass tag (TMT) and isobaric tag for absolute and relative quantification (iTRAQ). These techniques are amine-based labelling in nature, which target only amine functional group of the peptides (Savitski, et al. 2013). Using these techniques, the proteins are essentially labelled with chemical groups which are equal in mass (isobaric) and are fragmented under the pressure of tandem MS to produce reporter ions in a various mass range (Evans, et al. 2012). TMT is designed to analyse a maximum of ten samples, whereas iTRAQ allows analysis of up to eight samples in a single experiment (Latosinska, et al. 2015, Zhang, et al. 2016) . TMT and iTRAQ have been widely used due to their flexibilities of analysing multiple samples with a relative accuracy of protein quantification (Huang, et al. 2017). However, there are some 
limitations to using TMT/iTRAQ including the requirement of MS instruments with higher resolving powers, higher costs, non-specificity of reporter ions for peptides due to the impact of peptide co-isolation process during the MS run, and inaccuracy between peptide quantity and identity (Karp, et al. 2010). 
3.1.2.6.1.3. Enzymatic labelling 
Enzymatic labelling is another labelling technique used for protein quantification. 
18O labelling technique is an example of enzymatic labelling which uses protease 
enzymes such as trypsin to integrate two 18O atoms instead of 16O atoms in peptides, making a shift in peptides mass (Reynolds, Yao and Fenselau 2002). However,  it is 
not widely used in quantitative proteomics due to instability of enzymatic labels (Ramos-Fernandez, Lopez-Ferrer and Vazquez 2007, Zhang, et al. 2013) . 
3.1.2.6.2. Label-free quantitation methods Label-free quantitation methods have been widely used in proteomic studies as it provides easy options for global analysis of biological samples. Unlike label-based 
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methods, label-free methods allow analysis and comparison of many samples that are injected individually into MS (Wang, et al. 2008). Label-free approach is cost-effective, does not require expensive labelling reagents, and is not time consuming as compared to label-based methods (Megger, et al. 2014). All these advantages have allowed label-free method of the favoured approaches for large-scale protein quantification (Wang, et al. 2008) . Using label-free method, thousands of proteins can be identified from even complex samples such as blood, plasma, saliva, urine, cell line and tissues. Moreover, label-free approach produces highly sensitive MS analysis and is less vulnerable to technical or experimental errors (Megger, et al. 
2013). 
3.1.2.6.2.1. Spectral counting Spectral counting that determines the relative abundance of a protein by measuring the frequency of peptide identified of a protein. In spectral counting, the amount and  size of a protein is directly equivalent to frequency of peptide spectra identified that belong to a protein (Arike and Peil 2014). Protein abundance index (PAI) is also used in spectral counting method to measure the abundance of a protein in a given sample (Cutillas and Vanhaesebroeck 2007). PAI is defined by the number of identified peptides divided by the number of theoretically observable peptides for each protein. However, the spectral counting method is biased for MS analysis due to the frequent detection of peptides with various physico-chemical features (Zhang, et al. 
2013).  
3.1.2.6.2.2. Ion intensity  Ion intensity that measures the MS chromatographic signal intensity of peaks for peptides of a protein. This intensity-based method, which is also known as “the area under the curve” (AUC), quantifies proteins by integration and measuring of all chromatographic peak areas of identified peptides of a protein (Neilson, et al. 2011, 
Podwojski, et al. 2010) . However, several factors should be considered before using this method to ensure the accuracy and reproducibility of MS data analysis. These factors are co-eluting peptides that can affect peptides retention time, multiple signals of the same peptide, MS speed and sensitivity, and background noise due to chemical overlapping (Listgarten and Emili 2005, Cui, et al. 2013, Zhang, et al. 2013). 
131  
3.1.2.6.2.3. Data-dependent acquisition Data-dependent analysis or acquisition (DDA) has also been used for protein quantification. DDA is a conventional mode of the most tandem MS instruments, 
where the first mass analyser (MS1) is set to run a scan survey for all peptide-precursor ions  that are eluted from the LC column for multiple cycles (Wu and MacCoss 2002). In each cycle, the most abundant ions represented by “LC-MS peaks” are then recorded, selected and consecutively isolated for fragmentation by the second mass analyser to identify structural features and identity of proteins 
(Bateman, et al. 2014). MS1 quantification can be carried out in two different ways based on the method used for chromatogram processing. First, LC-MS feature-based 
MS1 quantification, where every LC-MS peak (feature) is detected and characterised 
from the MS1 data, and then all peaks are annotated using the peptide identifications from the MS2 data (Bilbao 2019). Examples of open source software packages implementing this method include SuperHirn (Mueller, et al. 2007), VIPER (Monroe, 
et al. 2007) and MzMine-2 (Pluskal, et al. 2010). Second, extracted ion chromatograms (XIC or EIC)-based MS1 quantification, this method is targeted analysis, where precursor ion signals from each confidently-identified peptide are extracted from MS1 data. Then XICs are listed to determine m/z targets of the confidently-identified peptides (Bilbao 2019). Skyline software package is used process the targeted MS analysis (Pino, et al. 2017, MacLean, et al. 2010) . However, DDA method is biased as only abundant peptides are selected for further analysis to identify and quantify proteins, whereas low-abundant peptides which may represent important low-abundant proteins are excluded from the analysis, thereby leading to irreproducible results specially for complex proteomic samples (Bateman, 
et al. 2014). 
3.1.2.6.2.4. Data-independent acquisition The limitations of DDA for protein quantification and identification have been overcome by the recent developments in hybrid MS instruments and data analysis software by which all precursor ions of peptides eluted from the LC-MS are fragmented and analysed regardless of their abundance levels and intensities in an operation mode called “data-independent acquisition (DIA)” (Hu, Noble and Wolf-
Yadlin 2016). DIA is unbiased method which comprehensively and frequently analyses all peptide precursor ions of a given sample in a wide precursor isolation 
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window , generating a complex set of mass spectra (peaks) (Chapman, Goodlett and 
Masselon 2014). Also, DIA provides a broad range of detected peaks (signals) with different m/z values of detected ions, and therefore increases the coverage rate of peptides and proteins identification with highly sensitive and reproducible results (Bilbao, et al. 2015). In addition, the efficient performance of DIA has enabled label-free shotgun approach to be as a valid alternative to isotope-labelling-based methods (Navarro, et al. 2016). The aforementioned successes of DIA has also been applied in another more specialised proteomics approach; middle-down approach, 
wherein the size of proteolytic peptides is much larger than those resulting from bottom-up approach. Carvalho et al. have developed another version of DIA, which is called XDIA (extended data-independent acquisition) for protein quantification using middle-down approach. The authors have confirmed that applying XDIA has increased the number and accuracy of peptide spectra and improved protein sequence coverage using middle-down approach which targets large molecules and detects post-translational modifications and various isoforms of proteins (Carvalho, 
et al. 2010). However, one of the considerations of using DIA is the complexity of data yielded post MS analysis which contains ions spectra of all detected peptides. Accordingly, several informatics acquisitions have been evolved to process these sophisticated MS datasets, including SWATH-MS (Gillet, et al. 2012), DIANA 
(Teleman, et al. 2014)and Skyline (Pino, et al. 2017). Another obstacle of DIA in the increased probability of interference due to the overlapping of fragments ion yielded from co-fragmented precursor ions, which can mislead the identification and quantification of proteins (Zhang, et al. 2015). However, several computational approaches have been developed to handle this issue to further extend the benefits of DIA, including SwathTUNER and NOFI (non-outlier fragment ion) (Bilbao, Lisacek 
and Hopfgartner 2016).  
3.1.2.7. Subcellular fractionation The complexity of the proteome within organisms is due to the presence of various types of tissues in which each cell undergoes a specific-lineage differentiation and thereby acquires a specific functional specialisation. A cell is also compartmentalised in nature, which means that each cell contains different organelles (subcellular components) performing specific functions within a cell. This compartmentalisation provides distinct and appropriate environments for 
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synthesis, localisation and interaction of subcellular proteins (Dreger 2003). The proteome of subcellular organelles within a cell is significantly less complex than the proteome of whole cells. Thus, this has allowed development different methods for Isolation and enrichment of subcellular components of a cell, which is called “subcellular fractionation” (Yates Iii, et al. 2005). Subcellular fractionation method has been widely used to reduce the complexity of proteomic samples, thereby leading to identify and quantify more proteins or interest. Subcellular fractionation has also enabled detection of peptides that belong to low-abundant proteins, thereby increasing the coverage rate of protein quantification using MS-based proteomics (Lee, Tan and Chung 2010). Subcellular fractionation has also enabled identification and quantification of plasma membrane proteins which are the key target of antibody-based therapies (Leth-Larsen, Lund and Ditzel 2010). There are several methods have been developed for subcellular fractionation, including differential centrifugation, density-gradient centrifugation, differential detergent fractionation, free-flow electrophoresis, immunoaffinity purification and fluorescent-assisted organelle sorting (Satori, Kostal and Arriaga 2012). Differential centrifugation is one of the conventional methods for subcellular fractionation and involves subsequent centrifugation of the cell or tissue homogenate to isolate organelles such as nuclei, mitochondria and lysosomes. The isolation or separation 
of organelles in this method is based on variations in size and density of organelles. However, the high organelles contamination with poor separation purity is the major disadvantage of differential centrifugation (Lee, et al. 2010). Density-gradient centrifugation is the most common conventional method for subcellular isolation, which separate organelles using various density-gradient media with different osmolarities, viscosities and densities. There are many types of media used in this 
method including Ficoll, Percoll, Nycodenz, Metrizamide and Sucrose. Sucrose is the most common medium used in this method as it is inexpensive and biologically inert 
(Araùjo, Hube and Stasyk 2008). The separation of organelles in density-gradient centrifugation is based on the differences between organelle and medium density which is affected by the organelle content and lipid to protein ratio (Graham 2001). However, the disadvantages of density-gradient centrifugation are time-consuming centrifugation steps and poor isolation purity. To overcome the disadvantages of deferential and density-gradient centrifugation methods, differential detergent 
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fractionation (DDF) method has been developed to isolate proteins in their native state from four subcellular localisations (cytosolic, membrane, membrane-associated and nuclear and cytoskeleton proteins) using different detergent-containing buffers (Abdolzade‐Bavil, et al. 2004, McCarthy, et al. 2005). Free-flow electrophoresis (FFE) is an alternative method which has been developed to segregate organelles such as peroxisomal membranes, secretory vesicles, plasma membrane vesicles and mitochondria (Satori, et al. 2012). By FFE, such organelles are separated according to their net isoelectric charges. FFE can also isolate proteins in their native state which is ideal for functional proteomic analysis (Weber, et al. 2004, McDonald, et al. 2006). However, FFE can result in co-migration of organelles that have similar isoelectric charges, thereby leading to isolation contamination and low isolation purity (Lee, et al. 2010). Immunoaffinity purification and immunoprecipitation are robust methods used to isolate organelles based on the interaction between antibodies (ligands) that are immobilised on solid plate and organelles of interest (targets). This affinity-based method yields high isolation purity as the purification process can be repeated for optimal organelle enrichment. However, immunoaffinity purification method is expensive and requires more time and effort for optimal purification (Fang and Zhang 2008). Fluorescent-assistance organelle sorting (FAOS) is a cell sorting-based method which has been used to sort and isolate subcellular organelles such as mitochondria, phagosomes, secretory granules and endocytic vesicles (Satori, et al. 2012). FAOS requires a well-known protein biomarker that is specific for the organelle of interest. This specific biomarker must be tagged with green fluorescent protein (GFP) and then transfected into cells, enabling cell sorting based on its fluorescence (Cao, et al. 
2008).                   
3.1.3. Aims of this study The aim of this chapter is to optimise methods of sample preparation to generate global and subcellular proteomic profile of biologically different subsets murine of CD4+ T cells for identifying distinct proteins which can distinguish natural and induced Tregs from other subsets of CD4+ T cells either individually or in combination.   
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The objectives of this chapter are: 
1- Determination of minimum cell number required for the generation of quantitative proteomics data using murine T cells. 2- Develop a suitable cell lysis condition to yield maximum amount of proteins from the optimised cell numbers 3- Optimisation of tryptic digestion conditions for the proteins prior to mass spectrometry analysis. 4- Determine cell sorting parameters for different subsets of CD4+ T cells populations including iTregs, naïve nTregs and naïve CD4 T cells. 5- Optimisation of subcellular fractionation of CD4+ T cells subpopulation prior to mass spectrometry-based analysis.   
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3.2. Material and Methods 
3.2.1. Optimisation protocols for global proteomic profiling of 
mouse splenocytes using LC-MS-MS proteomics 
3.2.1.1. Determination of optimal cell number for global MS profiling Mouse splenocytes were harvested from the spleen and counted using NucleoCounter machine (NucleoCounter® NC-250™, Chemometec). Then, different numbers of cells were used as a part of optimisation to determine the best number 
of cells that yields more proteins, including 10x106, 5x106, 2.5x106, 1x106 and 
0.5x106. Cells were centrifuged at 350 x g for 8 min, washed twice using DPBS. Then, cell pellets were resuspended and lysed by adding Ericka’s lysis buffer (EB) which 
contains 9.5M urea (Sigma Aldrich), 2% of DTT (0.5M dithiothreitol) and 1% N-Octyl-Beta-Glucopyranoside. 100 µL of EB were added into samples containing 
10x106 cells, whereas 50 µL of EB were added into the other samples.  MS-SAFE Protease and Phosphatase Inhibitor (PI, Sigma Aldrich) was added into cell lysates 
at ratio 1 to 100 dilution (1 µL of PI / 100 µL of EB). Cells were mixed thoroughly by vortexing. Cell lysates were sonicated for 5 minutes and placed on ice for other 5 minutes to ensure complete lysis of cells. Sonication and ice incubation cycles were repeated until cells were completely lysed. Bradford protein assay (Dye Reagent Concentrate, Bio-Rad, Cat No. 500-0006) was conducted to estimate the protein concentration in each cell lysate. 25 ug of proteins were taken from each cell lysate for mass spectrometry sample preparation. Prior to trypsinisation, proteins were reduced by adding 1 µL of 0.5 M dithiothreitol (DTT, Sigma Aldrich) into protein 
solutions and incubated at 56⁰C for 20 min for reduction. Alkylation of proteins was 
followed by adding 2.7 µL of 0.55 M iodoacetamide (IAA, Sigma Aldrich) and incubated at room temperature in the dark for 15 min. After the reduction and alkylation, the volume of proteins solutions was increased up to 100 µL by adding 50 mM of triethyl ammonium bicarbonate (TEAB) solution to reduce the 
concentration of urea in the protein solution below 1 M before trypsinisation. 
Protein digestion was carried out by adding trypsin (Trypsin Gold, Promega, UK) at 
a ratio 1:20 (1 µg trypsin : 20 µg protein) and incubated at 37⁰C with constant mixing 
for 16 h on a Bioer thermomixer. After the trypsinisation, the solutions of digested 
proteins were dried at 45⁰C using vacuum concentrator (Eppendorf). Dried pellets 
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were resuspended in 20 µL of 5% acetonitrile in 0.1% formic acid (LCMS grade, 
Sigma Aldrich, UK) and mixed well by pipetting several times. The resuspended 
samples were incubated at 37⁰C with constant mixing for 5 min and then centrifuged 
at 12000 x g for 3 min. The supernatants of samples were carefully transferred into 300 µL high recovery liquid chromatography (LC) vials (Chromatography Direct, 
UK) to be analysed using a 6600 TripleTOF mass analyser (SCIEX). Table 1A (shown in the appendix) summarises the amount and concentration of reagents that were used to prepare samples for proteomic MS analysis. 
3.2.1.2. Effect of RBC lysis on total protein yield and identification 
The results of experiments detailed in section 3.2.1.1 showed that the number of proteins identified by MS analysis was very low in all samples irrespective of the cell number used for that study. Accordingly, it was hypothesised that the reduction of protein identification might due to the presence of red blood cells (RBCs) in murine splenocytes. Herein, mouse splenocytes were harvested from the spleen. Then RBCs of splenocytes were lysed and eliminated using RBC lysis buffer (BD Pharm LyseTM, BD Biosciences, Cat no. 555899) according to the manufacturer’s instructions. Subsequently, splenocytes were counted and prepared as per the protocol explained 
in section 3.2.1.1. Table 2A (shown in the appendix) summarises the concentration of proteins yielded in each sample, and the amount and concentration of reagents that were used to prepare samples for MS analysis.                
3.2.1.3. Optimisation of the volume of cell lysis buffer for improved protein 
recovery The results of experiments discussed in section 3.2.1.2 confirmed that the use of RBC lysis buffer was beneficial as it increased the number of proteins identified by MS analysis. However, the concentration of proteins yielded from cell lysis was not improved. To address this, it was suggested to reduce the volume of cell lysis buffer (EB) to increase or improve the concentration of proteins in each sample (cell lysate). Herein, splenocytes were harvested from the spleen. RBCs were lysed by RBC lysis buffer. Then splenocytes were counted and aliquoted into 5 different samples based on cell number as shown in table 3A (shown in the appendix). Then 60 µL, 40 µL, 30 µL, 24 µL and 18 µL of EB were added to lyse samples containing 
10x106, 5x106, 2.5x106, 1x106 and 0.5x106 cells, respectively. Then samples were 
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prepared following the same steps mentioned in section 3.2.1.1. Table 3A (shown in the appendix) summarises the concentration of proteins resulted in each sample and the amount and concentration of reagents used for samples preparation. 
3.2.1.4. Effect of addition MS-compatible surfactant agent (protease max) on 
total protein yield and identification  To assess the effect of a surfactant (Protease Max) to enhance protein solubilisation 
and enzymatic performance of trypsin on the identification of proteins, optimised 
experiments carried out in section 3.2.1.3 were repeated with the addition of 1.25 
µL of 1% protease max solution immediately after adding trypsin. The samples were 
further processed following the same protocol mentioned in section 3.2.1.1. Table 4A (shown in the appendix) illustrates the concentration of proteins resulted in each sample and the amount and concentration of reagents used for samples preparation. 
3.2.1.5. Optimisation of enzymatic digestion of total proteins  To improve the identification of proteins by MS analysis, the enzymatic performance of trypsin and trypsin Lys-C was compared in the presence and absence of protease max (P.Max). Mouse splenocytes were isolated from the spleen. RBCs were lysed using RBCs lysis buffer, splenocytes were counted and aliquoted into 2.5x106 cells aliquotes. Samples were processed for MS analysis following the protocol mentioned in the previous sections. However, herein, samples were diluted using 
50mM TEAB to reduce the final concentration of urea below 1 M prior to protein digestion. Also, two different proteases, trypsin (Sigma Aldrich) and trypsin-Lys-C (a mixture of trypsin and Lys-C, Promega, UK) were used to enzymatically digest proteins in samples with and without the addition of surfactant (P.Max). In each experiment, 4 samples containing the same quantity (25 µg) of proteins were prepared. One set of sample was digested with trypsin only, another sample was digested with trypsin in addition to P.Max, third set was digested with trypsin-Lys-C, and the last was digested with trypsin-Lys-C in addition to P.Max. The total number of proteins identified by MS analysis was evaluated and compared between 
the 4 samples to determine the best enzymes cocktail for protein digestion by using the number of proteins identified as the readout. Table 5A (shown in the appendix) outlines the concentration of proteins yielded in each sample in all experiments, and the amount and concentration of reagents used for preparation samples.  
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3.2.1.6. Effect of urea concentration on tryptic digestion of total proteins  To evaluate the impact of urea concentration on tryptic digestion of proteins, 6 different lysis buffers were prepared and used for cell lysis. In this experiment, Ericka’s buffer (EB) and Urea solution buffer were used with titration in the molarity of urea in both buffers. The standard Ericka’s buffer which was used in the experiments mentioned above contains 9.5 M urea. However, in this section, EB with 
8 M urea and 7 M urea were prepared individually. In addition, urea 9.5 M, 8 M and 
7 M buffers were also prepared separately and used for cell lysis. Herein, samples 
containing 2.5x106 cells were lysed with the prepared buffers. Then they were toped 
up with 50 mM TEAB to reach 200 µL of volume as mentioned in section 3.2.1.5. Then samples were further processed for reduction, alkylation and trypsinisation following the same protocol mentioned in section 3.2.1.1. Herein, trypsin was only used for protein digestion. Table 6A (shown in the appendix) shows a summary of the concentration of proteins of each sample, and the amounts and concentrations of each reagent used for processing samples.  
3.2.1.7. Effect of peptide clean-up prior to MS analysis on total protein 
identification. To assess whether clean-up of peptides prior to MS analysis can efficiently purify tryptic peptides with higher recovery rates and improve the identification of proteins. Herein, samples were processed as mentioned in section 3.2.1.6. However, in this experiment, tryptic peptides of each sample were purified immediately after trypsinisation using C18 Hypersep columns (Thermo Scientific, UK) which were used to separate tryptic peptides from other interfering contaminants present in the digestion solution. Reagents required for the C18 Hypersep columns are as follows; 
releasing solution consists of 95% acetonitrile (ACN) and 0.1% formic acid (FA), the 
binding solution contains 0.1% FA. Labelled C18 columns were placed into 1.5 mL centrifuge tubes. C18 columns were then activated by washing with 50 µL of releasing solution and centrifuged at 4.5 x g for 45 sec at room temperature. This step was repeated three times. Flow-through solution was discarded, and the columns were equilibrated with 50 µL of binding solution and centrifuged again at the same settings. This step was also repeated three times. C18 columns were placed 
into new 1.5 mL centrifuge tubes to avoid contamination of flow-through solution. Then, samples were loaded into the C18 columns. Samples were loaded into the 
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columns in multiple batches; 50 µL of sample each time and centrifuged at 4.5 x g for 45 sec. This step was repeated until total volume of sample was completely loaded. After loading samples, columns were washed again with 50 µL of binding solution and centrifuged three times as mentioned above. C18 columns were then placed into fresh Lo-Bind Eppendorf tubes (Eppendorf, UK, Cat No 0030108116). Then, samples (peptides fragments) were eluted or released from C18 columns by washing with 50 µL of releasing buffer and centrifuged at 4.5 x g for 45 seconds. This step was repeated two times to ensure full recovery of samples. After elution, samples were dried in Eppendorf vacuum concentrator on V-AQ (vacuum-aqueous) setting at 60°C. Dried samples were then resuspended in 15 µL of 5% ACN in 0.1% FA solution and incubated at 37°C with constant mixing for 5 min. Then, samples 
were centrifuged at 12000 x g for 3 min. Supernatants of samples were transferred into LC (liquid chromatography) tubes for running on MS. Table 7A (shown in the appendix) shows a summary of protein concentrations of each sample and the concentrations and amounts of reagents used for preparation samples.   
3.2.1.8. Global shotgun proteomic profiling of purified murine T cells Mouse T cells were purified from splenocytes using Dynabeads™ Untouched™ 
Mouse T Cells Kit (Invitrogen, Thermo Fisher Scientific, catalog No. 11413 D). T cells were counted and aliquoted into several samples, each contains 2.5x106 cells. 
Samples were washed twice with DPBS and centrifuged at 350 x g for 8 min. Then, samples were lysed with Ericka’s buffer containing 8 M urea. Protease inhibitor (MS Safe Protease and Phosphate Inhibitor, Sigma Aldrich) was added into samples at a ratio of 1:100 dilution. Samples were sonicated and incubated on ice three times (5 min each) to ensure full lysis. The concentration of total proteins in sample was measured using Bio-Rad Bradford assay (Dye Reagent Concentrate, Bio-Rad). After that, 25 µg of proteins from each sample were transferred into fresh 1.5 mL centrifuge tubes. According to the concentration of proteins, samples were topped up with 50mM TEAB to reach 200 µL total volume. After that, samples were reduced with 1 µL of DTT and incubated at 56°C for 20 min in a shaking thermomixer. The 
samples were then alkylated with 2.7 µL of IAA and incubated at room temperature 
in the dark for 15 min. The total volume of each sample before trypsinisation was 
203.7 µL and the concentration of urea was maintained between 0.49 M and 0.56 M prior to digestion to enhance the performance of trypsin. The samples were digested 
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with trypsin at a ratio 1:20 (1 µg trypsin: 20 µg protein) and incubated at 37°C with 
constant mixing for 16 h in a thermomixer. After trypsinisation, peptides of samples were cleaned up from interfering contaminants and purified using C18 Hypersep columns and prepared for MS analysis as mentioned in section 3.2.1.7. Table 8A (shown in the appendix) shows a summary of protein concentrations of each sample and the concentrations and amounts of reagents used for preparation samples. 
3.2.2. Optimisation protocols for subcellular proteomic profiling of 
mouse CD4+ T cells using LC-MS-MS proteomics 
3.2.2.1. Optimisation a strategy for sorting a pure population of induced Tregs 
(iTregs) and natural Tregs (nTregs) prior to MS profiling. Induced Tregs (iTregs) were generated in vitro as mentioned in chapter 2 (section 2.2.4). Naïve CD4+CD25- T cells were sorted and rested overnight in complete T cell 
medium at 37⁰C, 5% CO2. A 24-well culture plate was prepared by adding 900 µL of complete T cell medium in each well with a hanging cell culture insert After that, 
2.5x105 of sorted naïve CD4+CD25- T cells resuspended in 200 µL of complete T cell medium were transferred into each of hanging cell culture inserts. Then, cells were activated using Dynabeads™ Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activation Kit according to the manufacturer’s instruction with IL-2 (30 U/mL) and TGF-β1 (5 ng/mL). The cultures were further incubated for 5 days at 37⁰C, 5% CO2. At day 5, cells were harvested, washed with DPBS twice and counted. Prior to sorting, 
0.5x106 of cells were stained with anti-CD4, anti-CD25 and anti-Foxp3 antibodies to assess the induction of Foxp3 of iTregs and to gate CD4+CD25++Foxp3+ iTregs based on the intensity of CD25 staining.  Herein, the strategy of sorting iTregs was based on the intensity of CD25 staining, not on the intensity of Foxp3 staining as the latter requires cell fixation and permeabilisation which damages the surface membrane of cells. Cells were stained with anti-CD4 and anti-CD25 antibodies for sorting CD4+CD25++Foxp3+ iTregs from activated CD4+CD25+Foxp3- using MoFlo XDP cell sorter, sorting mode: purify. Cell sorter was set to sort CD4+CD25++Foxp3+ iTregs based on the same gate that was used for identifying Foxp3+ iTregs on flow cytometry. After sorting, sorted CD4+CD25++Foxp3+ iTregs were rested for three 
hours in complete T cell medium at 37⁰C, 5% CO2. Cells were then centrifuged at 350 
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x g for 8 min and counted. 0.2x106 of iTregs were stained again with anti-CD4, CD25 and Foxp3 antibodies to assess the purity of iTregs sorting. The sorting of nTregs was mainly based on the intensity of CD25 staining. To achieve this, naïve CD4+ T cells were purified from splenocytes as mentioned in chapter 2 (section 2.2.2). purified CD4+ T cells were stained with anti-CD4 and CD25 antibodies and sorted into two separate populations CD4+CD25- T cells and CD4+CD25+ nTregs.  
3.2.2.2. Determination of the number of spleens required to obtain 2.5x106 of 
purely sorted CD4+CD25++Foxp3+ iTregs and CD4+CD25+Foxp3+ natural 
Tregs (nTregs) prior to subcellular fractionation. According to the optimised protocol used for global profiling of T cells, 2.5x106 was the optimal number of cells for identification higher number of proteins. Therefore, 
to obtain 2.5x106 of purely sorted iTregs and nTregs, splenocytes were harvested from two and three spleens in two separate experiments. After harvesting, splenocytes were pooled together and processed for isolation CD4+ T cells which were then processed for sorting naïve CD4+CD25+ nTregs and CD4+CD25- T cells as mentioned above. Then CD4+CD25- T cells were then cultured for generating iTregs 
in vitro as mentioned above.     
3.2.2.3. Optimisation subcellular fractionation of CD4+ T cells using Mem-PER 
Plus membrane protein extraction kit (pilot study). Subcellular fractionation of CD4+ T cells was carried out using Mem-PERTM Plus membrane proteins extraction kit (Thermo Fisher Scientific, Cat No. 89842) which has been designed to isolate and enrich integral membrane proteins and membrane-
associated proteins from cells. Following manufacturer’s instructions, 2x106 of CD4+ T cells were harvested and centrifuged at 350 x g for 8 min. The cell pellet was washed with 2 mL of cell wash solution which was included in the kit and centrifuged at 350 x g for 6 min. After washing, supernatants were carefully discarded, and the cell pellet was washed again with 2 mL of cell wash solution and centrifuged at 300 x g for 6 min. Following the final wash, 600 µL of permeabilisation buffer, which was included in the kit, was added to the cell pellet. Cells were resuspended by brief and gentle vortexing. After that, 6 µL of protease inhibitor (MS 
Safe, Sigma Aldrich) was added into the cell suspension at ratio 1 in 100 dilution. 
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The homogenous cell suspension was incubated for 20 min at 4⁰C with constant mixing using a rotary mixer. Permeabilised cells were centrifuged at 16000 x g for 
15 min at 4⁰C. The supernatants containing cytosolic or cytoplasmic proteins were carefully removed and transferred into a new 2 mL LoBind Eppendorf tube. The pellet containing membrane proteins fraction was resuspended with 300 µL of solubilisation buffer which was included in the kit to solubilise membrane proteins. The solution was mixed well by careful pipetting up and down for 2 min. Then, 3 µL 
of protease inhibitor was added into the protein solution at ratio 1 in 100 dilution. The protein solution was incubated at 4⁰C for 60 min with constant mixing. The protein solution containing solubilised membrane proteins was centrifuged at 
16000 x g for 15 min at 4⁰C. The supernatants containing membrane and membrane-associated proteins were transferred to a new 2 mL LoBind Eppendrof tube for further downstream analysis.  
3.2.2.4. Protein quantitation Assay. To quantify proteins in the cytoplasmic and membrane fractions enriched from cells, PierceTM 660 nm protein assay was carried out according to the manufacturer’s instructions. To purify and concentrate proteins of the cytoplasmic and membrane fractions isolated from the cells, proteins were precipitated using cold acetone. Acetone precipitation of proteins was also used to remove all interfering substances and detergents included in the permeabilisation and solubilisation buffers, which are incompatible with MS analysis. To achieve this, acetone was cooled to -20⁰C for a day. Then five times the sample volume of cold acetone (-20⁰C) was added into the cytoplasmic and membrane fractions. For cytoplasmic proteins fraction, the samples (600 µL volume) were transferred to a new 5 mL LoBind Eppendorf tubes, and then 3mL of cold acetone was added into the samples. For membrane proteins fraction, the samples (300 µL volume) were transferred to a new 2 mL LoBind Eppendorf tubes, and then 1.5 mL of cold acetone was added into the samples. Then both membrane and cytoplasmic proteins samples were incubated overnight at -
20⁰C. Samples were then centrifuged at 16000 x g for 30 min at 4⁰C. Supernatants were carefully discarded, and the protein pellet was precipitated again by adding 
1.5 mL of cold acetone and 300 µL of nano-pure distilled water to ensure removing 
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all interfering detergents in the protein solution. Proteins samples were then incubated for 60 min at -20⁰C. proteins samples were centrifuged at 16000 x g for 
15 min at 4⁰C. the protein pellet was then prepared for downstream process. 
3.2.2.5. Preparation of precipitated cytoplasmic and membrane protein 
samples for MS analysis. 
8 M urea dissolved in nanopore water was prepared. 1%, 0.1% and 0.2% protease max surfactant in 50 mM TEAB solutions were prepared. For membrane protein samples, the precipitated protein pellet was solubilised by adding 20 µL of 0.2% 
protease max in 50 mM TEAB and 15 µL of 8M urea. Samples were then incubated 
for 60 minutes at 4⁰C with constant mixing using rotary mixer. After the vortexing, 60 µL of 50mM TEAB were added into samples. The samples were reduced by 
adding 1 µL of 0.5 M DTT into samples, and samples were incubated at 56⁰C for 20 
min. Alkylation steps were performed by adding 2.7 µL of 0.55 M IAA into samples 
which were incubated at room temperature in the dark for 15 min. Then proteins were digested by adding trypsin at a ratio 1:20 (1 µg trypsin: 20 µg protein) and 1 
µL of 1% protease max surfactant. Samples were incubated overnight at 37⁰C with constant shaking at medium speed (200 rpm) on a thermomixer.  For cytoplasmic protein samples, the precipitated protein pellet was solubilised by 
adding 20 µL of 0.1% protease max in 50mM TEAB. Samples were then incubated 
for 60 min at 4⁰C with constant mixing by vortexing at 70 rpm. Then 75 µL of 50 mM TEAB were added into samples. Samples were then prepared similar to membrane proteins samples as mentioned above. Table 3.1 summarise the concentrations and volumes of reagents that were used for preparation membrane and cytoplasmic protein samples for MS analysis.  After trypsinisation, samples were dried in an Eppendorf vacuum concentrator on V-AQ setting at 60°C. Dried samples were then resuspended in 15 µL of 5% ACN in 
0.1% FA solution and incubated at 37°C with constant mixing for 5 min. Then, 
samples were centrifuged at 12000 x g for 3 min. Supernatants of samples were transferred into LC (liquid chromatography) tubes for running on MS.      
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Table 3.1: Summary of in-solution solubilisation and digestion reaction volumes for membrane and cytoplasmic proteins. 
Reagents Membrane 
proteins  Cytoplasmic proteins  
0.1% protease max in 50 mM TEAB  - 20 µL 0.2% protease max in 50 mM TEAB 20 µL - 
8 M Urea 15 µL - 50 mM TEAB 60 µL 75 µL 0.5 M DTT 1 µL 1 µL 0.55 M IAA 2.7 µL 2.7 µL Trypsin (1 µg/µL) 1.5 µL 1.5 µL 
1% protease max in 50 mM TEAB 1 µL 1 µL Total  101.2 µL 101.2 µL    
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3.3. Results 
3.3.1. Optimisation protocols for global proteomic profiling of 
mouse splenocytes and T cells using LC-MS-MS proteomics 
3.3.1.1. Determination of optimal cell number for global MS profiling  To determine the minimum cell number required to obtain maximum amounts of total proteins in calorimetric protein assay and mass spectrometry-based identification, five different cell numbers were tested. Highest amounts of total 
proteins were obtained from samples containing 10x106 cells (mean = 195.3 µg, 
SEM 24.16), compared with samples containing 2.5x106 cells (mean = 42.1 µg, SEM 
7.15), 1x106 cells (mean = 16.8 µg, SEM 1.05) and 0.5x106 cells (mean = 7.5 µg, SEM 
2.81). There was no significant difference in the amounts of total proteins between 
samples containing 10x106 and 5x106 cells (mean = 77.8 µg, SEM 3.56) (figure 3.4 A) as measured by the protein assay. Samples with 1x106 and 0.5x106 cells were not processed for MS analysis as they yielded less than 25 µg of total proteins. However, the number of proteins identified by MS analysis was not relatively correlated with the number of cells within samples. The number of proteins identified in samples 
with 10x106 cells was between 120 and 806 proteins (mean = 415 proteins, SEM 
158.9), whereas the mean of the number of proteins was 256 (SEM 38.18) and 226 (SEM 35.44) identified in samples with 5x106 and 2.5x106 cells, respectively (figure 3.4 B). There was no significant difference in the number of proteins identified by 
MS between samples with 10x106, 5x106 and 2.5x106 cells. These results also were seen in the number of distinct peptides and spectra as there was no significant difference in the number of distinct peptides and spectra between samples with 
10x106 (mean = 2615 (SEM 878.3) and 5364 (SEM 1631)), 5x106 (mean = 1667 
(SEM 219.3) and 3602 SEM 400.1)) and 2.5x106 (mean = 1534 (SEM 178.2) and 
3469 (SEM 350.7); peptides and spectra, respectively) (figure 3.4 C and D). However, 
compared to samples of 10x106 and 5x106 cells, samples containing 2.5x106 cells provided more reasonable results according to their cell number. These results confirmed that samples need further optimisation for MS analysis as the number of proteins, peptides and spectra identified in all samples was significantly low compared to the number of cells especially samples with higher number of cells.  
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Figure 3.4.  Bar graphs showing the amount and total number of proteins obtained from samples containing different cell number. (A) The amount of proteins in micrograms yielded from samples containing different number of cells. (B) The number of proteins that were identified in samples containing different number of cells using LC-MS-MS analysis. (C) The number of distinct peptides that uniquely match or belong to the identified proteins. (D) The number of peptides spectra that represent the MS-MS peaks of peptides fragments used to identify distinct peptides of proteins. Ordinary one-way ANOVA test was used for 
statistical analysis using GraphPad Prism 8.0.1 software. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data.  Bars errors represent the standard error (SE) of the mean. (****; P-value <0.0001, **; p-value <0.0046, 
*; p-value <0.0138). 
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3.3.1.2. Effect of RBC lysis on total protein yield and identification One of the potential problems with using total splenocytes for MS analysis is the presence of RBC in the cell preparation which may interfere with cell lysis, protein assays and other downstream processing. To improve the identification of total proteins by MS, the RBC lysis buffer was used to remove RBCs from splenocytes. The results showed that the amounts of proteins yielded after using RBC lysis buffer were decreased in samples with 10x106 cells (mean = 147.5 µg, SEM 32.5) and 5x106 (mean = 52.50 µg, SEM 2.5), whereas the amounts of proteins were significantly 
increased in samples with 1x106 cells (mean = 39 µg, SEM 1) and 0.5x106 (mean = 32.5 µg, SEM 0.5) (figure 3.5 A), compared to the results in section 3.3.1.1. The results also showed that there was no significant difference in the amounts of 
proteins yielded between all samples, especially samples with 5x106, 2.5x106, 1x106 
and 0.5x106 cells as they showed approximately similar values. These results suggested that there might be a background noise within samples, which might affect the accuracy of proteins quantitation assay. However, the results showed a significant increase in the number of proteins, distinct peptides and spectra in all 
samples after using RBC lysis buffer, compared to the results in section 3.3.1.1 where samples were processed without using RBC lysis buffer. According to the results, the mean of the number of proteins identified by MS was higher in samples with 5x106 
cells (1336, SEM 19) compared to samples with 10x106 (1133, SEM 43), 2.5x106 
(1202, SEM 28.5), 1x106 (473.5, SEM 84.5) and 0.5x106 cells (565, SEM 75) (figure 3.5 B). Also, the number of distinct peptides and spectra detected by MS was proportional to the number of proteins in all samples. The mean of the number of 
distinct peptides and  peptides spectra was higher, of course,  in samples with 5x106 
cells (7250 (SEM 103) and 11463 (SEM 162.5), respectively) compared to other samples with 10x106 (6183 (SEM 79) and 9541 (SEM 80)), 2.5x106 (6678 (SEM 
158.5) and 10567 (SEM 250.5)), 1x106 (1821 (SEM 324.5) and 2786 (SEM 496.5)) 
and 0.5x106 (2612 (SEM 347) and 3954 (SEM 525.5), respectively) (figure 3.5 C and D). Nevertheless, the number of proteins, peptides and spectra detected by MS was not correlated to the number of cells within samples. For example, the number of 
proteins identified in samples with 0.5x106 cells was ~50% less than number of 
proteins identified in samples with 10x106 cells which have 20 times more cells than 
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samples with 0.5x106 cells, although the same amounts of proteins (25 µg) were digested from both samples.                              
Figure 3.5. Bar graphs showing the amount and total number of proteins obtained from samples containing different cell number after using RBC lysis buffer.  (A) The amount of proteins in micrograms yielded from samples containing different number of cells. (B) The number of proteins that were identified in samples containing different number of cells using LC-MS-MS analysis. (C) The number of distinct peptides that uniquely match or belong to the identified proteins. (D) The number of peptides spectra that represent the MS-MS peaks of peptides fragments used to identify distinct peptides of proteins. Ordinary one-way ANOVA test was used for statistical analysis using GraphPad Prism 8.0.1 software. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (*; p-value < 0.0225, **; p-value <0.0044, ***; p-value <0.0006).         
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3.3.1.3. Optimisation the volume of cell lysis buffer for improved protein 
recovery To improve the yield of total proteins, samples were lysed with different volumes of cell lysis buffer based on the number of cells they contain. The results showed the amounts of proteins yielded in all samples were relatively correlated to the number of cells after titrating the volume of lysis buffer, compared to the results in section 
3.3.1.2 where there was no significant difference in the amount of proteins obtained 
from samples containing 5x106, 2.5x106, 1x106 and 0.5x106 cells. The results revealed that the amount of proteins yielded were higher, of course, in samples 
containing 10x106 cells (mean = 149 µg, SEM 11), compared to samples with 5x106 
(mean = 60 µg, SEM 4), 2.5x106 (mean = 38.3 µg, SEM 2.3), 1x106 (mean = 24.4 µg, 
SEM 1.6) and 0.5x106 (mean = 14.5 µg, SEM 0.8) (figure 3.6 A). For proteins identification by MS, the results generally showed an increase in the mean of the number of total proteins identified in all samples after reducing the volume of lysis buffer during preparation samples, except samples containing 5x106 cells which showed a reduction in the mean of the number of total proteins (mean = 
1096, SEM 4) compared to the results in section 3.3.1.2. The results also showed that 
samples with 2.5x106 cells specifically had the highest number of proteins (mean = 
1597, SEM 74) identified by MS, compared to samples with 10x106 (mean = 1316, 
SEM 74), 5x10 (1096, SEM 4), 1x106 (979, SEM 8) and 0.5x106 cells (mean = 803, SEM 50) (figure 3.6 B). The number of distinct peptides and spectra detected by MS analysis was correlated with the number of proteins identified in all samples (figure 3.6 C and D).          
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Figure 3.6. Bar graphs showing the amount and total number of proteins obtained from samples with different cell number which were lysed using different volumes of cell lysis buffer. (A) The amount of proteins in micrograms yielded from samples containing different number of cells. (B) The number of proteins that were identified in samples containing different number of cells using LC-MS-MS analysis. (C) The number of distinct peptides that uniquely match or belong to the identified proteins. (D) The number of peptides spectra that represent the MS-MS peaks of peptides fragments used to identify distinct peptides of proteins. Ordinary one-way ANOVA test was used for 
statistical analysis using GraphPad Prism 8.0.1 software. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (*; p-value < 
0.0275, **, p-value <0.0099, ***; p-value <0.0004, ****; p-value < 0.0001).           
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3.3.1.4. Effect of addition MS-compatible surfactant agent (protease max) on 
the protein identification To achieve higher identification of proteins by MS, protease max (P.Max), a surfactant agent compatible with MS, was added into samples immediately after 
addition of trypsin to enhance the enzymatic function of trypsin. The results showed a reduction in the number of total proteins identified by MS in samples containing 
10x106 and 2.5x106 cells, whereas samples with 5x106, 1x106 and 0.5x106 cells showed a slight increase in the number of total proteins (figure 3.7 A), compared to the results shown in section 3.3.1.3. Despite of the reduction and increase in the 
number of proteins after using P.Max , samples with 2.5x106 cells provided the 
highest number of proteins ( mean = 1467, SEM 35.5) compared to samples with 
10x106 (mean = 1172, SEM 52), 5x106 (mean = 1160, SEM 30.5), 1x106 (mean = 
1121, SEM 41) and 0.5x106 (mean = 820, SEM 44) (figure 3.7 A). The number of distinct peptides and spectra was also correlated with the number of proteins 
(figure 3.7 B and C).                 
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Figure 3.7. Bar graphs showing the total number of proteins, distinct peptides and peptides spectra identified in samples with different cell number which were digested in the presence of surfactant protease max. (A) The number of proteins that were identified in samples containing different number of cells using LC-MS-MS analysis. (B) The number of distinct peptides that uniquely match or belong to the identified proteins. (C) The number of peptides spectra that represent the MS-MS peaks of peptides fragments used to identify distinct peptides of proteins. Ordinary one-way ANOVA test was used for statistical analysis using 
GraphPad Prism 8.0.1 software. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (*; p-value < 0.0202, **, p-value <0.0069, ***; p-value <0.0004). 
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According to the results shown in sections 3.3.1.1, 3.3.1.2 and 3.3.1.3, samples with 
2.5x106 cells showed a significant increase in the number of total proteins identified by MS analysis and were corresponding to the optimisation of experimental protocols as mentioned in sections 3.3.1.1, 3.3.1.2 and 3.3.1.3 (table 3.2). Also, the 
mean of the amounts of total proteins yielded from samples with 2.5x106 was in 
range between 34.8 and 45.25 µg (range 10.45, SEM 5.23), which means that there were no significant variations in the amounts of proteins yielded from 2.5x106 cells 
in different experiments. For these reasons, 2.5x106 cell number was selected as an optimal cell number for optimising a protocol for global proteomic profiling of mouse T cells. 
Table 3.2: Summary of results representing the mean of the number of proteins identified by MS in samples containing different number of cells.  
Optimisation methods The mean of the number of identified 
proteins by MS analysis  
Lysis Buffer RBC lysis 
Buffer 
Digestion  0.5x106 1x106 2.5x106 5x106 10x106 
Ericka’s NO Trypsin - - 226.3 255.5 415 
Ericka’s Yes Trypsin 565 473.5 1202 1336 1133 
Ericka’s 
 (low volume) 
Yes Trypsin 803 979 1597 1096 1316 
Ericka’s   
(low volume) 
Yes Trypsin+P.Max 820 1121 1467 1160 1172 
        
3.3.1.5. Optimisation of enzymatic digestion of total proteins To achieve higher identification of proteins by MS, two different proteases, trypsin and trypsin-Lys-C, were used for protein digestion with and without addition of P.Max. The results showed that the number of proteins identified by MS analysis was significantly higher in samples in which proteins were digested using trypsin alone 
(mean = 1484, SEM 58.5) compared to samples in which proteins were digested using trypsin-Lys-C alone (mean = 1249, SEM 20.5) and trypsin-Lys-C with addition 
of P.Max (mean = 1044, SEM 26.8) (figure 3.8 A). The results also showed that there was no significant difference in the number of proteins identified between samples digested with trypsin and samples digested with trypsin in addition to P.Max (mean 
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= 1265, SEM 15.9), however samples digested with trypsin showed the highest number of identified proteins (figure 3.8 A). The results also showed a reduction in the number of proteins identified in samples which were digested in the presence of P.Max, compared to samples digested in the absence of P.Max (figure 3.8 A). The number of distinct peptides and spectra was also correlated with the number of proteins (figure 3.8 B and C). 
Figure 3.8. Bar graphs showing the total number of proteins, distinct peptides, peptides spectra identified from protein samples that were digested in different conditions. (A) The number of proteins that were identified in samples in which proteins were digested using different proteases with and without addition of P.Max. (B) The number of distinct peptides that uniquely match or belong to the identified proteins. (C) The number of peptides spectra that represent the MS-MS peaks of peptides fragments used to identify distinct peptides of proteins. Ordinary one-way ANOVA test was used for statistical analysis using GraphPad Prism 8.0.1 software. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (**, p-value <0.0083, ****; p-value <0.0001). 
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3.3.1.6. Effect of urea concentration on tryptic digestion of total proteins To assess the impact of urea concentration on the enzymatic performance of trypsin, cells were lysed using two different lysis buffers; Ericka’s buffer (EB) and urea buffer. Both buffers were prepared using different concentrations of urea. The results showed that there was no significant difference in the amounts of proteins yielded in samples lysed with different lysis buffers containing different concentrations of 
urea including EB 9.5 M, EB 8 M, EB 7 M, urea 9.5 M, urea 8 M and urea 7 M (figure 
3.9 A). The results also showed that the number of proteins identified in samples that were 
lysed by EB containing 8 M of urea concentration was the highest (mean = 1927 
proteins, SEM 28.5) compared to other samples lysed with different lysis buffers (figure 3.9 B). The results showed that the number of identified proteins was significantly higher in samples lysed by EB with different concentrations of urea than samples lysed by urea buffer with different concentrations, especially at 
concentration 9.5 M and 7 M of urea (figure 3.9 B). The mean of number of proteins 
identified in samples lysed with EB 9.5 M and EB 7 M was 1650 (SEM 20) and 1429 
(SEM 78.5), respectively, whereas it was 1089 (SEM 84) and 972 (85.5) in samples 
lysed with urea 9.5 M and 7 M, respectively (figure 3.9 B).  However, although the 
difference in the number of identified proteins between samples lysed with EB 8 M 
(mean = 1927 proteins, SEM 28.5) and urea 8 M (mean = 17347, SEM 67) was not 
significant, samples lysed by EB 8 M yielded more proteins than samples lysed with 
urea 8 M. Moreover, according to the results, the concentration 8 M in both buffers 
was sufficient to yield more soluble proteins from cells than concentrations 9.5 M 
and 7 M. The number of distinct peptides and spectra was also correlated with the number of proteins (figure 3.9 C and D).                   
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Figure 3.9. Bar graphs showing the amount and total number of proteins obtained from samples lysed with different lysis buffers containing different concentrations of urea (in molarity (M)).  (A) The amount of proteins in micrograms yielded from samples that were lysed with different lysis buffers containing different concentrations of urea (in molarity (M)). (B) The number of proteins that were identified in samples lysed with different lysis buffers containing different concentration of urea using LC-MS-MS analysis (C) The number of distinct peptides that uniquely match or belong to the identified proteins. (D) The number of peptides spectra that represent the MS-MS peaks of peptides fragments used to identify distinct peptides of proteins. Ordinary one-way ANOVA test was used for statistical 
analysis using GraphPad Prism 8.0.1 software. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (*; p-value < 0.0275, **, p-value <0.0099, 
***; p-value <0.0004 ****; p-value < 0.0001). 
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3.3.1.7. Effect of peptide purification prior to MS analysis on total protein yield 
and identification To assess the impact of peptide purification prior to MS analysis on identification of total proteins. In this experiment, tryptic peptides were purified and isolated from contaminants (such as urea) within digestion solution prior to MS analysis using C18 Hypersep columns. In general, the results showed that the number of proteins identified by MS analysis was significantly increased after using peptides 
purification columns compared to the results mentioned in section 3.3.1.6 where samples were analysed on MS without peptide purification (figure 3.10 A). The increase in the number of proteins was in range between 116 and 628 more proteins identified in samples after using C18 columns compared to samples prepared without using C18 columns (section 3.3.1.6) (figure 3.10 A). The results also showed that samples lysed with EB containing 8 M urea concentration yielded the highest 
number of proteins (mean = 2427, SEM 133.5) identified after using C18 columns compared to other samples that were lysed by different lysis buffers (figure 3.10 A). The results also showed that the number of distinct peptides was significantly 
increased after peptides purification in samples that were lysed with EB 9.5 M, urea 
9.5 M, EB 8 M, urea 8 M and urea 7 M lysis buffer. However, there was no significant increase in the number of peptides before and after purification in samples lysed 
with urea 7 M lysis buffers (figure 3.10 B). For peptide spectra, the results showed that there was a significant increase in the number of peptides spectra after peptide purification in samples that were lysed with EB 9.5 M, urea 9.5 M and EB 7 M only, 
compared to other samples lysed with EB 8 M, urea 8 M and urea 7 M (figure 3.10 C). These results confirmed the efficiency of the C18 columns in peptide purification which could enhance the identification of proteins.           
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Figure 3.10. Bar graphs showing the total number of proteins, distinct peptides and peptides spectra identified pre- and post-purification of peptides derived from samples lysed with different lysis buffers. 
(A) The number of proteins that were identified before and after purification of peptides using LC-MS-MS analysis. (B) The number of distinct peptides that uniquely match or belong to the identified proteins. (C) The number of peptides spectra that represent the MS-MS peaks of peptides fragments used to identify distinct peptides of proteins. Ordinary one-way ANOVA test was used for statistical analysis using 
GraphPad Prism 8.0.1 software. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (*; p-value < 0.0275, **, p-value <0.0099, ***; p-value <0.0004 ****; p-value < 0.0001). 
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3.3.1.8. Global shotgun profiling of purified murine T cells To create a library of proteins derived from mouse T cells using MS shotgun analysis, mouse T cells were isolated from splenocytes and lysed by EB 8 M lysis buffer to extract proteins. Proteins were digested and processed prior to MS analysis 
according to the optimised protocol mentioned in section 3.2.1.8. The results 
showed that the number of proteins identified from 2.5x106 of purified T cells was 
in range between 1053 and 1232 at 1% of false discovery rate (FDR) and 50% of confidence score based on four separate experiments as shown in table 3.3. Proteins 
showing confidence score ≥ 50% were defined as “confident proteins”. Functional information and subcellular location of proteins were retrieved from Uniprot database, an online resource of protein sequence and functional information (www.uniprot.org).  Figure 3.11 shows an example of how biological information of identified proteins was acquired from Uniprot database online.   
Table 3.3: Summary of the results of the total number of proteins, distinct peptides and peptides spectra that were identified from global proteomic profiling of murine T cells in four separate experiments. 
Experiment Cell Type Cell No. Proteins 
No. Distinct peptides Spectra 
1 Purified T cells 2.5x106 1225 6723 12940 2 Purified T cells 2.5x106 1101 5553 11585 3 Purified T cells 2.5x106 1232 6795 12907 4 Purified T cells 2.5x106 1053 5254 11009  For the first experiment, the results showed that the total number of proteins 
identified at 1% FDR was 1225. 272 (22.2%) of them showed confidence score 
≥50%, whereas 953 (77.8%) of proteins had confidence score < 50%. Of 272 confident proteins, 177 proteins (14.45% of total) were cytoplasmic and nuclear, 
while 95 (7.75%) proteins were identified as membrane proteins. 52 (4.24%) of membrane proteins were characterised as plasma membrane proteins or cell 
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surface membrane proteins, whereas the remaining 43 (3.51%) were characterised as organelles membrane proteins (Figure 3.12).                         In the second experiment, the results showed that the total number of proteins 
identified at 1% FDR was 1101. Out of which 265 (24.07%) showed confidence 
score ≥ 50%, whereas 836 (75.93%) of proteins had confidence score < 50%. Of 265 
confident proteins, 171 proteins (15.53% of total) were cytoplasmic and nuclear, 
Figure 3.11. An example of Bar graph showing subcellular locations of 226 confident proteins, which was obtained from Uniprot database. Membrane proteins highlighted by Red rectangle can be sorted by Uniprot into different subcellular locations of membrane-bound proteins including plasma membrane proteins and intracellular membrane proteins (organelles membrane and mitochondrial membrane).   
162  
while 94 (8.54%) proteins were identified as membrane proteins. 54 (4.91%) of membrane proteins were characterised as plasma membrane proteins or cell surface membrane proteins, whereas the remaining 40 (3.63%) were characterised as organelles membrane proteins (Figure 3.12). In the third experiment, the results showed that the total number of proteins 
identified at 1% FDR was 1232. 289 (23.46%) of them showed confidence score ≥ 
50%, whereas 943 (76.54%) of proteins had confidence score < 50%. Of 289 
confident proteins, 187 proteins (15.18% of total) were cytoplasmic and nuclear, while 102 (8.28%) proteins were identified as membrane proteins. 56 (4.55%) of membrane proteins were characterised as plasma membrane proteins or cell 
surface membrane proteins, whereas the remaining 46 (3.73%) were characterised as organelles membrane proteins (figure 3.12). In the last experiment, the results showed that the total number of proteins 
identified at 1% FDR was 1053. 226 (21.46%) of them showed confidence score ≥ 
50%, whereas 827 (78.54%) of proteins had confidence score < 50%. Of 226 confident proteins, 147 proteins (13.96% of total) were cytoplasmic and nuclear, 
while 79 (7.50%) proteins were identified as membrane proteins. 45 (4.27%) of membrane proteins were characterised as plasma membrane proteins or cell surface membrane proteins, whereas the remaining 34 (3.23%) were characterised as organelles membrane proteins (figure 3.12). According to the results of four experiments mentioned above, the percentage of 
plasma membrane proteins was in range between 4.24% and 4.91% in samples that 
were prepared using the optimised protocol detailed in section 2.3.1.8. Identification of proteins that are exclusively expressed on the plasma membrane was relatively limited compared to other proteins (cytoplasmic and nuclear). Therefore, it was suggested to attempt subcellular fractionation to specifically enriched membrane-bound proteins. The overall results were summarised in figure 
3.12.   
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3.3.2. Optimisation protocols for subcellular proteomic profiling of 
mouse CD4+ T cells using LC-MS-MS proteomics 
3.3.2.1. Optimisation a strategy for sorting a pure population of induced Tregs 
(iTregs) and natural Tregs (nTregs) prior to MS profiling. The sorting of iTregs was mainly based on the intensity of CD25 staining. The results 
showed that over 90% of cells with higher intensity of CD25 expression (> log101) were positive for Foxp3 expression and defined as “pure iTregs population (CD4+CD25++Foxp3+)” (figure 3.13 A), whereas cells with intensity of CD25 lower 
than log101 were mixed populations of CD4+CD25+Foxp3+ and CD4+CD25+Foxp3- T cells (figure 3.13 A). The percentage of pure iTregs (gate R3) for sorting was in range between 20% and 23% of total activated CD4+CD25+ T cells, whereas the percentage 
Figure 3.12. Pie of Pie graphs showing the percentages of proteins identified from global profiling of purified murine T cells based on their confidence score and subcellular locations in four separate experiments. EXP: experiment, Conf: Confidence rate of identification, Cyto: Cytoplasmic, Nuc: Nuclear. 
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of total iTregs induced from activated CD4+CD25+ T cells was between 50% and 55% 
(Figure 3.13 A). Figure 3.15 B showed the gating strategy for sorting the pure iTregs population from total activated CD4+CD25+ T cells using MoFlo XDP cell sorter. The 
results showed that the purity of iTregs sorting was in range between 90% and 92%, 
which means that 90-92% of sorted CD4+CD25++ T cells positive for Foxp3 expression based on the gating strategy which was followed (figure 3.13 B). The percentage of iTregs purity was significantly increased from 50-55% before sorting 
to 90-92% after sorting (figure 3.13 C). The sorting of naïve nTregs was also based on the expression of CD25. The results showed that the purity of sorting naïve nTregs from total purified CD4+ T cells was 
99.9%, which means that 99.9% of nTregs of total CD4+ T cells were effectively sorted (figure 3.14 A) following the optimised gating strategy (figure 3.15 A). The 
results also showed that 98% of sorted CD4+CD25+ nTregs were positive for Foxp3 
expression (figure 3.14 A). Similar results were obtained for sorting CD4+CD25- T cells as the purity of sorting was also 99.9%. after sorting, naïve CD4+CD25- T cells were completely negative for CD25 expression, confirming the effectiveness of the optimised gating strategy (figure 3.14 A). The results also showed that the percentage of purification of nTregs and CD4+CD25- T cells was significantly 
increased from 13% to ~100% and from 84% to ~100%, before and after sorting, 
respectively (figure 3.14 B).           
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Figure 3.13. Gating strategy for sorting a pure population of iTregs. (A) Flow cytometry density plots showing the gating strategy for sorting a pure population of iTregs from total activated CD4+CD25+ T cells. Gate R3 represents CD4+CD25++Foxp3+ iTregs (22.82% of total activated CD4+CD25+ T cells) that 
were selected for sorting based on the intensity of CD25 staining at log101. Gate N represents CD4+CD25+Foxp3+ iTregs (26.13%) that were mixed with CD4+CD25+Foxp3- T cells (gate S (46.99%). Gates R3 and N represent the percentage of total iTregs (48.95%) induced from the total activated CD4+CD25+ T cells. Gate S represents the percentage of activated CD4+CD25+ T cells (46.99%) that were not converted to iTregs. All gates were gated on live CD4+CD25+ T cells (gate L).  the percentage of total Foxp3+ iTregs (gate R3 and N) induced from total activated CD4+CD25+ T cells (gate L). (B) Flow cytometry density plots showing the percentage of Foxp3+ iTregs (R3 (92%)) sorted from CD4+CD25++ T cells based on the intensity of CD25 staining. (C) Bar graph representing the percentage of iTregs purification before and after cell sorting. Unpaired T test was used for statistical analysis 
using GraphPad Prism software 8.0.1. Three independent biological experiments were carried out (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (***; p-value < 0.0002).     
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Figure 3.14. Gating strategy for sorting a pure population of naïve CD4+CD25- T cells and naïve CD4+CD25+Foxp3+ nTregs. (A) Flow cytometric density plots showing the gating strategy for sorting naïve CD4+CD25- T cells and CD4+CD25+ nTregs from total population of purified naïve CD4+ T cells. Gate L represents live CD4+ T cells. Gate R14 represents naïve CD4+CD25- T cells. Gate R3 represents naïve CD4+CD25+ nTregs. 
Both R14 and R3 were gated on gate L. Gate D represents the percentage of Foxp3+ expression gated on the sorted naïve CD4+CD25+ nTregs. Gate Q represents the percentage of Foxp3+ expression gated on the sorted naïve CD4+CD25- T cells. (B) Bar graph showing the percentage of purification of both naïve CD4+CD25- T cells and CD4+CD25+ nTregs before and after cell sorting. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (*; p-value < 0.019, ***; 0.0009). 2way-ANOVA test was usded 
for statistical analysis using GraphPad Prism software 8.0.1. 
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Figure 3.15. Density plots showing the gating strategy that was followed for sorting CD4+ T cell subsets. 
(A) The gating strategy for sorting naïve CD4+CD25- T cells (gate R14) and naïve CD4+CD25+ nTregs (gate R3) from total population of purified naïve CD4+ T cells. (B) The gating strategy for sorting CD4+CD25++ iTregs (gate R3) from total population of activated CD4+CD25+ T cells. All gates were gated on gates R1 and R2 which represent total live cells and total singlets cells, respectively. Density plots were taken from cell sorting software (Summit 5.4). 
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3.3.2.2. Determination of the number of spleens required to obtain 2.5x106 of 
purely sorted CD4+CD25++Foxp3+ iTregs and CD4+CD25+Foxp3+ natural 
Tregs (nTregs) prior to subcellular fractionation. Despite the high purity of sorting, the number of iTregs and nTregs recovered after sorting was very low and insufficient for subcellular fractionation. For instance, the pure population of iTregs represented only 20-23% of total activated CD4+ T cells at 50% of total iTregs induction, which theoretically means that ~ 12.5x106 of activated CD4+ T cells are required to obtain 1x106 of purely sorted iTregs. For this reason, the number of spleens was increased to obtain enough number of cells after sorting for subcellular fractionation. The results showed that the mean of number 
of sorted iTregs and nTregs derived from one spleen was 0.53x106 each. Whereas the number of sorted iTregs and nTregs was significantly increased to 1.3x106 and 
1.4x106 after processing two spleens. The highest number of purely sorted iTregs 
and nTregs obtained was 2.6x106 and 2.4x106, respectively, after processing three spleens (figure 3.16).                           
 
 
 
 
Figure 3.16. Bar graph showing the cell number of purely sorted nTregs and iTregs derived from different 
number of spleens. 2way ANOVA test was used for statistical analysis using GraphPad Prism 8.0.1. Three independent biological experiments were carried out, (n=3). The statistical analysis was carried out on a limited data set (n=3) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (*; p-
value < 0.025, **; p-value 0.0016).  
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3.3.2.3. Subcellular fractionation of CD4+ T cells using Mem-PER Plus 
membrane protein extraction kit (pilot study). A pilot study was conducted to assess the efficiency of the Mem-PER Plus extraction kit for subcellular fractionation of CD4+ T cells. The results showed that the percentage of total purified membrane proteins was significantly increased using the fractionation kit. The results showed that the percentage of membrane proteins identification was significantly increased to 57% (mean) using the fractionation kit compared to the whole cell lysate protocol (section 3.3.1.8) where only ~ 8% (mean) of total membrane proteins were identified (figure 3.17). The results also showed a significant increase in the identification of plasma membrane proteins specifically; as 26% (mean) of plasma membrane proteins were identified using subcellular fractionation, whereas only 4.5% (mean) of plasma membrane proteins were identified using whole cell lysate without fractionation (figure 3.17). Subcellular location and functional information of identified membrane proteins were obtained from Uniprot database. Figure 3.18 displays an example of how total membrane proteins were searched and sorted using Uniprot database.         
Figure 3.17. Bar graph showing the percentage of identification of total membrane and plasma membrane-bound proteins using two different approaches including whole cell lysate and subcellular fractionation. Four independent biological experiments were carried out, (n=4). The statistical analysis was carried out on a limited data set (n=4) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. (***; p-value < 0.0007, **; p-value < 0.0016). 2way ANOVA test was used for statistical analysis 
using GraphPad Prism 8.0.1.   
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Figure 3.18. An example of Bar graph showing subcellular locations of 647 confident proteins, which was obtained from Uniprot database. 352 (54% of total confident proteins) membrane proteins highlighted by Red rectangle were sorted by Uniprot into different subcellular locations of membrane-bound proteins including 
plasma membrane proteins (26%) and intracellular membrane proteins (31%) (organelles membrane and mitochondrial membrane).   
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3.3.2.4. Protein quantitation Assay. The limitation of using the Mem-PER Plus membrane protein extraction kit was that the enriched cytoplasmic and membrane proteins were resuspended in a high volume of permeabilisation buffer (600 µL) and solubilisation buffer (300 µL), respectively. Therefore, the results of protein assay showed that the concentration of both cytoplasmic and membrane proteins was too low and even out of the experimental linear range of the protein assay. As a result, it was suggested to concentrate the proteins using acetone precipitation and subsequent resuspension in a small volume buffer prior to mass spectrometry. 
3.3.2.5. Acetone precipitation of proteins. The cytoplasmic and membrane proteins were precipitated using cold HPLC-grade acetone to concentrate proteins and replace permeabilisation and solubilisation buffers with MS-compatible reagents. Proteins pellet was clearly seen from the both proteins fractions, however the protein assay was not carried out after acetone precipitation to avoid losing more proteins. Therefore, subcellular proteomic profiling was carried out based on the number of cells not on the concentration of proteins. The number of cells used in each group was uniform and all samples were uniformly processed thereafter.         
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3.4. Discussion Advances in the MS-based proteomics instrumentations have enabled a global identification of proteins from complex biological samples, thereby elucidating the overall picture of the expression of functional proteins and their post-translational modifications that regulate protein cellular interactions and functions within a cell or tissue (Aebersold and Mann 2016). In contrast, although the development of transcriptomic profiling technologies, especially RNA-sequencing (RNA-Seq), has provided invaluable insights into discovering networks regulating gene expression at the RNA level, most of transcriptomic data have failed to translate into the clinic. These failures can be attributed to the poor correlation of transcriptome data to the protein expression. This highlights the importance of proteomic analysis as a powerful technology to investigate and discover the proteins as biomarkers and also druggable targets in the clinical settings (Kumar, et al. 2016). In the last decade, several studies have been carried out to the study the development and differentiation of human and murine CD4+ T cells using high throughput transcriptomic and proteomic analysis (Elo, et al. 2010, Tuomela, et al. 
2012, van den Ham, et al. 2013, Tuomela, et al. 2016, Proserpio, et al. 2016, Mohammad, et al. 2018, van den Ham, et al. 2019). However, all of these studies were 
focused only on the differentiation of T helper 1 (Th1), T helper 2 (Th2) and Th17 cells. Limited number of studies has analysed the development and function of Tregs using global proteomic analysis. Procaccini et al. have carried out a global comparative proteomic analysis between human CD4+CD25hi Foxp3+ CD127- Tregs and CD4+ CD25-Foxp3- T conventional (T conv) cells at the metabolic level. The authors have identified a set of distinct metabolic proteins which have a pivotal role in the proliferation of Tregs and T conv cells (Procaccini, et al. 2016). Another study by Duguet et al. has applied global label-free quantitative proteomics to identify a proteomic signature of both CD4+Foxp3+ Tregs and CD4+Foxp3- T cells. The authors have identified a specific nuclear protein called “Themis-1” that regulates the suppressive function of Tregs (Duguet, et al. 2017). A recent study by Cuadrado et al. has been conducted to identify human Tregs cell identity at the molecular levels using label-free quantitative proteomics in a combination with transcriptomic analysis. The authors have compared naïve subpopulations of CD4+CD25hiCD45RA+ 
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Tregs and CD4+CD25-CD45RA+ T conv cells with CD4+CD25hiCD45RA- effector Tregs and CD4+CD25-CD45RA- memory T conv cells and identified distinct proteins that govern and maintain cellular identity of each of the subpopulations (Cuadrado, et al. 
2018). Another recent study by Schmidt et al. has also applied global transcriptomic and proteomic analysis to study the differentiation of human induced Tregs (iTregs) from naïve CD4+CD25- T cells based on the induction of the expression of Foxp3 at 
different time points. The authors have found a panel of 37 distinct nuclear molecules that function as regulators of Foxp3 (Schmidt, et al. 2018). A final recent study by Mohammad et al. has analysed and compared the proteome signature of 
murine Th17 and iTregs during their differentiation in vitro from naïve CD4+CD62L+ T cells using global label-free proteomic profiling. The authors have only focused on the metabolic pathways that are implicated in the differentiation of Th17 and iTregs (Mohammad, et al. 2018). However, all of these studies mentioned above have not analysed the difference in the phenotypic features between natural Tregs (nTregs) and induced Tregs (iTregs) at the level of cell-surface membrane proteins, particularly plasma membrane proteins that are the main targets in the development of therapeutic agents, using subcellular fractionation. To date, no studies have reported the identification of membrane biomarkers that can distinguish induced Tregs from other subsets of CD4+ T cells, therefore it is an area which required further investigation. Identification of such biomarkers would help facilitate the development of therapeutic agents that can selectively target iTregs which could be generated as a result of highly inflamed tumour microenvironment. Accordingly, in this study, two different methods; global (total cell lysate) and subcellular fractionation were optimised to identify membrane biomarkers that could differentiate iTregs from other subpopulations of CD4+ T cells using a state-of-the-art MS-based instrumentation TripleTOF 6600 mass spectrometer with SWATH-MS acquisition, SCIEX. The novelty of this study is represented by optimising a protocol for subcellular fractionation of membrane and cytoplasmic proteins derived from five different subpopulations of CD4+ T cells for label-free quantitative proteomic analysis. 
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The results of optimisation of global proteomics profiling showed that the total number of proteins identified from whole cell lysate containing 2.5x106 T cells was 
in range between 1053 and 1232 at 1% FDR. Out of which, the total number of 
membrane proteins with confidence score ≥ 50% was in range between 79 (7.5%) 
and 102 (8.3%) (n=4), respectively. The percentage of plasma membrane proteins identified was in range between 4.2% and 4.9% from the total number of proteins. These results were not sufficient to meet the main aim of this stud as the optimisation of proteins isolation using whole cell lysate lysed by Erika’s or urea buffer has failed to purify sufficient percentage of membrane proteins. There are several limitations associated with the purification of plasma membrane proteins including low recovery rate, protein insolubility and hydrophobicity (Orsburn, 
Stockwin and Newton 2011). These limitations could justify the low percentage of membrane proteins identified by the global whole cell lysate protocol. As a result, subcellular fractionation was approached to overcome the limitation of the whole cell lysate method for isolation membrane proteins.  
As mentioned in the introduction (section 3.1.2.7), there are several methods for subcellular fractionation such as density-gradient centrifugation with sucrose medium as a common conventional method. However, some of these methods require a long processing with multiple centrifugations that might result in the loss of proteins during the isolation process. Also, the number of cells (2x106) from which membrane proteins were isolated has put another barrier for the selection of an appropriate method for the subcellular fractionation. For these reasons, the Mem-PERTM Plus membrane proteins extraction kit was selected for the isolation of membrane and cytoplasmic proteins from CD4+ T cells since it has been optimised for isolation membrane and cytoplasmic proteins in 2 hours using permeabilisation and solubilisation buffers. The time required for processing samples was of the main aims for isolation membrane proteins from in vitro cultured cells, especially induced Tregs, to prevent experimental variations in the processing of samples.  This kit was the most appropriate among other commercially available kits since it has been 
optimised to extract both membrane and cytoplasmic proteins from 5x106 T cells, whereas other kits require at least 10x106 or more for extraction membrane proteins which is 5 times higher than the cell number used in this study. 
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The results showed that the mean of the percentage of membrane proteins identified following subcellular fractionation was significantly increased to 57% compared to the results of whole cell lysate where the mean of the percentage of 
membrane proteins was only 8%. The results also revealed that the mean of the percentage of the plasma proteins was significantly increased to 26% of the total proteins identified following subcellular fractionation, while it was only 4.5% using the protocol of whole cell lysate. These results were relatively satisfactory since only 
2x106 cells were processed for the isolation of membrane proteins.  In summary, in this chapter, a subcellular fractionation method has been 
successfully optimised to isolate membrane proteins from 2x106 of murine CD4+ T cells for label-free quantitative proteomic analysis. 57% of membrane proteins and 26% of plasma membrane proteins were successfully identified from 2x106 cells. These results are sufficient to conduct a comprehensive quantitative proteomic profiling of five different subpopulations of murine CD4+ T cells using LC-MS-MS and SWATH-MS proteomics which will be discussed in more details in the next chapter (chapter 4).   
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Chapter 4.  
Identification, selection and verification of novel 
membrane markers of natural and induced T 
regulatory cells  
4.1. Introduction T regulatory cells (Tregs) play a pivotal role in maintaining immune tolerance by eliminating autoreactive T cells that induce immune response against self-tissues. However, in cancer, Tregs play a detrimental role by inhibiting the proliferation and activity of CD8+ effector T cells, thereby promoting the tumour progression and metastasis. The presence of tumour-infiltrating Tregs in the tumour microenvironment is of main obstacles for successful immunotherapy (Liu, Workman and Vignali 2016b). It has been proposed that the tumour-infiltrating Tregs might be nTregs which are recruited into the tumour microenvironment or iTregs that are developed from circulating naïve CD4+CD25- T cells (Chaudhary and 
Elkord 2016, Deng 2018). To date, distinct biomarkers that can differentiate between thymic-derived natural Tregs(nTregs) and peripheral-derived induced Tregs (iTregs) are still required to be identified for specifically targeting iTregs. This chapter will discuss the process of identification and verification of biomarkers using SWATH-MS proteomics. 
4.1.1. SWATH-MS based proteomics SWATH-MS (sequential window acquisition of all theoretical mass spectra) acquisition was initially developed to process the complicated datasets yielded by data independent acquisition (DIA)-MS analysis. SWATH-MS acquisition combines the high reproducibility and sensitivity of a DIA-MS approach and a targeted data extraction strategy to read out the complex datasets of fragments ions (Gillet, et al. 
2012) (figure 4.1).  
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Figure 4.1. Data Dependent versus Data Independent versus Selected Reaction Monitoring.  A comparison between the three different strategies for quantitative identification of proteins. DDA is biased untargeted acquisition that is widely used in conventional proteomics. MRM/SRM is targeted strategy used in targeted proteomics which is used to selectively analyse proteins of interest. Targeted proteomics require prior knowledge about the protein of interest; therefore, it is not suitable for biomarker discovery despite of its high sensitivity and accuracy. SWATH-MS has been developed to combine the features of conventional proteomics in terms of biomarker discovery with unlimited identification of proteins and the feature of targeted proteomics by which SWATH-MS allows to selectively analyse the identified proteins in a targeted data processing and analysis. Image was taken from Sciex.com website. Copyright permission was obtained from AB Sciex team.   
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 The original framework of SWATH-MS acquisition consisted of 32 sequential, slightly overlapping precursor isolation windows with isolation width of 25 m/z each. These windows were constructed to cover the mass range 400 – 1200 m/z (figure 4.2). The key principle of SWATH-MS is to obtain optimal correlation between precursor and fragment isotopes peaks at any time they elute from LC. This is achieved by setting consecutive isolation windows with (+1 m/z) overlap between windows to 
Figure 4.2.  Q1 Isolation Strategy in SWATH.  The width of the SWATH or Q1 window in blue has a correlation with the specificity of the analysis.  In a fixed SWATH window strategy, the smaller SWATH, window the more specific (fewer different peptides will be fragmented) the analysis will be and vice-versa.  Sensitivity of the analysis directly correlates with the cycle time (how long the instrument takes to fragment all the SWATH windows) and accumulation time (how long the instrument dwells on fragmenting each packet of precursor ions (contained in one SWATH window).  These can be optimised depending on the chromatographic conditions of the analysis, for analyses where each peptide peak from the chromatographic column is around 20 seconds wide, then approximately 2-3 seconds cycle time would be optimal to get enough data points for quantitation across a peak.  Typical accumulation times would be 25-50 msec. . Image was taken from Sciex.com website. Copyright permission was obtained from AB Sciex team.   
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ensure the transfer of any given precursor ions in at least one window. More recently SWATH methodologies have been optimised to use a higher number of variably sized windows (typically 100 windows), with larger windows in peptide sparse m/z regions and smaller windows over the m/z range where more peptides exist in the sample (figure 4.2).  
Figure 4.3. Schematic representation showing the workflow of SWATH-MS acquisition. In SWATH-MS mode, once 
peptides become ionised by the ion source, they enter the first mass analyser (quadrupole Q1) which scans and records the m/z values of eluted peptides. Ions of peptides within a “SWATH window” are then fragmented (second quadrupole 
or Q2/collision cell) to produce small fragment ions that enter the second mass analyser (TOF) which records the m/z values of the fragment ions with respect to the retention time and their intensity. By plotting the fragment ions within a SWATH-MS window over time,  specific ions spectra (coloured fragments) can be deconvoluted and assigned to a “parent” or precursor ion (peptide), based on the theory that the same type of molecule eluting off the chromatographic column at the same time will share the same peak apex.  These peptide ion fragments can then be matched to sequences and retention times using a pre-generated spectral or ion library derived by more standard Information/Data Dependent 
Acquisition (IDA/DDA) mode. This figure was adaptive from (Ludwig, et al. 2018). 
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SWATH-MS acquisition can also deal with complex samples in which many peptides of different size are able to co-elute simultaneously from the LC in a process called “coelution”. These co-eluting peptides are then differentially selected in the precursor ion selection window and undergo co-fragmentation by the scheme of SWATH-MS acquisition, generating multiplexed and complicated spectra of fragment ions (Ludwig, et al. 2018) as schematically represented in figure 4.3. To handle this issue, a novel data analysis approach has been proposed by Gillet et al., which is based on peptide centric scoring that requires previous information of a peptide of interest. This is called “peptides query parameters (PQPs) which can be acquired from previously generated spectral libraries (Gillet, et al. 2012). PQPs include the sequences of peptides that belong to proteins, the optimal or dominant precursor ion m/z values of peptides, four to six fragment ions with highest m/z values and intensities, precursor and fragment ions charges, types of fragment ions and normalised retention time of both precursor and fragment ions (Collins, et al. 
2017). The primary strategy of SWATH-MS as a targeted data extraction method using information from spectral libraries has been modified, automated and improved by other tools such as OpenSWATH and SWATHProphet which accurately identifies and quantifies peptide fragment ions and automatically uncovers and removes interfering precursor ions (Röst, et al. 2014, Keller, et al. 2015). The main advantage of SWATH-MS acquisition is its ability to quantitatively analyse peptides covering thousands of proteins with a high consistency and accuracy. It is perfectly tuned for projects that require proteomic analysis of a large number of samples with more accuracy and reproducibility (Ortea, et al. 2016). However, there are two main drawbacks of SWATH-MS. First, it is still significantly less sensitive in peptide quantification compared to the conventional methods of targeted proteomics (SRM and PRM) which are the best option for quantifying low abundant proteins. Second, SWATH-MS, until recently required a prerequisite spectral library and/or PQPs for peptides and proteins quantification, which adds additional effort to the data analysis  (Schmidlin, et al. 2016).  While SWATH/DIA data can now be searched directly against known proteomes by various software in a way similar to IDA/DDA 
data (PEAKS Studio X from Bioinformatic Solutions Inc,  Spectronaut Pulsar from Biognosys  AG) it is more optimal and much faster to reduce the search space with a reduced list of  peptide and peptide fragments corresponding to  proteins at known 
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retention times in the mass spectrometer’s acquisition file.  This is termed a spectral library.  The most basic spectral library contains the precursor ion m/z (Q1 m/z or  peptide ion), the fragment m/z (Q3 m/z corresponding to the peptide 
sequence/amino acids), retention time of the peptide, and the protein accession it is part of.  A spectral library may also contain other optional information such as charge state, intensity, modifications etc.  The key point to remember if searching using a spectral library – if the protein/peptide is not in the library, then no 
quantitative data can be determined for that peptide/protein.  It is therefore of paramount importance to have as comprehensive a spectral library as possible.  To this end there are various projects, such as the SWATHAtlas project at the Institute of Systems Biology, Seattle, USA that are generating large high quality spectral libraries that are publically available (http://www.swathatlas.org/) to complement locally generated libraries from the same samples that are being quantitified.  This 
is useful as the nature of SWATH/DIA means it can be inherently more sensitive than 
traditional IDA/DDA workflows which alone may not generate a good quality comprehensive library. 
4.1.2. Biomarker validation – journey toward the clinic The evolution of candidate biomarkers undergoes rigorous steps in order to be clinically approved. The first step is pre analytical validation which focuses on preparation and processing of samples that will be tested using a proposed assay. Several factors can affect the preparation of samples including time and storage conditions between sample collection and processing, the efficiency of reagents used for sample processing and the time of sample processing (Henry and Hayes 
2012). The second step is analytical validation which tests the technical efficiency of the biomarker assay through assessing sensitivity, specificity, limit of detection, linearity and potency of the assay. In addition to the accuracy and reproducibility of the biomarker assay (Masucci, et al. 2016). The final step is clinical validation which assesses the clinical validity and utility of the biomarker. To achieve this, several parameters must be measured including clinical sensitivity and specificity, false positive and false negative values as well as relative risk vales of the biomarker 
(Dobbin, et al. 2016). 
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4.1.3. Proteomics biomarker pipeline: from discovery to the clinic The validation of proteomic biomarkers is a step-wise process consisting of long-term distinct steps (figure 4.4). First, the discovery or screening step where candidate biomarkers are identified using shotgun proteomics. This step is usually carried out on small number of samples in which proteins will be extracted and analysed by LC -MSMS proteomics. Two main methods are used to quantify proteins in samples including label based and label free methods which have been mentioned in chapter 3 (section 3.1.2.6) (Surinova, et al. 2010). Second, the verification step by which proteins with high fold change values between the samples are selected for verification using targeted proteomics analysis. This step requires more samples to be analysed than the first step (Hathout 2015).  Different methods can be used for targeted proteomics analysis including SRM MS and MRM MS (mentioned in chapter 
3, section 3.1.2.5.2) and SWATH-MS. The final step is the validation of candidate biomarkers in the clinic. In the validation step, large cohort of samples is needed to assess the clinical validity and utility of the biomarker (Parker and Borchers 2014). Due to these long, expensive and uncertain steps, a large number of proteomics biomarkers has failed to reach the final stage of clinical validation (Chauvin and 
Boisvert 2018).   
 
4.1.4. Methods for biomarker verification 
4.1.4.1. Targeted proteomics SRM (Selected Reaction Monitoring, also known as MRM, multiple Reaction Monitoring) is one of the LC-MS-MS targeted proteomics methods that have been 
Figure 4.4. Schematic steps for the development of proteomics biomarkers. LC-MS-MS: liquid chromatography- tandem mass spectrometry, LFQ: label-free quantification, LBQ: label-based quantification, MRM: multiple reaction monitoring, SRM: selected reaction monitoring, SWATH: sequential window acquisition of all theoretical fragment ion spectra. This figure was adapted from  (Chauvin and Boisvert 2018) and (Parker and Borchers 
2014).     
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developed complementary to untargeted shotgun proteomics. SRM has substantial potential to close the chasm between biomarker discovery and the translation to clinical use (Harlan and Zhang 2014). It involves simultaneous targeted analysis of peptides that play as surrogates for the protein targets of interest which are usually selected from discovery proteomics assays. SRM based assays are highly specific, accurate and they can be multiplexed assays in which enormous number of peptides can be quantified in one assay (Thomas and Zhang 2016). However, SRM assay have shown some challenges including the detection sensitivity for the targeted proteins, establishment of a standardised methods for samples preparation and maintaining reproducibility of targeted peptides (Thomas and Zhang 2016, Picotti and Aebersold 
2012b). Also, SRM requires tremendous optimisation for selecting the optimal ionised peptides that carefully represent the protein of interest, assessing linearity and quantitative dynamic range coverage of targeted peptides (Hathout 2015). SWATH-MS, which is not considered as targeted proteomics approach, but is targeted data analysis method, has developed with potential to overwhelm some of SRM challenges. SWATH-MS is a powerful method for biomarker verification as a broad range of identified peptides that uniquely represent the identity of a protein can be selected for further analysis to measure the fold change of a proteins between samples (Thomas and Zhang 2016, Narasimhan, et al. 2019). 
4.1.4.2. Enzyme linked immunosorbent assays (ELISA) ELISA technique is the most common assay for biomarker validation as it can efficiently measure many samples simultaneously with low experimental variation. This technique is mainly used to validate secreted proteins (Katsila, et al. 2014, 
Chauvin and Boisvert 2018). As antibody based technique, ELISA requires highly specific antibodies that bind with high affinity to the target biomarker to assess the reliability and accuracy of the biomarker assay (del Campo, et al. 2015). Four different assays of ELISA are available including direct, indirect, sandwich and competitive ELISA. Among these assays, sandwich ELISA is the most accepted assay used in biomarker verification and validation as it is highly specific and sensitive 
(Aydin 2015). By this assay, the target biomarker will be detected by two different antibodies; capture and detection, where each antibody is specific for a particular epitope of the target biomarker (Aydin 2015). However, for numerous candidate 
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biomarkers, commercially specific antibodies are not available and required to be developed initially in order to design a new ELISA assay. The development of a novel ELISA assay entails an attentive design to provide more accurate measurements for the target biomarker (Kelley and DeSilva 2007). The workflow for designing ELISA assay includes antibody design, ELISA development, assay validation and clinical assessment. The most important step is the antibody design which requires optimal selection of the epitope (unique peptides) of the candidate biomarker detected in the proteomics discovery stage (Cox, et al. 2004). Selection the optimal epitope improves the specificity and sensitivity of the developed antibody and therefore increases the robustness of the biomarker assay. Thus, it is essential to have information about biological traits of the protein (marker) of interest, including its 3D structure, binding sites, hydrophobicity and post translational modifications. For examples, if the selected epitope of the protein of interest belongs to a highly glycosylated or hydrophobic portion of the protein, it may not be appropriate for ELISA as the target epitope can be masked by native conditions (Ramos-Vara 2005, 
del Campo, et al. 2015). 
4.1.4.3. Flow cytometry Flow cytometry (FC) is a powerful method that is widely used in verification and clinical validation of new biomarker. FC is used to assess the phenotypic and functional features of cells and quantify large number of cells by assessing their subsets percentage, distribution, activation status and other cellular functions (Baumgarth and Roederer 2000). Different assays can be carried out using FC, including immunophenotyping, intracellular staining, cell cycle, cell proliferation, apoptosis and phosphor flow assays. These applications enable FC to have more 
advantages over other similar assays such as ELISA and ELISPOT (enzyme linked immunospot) which measures only the total amount of secreted proteins or cytokines and detects a cell that secretes a specific protein or cytokine, respectively 
(Millán and Brunet 2015). In oncology, immunophenotyping is widely used in clinical laboratories for diagnosis and classification of various hematologic malignancies and leukaemias. The availability of clinically useful antibodies has enabled profiling complex immunophenotypic signatures. In addition to the advances in FC multicolour instrumentations that allow profiling co expression of different cell surface markers or cytokine receptors in a single experiment, 
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facilitating identification phenotypic signatures of specific subpopulations of cells 
(Maecker, McCoy and Nussenblatt 2012). Metrock et al. (Metrock, et al. 2017) have demonstrated the clinical importance of immunophenotyping as a non-invasive procedure for monitoring and diagnosing paediatric patients who are suspected to have acute leukaemia. The authors confirmed that immunophenotyping by FC could be more sensitive and specific for detecting the residual tumour cells after chemotherapy than bone marrow aspiration which is an invasive procedure 
(Metrock, et al. 2017). FC can also be used to predict the prognosis of many cancers by analysis the enrichment of T cells in the peripheral blood or tumour sections of patients. For example, in melanoma, low baseline of myeloid derived suppressor cells (MDSCs) and Tregs frequency, and high absolute eosinophil counts has been found associated with better outcome in patients who received ipilimumab 
(Martens, et al. 2016). Besides immunophenotyping, intracellular staining is an essential method used to assess functional pathways operating in the cytoplasm of a specific cell population. In immunology, intracellular staining is mainly used to detect expression of functional cytokines which are produced by a specific cell population of immune cells during an immune response. For instance, in organ transplantation, intracellular staining has been used to assess the production of interleukin 2 (IL 2), IL 10 and interferon gamma (IFN γ) as candidate biomarkers to predict the outcome of tissue grafting (Benítez and Najafian 2008). Akoglu et al. have 
found that IL 2 secreting CD8+ T cells were significantly enriched at the site of rejected liver tissue in patients who underwent liver transplantation, confirming 
that IL 2 production by CD8+ T cells could be as a biomarker for acute tissue rejection after organ transplantation (Akoglu, et al. 2009). Millán et al. have also identified 
that the percentage of IFN γ secreting CD4+ and IFN γ/IL 2 secreting CD8+ T cells was significantly increased in the peripheral blood of patients who experienced tissue rejection after receiving long term immunosuppression treatments for stable liver transplantation. The authors have suggested that soluble concentration and the 
intracellular expression of IL 2 and IFN γ could be used as predictive biomarkers of the risk of T cell mediated tissue rejection (Millán, et al. 2010). However, despite the advances in the application of FC, this technique has several limitations. First, complexity of optimisation the panel of fluorochrome conjugated antibodies which requires a careful multicolour compensation between different fluorochromes to 
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prevent signal overlapping between antibodies. Second, lack of method standards and external quality controls which are still needed for improving analysis and reporting of FC data and minimising subjectivity in the analysis of FC data (Millán 
and Brunet 2015). 
4.1.4.4. Bioinformatics  The biological data generated from high throughput omics approaches such as proteomics for the development of clinical biomarkers have become significantly complex and exceeded the potential of conventional data analysis (Luscombe, 
Greenbaum and Gerstein 2001). Bioinformatics has developed in the past years and played an essential role in biomarker discovery and validation. It is a multidisciplinary field combining biology, computational science, mathematics and statistics to deduce knowledge from biological omics data (Mount and Pandey 2005). Database resources, computational algorithms and statistical models are usually involved in the framework of bioinformatics to efficiently manage, process and analyse the complex biological data (Huang, Sherman and Lempicki 2008). For instance, proteomics approaches integrated with bioinformatics tools have markedly promoted the discovery of new novel serum biomarkers to detect cancer (Ueda, et al. 2010). 
4.1.4.4.1. Artificial neural networks (ANN) as a tool of bioinformatics ANNs are a form of machine learning approaches and have been initially developed to determine a panel of biomarkers based on their high predictive performance 
(Lancashire, Rees and Ball 2008a). The ANNs are often used to model complex biological datasets such as gene and protein expression datasets based on predictive performance and predictive test error. The architecture of ANNs is derived from the workings of human brain, which consists of an artificial network of computational elements (neurons) that are mathematically interconnected to perform the learning process (Zafeiris, Rutella and Ball 2018). The principle of ANNs is to create multiple models based on a stepwise approach to predict a distinct panel of biomarkers that can differentiate between various samples within a dataset (Lancashire, Rees and 
Ball 2008b). The schematic workflow of the ANNs stepwise modelling approach is shown in figure 4.5. Due to the complexity of proteomics data, ANNs have been used 
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to analyse proteomics data in order to identify and verify a panel of novel biomarkers based on their predictive performance (Swan, et al. 2013).             
4.1.5. Aims of this study The aim of this chapter is to generate proteomic profiles to enable discovery of biomarkers (differentially expressed proteins) of induced Tregs, which can differentiate them from natural Tregs and other subpopulations of CD4+ T cells. The objectives of this chapter are: 
1. Confirm purified distinct populations of induced and natural Tregs and other control populations. 2. Generate a list of all proteins and peptides identified in all Treg populations which can be used as a Spectral Library (ion library). 3. Generate quantitative SWATH MS profiles for subpopulations of Tregs. 4. Process data to identify differential biomarkers of iTregs. 5. Pathway analysis of differentially expressed proteins. 6. Verification and validation of identified biomarkers using bioinformatics tools and flow cytometry. 
Figure 4.5. The schematic workflow of the ANNs stepwise modelling approach. This figure was adaptive from (Lancashire, Rees and Ball 2008b). 
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4.2. Materials and Methods 
4.2.1. Proteomic profiling of mouse CD4+ T cells using mass 
spectrometry Five different subpopulations of CD4+ T cells were purified and sorted to create a library of subcellular proteins of CD4+ T cells, including naïve CD4+CD25 Foxp3  T cells, naïve CD4+CD25+Foxp3+ nTregs, activated (stimulated) CD4+CD25+Foxp3+ nTregs, activated (stimulated) CD4+CD25+Foxp3  T cells and activated (stimulated) CD4+CD25++Foxp3+ iTregs. Five separate replicates (samples) were processed from each of CD4+ subpopulations, each replicate contained 2x106 cells. Cytoplasmic and membrane proteins were isolated from each sample using the Mem PERTM Plus membrane proteins extraction kit as mentioned in chapter 3 section (3.2.2.3). Then proteins were precipitated using cold acetone (HPLC grade) as mentioned in section (3.2.2.4). Then protein samples were processed for MS analysis as mentioned in section (3.2.2.5) by the proteomics facility in the John van Geest Cancer Research Centre at Nottingham Trent University.  Cytoplasmic and membrane protein samples of 25 replicates were processed and digested simultaneously to minimise experimental variations between samples. Table 4.1 shows a summary of the subpopulations of CD4+ T cells and their culture conditions which were prepared for proteomic profiling. 
Table 4.1:  A summary of details of the CD4+ T cells subsets that were processed for proteomic profiling. Samples were processed to separate cytosolic and membrane fractions. 
CD4+ subsets Culture condition No. of 
cells 
No. of 
replicates Naïve CD4+CD25- Foxp3-    2x106 5 Naïve CD4+CD25+ Foxp3+ nTregs   2x106 5 Activated CD4+CD25+ Foxp3+ nTregs + CD3/CD28 beads + IL 2 (30 
U/mL) 2x106 5 Activated CD4+CD25- Foxp3- + CD3/CD28 beads + IL 2 (30 
U/mL) 2x106 5 Activated CD4+CD25++Foxp3+ iTregs + CD3/CD28 beads + IL 2 (30 
U/mL) + TGF β1 (5 ng/mL) 2x106 5  
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4.2.2. Proteomic data generation, processing and identification of 
differentially expressed proteins 4 μL of each sample was injected onto an Eksigent ekpert nanoLC 400 system (Eksigent 425 pump and autosampler) via a trapping column (YMC Triart-C18 trap 
column 300 μm ID, 0.3 × 5 mm) using mobile Phase A; 0.1% formic acid, B; 
Acetonitrile with 0.1% formic acid; at 10 μL/min mobile phase A for 2 min before a valve switch and gradient elution onto the analytical column (YMC Triart C18 150 × 
0.3mm ID, 3 μm).  The LC was hyphenated to a SCIEX TripleTOF 6600 mass spectrometer via the Duospray Source using a 50 μm electrode.  The instrument was set in positive mode +5500V. All samples were analysed both by SWATH (Data Independent Acquisition, to generate quantitative data) mode and by IDA (Information or Data Dependent Acquisition, DDA, for the generation of a list of identified proteins and peptides to create a spectral or ion library). The following linear gradients were used: for IDA, 
mobile phase B increasing from 2% to 30% over 68 min; 40% B at 72 min followed 
by column wash at 80% B and re-equilibration (87 min total run time). For SWATH, 3-30% B over 38 min; 40% B at 43 min followed by wash and re-equilibration as 
before (57 min total run time). IDA acquisition mode was used with a top 30 ion fragmentation (TOFMS m/z 400-1250; product ion 100-1500) followed by 15 sec 
exclusion using rolling collision energy, 50 ms accumulation time; 1.8 s cycle. SWATH acquisition used a 100 variable window method (previously optimised in the laboratory for complex protein sample types) using an accumulation time of 25 ms giving a 2.6 s total cycle time (over the range m/z 400-1250). IDA data was searched all together and by experimental group using ProteinPilot 5.0.2 (SCIEX) to generate a list of proteins and peptides for a local spectral library, with the following parameters; iodoacetamide alkylation, thorough search with emphasis on biological modifications (Swissprot human database Oct 2018). 
4.2.2.1. Generation of a local spectral library for SWATH data analysis The generated “.group” file from ProteinPilot search of the IDA runs contained all protein and peptide information from the samples.  This data was imported into PeakView 2.2 (SCIEX) using the SWATH microapp plugin (SCIEX) and aligned to the 
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SWATH data files using a selection of endogenous peptides with high intensity and unambiguous retention time. SWATH data was imported into the SCIEX OneOmics cloud processing software based on software developed from (Lambert, et al. 2013) and was extracted against a spectral library created from aligning both the locally generated library and a comprehensive mouse 3T3 cell external library (obtained from Dr Nick Morrice, 
SCIEX, UK) in OneOmics with the parameters 6 peptides per protein, 6 transitions per peptide, XIC width 30 ppm, 5 min retention time window.  This method has been previously published by the proteomics facility in the John van Geest Cancer Research Centre (Aldiss, et al. 2019). See figure 4.6 for schematic overview of the proteomics data generation and processing. 
4.2.3. Selection of novel membrane and cytoplasmic biomarkers of 
natural and induced Tregs using artificial neural networks (ANN) SWATH-MS protein peak area (intensity) data of confident 99 membrane and 344 cytoplasmic proteins across the samples were subjected to ANN analysis, a robust bioinformatics tool (Abdel-Fatah, et al. 2016, Furini, et al. 2018, Wagner, et al. 2019), to statistically identify and select novel markers that can individually or in combination distinguish between nTregs and iTregs. Herein, a bespoke 3 layered backpropagation ANN, coupled with a stepwise search and cross validation procedure was applied to evaluate protein peak area data for the confidently identified membrane and cytoplasmic proteins (Lancashire, et al. 
2008a, Lancashire, et al. 2010).  Membrane and cytoplasmic protein data were run on ANN using two different stepwise analysis runs. First, multiple stepwise analysis which included 20 loops, 
each loop consisted of 10 steps. Second, single stepwise analysis which included 20 loops, each loop consisted of one step. The ANN analysis was carried out under the supervision of Professor Graham Ball using in house software developed for ANN 
(Stepwise OpenCL version 1.3.0).  Data was exported from Excel as a .csv file in the appropriate format for importing into the Stepwise software for processing with the following parameters: 2 hidden nodes, momentum 0.5, 60%:20%:20% split for training:testing: validation, running time 50 and 3000 epochs. 
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After ANN analysis, the results of stepwise analysis of both runs were collected. For multistep analysis, a panel of markers with the lowest average test error (ATE) from each step of 20 loops were selected. Then markers were sorted based on the time of repetition in the 20 loops. For single stepwise analysis, as it included only one step for each loop, then only one marker with the lowest ATE was selected among other markers in each step by ANN. Then the resulting 20 markers were sorted based on the time of repetition in the 20 loops. 
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Figure 4.6. Schematic representation showing the overall method that was followed for identification, selection and verification of proteins. 
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4.2.4. Verification/validation of novel biomarkers of nTregs and 
iTregs using flow cytometry and in silico tools 
4.2.4.1. Conjugated antibodies  Conjugated anti mouse monoclonal antibodies, including anti CD25, CD4, Foxp3, CPOX and MAVS antibodies were purchased for flow cytometry as shown in table 4.2. 
Table 4.2: List of conjugated monoclonal antibodies that were used for flow cytometry analysis. 
Monoclonal Abs  Fluorochrome Clone  Company Cat No. CD25 PE PC61.5 Thermo Fisher 12 0251 82 CD4 eFluor 450 GK1.5 ThermoFisher 48 0041 82 Foxp3 eFluor 660 FJK 16s ThermoFisher 50 5773 82 MAVS PE E 6 Santa Cruz Biotechnology sc 365334 CPOX (HEM6) PE B 9 Santa Cruz Biotechnology sc 393388  
4.2.4.2. Unconjugated antibodies 
Conjugated antibodies against EPHX1 (HYEP), PLP2 and ITIH4 were not commercially available. Therefore, unconjugated polyclonal antibodies tested for immunofluorescence (IF) application specifically were purchased as IF antibodies are compatible to be conjugated for flow cytometry. Unconjugated monoclonal antibodies were not commercially available against those three proteins. 
Table 4.3: List of unconjugated antibodies compatible for conjugation used for flow cytometry. Polyclonal Abs  Concentration Host/Species Reactivity  Company Cat No. 
EPHX1 
(HYEP) 
1 mg/mL Rabbit Human Mouse Rat Biorbyt Orb48363 
PLP2 0.5 mg/mL Rabbit Human Mouse Rat Biorbyt Orb312802 
ITIH4 0.5 mg/mL Rabbit Human Mouse Rat Biorbyt Orb1128  
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4.2.4.3. Conjugation of unconjugated antibodies with Phycoerythrin (PE) 
fluorochrome Lightning link® R Phycoerythrin conjugation kit (Expedeon, Cat No. 703 0010) was used to conjugate or label unconjugated antibodies with PE fluorochrome. The kit included vials of lightening link (LL) mix, LL modifier reagent, and LL quencher reagent. Each vial of LL mix was designed to conjugate 60 µL volume of an antibody when the concentration of antibody is 1 mg/mL to give a 1:1 (antibody:R PE) conjugation ratio. For setting up conjugation reaction, 6 µL of LL modifier reagent were added into 60 µL of antibody and mixed gently. Then the antibody sample with LL modifier was immediately added into the vial of LL mix which included lyophilised PE fluorochrome, and resuspended gently by pipetting the solution up and down twice. Then, the vial containing the conjugation reaction was incubated for 6 h at room temperature (20-25⁰C) in the dark on standing position. After incubation, 6 µL of LL quencher reagent were added into the vial containing conjugation reaction and mixed very gently. Then the vial was incubated again for an hour at room temperature in the dark on standing position. Then PE conjugated antibody was ready to use and kept at 4⁰C. 
The concentration of PLP2 and ITIH4 antibodies was 0.5 mg/mL which was lower than the ratio limit of the conjugation kit. Also, the solution of both antibodies included higher concentration of BSA (0.5%) which was five time higher than the recommended concentration (<0.1%) for conjugation reaction. Therefore, antibodies were concentrated, and the BSA was removed from their solution using AbSelect™ BSA removal kit (Expedeon, Cat No. 820 0100). This kit included a vial of BSA removal buffer and a vial of re suspension buffer. Then BSA removal buffer was 
heated in warm water at 37⁰C for 30 min to dissolve the contents. Once dissolved, the buffer was placed at room temperature ~20⁰C for 10 min to prevent the formation of crystal. Then the buffer was centrifuged at 13000 x g for 1 min. After 
centrifuging, 160 µL of supernatants of BSA removal buffer were added into the solution of antibody (200 µL) and mixed gently. The solution then was incubated for 
10 min at room temperature. After that, the solution was centrifuged at 13000 x g for 5 min. The supernatants were carefully discarded. The pellet of antibody was 
resuspended in 100 µL of re suspension buffer. After that, 60 µL of the concentrated 
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antibody were taken for conjugation with PE fluorochrome following the protocol mentioned above. 
4.2.4.4. Pathway analysis of differentially expressed and identified proteins Proteins uniquely expressed in each category of T cell population from the IDA runs were identified using the Venn diagram. The uniport IDs of the unique proteins were 
exported into MetaCore™ (Clarivate Analytics, accessed Oct 2019) for further analysis. MetaCore is a functional analysis integrated software suite for the analysis of high-throughput genomics, metabolomics and proteomics data using curated database of human and mouse gene and protein expression information from the peer reviewed publications. Significant pathway enrichments in each group was calculated by comparing the unique proteins identified in each group to the mouse database. Any pathways below a corrected p-value of 0.05 was considered as significant. An enrichment report was generated using each of the unique protein list and bar graph was generated in GraphPad prism. Similarly, Pathway enrichment analysis was performed using the differentially expressed proteins in iTregs compared to nTregs and nTreg depleted CD4 T cells along with its expression values. Significant pathways are plotted using a bar graph and important alterations in major pathways are highlighted as in the expression context.   
4.2.4.5. Analysis of public datasets of markers of interest in cancer To check the expression of markers on murine immune cells, each gene corresponding to the identified protein was surveyed using BloodSpot (http://servers.binf.ku.dk/bloodspot/ accessed Oct 2019), an online database of healthy and malignant haematopoiesis comprising large amounts of gene expression data of human and murine immune system.  Although the markers were identified using a murine in vitro model, its translational validity in humans was explored using publicly available datasets. This study used OncoLnc (http://www.oncolnc.org/ accessed Oct 2019), a web-based tool to analyse The Cancer Genome Atlas (TCGA). OncoLnc designed to derive survival relationships of a query gene with gene expression data and survival information of 8,647 patients 
from 21 cancer types performed by TCGA. Genes were queried singly (FOXP3, ITIH4, 
PLP2, MAVS, HEM6 (CPOX), HYEP (EPHX1)) among 21 cancer types. Poor prognosis 
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using survival information of FOXP3 data among all the cancer types was considered 
as a surrogate marker for T reg enriched tumour. Kidney Renal Clear Cell Carcinoma 
(KIRC) was identified as the top cancer with significant association of FOXP3 expression and poor survival outcome. All the human equivalents of the shortlisted 
genes were subsequently queried in KIRC to see whether any of these genes explain similar survival outcome. The plots were generated using OncoLnc and the Significance of difference in survival probability between high and low group of each genes were calculated using Log rank p value, p-Value less than 0.05 was considered as significant.     
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4.3. Results 
4.3.1. Subcellular proteomic profiling of mouse CD4+ T cells using 
using LC-MS-MS. Membrane and cytoplasmic proteins derived from five different subsets of CD4+ T cells were profiled using LC-MSMS proteomics. The MS analysis was carried out in two different steps. First, a local library of proteins was created based on the total number of proteins identified from all subpopulations of CD4+ T cells using an 
information/data dependent acquisition approach (IDA/DDA). Second, samples were analysed by SWATH-MS, and the quantitative data extracted against this library combined with a comprehensive externally generated mouse library to give a list of proteins with relative quantitation across all samples. 
4.3.1.1. Information Dependent Acquisition (IDA) proteomic analysis of 
sorted mouse CD4+ cells (qualitative analysis) IDA acquisition was carried out on the 5 replicate samples in each sorted cell type for both membrane and cytosolic fractions and each set of biological replicates searched together.  Proteins were identified and enumerated in Table 4.4.  
Table 4.4: Number of proteins identified in each T cell subpopulation in both membrane and cytosolic fractions. 
 
Subsets of CD4+ T cells 
Membrane 
Fraction* 
Cytoplasmic 
Fraction* 
Total distinct 
protein groups 
Naïve CD4+CD25-  
 
656 677 1096 
Naïve CD4+CD25+Foxp3+ 
(nTregs) 
431 310 634 
Activated CD4+CD25-  
 
621 582 1000 
Activated CD4+CD25+Foxp3+ 
(nTregs) 
658 553 991 
CD4+CD25++Foxp3+ (iTregs) 
 
611 681 1090 
*Reversed sequences removed; results displayed at 1 % protein False Discovery Rate (FDR) 
cut off.  
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Qualitative analysis of the data showed that the fractionation into 
membrane/cytosolic fraction was not absolute with many proteins present in both 
samples for each cell type (figure 4.7).  The total cellular protein (membrane and 
cytosolic combined) is presented in figure 4.8 across all 5 sorted cell types.  
 Protein data was also analysed for each sorted cell type by cross referencing the proteins for each cell type with the known protein localisations from the literature 
based on the Uniprot database (http://www. Uniprot.org, accessed April 2019) this is shown in table 4.5.  The IDs of shared, unique and differentially expressed proteins of the five CD4+ T cell subsets were mapped using MetaCore software to identify 
Naïve CD4+CD25- Naïve CD4+CD25+Foxp3+ (nTreg) 
Activated CD4+CD25+Foxp3+ (nTreg) Activated CD4+CD25- 
CD4+CD25++Foxp3+ (iTreg) 
409 479 202 
419 440 237 
418 379 203 
324 202 107 
438 333 220 
Figure 4.7. Venn diagrams showing the overlap of proteins identified in membrane versus cytosolic fractions by IDA acquisition and protein search in each group of 5 replicate samples from the sorted cell types. 
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significantly enriched pathways based on p value (< 0.05) and FDR (<0.05) (figure 
4.9 and 4.10). 
 
 
Table 4.5: Characterisation of the known subcellular location (as defined by Uniprot) of the identified proteins from the sorted CD4+ cells from the qualitative IDA analysis.  
 
Subsets of CD4+  
T cells 
Known 
Membrane 
Location 
Known 
Cytoplasmic 
Location 
Proteins with 
unknown 
location 
Naïve CD4+CD25   
 
466 708 15 
Naïve 
CD4+CD25+Foxp3
+ (nTregs) 
300 404 0 
Activated 
CD4+CD25  
 
409 687 4 
Activated 
CD4+CD25+Foxp3
+ (nTregs) 
438 643 6 
CD4+CD25++Foxp
3+ (iTregs) 
 
437 745 9 
 
Figure 4.8. Venn diagram comparing the total number of proteins identified in five different subsets of CD4+ T cells.  
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Figure 4.9. Significantly enriched pathways derived through mapping the IDs of proteins identified in the DDA-library using Metacore analytics based on p-value < 0.05 and FDR < 0.05. (A) Significantly enriched pathways that are shared between five different subsets of CD4+ T cells. (B) Significantly enriched pathways derived from the IDs of the unique proteins of naïve CD4+CD25- T cells. (C) Significantly enriched pathways derived from the IDs of the unique proteins of activated CD4+CD25- T cells.   
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Figure 4.10. Significantly enriched pathways derived through mapping the IDs of proteins identified in the DDA-library using Metacore analytics based on p-value < 0.05 and FDR < 0.05. (A) Significantly enriched pathways derived from the IDs of the unique proteins of naïve CD4+CD25+ nTregs. (B) Significantly enriched pathways derived from the IDs of the unique proteins of activated CD4+CD25+ nTregs. (C) Significantly enriched pathways derived from the IDs of the unique proteins of iTregs. 
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4.3.1.2. Generation of a local spectral library (ion library) for SWATH MS 
profiling A local (generated from the real samples) spectral library was generated from searching the mass spectrometer acquisition file of all fractions of all sorted cells together into a single result (.group) file (Table 4.6). 1414 proteins from 5441 peptides were identified from the Swissprot Human database in all samples.  
Table 4.6 Summary of proteins, peptides and spectra identified in all the cell fractions and sorted cell types analysed by IDA mass spectrometry and searched in ProteinPilot. 
  Summary of Identification Yields 
  Data Level FDR Type  FDR ID Yield 
Id
en
tif
ica
tio
n 
Yi
el
d 
at
 F
DR
 
Th
re
sh
ol
d 
Protein 
Local 
1% 1056 
5% 1429 
10% 1546 
Global 
1% 1414 
5% 1846 
10% 2050 
Distinct peptide 
Local 
1% 3753 
5% 5425 
10% 6169 
Global 
1% 5441 
5% 7657 
10% 9145 
Spectral 
Local 
1% 41703 
5% 57653 
10% 69601 
Global 
1% 59683 
5% 90162 
10% 115479   *Global FDR at 1% values accepted. The .group results file was then converted to the spectral library format (.txt) as previously described (section 4.2.2.1) after removal of all proteins with shared peptides. 
4.3.1.3. Improvement of the spectral library (ion library) 
While reasonably good, 1414 proteins and 5441 peptides in a spectral library will 
allow fewer than 1414 proteins to be quantified from SWATH data.  In order to improve the quantitation an external library was obtained from Dr Nick Morrice 
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(SCIEX) containing a large pre-generated (from a TripleTOF 6600 instrument) mouse 3T3 cell spectral library in .txt format.  This library contained 8,446 proteins and it was reasonably speculated that many of these mouse proteins would also be present in the cell lysate protein fractions from this study. 
4.3.1.4. SWATH-MS quantitative profiling As the subcellular profiling was carried out based on the number of cells (2x106) in each replicate of the five subsets of CD4+ T cells, the reproducibility in SWATH-MS profiling data of the five subsets of CD4+ T cells was firstly assessed based on the percentage of reproducible transitions of peptides detected in each sample. The results showed that the percentage of reproducible transitions of peptides was in range between 33% and 55% among 50 samples that were analysed on MS (figure 4.6). The variability of SWATH MS data was relatively low in the most of samples 
(40/50) as the percentage of reproducible transitions of peptides to fragment ions was in range of 44 -55%, whereas only 10 samples showed higher variability with 33-43% of reproducible transitions of peptides (figure 4.11).  A high % of reproducible transitions would not be expected here as the cells have been fractionated into different sub-types likely with significant differences in protein profiles, what matters is the variation between all samples.  While there are a few samples that vary more, having a reduced % reproducible transitions, on discussion 
Figure 4.11. The percentage of reproducible transitions of peptides in each of 50 samples of the five different subsets of CD4+ T cells that were prepared for SWATH-MS profiling. Cytoplasmic and membrane proteins samples derived from each replicate of the five subsets of CD4+ T cells. Five replicates for each subset were prepared. 
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with the OneOmics software application specialists at SCIEX, the advice was to keep all data in as the algorithm would take this into account when processing. After assessing the variability, the SWATH-MS data were then normalised to minimise the differences due to experimental artefacts and protein/peptide load between samples and improve the data quality using SCIEX OneOmics software. The data normalisation was performed internally in the software suite using MLR (Most Likely Ratio) normalisation strategy which has been found to be the best strategy for SWATH-MS data normalisation (Lambert, et al. 2013). Figure 4.12 shows the log10 transformed intensity ratios of peaks derived from peptide fragments within each sample before and after normalisation.          
  
Figure 4.12. The log10 intensity peaks of peptide fragments of samples before and after normalisation. (A) Pre-normalisation. (B) Post-normalisation.  
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4.3.1.5. SWATH-MS quantitative profiling Using the combined locally generated and external mouse 3T3 cell spectral library, a total of 3910 proteins were detected and selected for quantitation by SWATH MS analysis based on their expression across all five subsets of CD4+ T cells. The expression (peak area, intensity) of each protein was compared between the five subsets of CD4+ T cells to identify up and down regulated proteins for each subset. Using the Uniprot database and website, among the 3910 proteins, 1236 (31.6%) 
proteins were identified as membrane proteins, whereas 2294 (58.7%) proteins were classified as cytoplasmic and nuclear proteins. The remaining 380 (9.7%) proteins were identified with unknown (not mapped) subcellular locations (figure 4.13).                           
Figure 4.13. Pie chart showing the number and percentage of SWATH-MS-identified proteins based on their subcellular locations. Cyto: Cytoplasmic, Nuc: Nuclear. 
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To assess the reproducibility of SWATH MS profiling normalised and log transformed peak areas (intensity) of 3910 proteins were subjected to a principle component analysis (PCA). Most of the variation in the data was captured using the 
first two components (PC1 and PC2). For membrane proteins, the percentage of variability in the data was 45% and 9.4% at PC1 and PC2, respectively (figure 4.14 A). For cytoplasmic proteins, the percentage of variability in the data was 50.1% and 
7.4% at PC1 and PC2, respectively (figure 4.14 B). There was minimum intra replicate variability observed within each group indicating good reproducibility between the samples, while five biologically different groups were well separated. Moreover, the analysis showed that groups representing naïve subsets of CD4+ T cells were well separated from groups which represented activated subsets of CD4+ T cells confirming the trend of reproducibility between the samples of both membrane and cytoplasmic proteins. The results also showed that there was an increase in the variability within activated groups, which allowed the group of iTregs to be nicely separated from other activated groups in both membrane and cytoplasmic protein samples.              
Figure 4.14. PCA analysis showing the percentage of variability between five different subsets of CD4+ T cells at the first two principle components (PC1 and PC2). (A) PCA analysis for the samples of membrane proteins. (B) PCA analysis for the samples of cytoplasmic proteins. Group highlighted with green (naïve CD4+CD25- T cells), blue (naïve CD4+CD25+ nTregs), violet (stimulated/activated CD4+CD25- T cells), orange (stimulated/activated CD4+CD25+ nTregs) and red (iTregs). 
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 The SWATH MS identified proteins were then sorted based on their confidence score of identification from OneOmics (this confidence score is based on a proprietary algorithm from SCIEX and has no equivalent in any classical statistical test). Proteins with confidence score ≥ 50% were classified as “possible proteins with real expression changes between experimental groups” and selected for further analysis. The total number of confident proteins was 443 (11.3%) from the 
total 3910 identified proteins. Of 443 proteins, 99 (22.3%) proteins were classified 
as membrane proteins, whereas the remaining 344 (77.7%) proteins were classified as cytoplasmic and nuclear proteins (figure 4.15).                                                                                                                                                                                                                                   
The SWATH quantitative data (peak area/intensity) of confidently differentially expressed proteins were analysed based on two different approaches: OneOmics-based approach and ANN-based approach.   
4.3.1.6. OneOmics-based approach The OneOmics-based results showed the fold change and confidence score of identified proteins based on a pairwise comparison of the 5 different 
Figure 4.15. Pie chart showing the number and percentage of SWATH-MS-identified “confident proteins” based on their subcellular locations. 
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subpopulations of CD4+ T cells against each other. The overall results of OneOmics algorithm can be found in the appendix (tables 9A, 10A, 11A, 12A). The expression of identified proteins was compared between the population of iTregs and naïve nTregs as a control population to identify distinct proteins that are exclusively upregulated in iTregs. The results showed that 239 membrane and cytoplasmic proteins with confidence score ≥ 50% were found highly expressed in iTregs compared to nTregs at fold-change 1.5 cut-off value (results shown in the appendix, table 10A). Table 4.7 shows a list of the top 32 of 239 membrane and cytoplasmic proteins that are differentially expressed in iTregs compared to naïve nTregs. 
Table 4.7. List of the top 32 cytoplasmic and membrane proteins that are differentially expressed in iTregs compared to naive nTregs. 
Protein ID Protein Name Fold-change OneOmics Confidence score* 
Q8BHX1 HAUS1 6.0 71% A2A4U6 ZFP334 5.0 55% 
Q80XI6 M3K11 4.7 57% 
Q3KNJ2 NHEJ1 4.5 55% 
E9Q1M6 ANKHD1 3.9 75% Q3UMA3 HGFS 3.9 57% A0A0R4J0F6 GAK 3.8 56% 
Q8BMC4 NOP9 3.8 59% 
Q9QYG0 NDRG2 3.8 64% 
Q8BV13 CSN7B 3.7 61% 
Q9R1Q7 PLP2 3.7 86% D3YXP6 PMVK 3.6 50% 
Q811B1 XYLT1 3.5 72% 
Q8VEJ9 VPS4A 3.5 53% 
Q9D1C1 UBE2C 3.4 60% 
Q0HA38 TT21B 3.4 64% A2A4U6 Zfp334 3.3 57% 
Q8BXQ2 PIGT 3.3 63% 
Q9CX56 PSMD8 3.2 83% 
Q920E5 FPPS 3.2 78% 
E9PWW6 Zc3h7a 3.2 60% 
E9PVX6 KI67 3.2 77% 
K3W4Q8 Basigin 3.2 78% 
Q8BKX1 BAIP2 3.2 69% 
P17751 TPIS 3.2 87% 
P57787 MOT4 3.1 55% 
Q80VJ2 SRA1 3.1 53% 
E9PX68 Slc4a1ap 3.1 57% 
P70333 HNRH2 3.1 51% 
Q99N92 RM27 3.1 51% 
Q05920 PYC 3.1 80% 
Q8VCF0 MAVS 3.1 55% 
* Confidence score is based on Sciex OneOmics proprietary algorithm. <50% unlikely to be a real     fold change. 
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The results also showed that 79 membrane and cytoplasmic proteins with 
confidence score ≥ 50% were found upregulated in naïve nTregs compared to iTregs 
at 1.5-fold-change cut-off value (data shown in the appendix, table 10A). Table 4.8 
shows a list of the top 32 among 79 cytoplasmic and membrane proteins that are found to be upregulated in naïve nTregs compared to the population of iTregs.  
Table 4.8. List of the top 32 cytoplasmic and membrane proteins that are differentially expressed in nTregs compared to iTregs. 
Uniprot 
protein ID 
Protein Name Fold-change OneOmics Confidence score 
Q3KNJ2 NHEJ1 4.5 59% 
Q792Z1 Q792Z1 4.5 77% 
P58501 PAXB1 4.2 61% 
Q8VE19 MIO 4.0 76% 
Q8BGS2 BOLA2 4.0 61% 
Q8BHS6 ARMX3 3.9 57% Q64525 H2B2B 3.8 57% 
Q8R422 CD109 3.5 83% 
B0R091 B0R091 3.5 56% 
E9QA45 E9QA45 3.5 89% 
Q8BR76 MKS3 3.5 57% 
Q920Q2 REV1 3.5 57% 
Q8CC88 VWA8 3.4 51% 
O89079 COPE 3.4 63% 
Q9CZP3 Q9CZP3 3.4 65% 
Q9D379 HYEP 3.3 76% Q0PD20 Q0PD20 3.3 56% 
Q8K2M0 RM38 3.3 52% A0A0R4J0J3 A0A0R4J0J3 3.3 50% 
O35609 SCAM3 3.3 50% 
P16330 CN37 3.1 53% 
Q9CRD2 EMC2 3.0 51% 
Q9JIZ9 PLS3 2.9 57% 
Q64327 MEA1 2.9 51% 
Q9Z1R9 Q9Z1R9 2.9 85% 
Q9R207 NBN 2.9 50% 
O35598 ADA10 2.8 62% 
Q3UD82 PARP8 2.8 53% 
E9Q0G1 E9Q0G1 2.8 55% 
A2A513 A2A513 2.7 91% 
E9Q0A7 E9Q0A7 2.6 50% Q6NS45 CCD66 2.6 53%  The expression of identified cytoplasmic and membrane proteins was also compared between the population of iTregs and stimulated CD4+CD25- T cells as a second control population. The results showed that 56 cytoplasmic and membrane proteins were found differentially expressed in iTregs compared to stimulated CD4+CD25- T cells population at 1.5-fold-change cut-off value (data shown in the 
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appendix, table 9A). Table 4.9 shows the top 32 among 56 cytoplasmic and membrane proteins that are upregulated in iTregs compared to stimulated CD4+CD25- T cells.  
Table 4.9. List of the top 32 cytoplasmic and membrane proteins that are differentially expressed in iTregs compared to activated CD4+CD25- T cells. 
Uniprot 
Protein ID 
Protein Name Fold-change OneOmics Confidence score A2AH22 AMRA1 5.2 66% A0A0R4J0F6 GAK 4.7 53% 
Q61545 EWS 4.4 64% 
A0A0R4J187 XRCC6 4.0 51% Q3UMA3 HGFRTKS 4.0 57% 
Q80TA6 MTMRC 3.7 52% 
A6PW84 P3H1 3.7 57% 
Q80XJ3 TTC28 3.3 59% 
P14094 AT1B1 3.3 74% 
P02798 MT2 3.2 51% 
Q8R2Y8 PTH2 3.2 60% D5MCW4 CUTA 3.2 63% 
Q8VDD8 WASH1 3.2 59% 
Q91W63 NRK1 3.2 65% Q3UL36 ARGL1 3.0 59% 
Q8C522 ENDD1 2.9 65% 
Q9ERE7 MESD 2.8 58% 
A2AQ07 TBB1 2.8 52% 
Q80U19 DAAM2 2.8 56% 
Q9EQ08 HNS 2.7 52% 
Q8BX09 RBBP5 2.7 62% 
Q61127 NAB2 2.6 52% 
O35215 DOPD 2.6 64% 
P97864 CASP7 2.5 69% 
Q80XI6 M3K11 2.4 77% 
Q8BVG4 DPP9 2.4 51% 
P84078 ARF1 2.3 50% 
Q8BI72 CARF 2.3 54% 
E9Q6R7 UTRN 2.2 66% 
P02089 HBB2 2.2 82% 
Q9CPX4 Ferritin 2.2 59% 
Q8CAK1 CAF17 2.1 51%  
The results also revealed that 98 cytoplasmic and membrane proteins were found expressed at high levels in stimulated CD4+CD25- T cells compared to iTregs at 1.5-fold-change cut-off value (data shown in the appendix, 9A). Table 4.10 shows the top 
32 of 98 cytoplasmic and membrane proteins that are upregulated in stimulated CD4+CD25- T cells compared to iTregs population.   
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Table 4.10. List of the top 32 cytoplasmic and membrane proteins that are differentially expressed in activated CD4+CD25- T cells compared to iTregs.  
Uniprot 
Protein ID 
Protein Name Fold-change OneOmics Confidence score 
Q80UF4 SDCG8 6.643856 0.758175 
Q9D0S9 HINT2 6.485372 0.547028 
Q45VK7 DYHC2 5.343186 0.615735 
Q9CX56 PSMD8 4.357873 0.663257 
Q3KNJ2 NHEJ1 4.157255 0.600902 A0A0R4J0J3 ADNHQ4 4.099722 0.582634 
Q9JLV1 BAG3 3.828483 0.615726 
P21981 TGM2 3.769342 0.842697 
G3X920 ARMC8 3.663181 0.729015 
Q792Z1 MCG140784 3.621907 0.623682 
Q8BYH8 CHD9 3.614892 0.586976 
B1ASU9 TLK2 3.478489 0.627116 
P43277 H13 3.454123 0.701737 
Q923D4 SF3B5 3.391455 0.626311 
A2APB8 TPX2 3.378938 0.741857 
Q8CAH8 GDPK 3.357312 0.590024 
P27661 H2AX 3.303716 0.604916 
Q91YR5 MET13 3.292886 0.551793 
Q9D824 FIP1 3.283845 0.53197 
Q8BH15 CNO10 3.249924 0.537365 
Q80UF4 SDCG8 3.197587 0.64159 Q8BGS2 BOLA2 3.192564 0.828886 P40336 VP26A 3.137329 0.591784 
P32037 GTR3 3.117137 0.87764 
B1AW21 Myotubularin 3.091522 0.554631 
Q91ZU1 ASB6 3.076995 0.631676 
P07356 ANXA2 3.070642 0.753384 
E9Q0G1 DRP 3.053311 0.600026 
Q8CGP7 H2A1K 3.02566 0.597722 
O35409 FOLH1 3.012569 0.881223 
Q64735 CR1L 3.004373 0.619048 
Q9ERH4 NUSAP 2.915646 0.635705  The differentially expressed proteins were further analysed using MetaCore pathway enrichment tool. The most differentially regulated pathways in iTregs in comparison to nTregs and cultured CD25 depleted CD4 T Cells are depicted in figure 
4.16.  the significant pathways altered in each of the comparisons are represented in a pathway context using MetaCore (Figure 4.17-4.19). 
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Figure 4.16. Significantly enriched pathways in iTregs compared to stimulated CD4 (CD25- FOXP3-) and nTregs.  
(A). Bar graph showing significance of enrichment of pathways in iTregs compared to CD4 (CD25- FOXP3-) T 
cells cultured in the same way as iTregs for 5 days but without TGFβ. Y axis describe the pathways and the X axis represent corrected p value in log10 scale. Red colour indicating the upregulated and the green indicating down regulated pathways in iTregs. (B). Bar graph showing significance of enrichment of pathways in iTregs compared to pure population of nTregs (CD25+ FOXP3+). Y axis describe the pathways and the X-axis represent corrected p value in log10 scale. Dark Red colour indicating the upregulated and the green indicating down regulated pathways in iTregs comparison to nTregs. 
  
A 
B 
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Figure 4.17. Pathway maps of glycolysis and gluconeogenesis with significant downregulated proteins were highlighted using a thermometer icon. Differentially expressed proteins shortlisted by pairwise comparison of quantitative mass spectrometry data generated from iTregs and cultured nTreg depleted CD4 T-cells were analysed using MetaCore functional enrichment tool. Glycolysis and gluconeogenesis are one of the most significantly down pathways in iTregs compared to CD4 T cells, significant proteins upregulated in iTregs compared to CD4 T cells are overlaid in the whole pathway context.       
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Figure 4.18. Several HIF-1 targets were found to be down regulated in iTregs in comparison to cultured nTreg depleted CD4 T-cells. Pathway maps of HIF-1 targets proteins altered in iTregs compared to nTregs are highlighted using thermometer signs (red colour). Differentially expressed proteins shortlisted by pairwise comparison of quantitative mass spectrometry data generated from iTregs and cultured CD4 T-cells were analysed using MetaCore functional enrichment tool. Transcription of HIF-1 targets are one of the most significantly downregulated pathways in iTregs compared to CD4 T- cells. Significant proteins upregulated in iTregs compared to CD4 T cells are overlaid in the whole pathway context.   
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Figure 4.19. Ubiquinone metabolism with significant up regulated in iTregs compated to cultured CD4 T cells. The significant proteins were highlighted using a thermometer icon (red colour). Differentially expressed proteins shortlisted by pairwise comparison of quantitative mass spectrometry data generated from iTregs and cultured nTreg depleted CD4-T cells were analysed using MetaCore functional enrichment tool. Ubiquinone metabolism is one of the most significantly altered pathway in iTregs compared to CD4-T cells, significant proteins downregulated in iTregs compared to CD4 -T cells are overlaid in the whole pathway context.         
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4.3.1.7. ANN-based approach The quantitative protein data (peak area) of 99 membrane proteins and 344 cytoplasmic proteins were analysed using ANN modelling stepwise approach to identify a predictive panel of proteins (biomarkers) that can differentiate iTregs among other CD4+ T cells subpopulations. Two different methods of ANN analysis were used to analyse proteomic quantitative data, including single stepwise and multiple stepwise analysis.  The results of single stepwise analysis showed that 7 distinct proteins among 443 cytoplasmic and membrane proteins with the lowest average test error (ATE) were mathematically selected by the ANN as predictive biomarkers that differentiate iTregs from other CD4+ T cells subpopulations. The distinct proteins are MAVS, PLP2, 
ITIH4, HEM6, CUL4A, P85A, XYLT1. Table 4.1 shows the summary results of novel membrane and cytoplasmic markers of iTregs selected by the ANN single stepwise analysis. 
Table 4.11. A summary of the results of novel biomarkers of iTregs selected by the ANN single stepwise analysis. 
Protein Subcellular location Number of selection* Range of ATE MAVS Mitochondrial membrane 15 0.032 – 0.046 PLP2 Membrane 6 0.048 – 0.060 ITIH4 Membrane 5 0.050 – 0.058 HEM6 Mitochondrial membrane 5 0.030 – 0.046 CUL4A Cytoplasmic, Nuclear 4 0.049 – 0.059 
P85A Membrane 3 0.046 – 0.060 
XYLT1 Membrane, Intracellular 2 0.053 – 0.054 
* Number of selection represents how many times a biomarker has been selected by the ANN in the overall single stepwise analysis.   The results of single stepwise analysis revealed that 6 distinct proteins among 443 cytoplasmic and membrane proteins were also selected by the ANN as predictive biomarkers that distinguish naïve nTregs from other CD4+ T cells subpopulations. 
These proteins include HYEP, FERRITIN, SERPINB6A, NDKA, VWA8 and SAMH1. The summary results of novel membrane and cytoplasmic biomarkers of naïve nTregs are detailed in table 4.12. 
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Table 4.12. List of 6 novel biomarkers selected by the ANN single stepwise analysis to differentiate naive nTregs from other CD4+T cells subsets. 
Protein Subcellular location Number of selection Range of ATE HYEP Membrane 12 0.048 – 0.060 FERRITIN Cytoplasmic 10 0.040 – 0.050 SERPINB6A Membrane 8 0.042 – 0.054 
NDKA Cytoplasmic 5 0.043 – 0.049 
VWA8 Cytoplasmic, mitochondrial 3 0.041 – 0.053 
SAMH1 Cytoplasmic, Nuclear 2 0.045 – 0.055  
For multiple stepwise analysis, the results showed that 12 distinct proteins were selected by the ANN based on their ATE among 443 membrane and cytoplasmic proteins. These distinct proteins include MAVS, PLP2, ITIH4, CUL4A, HEM6, P85A, GSHR, SYAM, XYLT1, TFR1, CO4B and OGFR. Table 4.13 shows the summary results of novel membrane and cytoplasmic markers of iTregs selected by the ANN multiple stepwise analysis. 
Table 4.13. A summary of the results of novel biomarkers of iTregs selected by the ANN multiple stepwise analysis. 
Protein Subcellular location Number of selection Range of ATE MAVS Mitochondrial membrane 17 0.018 – 0.050 PLP2 Membrane 12 0.017 – 0.039 ITIH4 Membrane 11 0.018 – 0.053 CUL4A Cytoplasmic, Nuclear 11 0.030 – 0.058 HEM6 Mitochondrial membrane 10 0.013 – 0.046 
P85A Membrane 8 0.011 – 0.056 GSHR Cytoplasmic, mitochondrial 5 0.006 – 0.025 SYAM Cytoplasmic, mitochondrial 5 0.010 – 0.035 
XYLT1 Membrane, Intracellular 4 0.017 – 0.029 
TFR1 Membrane 3 0.015 – 0.036 CO4B Extracellular 2 0.020 – 0.044 OGFR Cytoplasmic, Nuclear 2 0.020 – 0.024  
The results of multiple stepwise analysis also showed that 10 proteins were selected by the ANN as predictive distinct biomarkers that characterise naïve nTregs from 
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other subsets of CD4+ T cells. The results of these distinct biomarkers are summarised in table 4.14.  
Table 4.14. List of distinct proteins selected by the ANN multiple stepwise analysis as predictive biomarkers of naive nTregs 
Protein Subcellular location Number of selection Range of ATE HYEP Membrane 22 0.010 – 0.056 SERPINB6A Membrane 17 0.011 – 0.057 SPA3F Extracellular  15 0.018 – 0.052 
VWA8 Cytoplasmic, mitochondrial 12 0.012 – 0.029 
NKDA Cytoplasmic 10 0.012 – 0.031 FERRITIN Cytoplasmic 6 0.013 – 0.034 TCTP Cytoplasmic 2 0.017 – 0.061 MIC26 Membrane, Intracellular 2 0.013 – 0.035 
COF1 Membrane 2 0.015 – 0.033 ENOA Membrane 2 0.020 – 0.057   
4.3.1.8. Differentially expressed proteins in the membrane fraction of CD4+ T 
cells The most significant results of fold change in the expression of membrane proteins identified by SWATH MS profiling were shown in figure 4.20. The results showed 
that ITIH4 (inter alpha trypsin inhibitor heavy chain 4), XYLT1 (xylosyltransferase 
1) and PLP2 (proteolipid protein 2) proteins were highly up regulated in iTregs compared to other subsets of CD4+ T cells in which these proteins were found 
significantly downregulated. The results also showed that P85A (Phosphatidylinositol 3 kinase regulatory subunit alpha) and CUL4A (proteins were significantly overexpressed in iTregs compared to other CD4+ T cell subsets which 
showed significant low expression for P85A and CUL4A proteins (figure 4.20). All the differentially expressed membrane proteins from all the pairwise comparisons are represented as a heatmap (Figure 4.21). 
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Figure 4.20. Scatter plots showing the protein peak area intensity (fold-change) of proteins identified significantly up-regulated in iTregs compared to other subsets of CD4+ T cells. Ordinary one-way ANOVA test 
was used for statistical analysis using GraphPad Prism 8.0.1 software. (****; p-value < 0.0001, **; p-value < 
0.0019). “Stim” means activated. Five independent experiments were carried out (n=5), each experiment compared five different cell populations. The statistical analysis was carried out on a limited data set (n=5) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. 
220  
Figure 4.21. Heatmap and hierarchical clustering showing relative fold-change protein expression values (log10 
transformed peaks intensity) of the 99 differentially expressed membrane proteins identified in the five different subsets of CD4+ T cells using SWATH-MS proteomics. One minus pearson correlation metric with single linkage method was used for hierarchical clustering using MORPHEUS online software (https://software.broadinstitute.org/morphe
us/. (Accessed on Sep 2019). 
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The results also showed that the expression of GTR1 (solute carrier family 2, 
facilitated glucose transporter member 1), MOT4 (monocarboxylate transporter 4), 
NDRG1 (N myc downstream regulated gene 1 protein), ALDOA (fructose 
biphosphate aldolase A), PGK1 (phosphoglycerate kinase 1), KPYM (pyruvate kinase 
PKM), LEG1 (Gelectin 1) and RIPK3 (receptor interacting serine/threonine protein kinase 3) proteins was found significantly up regulated in activated nTregs and CD4+CD25  T cells subsets compared to iTregs and other naïve subsets (figure 4.22).                    
Figure 4.22. Scatter plots showing the protein peak area intensity (fold-change) of proteins identified significantly down-regulated in iTregs compared to other activated CD4+CD25- T cells and activated nTregs subsets of CD4+ T cells. Ordinary one-way ANOVA test was used for statistical analysis using GraphPad Prism 
8.0.1 software. (****; p-value < 0.0001, ***; p-value < 0.0007, **; p-value < 0.0022). “Stim” means activated. Five independent experiments were carried out (n=5), each experiment compared five different cell populations. The statistical analysis was carried out on a limited data set (n=5) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. 
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The results also showed that the expression of HYEP (Epoxide hydrolase 1) protein was found significantly up regulated in naïve nTregs, while it was significantly down regulated in other subsets of CD4+ T cells. Another protein known as “SERPINB6A (serpin B6 domain A) was also found significantly up regulated in naïve nTregs compared to other CD4+ subsets (figure 4.23A).            
 The results also showed that the expression SPA3F (serine protease inhibitor A3F) protein was identified significantly up regulated in stimulated or activated nTregs, while it was significantly down regulated or expressed at very low levels in other subsets of CD4+ T cells (figure 4.23B). 
Figure 4.23. (A) Scatter plots showing the protein peak area intensity (fold-change) of proteins identified significantly up-regulated in naïve nTregs compared to other subsets of CD4+ T cells. (B) The protein peak area intensity (fold-change) of proteins identified significantly up-regulated in stimulated nTregs compared to other subsets of CD4+ T cells.  Ordinary one-way ANOVA test was used for statistical analysis using 
GraphPad Prism 8.0.1 software. (****; p-value < 0.0001, ***; p-value < 0.0005, **; p-value < 0.0016). “Stim” means activated. Five independent experiments were carried out (n=5), each experiment compared five different cell populations. The statistical analysis was carried out on a limited data set (n=5) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. 
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4.3.1.9. Differentially expressed proteins in the cytoplasmic fraction of CD4+ 
T cells  The results of cytoplasmic and nuclear proteins quantification showed that the expression of MAVS (mitochondrial antiviral signalling), HEM6 (oxygen dependent coproporphyrinogen ІІІ oxidase, mitochondrial (CPOX)), ICS10 (integrator complex 
subunit 10), SYAM (alanine tRNA ligase, mitochondrial), OGFR (opioid growth receptor) and TYSY (thymidylate synthase) proteins was significantly up regulated in iTregs compared to other subsets of CD4+ T cells in which the expression of these proteins was detected at low levels (figure 4.24). 
 
Figure 4.24. Scatter plots showing the protein peak area intensity (fold-change) of cytoplasmic and nuclear proteins identified significantly up-regulated in iTregs compared to other subsets of CD4+ T cells. Ordinary one-way ANOVA test was used for statistical analysis using GraphPad Prism 8.0.1 software. (****; p-value < 0.0001, 
***; p-value < 0.0007, **; p-value < 0.0012, *; p-value < 0.0325). “Stim” means activated. Five independent experiments were carried out (n=5), each experiment compared five different cell populations. The statistical analysis was carried out on a limited data set (n=5) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean.  
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The results also showed that among cytoplasmic and nuclear proteins identified, 12 proteins were found significantly up regulated in all stimulated or activated subsets of CD4+ T cells, except iTregs in which the expression of proteins was significantly low compared to stimulated nTregs and CD4+CD25  T cells although iTregs were activated at the same level of nTregs and CD4+CD25  T cells. These proteins include TPIS (triosephosphate isomerase), G3P (glyceraldehyde 3 phosphate dehydrogenase), SERC (phosphoserine aminotransferase), SYYC (tyrosine tRNA 
ligase, cytoplasmic), RP10 (ribosomal protein 10), PGAM1 (phosphoglycerate 
mutase 1), PGM1 (phosphoglucomutase 1), GALK1 ( galactokinase 1), LDHA (L lactate dehydrogenase A chain), RL34 (60S ribosomal protein L34), TPP2 (tripeptidyl peptidase 2) and SYSC (serine tRNA ligase, cytoplasmic) (figure 4.25).  
The results showed that the expression of SAMH1 (Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1) and VWA8 (von Willebrand factor A domain 
containing protein 8) proteins was found significantly up regulated in naïve nTregs compared to other four subsets of CD4+ T cells, especially stimulated nTregs in which the expression of SMAH1 and VWA8 proteins was significantly diminished after TCR activation (figure 4.26A). For cytoplasmic protein signature of activated nTregs, the results showed that the expression of CCS (Copper chaperone for superoxide dismutase) protein was significantly increased in activated nTregs, while its expression was detected at very low levels in naïve nTregs without activation (figure 4.26B). The results also showed that the expression of DYR (Dihydrofolate reductase) protein was identified significantly up regulated in activated CD4+CD25  T cells, while its expression was found significantly down regulated in other subsets of CD4+ T cells (figure 4.26C).
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Figure 4.25. Scatter plots showing the protein peak area intensity (fold-change) of cytoplasmic and nuclear proteins identified significantly up-regulated in activated nTregs and CD4+CD25- T cells, but down-regulated in iTregs. Stim CD4+CD25- T cells, stim nTregs and iTregs were received the same TCR activation signals. Naïve CD4+CD25- T cells and nTregs were not activated.  Ordinary one-way ANOVA test was used for statistical analysis using GraphPad Prism 8.0.1 software. (****; p-value < 0.0001, ***; p-value < 0.0007, **; p-value < 
0.0019, *; p-value < 0.0425). “Stim” means activated. Five independent experiments were carried out (n=5), each experiment compared five different cell populations. The statistical analysis was carried out on a limited data set (n=5) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean.   
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Figure 4.26. Scatter plots showing the protein peak area intensity (fold-change) of cytoplasmic and nuclear proteins identified significantly up-regulated in (A) naïve nTregs, (B) activated nTregs and (C) activated CD4+CD25- T cells, compared to other subsets of CD4+ T cells.  Ordinary one-way 
ANOVA test was used for statistical analysis using GraphPad Prism 8.0.1 software. (****; p-value < 
0.0001, ***; p-value < 0.0004, **; p-value < 0.0030, *; p-value < 0.0444). “Stim” means activated. Five independent experiments were carried out (n=5), each experiment compared five different cell populations. The statistical analysis was carried out on a limited data set (n=5) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean. 
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To distinguish naïve from activated subpopulations of CD4+ T cells, the results showed that six distinct proteins were identified overexpressed mainly in both naïve subsets of CD4+ T cells; naïve CD4+CD25  T cells and nTregs, whereas these six proteins were identified expressed at low levels in all activated subsets of CD4+ T cells (figure 4.27). These proteins included ACOT2 (Acyl coenzyme A thioesterase 2, mitochondrial), MDHC (Malate dehydrogenase, cytoplasmic), SPRE (Sepiapterin reductase), PGM2 (Phosphoglucomutase 2), TRNT1 (CCA tRNA 
nucleotidyltransferase 1, mitochondrial), and GSHR (Glutathione reductase, mitochondrial).                   
Figure 4.27. Scatter plots showing the protein peak area intensity (fold-change) of cytoplasmic and nuclear proteins identified significantly up-regulated in naïve subsets of CD4+ T cells, compared to stimulated subsets.  Ordinary one-way ANOVA test was used for statistical analysis using GraphPad Prism 8.0.1 software. (****; p-
value < 0.0001, ***; p-value < 0.0008, **; p-value < 0.0026, *; p-value < 0.0387). “Stim” means activated. Five independent experiments were carried out (n=5), each experiment compared five different cell populations. The statistical analysis was carried out on a limited data set (n=5) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean.   
228  
The results also showed that 11 distinct proteins were identified overexpressed particularly in activated subsets of CD4+ T cells including activated CD4+CD25  T cells, activated nTregs and iTregs compared to naïve subsets; naïve CD4+CD25  T cells and nTregs, in which these proteins were detected at low levels of expression (figure 4.28). these proteins were SYMC (Methionine tRNA ligase, cytoplasmic), SYVS (Valine tRNA ligase), IPYR (Inorganic pyrophosphatase), STATHMIN, IMPA2 
(Inositol monophosphatase 2), EF1G (Elongation factor 1 gamma), MCM2 (DNA replication licensing factor MCM2), MCM3 (DNA replication licensing factor MCM3), MCM5 (DNA replication licensing factor MCM5), MCM6, DNA replication licensing 
factor MCM6, MCM7 (DNA replication licensing factor MCM7). The overall results of the expression fold change of 344 cytoplasmic and nuclear proteins identified and compared between five different subsets of CD4+ T cells using SWATH MS proteomics are shown in figures 4.29, 4.30, 4.31 and 4.32).             
229  
 
Figure 4.28. Scatter plots showing the protein peak area intensity (fold-change) of cytoplasmic and nuclear proteins identified significantly up-regulated in activated subsets of CD4+ T cells, compared to naïve subsets.  Ordinary one-way ANOVA test was used for statistical analysis using GraphPad Prism 8.0.1 software. (****; p-value < 0.0001, ***; p-value < 0.0008, **; p-value < 
0.0032, *; p-value < 0.0404). “Stim” means activated. Five independent experiments were carried out (n=5), each experiment compared five different cell populations. The statistical analysis was carried out on a limited data set (n=5) and hence is not powered adequately. However, the results shown here confirmed the reproducibility and robustness of the data. Bars errors represent the standard error (SE) of the mean.  
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Figure 4.29. Heatmap and hierarchical clustering showing relative fold-change protein expression values (log10 transformed peaks intensity) of the 344 differentially expressed cytoplasmic and nuclear proteins identified in the five different subsets of CD4+ T cells using SWATH-MS proteomics. One minus pearson correlation metric with single linkage method was used for hierarchical clustering using MORPHEUS online software.    
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Figure 4.30. Heatmap and hierarchical clustering continued from figure 4.29.  
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Figure 4.31. Heatmap and hierarchical clustering continued from figure 4.29.  
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Figure 4.32. Heatmap and hierarchical clustering continued from figure 4.29. 
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4.3.1.10. Selection a panel of novels biomarkers of iTregs and nTregs for 
further verification and validation The selection criteria of novel biomarkers for further verification and/ or validation was based on the subcellular location of differentially expressed proteins, selection by the ANN approach in a correlation with the results of statistical analysis (as shown in the sections 4.3.1.8 and 4.3.1.9). The selection priority was for differentially expressed membrane proteins of iTregs and nTregs. Accordingly, MAVS, HEM6, PLP2 and ITIH4 proteins were selected as novel markers of iTregs for further verification and validation based on the results of the ANN approach and statistical analysis. HYEP protein was also selected as a novel biomarker of naïve nTregs for further verification and validation using flow cytometry.  Prior to verification and validation, the results of ANN approach and statistical analysis were further tested using a receiver operating characterisation (ROC) analysis to assess the sensitivity and specificity of selected proteins and to assess the performance level of the ANN stepwise modelling approach in differentiating iTregs and naïve nTregs among other CD4+ T cells subpopulation. The results of ROC analysis showed that the combination of MAVS, HEM6, PLP2 and ITIH4 proteins could be used as novel biomarkers to distinguish iTregs from other CD4+ T cells subsets (figure 4.33). The results of ROC analysis also revealed that the panel of HYEP and SERPINB6A proteins could be used as novel biomarkers to differentiate naïve nTregs from other subpopulations of CD4+ T cells (figure 4.34). The results of ROC analysis confirm the efficiency of the ANN modelling approach in identifying biomarkers that can distinguish a group of samples among various groups.          
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                           Figure 4.33. (A) ROC curve showing the sensitivity and specificity of MAVS, HEM6, ITIH4 and PLP2 as a predictive panel of novel biomarkers that are differentially expressed in iTregs compared to other CD4+ T cells subpopulations. Extracted SWATH-MS quantitative data of protein were used for ROC analysis. (B) Table illustrating a summary of the area under the curve (AUC) results for the selected proteins. (C) Bar graph showing the overall model quality and performance of the proteins selected by the ANN modelling approach.  IBM SPSS Statistics 26 software was used for ROC curve analysis.   
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Figure 4.34. (A) ROC curve showing the sensitivity and specificity of HYEP and SERPINB6A as a predictive panel of novel biomarkers that are differentially expressed in naïve nTregs compared to other CD4+ T cells subpopulations. Extracted SWATH-MS quantitative data of protein were used for ROC analysis. (B) Table illustrating a summary of the area under the curve (AUC) results for the selected proteins. (C) Bar graph showing the overall model quality and performance of the proteins selected by the ANN modelling approach.  IBM SPSS Statistics 26 software was used for ROC curve analysis. 
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4.3.1.11. Verification and/or validation of the selected proteins using flow 
cytometry and in silico tools Different commercial conjugated and unconjugated antibodies were used to validate the selected proteins using flow cytometry as mentioned in section 4.2.4. The four different subpopulations of CD4+ T cells were stained with anti- HEM6, MAVS, PLP2, ITIH4 and HYEP antibodies to verify the expression of the selected proteins in the population of iTregs and nTregs, in addition to the other subpopulations as negative controls (naïve CD4+CD25- and stimulated CD4+CD25- T cells). Unfortunately, the results of flow cytometry did not show any staining for the expression of the selected biomarkers in all of the subpopulations (figure 4.35).  Possible reasons are discussed in section 4.4 BloodSpot in silico analysis of the shortlisted biomarkers highlighted its expression pattern in haematopoietic cell lineages. The analysis of the gene expression data found that there is a ubiquitous expression of MAVS and ITIH4 in most of the cell types in the murine immune system (Figure 4.36B and 4.38). The expression of PLP2, HEM6 (CPOX), and HYEP (EPHX1) were found to be minimum in most of the murine 
immune cells (Figure 4.36A, 4.37 A&B).  Web-based analysis of The Cancer Genome Atlas (TCGA) using OncoLnc in 8,647 patients of 21 cancer types indicated Kidney Renal Clear Cell Carcinoma (KIRC) as one of the top cancers with FOXP3 expression correlated with poor prognosis 
indicating a significant role of Tregs in KIRC (Figure 4.39A). Therefore, all the human equivalents of the shortlisted genes (ITIH4, PLP2, MAVS, HEM6 (CPOX), and HYEP (EPHX1)) were subsequently investigated in KIRC to see whether any of these genes explain similar survival outcome. Three out of five genes were found to be highly correlated with poor survival prognosis indicating possible role of induced Treg population in KIRC microenvironment (Figure 4.39 B, C, and D). This need further validation and confirmation using a human specific antibody against the above-mentioned genes.    
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Figure 4.35. Flow cytometric density plots showing the results of verification of the selected proteins. Naïve nTregs were negative for the expression of HYEP, whereas iTregs showed negativity for the expression of HEM6, MAVS, ITIH4 and PLP2. Naïve and stimulated CD4+CD25- T cells as a control were also negative for the 
expression of all selected proteins. Kalusa software 1.3 was used for flow cytometry analysis. 
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Figure 4.36. Hierarchical differentiation tree of markers PLP2 and MAVS generated using normal murine haematopoiesis data set through BloodSpot online portal. The expression pattern of each gene from haematopoietic stem cell through its progenitors up to the effector cells are displayed. Red colour indicates maximum expression and blue colour represent minimum expression.   
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Figure 4.37. Hierarchical differentiation tree of markers HEM6 (CPOX) and HYEP (EPHX1) generated using normal murine haematopoiesis data set through BloodSpot online portal. The expression pattern of each gene from haematopoietic stem cell through its progenitors up to the effector cells are displayed. Red colour indicates maximum expression and blue colour represent minimum expression.   
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Figure 4.38. Hierarchical differentiation tree of marker ITIH4 generated using normal murine haematopoiesis data set through BloodSpot online portal. The expression pattern of each gene from haematopoietic stem cell through its progenitors up to the effector cells are displayed. Red colour indicates maximum expression and blue colour represent minimum expression.   
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Figure 4.39. Three out of five shortlisted markers associated with poor survival in cancer patients. (A-D). Survival analysis was performed using OncoLnc online survival analysis tool (TCGA). First, Tumour which showed high association of FOXP3 expression with poor survival outcome was 
identified as kidney renal clear cell carcinoma (KIRC) among 21 cancer types. The association of shortlisted biomarkers were then assessed in KIRC using upper and lower quartiles (33%). X- axis represent % survival and Y-axis represent number of days survived. Blue line indicates patient with low expression of corresponding gene and the red line indicates the high expression. Significance of difference in survival probability between high and low group of each genes were calculated using Log rank p value, p-Value less than 0.05 was considered as significant.     
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4.4. Discussion The presence of Tregs within the tumour microenvironment is found significantly correlated with poor prognosis in different types of cancer (Tanaka and Sakaguchi 
2017, Shang, et al. 2015b). Although the origin of tumour infiltrating Tregs is still controversial, a study has been reported that tumour infiltrating Tregs are mainly developed or induced from naïve CD4+ T cells that are recruited into the site of tumour (Su, et al. 2017a). Tumour infiltrating Tregs contribute to the progression of tumour growth via immune evasion by inhibiting anti-tumour immune response 
(Takeuchi and Nishikawa 2016).  Systemic depletion of Tregs has contributed to the development of autoimmune diseases in humans, thereby suggesting the requirement for approaches to selectively targeted tumour infiltrating Tregs to enhance anti-tumour immunity (Togashi, et al. 2019). Such approaches require 
sensitive and specific cell surface drug targets/biomarkers that can distinguish between naturally occurring Tregs (nTregs) and induced or peripherally developed Tregs (iTregs). To date, phenotypic signature of Tregs is defined by the expression of CD25 and Foxp3 proteins which are expressed in both nTregs and iTregs. Therefore, neither CD25 nor Foxp3 can be used for differentiating nTregs from iTregs (Lin, et al. 2013).  Many studies have been conducted to identify distinct biomarkers that can differentiate nTregs from iTregs. Neuropilin-1 (Nrp-1) was firstly identified as a surface marker expressed constitutively on nTregs (Bruder, et al. 2004). However, Milpied et al. have demonstrated that Nrp-1 is not a specific marker for nTregs as a population of CD4+Foxp3- T cells were found to express Nrp-
1. Also, the authors found that Nrp-1 expression was acquired by T cells after activation, suggesting that Nrp-1 could be used as an activation marker for T cells 
(Milpied, et al. 2009). Soon after, Thornton et al. have found that Helios is exclusively expressed on nTregs and can be used as a nuclear marker to differentiate nTregs from iTregs (Thornton, et al. 2010). However, Himmel et al. have found that not all nTregs express Helios as both Helios+ and Helios- cells were found within nTregs. The authors also found that both Helios+ and Helios-  nTregs have a similar suppressive activity, indicating that Helios cannot be used as a distinct marker for nTregs (Himmel, et al. 2013). 
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In the last three years, transcriptomic profiling of Tregs was the key topic for deeply understanding the biology of Tregs to identify specific molecular pathways which control the development and differentiation of Tregs. Cuadrado et al. have performed proteomics and transcriptomics on human naïve and effector nTregs and CD4+CD25+ T cells. The authors have identified the mechanistic pathways that define the identity of both naïve and effector nTregs with the difference between them at the RNA and protein level. The authors have found that there was no correlation between the transcriptomic and proteomic data for the expression of identified proteins, confirming the importance of proteomics analysis for the identification of proteins that are involved in the biological pathways (Cuadrado, et al. 2018). Similar approach has been conducted by Mohammad et al. the authors analysed the difference between T helper 17 (Th17) and iTregs using transcriptomic and proteomic profiling approach. The authors have demonstrated that the changes in the protein expression were not associated with changes in the transcriptional level, highlighting the importance of proteomics analysis since proteins are the functional product of the gene and easily targetable (Mohammad, et al. 2018). Another recent 
study conducted by Schmidt et al. has identified 37 novel molecules that regulate the induction of Foxp3 during the differentiation of iTregs in vitro (Schmidt, et al. 
2018). The results of all studies discussed above were only analysed mechanistic pathways at the transcriptional level. Also, none of previous studies have analysed or compared the differences between naïve CD4+CD25- T cells, naïve CD4+CD25+Foxp3+ nTregs, activated nTregs, activated CD4+CD25-  T cells and CD4+CD25++Foxp3+ iTregs at the protein level, particularly at the level of membrane proteins since membrane proteins can be easily targeted using antibody based applications either for targeting or for viable isolation using flow cytometry.                          In this study, the high throughput proteomic subcellular profiling was performed on five different purely sorted subsets of CD4+ T cells including naïve CD4+CD25- T cells, naïve CD4+CD25+Foxp3+ nTregs, activated CD4+CD25- T cells, activated nTregs and CD4+CD25++Foxp3+ iTregs. Using SWATH-MS proteomics, 99 confident membrane proteins and 344 cytoplasmic and nuclear proteins were identified in the five different subsets of CD4+ T cells. The confident proteins were defined based their 
OneOmics confidence score at ≥ 50% cut-off value. The fold change of the confident proteins was compared pairwise manner in five subsets using OneOmics software. 
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The functional association of significant proteins were elucidated using pathway analysis in MetaCore. Several pathways found to be differentially regulated in iTregs in comparison to nTregs and CD25- T cells indicating completely different molecular mechanisms operating in iTregs. Major pathways upregulated in iTregs in comparison to the nTregs are mainly associated with cell cycle progression. This is not surprising because iTregs are cultured for 5 days in a proliferative condition for the induction, whereas, the nTregs have been isolated ex vivo without any manipulations. For that reason, an appropriate comparison would be iTregs against nTreg depleted CD4 T cells cultured in the same way as iTregs but without TGF-beta. Pathway analysis of this comparison showed a complete different metabolic status for induced Tregs indicating a possible mechanism for converting CD4 into iTregs. The major patways down regulated in iTregs in comparison to cultured CD4s are 
glycolysis, HIF1 targets whereas the upregulated pathway is Ubiquinone metabolism. Studies have previously shown that inhibiting glycolysis prevented 
TH17 progression and supported Treg differentiation. More over same study also revealed that HIF1-α downregulation possibly by abolishing mTOR patway was critical in the development of Treg differentiation (Shi, et al. 2011). Our studies showed that presence of TGF-beta in the proliferating condition is good enough to convert naïve CD4 T cells in to iTreg possibly through the same mechanism.  An ANN based pattern recognition approach was employed to analyse the intensity of the expression of proteins in all of the subpopulations simultaneously in one run. The main advantage of using the ANN approach is due to its ability to recognise the pattern of variability, dimensionality and non-linearity of complex proteomics datasets and train the data by throughput stepwise modelling cycles with high performance to identify a panel of predictive biomarkers (Lancashire, Lemetre and 
Ball 2009). For the population of iTregs, the results showed that 5 different novel membrane 
proteins were significantly up regulated in iTregs including ITIH4, PLP2, XYLT1, 
CUL4B and P85A. The overexpression of these proteins might be mediated via TGF-
β1 signalling and could be linked to the suppressive activity of iTregs, while these proteins were detected at low levels in activated CD4+CD25- T cells and other subsets of CD4+ T cells analysed in this study. Activated CD4+CD25- T cells and iTregs 
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were received the same strength of TCR activation signals via CD3/CD28 co- stimulatory signalling in vitro in the presence of IL-2. However, the only difference was that iTregs were generated in the presence of TGF-β1.  The results also showed that the expression of MAVS, HEM6 and SYAM proteins, as intracellular mitochondrial membrane proteins, was found significantly up regulated in iTregs compared to other subsets of CD4+ T cells. These proteins also could be correlated to the suppressive activity of iTregs which was acquired due to exposure to TGF-β1 after TCR activation. The results suggest that these novel intracellular proteins could be used for defining the phenotypic features of iTregs. 
To date, the expression of CD73 and CTLA-4 ,as intracellular membrane proteins,  has been used to detect to both nTregs and iTregs (Zhao, Liao and Kang 2017), however the expression of MAVS, HEM6 and SYAM proteins was specifically up regulated in iTregs. Therefore, these results suggest that these proteins could be a suitable target for detecting iTregs from other CD4+ T cells subsets.   
The results also showed that 20 distinct proteins, including GTR1, MOT4, NDRG1, 
ALDOA, PGK1, KPYM, LEG1, RIPK3, TPIS, G3P, SERC, SYYC, RP10, PGAM1, PGM1, 
GALK1, LDHA, RL34, TPP2, SYSC were found significantly overexpressed in activated CD4+CD25- T cells and nTregs after TCR activation, while they were down expressed in iTregs. However, the expression of these proteins was detected at very lower levels in naïve subsets. When compared to naïve subsets, the overexpression of these proteins could be due to TCR activation, suggesting that these proteins are activation markers for CD4+ T cells. However, the expression of these proteins was significantly decreased in iTregs subset even after TCR activation, suggesting that the expression of 20 different proteins could be affected by TFG-β1 cytokine during the differentiation of iTregs in vitro. The phenotypic features of naïve nTregs are characterised by the expression of CD25 as a membrane protein and Foxp3+ as a nuclear protein. However, CD25 protein is also upregulated upon TCR activation and considered as an activation marker for T cells (Bajnok, et al. 2017). Therefore, the expression of CD25 is not a good marker to distinguish naïve nTregs from other activated CD4+ T cells. Moreover, the expression of Foxp3 is not a distinct marker for naïve nTregs as it is also expressed in both activated nTregs and iTregs. However, the results of this 
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study showed that the expression of HYEP, a membrane protein, was significantly up regulated in naïve nTregs only, while it was significantly down regulated in other subsets of CD4+ T cells that were analysed in this study. The results also showed that the expression of SERPINB6A, an extracellular protein, was detected significantly up regulated in naïve nTreg, compared to other CD4+ T cell subsets. These results suggest that HYEP and SERPINB6A can be novel surface markers to distinguish naïve nTregs from activated nTregs and iTregs. To distinguish activated nTregs from naïve and iTregs, the results showed that the expression of SPA3F, an extracellular protein, was found significantly up regulated in activated nTregs, compared to other subsets of CD4+ T cells that were analysed in this study.  The identified proteins mentioned above were subjected for further validation on the subpopulations of CD4+ T cells that were sorted and generated in the developed 
BALB/c mouse model. However, unfortunately, the validation experiment failed to show any positive staining for the identified proteins on the subpopulations of CD4+ 
T cells that were used for validation. The possible reasons of failing include: (1) the quality of commercially-available antibodies that were used for the validation as majority of them were unconjugated polyclonal antibodies that have not been tested for flow cytometry analysis. The multi-reactivity of polyclonal antibodies in different species such as human, rat and mouse could affect their recognition and specific binding pattern for the protein of interest (Voskuil 2014). (2) failure in the conjugation experiment; since incomplete or insufficient fluorochrome-conjugation might prevent the antibody to be recognised by the lasers of flow cytometer. (3) the selected proteins might undergo posttranslational modifications which alter the structure and stability of proteins and contribute to the production of neo-epitopes which might not be recognised by the already designed antibody. Alternative methods such as western blotting or ELISA will be tested in the future using the same antibodies to confirm the results.  Once validated in humans these 
markers/targets can be used to inhibit iTregs in tumours or any other inflammatory diseases. Also, all of the identified markers are on the cell surface will allow the user to purify the cells without fixing and permeabilising these cells. This will allow the scientist to understand the immunobiology of iTregs in more details.  
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All proteins identified in this study were searched in the literature using NCBI Pubmed and Google Scholar, however there were not any published studies found where the levels of these proteins were discussed in relevance to Tregs to confirm the results of this study. It is likely therefore, the lack of information in the literature confirms the novelty of the results of this study in identifying membrane markers that can discriminate iTregs from nTregs.       
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Chapter 5.  
Summary of Discussion 
5.1. Background and overall aim Tregs are a distinct immunosuppressive subpopulation of CD4+ T cells and function to control the immune homeostasis and tolerance by inhibiting the proliferation and function of autoreactive T cells, thereby preventing autoimmunity (Fehervari and Sakaguchi 2004). Tregs are broadly grouped into two main subpopulations based on the site of development, including thymic-derived natural Tregs (nTregs) and peripheral-derived induced Tregs (iTregs). Both nTregs and iTregs are characterised by the expression of CD25 and Foxp3. (de Lafaille, Maria A Curotto 
and Lafaille 2009). In cancer, Tregs are found to enhance tumour progression by inhibiting the 
proliferation and function of CD8+ T effector cells which induce anti-tumour immune response (Elkord, et al. 2010). The enrichment of CD4+CD25+Foxp3+ Tregs within the tumour microenvironment has been correlated with worse prognosis and reduced survival rates in various types of cancer including breast cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, renal carcinoma, pancreatic ductal carcinoma, non-Hodgkin’s lymphomas, melanoma and other malignancies (Zhang, et al. 2017, Curiel, et al. 2004, Tao, et al. 2012, Sun, et al. 2017, 
Sayour, et al. 2015, Tang, et al. 2014, Yang, et al. 2014, Yang, et al. 2006, Li, et al. 2010, 
Gerber, et al. 2014, Shang, et al. 2015a). The accumulation of Tregs within the tumour milieu is thought to be as a major hurdle for the development of effective immunotherapy (Liu, Workman and Vignali 2016c). Therefore, several attempts have been carried out to target Tregs within the tumour nest for enhancing anti-tumour immunity. Tregs have been targeted through developing antibodies against the CD25, CTLA-4, PD-1, CCR4 and CCR8. However, targeting Tregs via the expression of these biomarkers has resulted in the development of autoimmune disease as a side effect of non-selective treatment since these specific surface receptors are also expressed by Tregs circulating in the periphery where they maintain the peripheral immune tolerance and homeostasis (Bakacs, et al. 2012, 
Kurose, et al. 2015, Larkin, et al. 2015). In addition, CD25 and CTLA-4 are also 
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expressed by activated T effector cells, and thus targeting Tregs via these receptor could inhibit both Tregs and T effector cells, thereby promoting tumour progression indirectly (Ha, et al. 2019). Therefore, to selectively inhibit or block the function of tumour-infiltrating Tregs without affecting the function of circulating Tregs and other T effector cells, biomarkers that are exclusively expressed tumour-infiltrating Tregs are still required (Liu, et al. 2016a, Togashi, et al. 2019). The question about the root of tumour-infiltrating Tregs is still debatable. It has been hypothesised that the origin of  tumour-infiltrating Tregs could be from (1) nTregs which have been recruited into the tumour microenvironment via the expression of various chemokine receptors including CCR4, CCR5, CCR10 and CXCR3, (2) naive CD4+CD25- T cells which have been recruited into the tumour microenvironment where they are converted into induced Tregs (iTregs) in the presence of TGF-β, or (3) from both nTregs and iTregs subpopulation (Chaudhary 
and Elkord 2016, Deng 2018). However, a novel study by Su et al. has proven that tumour-infiltrating Tregs within the tumour microenvironment of breast cancer are mainly developed from naïve CD4+ T cells that are recruited into the tumour bed, but not from circulating Tregs (Su, et al. 2017b). Therefore, to answer the question about the origin of tumour-infiltrating Tregs, it is still essential to identify biomarkers that can differentially distinguish iTregs that are generated from naïve CD4+CD25- T cells from nTregs and other T cells. Identifying such biomarkers would facilitate the development of selective Tregs targeting therapy without affecting the function and homeostasis of other T effector cells. Accordingly, the aim of this study was to identify membrane biomarkers that can differentially characterise phenotypic signature of iTregs from nTregs using SWATH-MS proteomics. To achieve this aim, the study was divided into 3 major 
objectives: (1) development of murine model for generating CD4+CD25+Foxp3+ iTregs from naïve CD4+CD25-Foxp3- T cells in the presence and absence of tumour cells in vitro, (2) optimisation of a quantitative proteomics method to profile iTregs and nTregs , and (3) identification and verification of novel biomarkers of iTregs and nTregs.   
251  
5.2. The generation of iTregs from naïve CD4+CD25- T cells 
in vitro 
In this study, the BALB/c mouse strain was selected to develop a murine model for studying nTregs and iTregs since the percentage of CD4+CD25+Foxp3+ nTregs in the 
spleen of BALB/c was significantly higher than in the spleen of C57BL/6 mice. These results have been supported by several previous studies (Chen, et al. 2005, 
Vogelsang, et al. 2009b, Blankenhaus, et al. 2014b). This higher percentage of nTregs was important to obtain a sufficient cell number for further downstream experiments. For generating iTregs, naïve CD4+CD25- T cells were purely purified and sorted 
using cell sorting. The purity of cell sorting was ≥ 98% and assessed by analysing the expression of CD25 on the sorted cells using flow cytometry. The sorted cells were grown in vitro in the presence of CD3/28 TCR activation beads, IL-2 (30 U/mL) and TGF-β1 (5 ng/mL) over a period of 5 days in the presence of tumour cells. The induction of iTregs from naïve CD4+CD25-Foxp3- T cells was confirmed by the positive expression of CD25 and Foxp3 on the generated iTregs using flow cytometry and defined as CD4+CD25++ Fxop3+ iTregs.    
5.2.1. The differentiation of iTregs requires a synergistic 
interaction of CD3/CD28 TCR and TGF-β1 signals in a time-
dependent manner The generation of iTregs in this model was mainly based on the activation of TCR in the presence of TGF-β1 and IL-2. In the absence of CD3/28 TCR activation signals, there was no induction of iTregs even in the presence of TGF-β1 and IL-2. However, the presence of both TCR activation signals, IL-2 and TGF-β1, the induction of iTregs 
was significantly increased, confirming the significance of the CD3/28 TCR activation signals in mediating the development of iTregs. These results were consistent with the finding that suboptimal TCR activation signals mediate the differentiation of iTregs from naïve CD4+CD25-Foxp3- T cells by promoting the expression of Foxp3 via NFAT (nuclear factor of activated cells) pathway (Vaeth, et 
al. 2012). Moreover, the stimulation of TCR signals has also been found to induce the 
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expression of Foxp3 in iTregs through the activation of NF-kB pathway in which c-Rel, a member of NF-kB family, promotes the expression of Foxp3 by binding to the Foxp3 promoter (Ruan, et al. 2009). The pivotal role of the TCR activation signals in the development of iTregs has also been confirmed by the finding that TCR-deficit Tregs lost their suppressive activity and failed to inhibit T cells response in vivo 
(Vahl, et al. 2014).  
However, the stimulation of CD3/28- TCR signals solely was not enough to generate iTregs from naïve CD4+CD25-Foxp3- T cells in vitro in the presence of IL-2 in the absence of TGF-β1, whereas the induction of iTregs was significantly increased in the presence of IL-2 and TGF-β1 following TCR activation, confirming the crucial role of TGF-β1 signalling in the differentiation of iTregs. The role of TGF-β1 signalling in the development of iTregs has been extensively acknowledged by many studies. Upon binding to its receptor, TGF-β1 activate its downstream transcription factor complex “ Smad2/3” which is recruited into the nucleus where Smad2/3 binds the Foxp3 enhancer element, thereby inducing the expression of Foxp3 
(Zheng, et al. 2010a, Tone, et al. 2008). The induction of Foxp3 has been also found t to be mediated by TGF-β receptor and IL-2 receptor through CNS2-5-azacytidine (5-aza-C) mechanism (Freudenberg, et al. 2018).  In this model, it was found that induction of iTregs from naïve CD4+CD25-Foxp3- T cells was significantly decreased following continuous TCR engagement in the absence of TGF-β1 for 24 hours, whereas the induction of iTregs was significantly increased when the TGF-β1 was immediately added following TCR engagement. This finding confirms that naïve CD4+CD25-Foxp3- T cells following constant TCR engagement become irresponsive to the TGF-β1 signalling, whereby preventing the differentiation into iTregs. These results also confirm that both TCR and TGF-β1 signals synergistically act to mediate the induction of iTregs from naïve CD4+CD25-Foxp3- T cells in a time-dependent manner. These results were consistent with the finding that that CD3/28 co-stimulation could overcome TGF-β-mediated repression of the proliferation of activated T effector cells, and after persistent 
CD3/28 co-stimulation, effector activated T cells become more resistant to the influence of TGF-β signalling (Koehler, et al. 2007). Moreover, it has been reported that activated T cells could reduce the expression of TGF-β receptor II (TGF-βRII) on 
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their surface following TCR activation via CD28 engagement, thereby avoiding the effect of TGF-β  signalling (Sanjabi, et al. 2017).             
5.2.2. The presence of 4T1 tumour cells significantly increases the 
development of iTregs in the presence of TGF-β1 In this model, the induction of iTregs from naïve CD4+CD25-Fox3- T cells was 
significantly increased in the presence of 4T1 tumour cells, TGF-β1 and IL-2, compared to those induced in the presence of TGF-β1 and IL-2 only. However, the induction of iTregs was at very low percentages (2%) in the presence of IL-2 and 
4T1 cells but in the absence of TGF-β1, confirming that there is a cellular synergy 
between 4T1 cells and TGF-β1 signalling which in turn could enhance or increase the percentage of the iTregs induction. These findings suggest that the presence of TGF-β1 may influence 4T1 cells to initiate TGF-β1 signalling to produce TGF-β1 in an autocrine signalling loop-dependent manner (Daroqui, et al. 2012, Dumont, Bakin and Arteaga 2003), since 4T1 cells have been found to express functional TGF-
β receptors (McEarchern, et al. 2001). In addition, the increase in the induction of iTregs was also correlated with the number of 4T1 cells co-cultured with naïve CD4+CD25-Foxp3- T cells in the presence of IL-2 and TGF-β1. The results revealed 
that the increase in the ratio of 4T1 cells to naïve CD4+CD25-Foxp3- T cells in the presence of TGF-β1 and IL-2 results in the increase of iTregs induction. Even at low concentrations of TGF-β1, particularly at 0.05 ng/mL, the induction of iTregs was 
significantly higher (20.6%) in the presence of 4T1 cells and IL-2, where the induction of iTregs at the same concentration of TGF-β1 in the presence of IL-2 only was 4.46%. These results confirm that the presence 4T1 tumour cells under the effect of TGF-β1 signalling promotes the induction of iTregs.  
5.2.3. The generated iTregs are highly immunosuppressive A functional assay was optimised to assess whether the generated iTregs are immunosuppressive and can inhibit the proliferation of CD8+ T cells. To achieve this, 
naïve CD8+ T cells were purely sorted, stained with CFSE (5 µM) and activated with 
CD3/28 T cell activator beads. The CD8+ T cells were then co-cultured with the generated iTregs at different ratios. The overall results showed that the generated 
iTregs were highly immunosuppressive and could inhibit the proliferation of CD8+ 
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T cells. The percentage of the CD8+ T cells inhibition by iTregs was based on the co-
culture ratio of iTregs and CD8+ T cells. 
5.2.4. The Foxp3-TSDR of iTregs and stimulated nTregs is 
hypermethylated   The methylation status of the Foxp3-TSDR at four different CpG sites was assessed in the five different subpopulations of CD4+ T cells. The naïve unstimulated nTregs were considered as a control population since their TSDR is completely demethylated (Schreiber, et al. 2014). The TSDR of the generated iTregs was significantly hypermethylated compared to naïve unstimulated nTregs. Similar results have been also found in a study carried out by Schmidt et al. where the 
authors assessed the methylation status of 15 different CpG regions within human Foxp3 gene locus and found that iTregs were significantly hypermethylated in all CpG sites, compared to unstimulated naïve nTregs (Schmidt, et al. 2016). It has been reported that the high methylation of the Foxp3-TSDR affects the stability and suppressive activity of iTregs (Huehn, Polansky and Hamann 2009, Zheng, 
Josefowicz, Chaudhry, Peng, Forbush and Rudensky 2010b, Baron, et al. 2007). However, the iTregs generated in this model were highly suppressive, could inhibit 
the proliferation of CD8+ T cells and were stable over 5 days after induction. Also, other studies have generated highly suppressive human and murine stable iTregs in which the TSDR was hypermethylated (Hippen, et al. 2011, Lee, et al. 2012, Strainic, 
et al. 2013, Gu, et al. 2014). These results confirm that the TSDR methylation status is not correlated with the suppressive activity of iTregs, although the demethylation status of Foxp3-TSDR is considered as a marker for the stability of Foxp3 expression. The stability of the Foxp3 expression of iTregs has been discussed to be affected by the experimental protocols used for the generation of iTregs. For instance, iTregs 
that were generated using CD3/28 T cell activator beads have been found to acquire stable Foxp3 expression more than iTregs which were generated using plate-bound anti-CD3 and soluble anti-CD28 antibody, confirming the importance of the quality and affinity of TCR signals for maintaining the stability of Foxp3 expression  (Geiger 
and Tauro 2012, Gottschalk, Corse and Allison 2010, Lu, et al. 2010, Hippen, et al. 
2011, Qian, et al. 2011, Gu, et al. 2014). These findings were consistent with the results of the Foxp3 stability revealed in this study. 
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Intriguingly, in this study, it was found that naïve nTregs lost their demethylation status and became significantly hypermethylated following TCR activation. This finding was also supported by Zhang et al.; where the authors demonstrated that nTregs lost their Foxp3 expression after TCR engagement and experienced re-
methylation of the CNS1 region within Foxp3 locus (Zhang, et al. 2017). A similar finding was also found in an earlier study by Bailey-Bucktrout et al. in 2013. There the authors demonstrated that nTregs underwent Foxp3 instability and secreted pro-inflammatory cytokines following self-antigen-driven activation during inflammation in the CNS (Bailey-Bucktrout, et al. 2013). Taken together, it seems that not only iTregs, but nTregs may lose their stability in vivo following TCR engagement. This may justify the notion that the acquired immunosuppressive activity of Tregs is inducible based on the presence of stressful stimuli that promote prolonged acute or chronic inflammation, which can make Tregs behave with more flexibility based on the physiological condition in the milieu. 
5.3. Optimisation methods for protein isolation and 
preparation for quantitative proteomic profiling  The percentage of the induction of iTregs generated in this study allowed to obtain sufficient cell number of iTregs to be used for optimising different methods for quantitative proteomic profiling. Prior to approaching proteomics, it was initially planned to carry out transcriptomic profiling for five different subsets of CD4+ T cells to identify distinct biomarkers that can differentiate iTregs from nTregs and other control subpopulation of CD4+ T cells. However, information derived from transcriptomic profiling reflects the level of RNAs abundance, not proteins. Therefore, the interpretation of transcriptomic data is difficult to predict the phenotypic feature of a cell or tissue (Misra, et al. 2018). In addition, several studies have applied a transcriptomic profiling integrated with proteomic profiling on different subsets of T cells and confirmed that the differential changes in the expression of biomarkers at RNA level were not correlated with the changes at the protein level (Cuadrado, et al. 2018, Mohammad, et al. 2018). For this reason (and that of cost and logistics), it was decided to carry out proteomic profiling that enable discovery biomarkers to distinguish iTregs from nTregs and other control subpopulation of CD4+ T cells.                        
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In this study, two different methods were optimised for isolation and preparation protein samples for proteomic analysis, including whole cell lysate and subcellular fractionation. The main aims of the optimisation were to isolate sufficient quantity 
of proteins from samples containing a low cell number (2x106), to identify a sufficient number of proteins yielded from MS (mass spectrometry) analysis and to increase the identification coverage of membrane proteins of total proteins identified by MS analysis. Initially global (total cell lysate) proteomic profiling has been carried out using the method of whole cell lysate. Here, proteins were isolated from whole cell lysates 
derived from samples containing 2.5x106 of purified murine T cells. 25µg of proteins were then processed for MS analysis. The total number of proteins identified from each sample was in range between 1053 and 1232 at 1% FDR (false discovery rate). 
The percentage of the identified membrane proteins was in range between 7.5% and 
8.3% from total proteins, whereas the identified plasma membrane proteins constituted about 4.2-4.9% of total membrane proteins and more than 50% of total membrane proteins. These percentages were not sufficient to reach the aims of this study and confirm that the optimisation of proteins isolation using whole cell lysate lysed by Erika’s or urea buffer failed to purify sufficient percentages of membrane proteins. Purification of plasma membrane proteins using whole cell lysate method was limited due to insolubility and hydrophobicity of plasma membrane proteins and low recovery rate of lipid-anchored surface proteins (Orsburn, et al. 2011).  To overcome the limitation of the whole cell lysate methods for identifying membrane proteins, the method of subcellular fractionation was optimised in this study to increase the coverage rate of quantification of plasma membrane proteins. Subcellular fractionation has also enabled identification and quantification of plasma membrane proteins which are the key target of antibody-based therapies (Leth-Larsen, et al. 2010). Moreover, Subcellular fractionation has enabled detection of peptides that belong to low-abundant proteins, thereby increasing the coverage rate of protein quantification using MS-based proteomics (Lee, et al. 2010).  In this study, the subcellular fractionation for isolation membrane and cytoplasmic proteins was carried out prior to proteomic analysis. The percentage of total known membrane proteins identified following subcellular fractionation was significantly 
increased to 57% of the total proteins identified by MS analysis, while it was only 
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around 8% using the whole cell lysate method. For plasma membrane proteins, the main of the percentage of identification was significantly increased to 26% of total proteins identified using subcellular fractionation method, whereas it was only 4.5% using the whole cell lysate method. These results were relatively reasonable 
according to the low cell number (2x106) which was used for isolation of membrane proteins. It was noticed that the kit does not completely separate membrane and 
cytosolic proteins and both fractions share a significant (10-30%) proportion of proteins which was not unexpected. Based on these results, the optimised method of the subcellular fractionation was followed to carry out a comprehensive quantitative proteomic profiling of the five different subsets of CD4+ T cells using LC-MS-MS and SWATH-MS proteomics.   
5.4. Identification and verification of distinct biomarkers 
of nTregs and iTregs using LC-MS-MS/SWATH-MS 
proteomics 
3910 proteins were quantified from the five subpopulations of CD4+ T cells by SWATH-MS analysis. The quantified proteins were sorted based on their confidence 
score as mentioned in chapter 4 (section 4.3.1.1). Accordingly, 99 membrane 
proteins and 344 cytoplasmic and nuclear proteins with confidence score ≥ 50% were selected for further analysis. The data of protein peak area of 99 membrane proteins and 344 cytoplasmic proteins were further analysed the ANN as a powerful bioinformatics tool to identify a panel of biomarkers that can differentiate iTregs from nTregs and other subpopulations of CD4+ T cells. The ANN has been used as a machine learning approach to train and analyse complex proteomic data in order to identify and verify a combination of novel biomarkers (Swan, et al. 2013).      A panel of proteins, including PLP2, IHIT4, MAVS and HEM6, was identified to be significantly upregulated in the population of iTregs compared to the other subsets of CD4+ T cells in which the proteins were detected at low levels. These proteins were also selected by the ANN as a predictive panel with the best predictive performance which can differentiate iTregs from other CD4+ T cells subsets included the analysis. The sensitivity and specificity of these biomarkers were further tested 
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using a receiver operating characteristic (ROC) analysis which confirmed that the combination of PLP2, IHIT4, MAVS and HEM6 proteins could be as novel biomarkers of iTregs. The upregulation of these proteins in iTregs might be mediated by TGF-β1 signalling and could be associated with the suppressive activity of iTregs, since all other subpopulations were grown in vitro in the presence of CD3/28 T cell activator beads and IL-2, except iTregs were generated in the presence of CD3/28 beads, IL-2 and TGF-β1. According to the Uniprot database, PLP2 (proteolipid protein 2) is classified as a multi-pass membrane protein which has been found predominantly localised on plasma membrane and endoplasmic reticulum membrane (www.uniprot.org, 
accessed on 25 Nov 2019). PLP2, which is also known as intestinal membrane A4 protein, has been initially found to be enriched in the differentiated colonic epithelial cells (Oliva, Wu and Yang 1993). PLP2 has been found to play a role in the differentiation of colonic epithelial cells in which, upon activation, PLP2 could localise to the endoplasmic reticulum and multimerise to form ion channels 
(Breitwieser, et al. 1997). PLP2 has been also found to mediate the migration of 
human osteogenic sarcoma (HOS) cells via the interaction with CCR1 expressed on the surface of HOS cells, indicating that PLP2 might act as a chemotactic ligand for 
chemokines receptors such as CCR1 (Lee, et al. 2004). In melanoma, PLP2 has been found to promote the progression and metastasis of tumour cells by inducing the secretion of MMP-2 (metalloproteinase-2) which serves as invasion-related molecule (Sonoda, et al. 2010). A study by Li et al. has shown that IL-10- and TGF-β-secreting Tregs promotes the invasiveness and proliferation of endometrial stromal cell derived from endometrial tumour cells by enhancing the expression of MMP-2 
(Li, et al. 2014). A recent study by Chen et al. has shown that the upregulation of PLP2 in glioma tumour cells promotes the aggressiveness of tumour via the expression of MMP-2 and is associated with poor prognosis (Chen, Hueng and Tsai 
2018). Based on these results, it seems that PLP2 can be as novel biomarker of iTregs that may promote the progression of tumour cells via the promotion of MMP-2 expression. There was no published work found confirming the expression of PLP2 in Tregs or any other T cells subsets, confirming the novelty of this discovery.  ITIH4 (Inter-alpha-trypsin inhibitor heavy chain H4) was also identified in this novel study to be significantly upregulated in iTregs compared to other subsets of 
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CD4+ T cells. ITIH4 is a member of Inter-alpha-trypsin inhibitor family (ITIH1, ITIH2, ITIH3, ITIH4 and ITIH5), a family of plasma protease inhibitors. ITIH4 has been found to interact with hyaluronic acid (HA), which is of major molecules of the extracellular matrix, via forming a covalent bound (Hamm, et al. 2008). HA is a negatively-charged glycosaminoglycan which has been detected to be predominantly enriched on endothelial cells and in the extracellular matrix. HA has been found highly enriched in the tumour stroma of breast cancer. HA has also been found to mediate the recruitment of Tregs via the expression of CD44 and participate to enhance expression of Foxp3, thereby promoting the suppressive activity of Tregs. HA-binding Tregs have been found significantly enriched in the peripheral blood of patients with breast cancer (Perfilyeva, et al. 2015). HA has been found to function as a ligand with high affinity for the CD44 and HA-CD44 binding promotes the production of TGF-β1 and IL-10 by Tregs (Bollyky, et al. 2009)        ITIH4 has been also found as an anti-inflammatory protein, and its expression was found highly correlated with the expression of IL-10 and IL-2 (Kashyap, et al. 2009). These finding could justify that ITIH4 might be a novel biomarker of iTregs that could recruited to the tumour microenvironment via the expression of HA on endothelial cells or in the extracellular matrix, since there was no any published work confirming the expression of ITIH4 on Tregs. MAVS (mitochondrial antiviral signalling protein) was also identified to be significantly upregulated in iTregs compared to other subsets of CD4+ T cells that were analysed in this study. MAVS has been found to mediate host innate immune responses against viral infection through the activation of the transcription factors NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) and IRF3 (interferon regulatory factor 3). Both NF-kB and IRF3 have been found to regulate the expression of type-1 interferons (IFNs) including IFN-α and IFN-β which suppress viral replication (Seth, et al. 2005). As a signalling adapter protein, MAVS is activated by retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) which recognise and bind viral RNA in the cytoplasm of infected cells (Hou, et al. 2011). 
The activation of MAVS stimulates the cytosolic kinases IKK and TBK1 which in turn induce the activation of NF-kB and IRF3 (McWhirter and Maniatis 2005).  RLRs have been found to be expressed by T cells including Tregs and T effector cells (Suthar, et al. 2012, Anz, et al. 2010). In Treg, the question whether MAVS signalling 
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has an impact on the function of Tregs has been investigated by Da Costa et al. where the authors found that MAVS signalling was not essential for the proliferation and suppressive activity of Tregs in MAVS-deficient mice following West Nile virus (WNV) infection (Da Costa, et al. 2017). However, the inhibition of MAVS signalling has been found to suppress the expansion of Tregs following WNV infection, and this was correlated with uncontrolled inflammatory response (Suthar, et al. 2010). A recent study by Kawano et al. has demonstrated that the overproduction of type 1 IFNs by myeloma cells could induce the recruitment and expansion of Tregs within the tumour microenvironment via IFN-α/β receptor 1 (IFNAR1) expressed on Tregs. The authors also found that the immunosuppressive of Tregs was significantly 
diminished following blocking IFNAR1 on Tregs (Kawano, et al. 2018). Therefore, based on the studies discussed above, the expansion of Tregs in response to the 
overproduction of type 1 IFNs might be regulated by MAVS signalling which induces the production of type IFNs via the activation of NF-kB and IRF3. However, the 
question whether the expression of IFNAR1 on Tregs can be regulated by MAVS signalling remains unanswered. The answer of this question might help in understanding the upregulation of MAVS in iTregs that was identified in this study. HEM6, which is known as CPOX (Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial), was also identified to be significantly upregulated in iTregs compared to other subsets of CD4+ T cells. According to Uniprot online database, the CPOX (HEM6) is a mitochondrial inner membrane protein which is implicated in the biosynthesis of heme (Uniprot online database, accessed on 25 Nov 2019). The role or function of this proteins in the biology of T cells was searched, however there was no any published study investigated its role.    Even though all proteins mentioned above are uniquely upregulated in iTregs, HYEP (epoxide hydrolase-1 (EPHX-1)) was found to be downregulated in iTregs compared nTregs and all other subsets of CD4+ T cells that were analysed in this study. EPHX-
1 is an enzyme localised in the endoplasmic reticulum membrane and involved in the metabolism of lipids (Uniprot online database, Accessed on 25 Nov 2019). There was no any published study investigated this protein in detail, therefore the role of HYEP in differentiating nTregs from iTregs should be further explored. Validation of the biomarkers identified in this study using antibody-based flow cytometry assay was attempted. Very few antibodies were commercially available 
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for the identified biomarkers, and those that were, were not originally developed for flow cytometry and were unlabelled (unconjugated). Therefore, it was attempted to 
label/conjugate the antibodies with PE (Phycoerythrin) fluorochrome. The labelled antibodies were further tested on the subpopulations of CD4+ T cells analysed in this model. However, the results showed that there was no positive staining for the antibodies on all the subpopulations, indicating that further work is needed to develop the identified panel of biomarkers for validation and testing in a large cohort of populations.   
Conclusion and future work 
 Successfully established a murine iTreg induced model for studying its biology at proteome level and identification of markers which could distinguish iTregs from other CD4 subsets. As far as the literature search suggested, this is the first study carried out either in humans or mouse combining membrane fractionation with quantitative mass spectrometry.  The ANN based analysis have identified five markers (PLP2, MAVS, HYEP, HEM6 and ITH4) as potential biomarkers. However, attempted validation of these markers using commercially available antibodies were not successful due to the antibody failure to detect the protein in flow cytometry. This could be negotiated in the future by either using a different technique such as western blot using the same antibody or developing a completely new antibody panel specifically suited for flow cytometry. Pathway enrichment analysis using literature curated database (MetaCore) and most differentially expressed proteins in iTreg compared to its control CD4 cells suggested a potential mechanistic role as supressed metabolic glycolytic pathway and HIF-target protein. Which agrees with the existing literature using other murine models.  The role of TGF beta in metabolic alteration of iTregs were reported in the literature (Priyadharshini et al 2018). However, this study has identified precise molecular targets preferentially altered at protein level was identified. This study also has identified several target proteins involved in Ubiquinone metabolism (CoenzymeQ) up regulated in iTregs suggesting potential difference in mitochondrial activity. Further works needs to validate these findings which could not be completed within the time frame of this project. One of the potential drawbacks of this project is translation into human settings. Although, biomarkers and mechanistic insights 
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were gained using mouse model, its potential translation depend on how well these markers represent human iTreg counter parts, which was lacking at this moment due to the unavailability of suitable antibodies and human samples. This will be the priority in the immediate future. Overall this study achieved its objective in generating quantitative proteomics data using purified subsets of CD4 T cells and identified markers to distinguish iTreg, future validations needed to fully translate these findings into humans.    
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Appendix  
Table 1A summary of  the amount and concentration of reagents that were used to prepare samples for proteomic MS analysis. 
Cell Type 
(Splenocyte
) 
Cell 
No. 
(x106) 
EB 
(µL) 
Protein 
Conc. 
(µg/µL) 
25 µg of 
protein 
in 
volume 
(µL) 
TEAB 
(µL) 
DTT 
(µL) 
IAA 
(µL) 
Total 
volume 
at 
digestio
n 
(µL) 
Urea 
Conc. At 
digestio
n (M) 
Trypsin 
(µL) 
 
 
Experiment 
1 
10 100 2.36 10.6 89.4 1 2.7 103.7 0.97 1.25 5 50 1.72 14.5 85.5 1 2.7 103.7 1.33 1.25 2.5 50 1.25 20 80 1 2.7 103.7 1.83 1.25 
1 50 0.39 63.8 There two samples were excluded from preparation because there were no enough proteins yielded from cell lysis 0.5 50 0.15 166.6 
 
 
Experiment 
2 
10 100 2.63 9.5 90.5 1 2.7 103.7 0.87 1.25 5 50 1.62 15.5 84.5 1 2.7 103.7 1.42 1.25 2.5 50 0.83 30.2 69.8 1 2.7 103.7 2.77 1.25 
1 50 0.34 73.5  0.5 50 0.18 136.4 
 
 
Experiment 
3 
10 100 1.41 17.8 82.2 1 2.7 103.7 1.63 1.25 5 50 1.48 16.8 83.2 1 2.7 103.7 1.54 1.25 2.5 50 0.67 37.4 62.6 1 2.7 103.7 3.43 1.25 
1 50 0.29 85.6  0.5 50 0.27 91.5 
 
 
Experiment 
4 
10 100 1.68 14.9 85.1 1 2.7 103.7 1.36 1.25 5 50 1.40 17.9 82.1 1 2.7 103.7 1.64 1.25 2.5 50 0.62 40.5 59.5 1 2.7 103.7 3.71 1.25 
1 50 0.32 77.9  0.5 50 0 0  Table 2A. summary of summarises the concentration of proteins yielded in each sample, and the amount and concentration of reagents that were used to prepare samples for MS analysis.                 
Cell Type 
(Splenocytes) 
Cell 
No. 
(x106) 
EB 
(µL) 
Protein 
Conc. 
(µg/µL) 
25 µg of 
protein 
in 
volume 
(µL) 
TEAB 
(µL) 
DTT 
(µL) 
IAA 
(µL) 
Total 
volume 
at 
digestion 
(µL) 
Urea 
Conc. At 
digestion 
(M) 
Trypsin 
(µL) 
 
 
Experiment 1 
10 100 1.15 21.7 78.3 1 2.7 103.7 1.98 1.25 5 50 1 25 75 1 2.7 103.7 2.37 1.25 2.5 50 0.99 25.3 74.7 1 2.7 103.7 2.40 1.25 
1 50 0.76 32.9 67.1 1 2.7 103.7 3.13 1.25 0.5 50 0.66 29.9 70.1 1 2.7 103.7 2.84 1.25 
 
 
Experiment 2 
10 100 1.8 13.9 86.1 1 2.7 103.7 1.32 1.25 5 50 1.1 22.7 77.3 1 2.7 103.7 2.15 1.25 2.5 50 0.82 30.5 69.5 1 2.7 103.7 2.89 1.25 
1 50 0.8 31.3 68.7 1 2.7 103.7 2.97 1.25 0.5 50 0.64 35.7 64.3 1 2.7 103.7 3.39 1.25   
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Table 3A.  Summary of  the concentration of proteins resulted in each sample and the amount and concentration of reagents used for samples preparation. 
Cell Type 
(Splenocytes) 
Cell 
No. 
(x106) 
EB 
(µL) 
Protein 
Conc. 
(µg/µL) 
25 µg of 
protein 
in 
volume 
(µL) 
TEAB 
(µL) 
DTT 
(µL) 
IAA 
(µL) 
Total 
volume 
at 
digestion 
(µL) 
Urea 
Conc. At 
digestion 
(M) 
Trypsin 
(µL) 
 
 
Experiment 1 
10 60 2.5 10 90 1 2.7 103.7 0.95 1.25 5 40 1.4 17.9 82.1 1 2.7 103.7 1.70 1.25 2.5 30 1.35 18.5 81.5 1 2.7 103.7 1.75 1.25 
1 24 1.08 23.1 76.9 1 2.7 103.7 2.19 1.25 0.5 18 0.85 29.4 70.6 1 2.7 103.7 2.79 1.25 
 
 
Experiment 2 
10 60 2.3 10.9 89.1 1 2.7 103.7 1.03 1.25 5 40 1.6 15.6 84.4 1 2.7 103.7 1.48 1.25 2.5 30 1.2 20.8 79.2 1 2.7 103.7 1.97 1.25 
1 24 0.95 26.3 73.7 1 2.7 103.7 2.49 1.25 0.5 18 0.76 32.9 67.1 1 2.7 103.7 3.12 1.25  Table 4A. Summary of the concentration of proteins resulted in each sample and the amount and concentration of reagents used for samples preparation. 
Cell Type 
(Splenocytes) 
Cell 
No. 
(x106) 
EB 
(µL) 
Protein 
Conc. 
(µg/µL) 
25 µg 
of 
protein 
in 
volume 
(µL) 
TEAB 
(µL) 
DTT 
(µL) 
IAA 
(µL) 
Total 
volume 
at 
digestion 
(µL) 
Urea 
Conc. At 
digestion 
(M) 
Trypsin 
(µL) 
P. 
Max 
(µL) 
 
 
Experiment 1 
10 60 1.8 13.9 86.1 1 2.7 103.7 1.32 1.25 1.25 5 40 1.4 17.9 82.1 1 2.7 103.7 1.70 1.25 1.25 2.5 30 1.09 22.9 77.1 1 2.7 103.7 2.18 1.25 1.25 
1 24 1.0 25 75 1 2.7 103.7 2.37 1.25 1.25 0.5 18 0.77 32.5 67.5 1 2.7 103.7 3.08 1.25 1.25 
 
 
Experiment 2 
10 60 2.3 10.9 89.1 1 2.7 103.7 1.04 1.25 1.25 5 40 1.6 15.6 84.4 1 2.7 103.7 1.48 1.25 1.25 2.5 30 1.23 20.3 79.7 1 2.7 103.7 1.93 1.25 1.25 
1 24 1.02 24.5 75.5 1 2.7 103.7 2.33 1.25 1.25 0.5 18 0.85 29.4 70.6 1 2.7 103.7 2.79 1.25 1.25    
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Table 5A. Summary of the concentration of proteins yielded in each sample in all experiments, and the amount and concentration of reagents used for preparation samples.  
Experim
ents 
Cell 
No. 
(x106) 
EB 
(µL) 
Protein 
Conc. 
(µg/µL) 
25 µg of 
proteins 
in 
volume 
(µL) 
TEAB 
(µL) 
DTT 
(µL) 
IAA 
(µL) 
Total 
volume 
at 
digestio
n 
(µL) 
Urea 
Conc. At 
digestio
n (M) 
Trypsin 
/ 
*Trypsi
n Lys-C 
(µL) 
P. Max 
(µL) 
E
xp 1 
2.5 30 0.9 27.8 172.2 1 2.7 203.7 1.3 1.25  2.5 30 1.2 20.8 179.2 1 2.7 203.7 0.97 1.25 1.25 2.5 30 1.14 21.9 178.1 1 2.7 203.7 1.02 *1.25  2.5 30 0.99 25.3 174.7 1 2.7 203.7 1.18 *1.25 1.25 Exp 2 
2.5 30 0.98 25.5 174.5 1 2.7 203.7 1.19 1.25  2.5 30 0.96 26 174 1 2.7 203.7 1.21 1.25 1.25 2.5 30 1.21 20.7 179.3 1 2.7 203.7 0.96 *1.25  2.5 30 1.10 22.7 177.3 1 2.7 203.7 1.06 *1.25 1.25 Exp 3 
2.5 30 1.15 21.7 178.3 1 2.7 203.7 1.01 1.25  2.5 30 0.99 25.3 174.7 1 2.7 203.7 1.18 1.25 1.25 2.5 30 1.25 20 180 1 2.7 203.7 0.93 *1.25  2.5 30 1.18 21.2 178.8 1 2.7 203.7 0.99 *1.25 1.25 Exp 4 
2.5 30 0.96 26 174 1 2.7 203.7 1.21 1.25  2.5 30 0.92 27.2 172.8 1 2.7 203.7 1.27 1.25 1.25 2.5 30 1.3 19.2 180.8 1 2.7 203.7 0.90 *1.25  2.5 30 1.05 23.8 176.2 1 2.7 203.7 1.11 *1.25 1.25   Table 6A. Summary of the concentration of proteins of each sample, and the amounts and concentrations of each reagent used for processing samples.  
Cell 
No. 
(x106) 
1 EB 
9.5M 
2 EB 8M 
3 EB 7M 
(µL) 
1 Urea 9.5M 
2 Urea 8M 
3 Urea 7M 
(µL) 
Protein 
Conc. 
(µg/ µL) 
25 µg of 
protein 
in 
volume 
(µL) 
TEAB 
(µL) 
DTT 
(µL) 
IAA 
(µL) 
Total 
volume 
at 
digestio
n (µL) 
Urea 
Conc. At 
digestio
n 
(M) 
Trypsin 
(µL) 
 
2.5 1 30  1.05 23.8 176.2 1 2.7 203.7 1.11 1.25 
2.5  1 30 1.10 22.7 177.3 1 2.7 203.7 1.05 1.25 
2.5 2 30  1.2 20.8 179.2 1 2.7 203.7 0.82 1.25 
2.5  2 30 1.08 23.1 176.9 1 2.7 203.7 0.91 1.25 
2.5 3 30  0.9 27.8 172.2 1 2.7 203.7 0.95 1.25 
2.5  3 30 0.96 26.0 174 1 2.7 203.7 0.89 1.25 
2.5 1 30  1.2 20.8 179.2 1 2.7 203.7 0.97 1.25 
2.5  1 30 1.1 22.7 177.3 1 2.7 203.7 1.05 1.25 
2.5 2 30  1.02 24.5 175.5 1 2.7 203.7 0.96 1.25 
2.5  2 30 1.06 23.6 176.4 1 2.7 203.7 0.92 1.25 
2.5 3 30  0.87 28.7 171.3 1 2.7 203.7 0.98 1.25 
2.5  3 30 0.84 29.8 170.2 1 2.7 203.7 1.02 1.25     
Table 7A. Protein concentrations of each sample and the concentrations and amounts of reagents used for preparation samples.  
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Cell N
o. 
(x10
6) 
1 EB 9.5M 
2 EB 8M 
3 EB 7M 
(µL) 
1 Urea 9.5M 
2 Urea 8M 
3 Urea 7M 
(µL) 
Protein 
Conc. 
(µg/µL) 
25 µg of 
protein 
in 
volume 
(µL) 
TEAB 
(µL) 
DTT 
(µL) 
IAA 
(µL) 
Total 
volume 
at 
digestio
n (µL) 
Urea 
Conc. At 
digestio
n 
(M) 
Trypsin 
(µL) 
 
2.5 1 30  1.24 20.2 179.8 1 2.7 203.7 0.94 1.25 
2.5  1 30 1.1 22.7 177.3 1 2.7 203.7 1.06 1.25 
2.5 2 30  1.5 16.7 183.3 1 2.7 203.7 0.65 1.25 
2.5  2 30 1.04 24 176 1 2.7 203.7 0.94 1.25 
2.5 3 30  0.85 29.4 170.6 1 2.7 203.7 1.01 1.25 
2.5  3 30 0.91 27.5 172.5 1 2.7 203.7 0.94 1.25 
2.5 1 30  1.07 23.4 176.6 1 2.7 203.7 1.09 1.25 
2.5  1 30 1.17 21.4 178.6 1 2.7 203.7 1.00 1.25 
2.5 2 30  1.6 15.6 184.4 1 2.7 203.7 0.61 1.25 
2.5  2 30 1.2 20.8 179.2 1 2.7 203.7 0.82 1.25 
2.5 3 30  0.82 30.5 169.5 1 2.7 203.7 1.05 1.25 
2.5  3 30 0.89 28.1 171.9 1 2.7 203.7 0.97 1.25   
Table 8A. Summary of the Protein concentrations of each sample and the concentrations and amounts of reagents used for preparation samples.     
Cell 
No. 
(x106) 
EB 8M 
(µL) 
Protein 
Conc. 
(µg/ µL) 
25 µg of 
protein 
in 
volume 
(µL) 
TEAB 
(µL) 
DTT 
(µL) 
IAA 
(µL) 
Total 
volume 
at 
digestio
n (µL) 
Urea 
Conc. At 
digestio
n 
(M) 
Trypsin 
(µL) 
 
2.5 30 2.02 12.4 187.6 1 2.7 203.7 0.49 1.25 
2.5 30 1.86 13.4 186.6 1 2.7 203.7 0.53 1.25 
2.5 30 1.76 14.2 185.8 1 2.7 203.7 0.56 1.25 
2.5 30 1.98 12.6 187.4 1 2.7 203.7 0.49 1.25  
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Table 9A. List of upregulated and downregulated proteins in iTregs vs Stim CD4, sorted based on the 
fold-change and Confidence score ≥50%. Protein Fold-change Confidence Score 
EWS 4.42 64% 
A0A0R4J187 4.01 51% 
Q3UMA3 4.00 57% 
MTMRC 3.75 52% 
A6PW84 3.68 57% 
TTC28 3.30 59% 
MT2 3.24 51% 
D5MCW4 3.22 63% 
ARGL1 2.96 59% 
MESD 2.84 58% 
Q9EQ08 2.69 52% 
RBBP5 2.68 62% 
NAB2 2.60 52% 
DOPD 2.58 64% 
CASP7 2.46 69% 
ARF1 2.34 50% 
HBB2 2.18 82% 
Q9CPX4 2.18 59% 
WASH1 2.07 54% 
CS012 2.02 74% 
STAT2 1.98 54% 
HEM6 1.92 80% 
CAPG 1.92 87% 
HBB1 1.88 53% 
RING2 1.86 65% 
Q9DCC5 1.83 68% 
Q99LB4 1.81 86% 
RS23 1.78 51% 
CRYL1 1.77 52% 
CYTB 1.67 52% 
PTMS 1.56 63% 
PPP5 1.43 65% 
ALDR 1.36 90% 
MCRI1 1.35 61% 
CYH3 1.35 72% 
SUOX 1.13 58% 
TT39B 1.12 63% 
ASSY 1.10 77% 
PLRG1 1.08 54% 
A0A0A6YY34 1.07 84% 
DJC16 1.02 70% 
ORN 0.90 57% 
TBA1A 0.90 71% 
PNKP 0.87 56% 
E9Q9M1 0.84 60% 
SRSF1 0.81 72% 
P85A 0.77 51% 
E9PYG6 0.74 51% 
RUXG 0.74 65% 
RL30 0.72 54% 
RNH2C 0.69 60% 
UBCP1 0.68 71% 
TBCA 0.67 52% 
CNDP2 0.65 79% 
E9QA45 0.65 79% 
Q6ZWZ4 0.64 53% 
GSH0 0.64 53% 
LPXN 0.60 55% 
LKHA4 0.60 53% 
LGUL 0.59 59% 
KAPCB 0.58 62% 
GDIB 0.52 66% 
VIME 0.50 69% 
UBA1 0.48 75% 
COPZ1 0.47 61% 
PDCD4 0.44 59% 
TPM3 -0.29 59% 
MARK4 -0.30 52% 
MCM5 -0.31 62% 
RSSA -0.35 58% 
A2A547 -0.38 80% 
RS28 -0.39 66% 
RL19 -0.42 71% 
EYA4 -0.42 70% 
EF2 -0.42 54% 
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ARP5L -0.43 59% 
CLIC1 -0.43 51% 
PSDE -0.44 58% 
A0A0A6YX26 -0.44 63% 
PSB10 -0.44 57% 
D3Z6X7 -0.44 68% 
SH3L3 -0.45 54% 
SET -0.46 63% 
LRRF1 -0.46 58% 
PSA4 -0.47 52% 
Sep-05 -0.47 57% 
Q6ZWZ7 -0.47 63% 
IF4G1 -0.47 55% 
PDC10 -0.47 62% 
SRSF4 -0.47 57% 
EF1B -0.48 54% 
UH1BL -0.49 63% 
Sep-06 -0.50 65% 
Q9Z1A1 -0.51 57% 
SETD2 -0.51 80% 
CDK2 -0.52 74% 
D3Z5F7 -0.52 55% 
ALKB5 -0.52 54% 
PA2G4 -0.52 62% 
TCPD -0.53 62% 
IMB1 -0.53 63% 
RL11 -0.53 55% 
E9PYJ6 -0.54 56% 
LASP1 -0.54 79% 
CAC1H -0.54 61% 
PKHH2 -0.55 62% 
RL13 -0.55 78% 
RL31 -0.55 69% 
PLSL -0.55 65% 
MYG1 -0.55 57% 
A0A1B0GSG5 -0.55 58% 
RINI -0.55 57% 
AMRA1 -0.56 66% 
GBLP -0.56 50% 
ACLY -0.56 65% 
PCBP2 -0.57 53% 
SMYD5 -0.57 50% 
M3K12 -0.57 75% 
EI2BE -0.57 54% 
SBNO2 -0.57 72% 
RLA0 -0.57 80% 
ASC -0.57 57% 
DPY30 -0.58 54% 
TXD17 -0.58 68% 
RL17 -0.59 79% 
COR1C -0.59 55% 
COR1A -0.59 67% 
ARBK1 -0.60 60% 
E9PWW6 -0.60 71% 
BUB3 -0.60 64% 
MYO9B -0.60 52% 
A0A1L1SQA8 -0.61 78% 
PSB2 -0.61 60% 
PSA3 -0.61 58% 
CAPZB -0.61 61% 
ZCCHV -0.61 55% 
PFKAL -0.62 51% 
COF1 -0.62 56% 
INPP -0.63 73% 
RS20 -0.63 82% 
PSA1 -0.63 70% 
NH2L1 -0.63 77% 
FUS -0.64 56% 
RAC2 -0.64 83% 
Q8C605 -0.64 58% 
O08797 -0.64 64% 
NUCL -0.65 73% 
SRA1 -0.65 52% 
BCL10 -0.66 68% 
SYFB -0.66 55% 
ALDOC -0.67 66% 
GABR1 -0.67 54% 
IF2G -0.67 55% 
SYHC -0.67 74% 
1433G -0.67 66% 
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PAIRB -0.68 77% 
THADA -0.68 55% 
RL35 -0.68 66% 
S10AB -0.70 60% 
RLA1 -0.70 72% 
COX17 -0.70 56% 
FKBP5 -0.70 55% 
DGKA -0.70 79% 
PGP -0.70 53% 
RADI -0.70 60% 
ARC1B -0.70 80% 
TLK1 -0.71 61% 
ENOA -0.71 73% 
ZER1 -0.71 68% 
ACTC -0.72 59% 
RL34 -0.72 80% 
RL27A -0.72 70% 
ASPM -0.72 72% 
MIF -0.73 70% 
TEX10 -0.73 58% 
RL14 -0.73 61% 
RL26 -0.73 61% 
HNRPD -0.73 53% 
HDDC2 -0.73 55% 
SYYC -0.73 69% 
RIPK3 -0.73 69% 
SYG -0.73 70% 
ISG15 -0.74 68% 
Q3U741 -0.74 53% 
GRB2 -0.75 68% 
PYM1 -0.75 70% 
IF6 -0.76 59% 
HINT1 -0.77 73% 
RUVB1 -0.77 76% 
TPM4 -0.77 74% 
PGAM1 -0.78 69% 
THIO -0.79 68% 
RLA2 -0.80 77% 
AIMP1 -0.80 56% 
FKB1A -0.80 84% 
BIN2 -0.80 77% 
6PGD -0.80 74% 
RL29 -0.80 97% 
ELMO1 -0.81 62% 
F7DEU6 -0.81 80% 
UB2V1 -0.81 51% 
SR140 -0.82 55% 
GNPI1 -0.82 61% 
AEDO -0.82 61% 
ADK -0.83 52% 
RS25 -0.83 70% 
ECHD1 -0.83 68% 
SAP -0.83 55% 
F8WJB9 -0.84 50% 
NOP56 -0.85 51% 
RUVB2 -0.85 68% 
GIMA4 -0.85 89% 
TBCD1 -0.85 53% 
SYAC -0.86 63% 
SH3K1 -0.87 52% 
PRDBP -0.87 56% 
STK4 -0.88 54% 
G5E8E4 -0.88 75% 
PP1G -0.88 55% 
UFC1 -0.88 56% 
HDAC7 -0.88 57% 
H2AV -0.89 52% 
ROAA -0.89 72% 
A6ZI44 -0.90 63% 
GALK1 -0.90 78% 
GMFB -0.90 52% 
SERC -0.90 66% 
SYSC -0.91 68% 
CYC -0.91 63% 
KIF15 -0.91 76% 
KCC4 -0.92 64% 
E9Q5C9 -0.92 64% 
TAGL2 -0.92 68% 
A0A087WRY3 -0.93 54% 
Q6PE70 -0.93 67% 
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RAD50 -0.94 59% 
THIC -0.94 55% 
RL10A -0.94 71% 
F8WJI3 -0.95 74% 
TITIN -0.95 52% 
PGM1 -0.95 77% 
GBP1 -0.96 64% 
KCRB -0.96 76% 
A2AMV1 -0.98 57% 
MDHM -0.98 76% 
KPYM -0.99 71% 
AB17C -1.02 91% 
SAMH1 -1.02 79% 
TSN -1.02 50% 
SERB -1.02 58% 
PFKAP -1.03 82% 
STS -1.03 66% 
TPIS -1.03 75% 
A0A0R4J0J3 -1.05 67% 
SAP3 -1.05 78% 
DDRGK -1.05 52% 
DHPR -1.06 78% 
FPPS -1.07 74% 
CLCB -1.08 58% 
CH10 -1.08 53% 
GBB2 -1.09 58% 
A0A087WR57 -1.09 73% 
HPCL1 -1.10 80% 
ALDOA -1.10 73% 
LRCH1 -1.11 57% 
PGK1 -1.12 75% 
KAD2 -1.13 64% 
TCOF -1.13 63% 
AATM -1.14 76% 
SON -1.16 71% 
LSP1 -1.18 84% 
Q8BFQ1 -1.19 82% 
CCD66 -1.21 68% 
PML -1.21 83% 
THMS1 -1.22 82% 
SEC20 -1.23 66% 
HA1D -1.23 55% 
GAPR1 -1.24 76% 
F107B -1.26 68% 
F8WJE0 -1.27 88% 
NDRG1 -1.28 93% 
RU1C -1.30 76% 
RS2 -1.32 54% 
A2A6J4 -1.32 82% 
RL7A -1.32 77% 
RED -1.32 56% 
PTPRC -1.33 75% 
H9H9T1 -1.34 57% 
A0A0B4J1E7 -1.34 70% 
MLKL -1.34 57% 
TCP4 -1.36 60% 
IKZF1 -1.37 54% 
F6ZHD8 -1.38 65% 
E9QP46 -1.38 55% 
KI13A -1.39 75% 
CA198 -1.41 53% 
PRAF3 -1.41 72% 
KBTBB -1.42 76% 
PLXA2 -1.42 71% 
GNAS1 -1.45 54% 
PDLI2 -1.46 63% 
E9PUA7 -1.46 57% 
BRD2 -1.50 58% 
TT21B -1.54 70% 
ESYT1 -1.54 60% 
CO6A2 -1.54 63% 
HXK2 -1.67 56% 
E9Q8L9 -1.76 67% 
KTHY -1.77 58% 
G3X8R0 -1.79 55% 
Q5PPR2 -1.80 55% 
HIKES -1.80 57% 
GRIN3 -1.82 64% 
PPIL2 -1.84 78% 
Q8CBB6 -1.84 57% 
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DYST -1.86 58% 
RBP1 -1.96 53% 
SBP1 -2.00 75% 
APOB -2.05 69% 
RHG22 -2.07 93% 
SMU1 -2.17 65% 
KIN17 -2.17 57% 
SAHH3 -2.18 63% 
UGDH -2.20 56% 
GOGA5 -2.24 53% 
AQR -2.24 50% 
COX7C -2.31 61% 
UBE3C -2.32 51% 
ANXA2 -2.32 83% 
RP1 -2.40 51% 
CWC27 -2.47 54% 
CD97 -2.52 52% 
H14 -2.53 68% 
H15 -2.54 56% 
NOL10 -2.57 50% 
H2A2A -2.59 58% 
H4 -2.61 80% 
CO4B -2.64 52% 
ATG3 -2.64 52% 
RHG25 -2.69 54% 
GTR3 -2.72 82% 
AP4A -2.77 55% 
FOLH1 -3.01 88% 
H2A1K -3.03 60% 
ASB6 -3.08 63% 
B1AW21 -3.09 55% 
VP26A -3.14 59% 
BOLA2 -3.19 83% 
CNO10 -3.25 54% 
FIP1 -3.28 53% 
H2AX -3.30 60% 
SF3B5 -3.39 63% 
H13 -3.45 70% 
B1ASU9 -3.48 63% 
CHD9 -3.61 59% 
TGM2 -3.77 84% 
BAG3 -3.83 62% 
NHEJ1 -4.16 60% 
HINT2 -6.49 55% 
SDCG8 -6.64 76% 
AMRA1 5.16 66% 
A0A0R4J0F6 4.69 53% 
AT1B1 3.29 74% 
PTH2 3.22 60% 
WASH1 3.16 59% 
NRK1 3.16 65% 
ENDD1 2.92 65% 
TBB1 2.82 52% 
DAAM2 2.78 56% 
M3K11 2.45 77% 
DPP9 2.37 51% 
CARF 2.31 54% 
E9Q6R7 2.19 66% 
CAF17 2.09 50% 
SIVA 2.08 51% 
XYLT1 2.03 60% 
MAVS 1.92 84% 
ITIH4 1.84 72% 
Q0VBL3 1.78 66% 
PLP2 1.73 56% 
A2A6J4 1.67 71% 
E9QP00 1.61 52% 
A0A0N4SVQ1 1.58 89% 
Q91VB8 1.54 52% 
NDUA4 1.46 91% 
OAT 1.35 74% 
MYH9 1.19 74% 
MYL6 1.13 58% 
ML12B 1.07 83% 
COR1A 1.03 80% 
CS012 0.99 67% 
ACON 0.94 76% 
D3Z5F7 0.86 59% 
A2AP32 0.79 60% 
CX6B1 0.79 72% 
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VIME 0.78 75% 
CD47 0.73 56% 
P5CS 0.71 64% 
SP110 0.70 50% 
ADT2 0.70 64% 
NDUS7 0.67 68% 
PTN1 0.64 72% 
H32 0.63 52% 
CASP7 0.61 51% 
LAT 0.57 65% 
SUMO2 0.55 88% 
NDUB3 0.50 67% 
A2BIE1 0.46 54% 
E41L2 0.44 57% 
NDUA5 0.44 55% 
RAB8B 0.43 56% 
COX6C 0.42 55% 
NDUS3 0.42 57% 
NDUV2 0.32 55% 
CBR4 -0.27 52% 
RL31 -0.34 51% 
TM109 -0.40 57% 
RAC2 -0.40 57% 
FKBP2 -0.40 51% 
RL27A -0.41 61% 
Q6PE70 -0.43 59% 
RRBP1 -0.45 51% 
AT1A1 -0.47 57% 
H2AV -0.49 51% 
PDIA3 -0.50 71% 
GNAS1 -0.51 54% 
ROAA -0.51 54% 
RL10A -0.51 69% 
A0A1B0GX27 -0.53 52% 
RS28 -0.53 56% 
K2C79 -0.54 74% 
H14 -0.54 51% 
A0A1L1SQA8 -0.54 51% 
GRP78 -0.56 69% 
CBX5 -0.56 52% 
CD3G -0.57 56% 
MOT1 -0.57 67% 
RAP1B -0.58 55% 
RRAS2 -0.58 52% 
RL40 -0.59 50% 
LIMD2 -0.59 57% 
HA1D -0.60 59% 
DNJC9 -0.60 60% 
SET1B -0.61 55% 
CH60 -0.61 60% 
GLU2B -0.62 74% 
Sep-05 -0.63 50% 
ITB2 -0.65 53% 
CD2 -0.66 53% 
AT1B3 -0.68 62% 
EF1B -0.68 55% 
URP2 -0.70 55% 
SPTN1 -0.71 81% 
FLOT1 -0.73 55% 
ENPL -0.74 78% 
CATE -0.75 86% 
HMGN2 -0.75 58% 
ITAL -0.75 71% 
BASI -0.76 79% 
SPTB2 -0.76 74% 
RLA2 -0.77 70% 
MANF -0.83 52% 
Sep-07 -0.83 56% 
TXD12 -0.83 64% 
ARHG2 -0.86 66% 
RFC4 -0.87 62% 
RASA3 -0.89 57% 
KAD4 -0.89 58% 
H2AY -0.90 67% 
CD6 -0.93 74% 
FBLN1 -0.96 53% 
IKZF1 -0.99 50% 
PTCA -1.00 56% 
DHC24 -1.00 56% 
HXK2 -1.00 64% 
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D3YX85 -1.01 65% 
Q5SUH6 -1.01 54% 
CD48 -1.01 72% 
PTPRC -1.01 81% 
CD3D -1.02 83% 
K3W4Q8 -1.02 72% 
CD5 -1.03 93% 
TCB1 -1.05 86% 
SYYC -1.05 57% 
LY9 -1.06 81% 
ERO1A -1.08 74% 
PDIA1 -1.09 69% 
GAPR1 -1.12 87% 
NUCB1 -1.13 53% 
KI13A -1.17 68% 
GTR1 -1.23 77% 
GIMA5 -1.24 61% 
MIF -1.24 57% 
A0A0A0MQF6 -1.29 76% 
G3P -1.33 67% 
ALDOA -1.34 55% 
G3UZK1 -1.38 70% 
E9Q0A7 -1.39 51% 
Q9DC42 -1.44 53% 
WASP -1.45 64% 
MOT4 -1.49 84% 
PAXB1 -1.51 53% 
HMGA1 -1.52 60% 
KPYM -1.53 68% 
WAPL -1.61 51% 
AB17C -1.63 90% 
KRT85 -1.64 72% 
CD97 -1.66 81% 
SH3K1 -1.67 63% 
DDX54 -1.67 57% 
PROS -1.83 50% 
THMS1 -1.98 72% 
GRAB -2.00 75% 
SATB2 -2.09 86% 
SATB1 -2.16 82% 
INCE -2.19 61% 
RBX1 -2.19 52% 
MIO -2.48 61% 
UH1BL -2.51 54% 
Q3U125 -2.61 70% 
ITB3 -2.75 66% 
Z4YJR1 -2.88 64% 
NUSAP -2.92 64% 
CR1L -3.00 62% 
E9Q0G1 -3.05 60% 
ANXA2 -3.07 75% 
GTR3 -3.12 88% 
SDCG8 -3.20 64% 
MET13 -3.29 55% 
Q8CAH8 -3.36 59% 
TPX2 -3.38 74% 
Q792Z1 -3.62 62% 
G3X920 -3.66 73% 
A0A0R4J0J3 -4.10 58% 
PSMD8 -4.36 66% 
DYHC2 -5.34 62%        
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HAUS1 5.976176337 71% 
E9Q1M6 3.947804713 75% 
Q3UMA3 3.915017274 57% 
NOP9 3.783097989 59% 
VPS4A 3.500980564 53% 
TT21B 3.39013993 64% 
A2A4U6 3.34175052 57% 
PSMD8 3.241019382 83% 
FPPS 3.232690314 78% 
E9PWW6 3.217973811 60% 
BAIP2 3.165469907 69% 
TPIS 3.153365419 87% 
HEM6 3.110451987 59% 
LRC47 3.055577367 65% 
MTMR2 3.052956905 61% 
D3Z5N2 3.022273833 77% 
PRI2 2.99301149 65% 
TRAF6 2.960251077 71% 
AB17C 2.936095762 91% 
Q9CQ43 2.893899119 64% 
PIGT 2.867384406 58% 
3BP1 2.862409805 57% 
TYSY 2.841712078 76% 
STMN1 2.838682374 83% 
MA2B1 2.789088052 50% 
SETD3 2.77106176 63% 
NUBP2 2.768789464 70% 
ALDOC 2.764492699 85% 
AACS 2.756559219 68% 
DHX57 2.741935108 52% 
SPA3F 2.728216736 77% 
BGAL 2.688703985 52% 
NXN 2.687786201 51% 
PSME3 2.662295271 53% 
ESPL1 2.656615938 56% 
PGK1 2.643863611 83% 
A6ZI44 2.639074038 83% 
RNH2C 2.636608515 53% 
MA2B2 2.592720359 59% 
VIME 2.576606747 82% 
FAS 2.575171276 77% 
GALK1 2.560187458 77% 
STAT2 2.542360335 77% 
Q5SRW8 2.524306234 51% 
E9Q496 2.507824385 56% 
Q8C605 2.473801304 73% 
ALDOA 2.464310915 85% 
PTN9 2.461547455 52% 
A2AGL5 2.443456543 53% 
4ET 2.43542392 54% 
PGAM1 2.429740756 79% 
Q9DCC5 2.408305778 54% 
DYR 2.400061967 74% 
PCH2 2.383706385 71% 
ENOPH 2.359927238 57% 
CCD25 2.356476431 53% 
PPP5 2.346188422 55% 
XYLT1 2.325469223 71% 
PFKAM 2.318423243 62% 
E9PW66 2.314192542 52% 
CCD43 2.311145198 51% 
ITPA 2.310923112 55% 
KIF15 2.30297472 53% 
DHX29 2.295129906 57% 
RL7L 2.264498293 61% 
SPF30 2.242098664 56% 
TBA1B 2.241235524 62% 
MCM4 2.236390131 74% 
PFKAL 2.229996817 63% 
NAMPT 2.227069358 74% 
BROX 2.225183009 57% 
ENOA 2.22360986 90% 
LDHA 2.218481401 77% 
KPYM 2.213124427 88% 
NDRG1 2.209128209 71% 
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TBB5 2.204592625 89% 
TF2AA 2.182018603 50% 
CNDP2 2.163824104 83% 
MARK4 2.150629986 70% 
MCM7 2.132796062 78% 
D3Z4B2 2.132703544 55% 
PCNA 2.130458947 64% 
RL5 2.12375492 57% 
Q564E2 2.070048597 81% 
NP1L1 2.04881197 51% 
D3Z7B5 2.045407879 68% 
RL8 2.032850948 53% 
RIR1 2.031533295 74% 
XPO1 2.025047568 51% 
OGFR 2.018750591 79% 
E9PYG6 2.006828693 58% 
FABP5 2.004846918 83% 
VAMP7 2.003756692 58% 
RL10 1.980682052 54% 
CRADD 1.971719346 76% 
IMPA2 1.944394486 73% 
PFKAP 1.911252199 73% 
SEC20 1.894501153 51% 
THADA 1.891698906 77% 
PA2G4 1.88381308 81% 
SERC 1.88318566 56% 
MCM2 1.860913467 77% 
SYK 1.851941703 57% 
NFAC2 1.834407739 71% 
CC186 1.831752371 58% 
MCM5 1.825241863 82% 
HPRT 1.794280606 74% 
OSTF1 1.783409931 61% 
IPO5 1.768907712 69% 
EF1B 1.757933732 77% 
TNC18 1.755830362 69% 
MCM3 1.752651383 80% 
PGM1 1.736356876 72% 
Q9QXJ2 1.731975426 84% 
RL27 1.728826923 55% 
ORN 1.72550424 57% 
P85A 1.710538315 57% 
ZN827 1.707143544 73% 
A2BHP6 1.706029751 54% 
PYR1 1.695693529 72% 
IMDH2 1.690839328 80% 
B1B1A8 1.688550334 63% 
MCM6 1.688462923 75% 
RL26 1.687992864 72% 
RIPK3 1.681862973 50% 
SYWC 1.679250802 70% 
Q5XJF6 1.66836229 70% 
COX17 1.658044526 58% 
MIF 1.645344938 89% 
UBQL1 1.636652037 69% 
UBE2K 1.631591734 59% 
G3P 1.5724389 83% 
IPYR 1.561162765 76% 
TLK1 1.558614959 50% 
TCPZ 1.557336829 70% 
EF1G 1.531146268 74% 
A0A0R4J1E2 1.519931528 63% 
A0A0A0MQF6 1.519015517 81% 
NUDC 1.517516049 57% 
E9PYH2 1.500569451 69% 
LEG1 1.495421145 53% 
KRT85 1.487862328 80% 
EF1A1 1.487034822 73% 
RL39 1.474656244 74% 
A0A0R4J138 1.466401373 53% 
RL29 1.464346999 88% 
ZER1 1.463157379 71% 
GRHPR 1.45800026 84% 
TBB4B 1.456429503 86% 
EEA1 1.454507141 50% 
IF4A1 1.451667011 59% 
CUL4A 1.451307141 50% 
G6PI 1.447645256 79% 
SAP3 1.444361431 75% 
SPEE 1.398736585 62% 
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TBA1A 1.388304409 68% 
IF5A1 1.374934077 80% 
SYVC 1.367969209 69% 
SERA 1.367452431 81% 
A0A0A6YX26 1.358182054 65% 
RS3A 1.356923041 71% 
THIO 1.351840481 82% 
RL23A 1.341293138 56% 
ANKL2 1.34027211 60% 
EF2 1.327727052 81% 
NDKA 1.32356167 70% 
EF1D 1.314252729 86% 
RLA2 1.310930885 82% 
RS15A 1.30910125 74% 
RS25 1.302317658 70% 
GALE 1.300421309 58% 
RFC4 1.285967475 57% 
RL10A 1.280392803 71% 
RS27 1.274944358 77% 
RL19 1.262343666 82% 
PTN6 1.259582568 74% 
BTF3 1.240861495 52% 
PAIRB 1.239814502 74% 
A2A5V4 1.221328507 53% 
F8VPV0 1.218844752 62% 
RS14 1.214249505 71% 
IMA4 1.211509959 61% 
Q6ZWZ7 1.206416727 75% 
A0A1B0GTA4 1.184590631 74% 
HNRH2 1.181683292 51% 
RL35 1.179136411 68% 
PRPS1 1.170845851 81% 
RL7 1.167450664 64% 
E9PZF0 1.164873514 71% 
G3UYV7 1.163791019 85% 
PDLI4 1.150034377 55% 
SYMC 1.147962468 66% 
M3K12 1.143498381 89% 
SYHC 1.14221261 60% 
NDKB 1.142086175 79% 
E9PVU0 1.140218058 58% 
Q8BFQ1 1.137245214 67% 
RS11 1.135658301 51% 
Q6ZWZ6 1.135390247 61% 
PUR6 1.133971147 52% 
RS13 1.133128273 68% 
AIMP1 1.126484354 58% 
SYYC 1.126305311 66% 
NPM 1.120060761 77% 
URP2 1.115548349 61% 
RL17 1.112931528 69% 
RL11 1.111591543 75% 
PPIA 1.1094904 81% 
PTMA 1.105381192 81% 
RS29 1.100403605 52% 
Q8R2P8 1.100069998 51% 
CALM 1.098891859 57% 
Q3UKW2 1.098891859 57% 
UMPS 1.098349016 51% 
TCPE 1.094121076 76% 
HS90B 1.093053431 77% 
NTAN1 1.091822827 56% 
RS18 1.080926284 79% 
GLRX3 1.061449173 51% 
RS20 1.059206356 85% 
1433F 1.058567154 74% 
RL13 1.058281259 71% 
RL27A 1.050752801 62% 
TCTP 1.050407451 66% 
RS7 1.050101572 72% 
Q8C3V4 1.043198793 68% 
RLA0 1.039473793 81% 
UBA1 1.034484634 79% 
CDK2 1.028900088 61% 
RL12 1.026560044 81% 
IIGP1 1.024528229 58% 
ERF1 0.999784978 55% 
A0A1L1SQA8 0.99586945 74% 
RS16 0.991578779 79% 
RS2 0.991412376 80% 
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RL34 0.986133915 50% 
EIF3G 0.985728436 50% 
DOK2 0.983235507 56% 
RS4X 0.983096934 73% 
TCPB 0.971956541 68% 
RL23 0.962146625 74% 
PRDX1 0.961155009 82% 
1433E 0.958981736 70% 
Q91V55 0.95615805 74% 
IF4E 0.951740658 50% 
PSD11 0.946182502 66% 
RL31 0.938696744 87% 
RL4 0.936012172 69% 
IMB1 0.932987815 60% 
SYSC 0.926338362 58% 
RS19 0.920804793 75% 
Q6ZWZ4 0.919466223 59% 
CAPG 0.918621095 74% 
RL6 0.916754952 54% 
PNKP 0.914344555 100% 
AGAP2 0.914032087 58% 
RS26 0.908594553 54% 
CATZ 0.899439817 54% 
TCPD 0.88990838 82% 
STAT1 0.881640735 62% 
HS90A 0.86865842 69% 
RSSA 0.863926767 82% 
Q99LB4 0.862002244 78% 
A2A547 0.862001121 80% 
ARPC3 0.861398782 57% 
EIF3I 0.857038637 55% 
TCPG 0.841910771 70% 
RS28 0.841035908 76% 
DPYL2 0.839158146 75% 
PSMG3 0.83889422 68% 
GDIB 0.832597611 74% 
TCPQ 0.827081546 72% 
Q9CPS5 0.803562305 64% 
CSK22 0.79620706 52% 
PKHH2 0.79501471 52% 
CATC 0.777690394 70% 
RAN 0.775742365 64% 
TKT 0.763445033 72% 
TCPH 0.759557535 71% 
AATC 0.754347194 62% 
RL18 0.75393001 57% 
TCPA 0.740563185 73% 
FKB1A 0.740391013 79% 
RL24 0.736755791 62% 
A0A0A0MQA5 0.735928861 58% 
TPP2 0.71591284 52% 
Q8C2Q7 0.710130508 53% 
PSB9 0.704755524 61% 
PSA1 0.704544265 60% 
5NT3B 0.685513127 55% 
SNX27 0.683191104 54% 
CCS 0.678453029 52% 
DDX3X 0.669260891 50% 
SERB 0.665037647 55% 
PCBP1 0.646977304 78% 
RL14 0.642916608 51% 
PSDE 0.632522582 65% 
RAB10 0.605001071 51% 
NUCL 0.600883627 67% 
A0A1C7CYV0 0.577432374 67% 
PSB4 0.577338146 62% 
AN32E 0.563990502 71% 
SAR1B 0.558312564 50% 
HSP7C 0.533118294 69% 
COF1 0.506969854 60% 
IF4G1 0.458176452 54% 
RAB3A 0.402610527 51% 
ML12B 0.350682789 50% 
SUMO2 -0.437906772 74% 
BAG5 -0.488128881 57% 
ARP5L -0.515388739 55% 
APEH -0.555301136 54% 
KBTBB -0.582750783 73% 
GIMA4 -0.586958532 82% 
LASP1 -0.605192482 81% 
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ISG15 -0.615980192 52% 
MYO9A -0.633907244 55% 
LSM7 -0.643097025 68% 
RAC2 -0.649705384 67% 
COR1A -0.656773075 74% 
SPRE -0.66364491 61% 
ANX11 -0.668745171 51% 
A2AQN4 -0.676396627 58% 
EYA4 -0.676961195 70% 
MIO -0.683987047 52% 
Q3UDM0 -0.69896521 54% 
NSF1C -0.699207077 68% 
GDIR2 -0.708360074 57% 
ANXA5 -0.716944179 73% 
NH2L1 -0.780835972 76% 
IL16 -0.790376457 77% 
Q924B0 -0.820365322 73% 
RAB35 -0.825073078 56% 
DCPS -0.832661562 57% 
MGDP1 -0.836458482 69% 
NAA35 -0.839041148 67% 
NC2B -0.847865948 56% 
PP1G -0.85088241 61% 
SH3L1 -0.870319261 66% 
ALDR -0.913791336 76% 
F193A -0.941189771 59% 
B7FAU9 -0.943674952 76% 
FLNA -0.98740393 83% 
E9QMV2 -0.990226805 80% 
SUMO1 -1.011031426 51% 
TRNT1 -1.023985754 61% 
COTL1 -1.070273899 66% 
THUM1 -1.090353667 68% 
ARHL2 -1.090762814 90% 
H4 -1.101741029 69% 
K1671 -1.127870326 71% 
COA7 -1.205892258 61% 
ADK -1.209179347 74% 
NCK5L -1.253254215 70% 
NT5D1 -1.260329357 52% 
FETUA -1.269541086 67% 
F8WIV2 -1.310106855 64% 
CRYL1 -1.318626918 75% 
Q9D3L3 -1.335593554 50% 
PI42A -1.350272376 51% 
ACTN1 -1.355551085 78% 
SH3L3 -1.382962303 84% 
CBR1 -1.384967919 73% 
Q9Z1R9 -1.407690967 64% 
RASF2 -1.432516526 77% 
LDHB -1.450042124 73% 
HBB2 -1.452646404 71% 
LSP1 -1.459802441 82% 
ALBU -1.472934882 54% 
RP1 -1.478193371 60% 
SAMH1 -1.509903903 84% 
PGM2 -1.530752445 63% 
NUF2 -1.562914648 68% 
E9QA45 -1.615720156 87% 
MDHC -1.618283509 84% 
ALG5 -1.643446007 55% 
CCD66 -1.716910781 55% 
A0A0N4SVU1 -1.741225317 51% 
AL3A1 -1.762505859 69% 
A2A6J4 -1.76861937 82% 
ZNFX1 -1.799250899 60% 
HBB1 -1.947805141 69% 
SMU1 -1.952024419 54% 
GDE1 -2.122937652 58% 
GSHR -2.167151945 87% 
NXP20 -2.188672871 51% 
F6QFD1 -2.203205713 82% 
2A5A -2.308269452 69% 
CO4B -2.363107995 59% 
PPM1A -2.412952867 52% 
DEGS1 -2.428721472 61% 
Q9CPX4 -2.474955864 70% 
A7L3B -2.502508629 55% 
SPT6H -2.566254597 63% 
PARP8 -2.784452396 53% 
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ADA10 -2.786631474 62% 
NBN -2.874122083 50% 
MEA1 -2.932147383 51% 
PLS3 -2.944291467 57% 
EMC2 -3.028877048 51% 
CN37 -3.06436379 53% 
SCAM3 -3.259336624 50% 
RM38 -3.280625557 52% 
Q0PD20 -3.29537635 56% 
COPE -3.416868567 63% 
VWA8 -3.430355112 51% 
REV1 -3.490632586 57% 
MKS3 -3.493715443 57% 
B0R091 -3.534464722 56% 
CD109 -3.53944641 83% 
ARMX3 -3.880537772 57% 
BOLA2 -4.010263922 61% 
PAXB1 -4.201515599 61% 
NHEJ1 -4.496686829 59% 
A2A4U6 4.982689692 55% 
M3K11 4.740146814 57% 
NHEJ1 4.515149001 55% 
A0A0R4J0F6 3.789269464 56% 
NDRG2 3.750100815 64% 
CSN7B 3.719436073 61% 
PLP2 3.689022256 86% 
D3YXP6 3.628123708 50% 
XYLT1 3.519154323 72% 
UBE2C 3.41624116 60% 
PIGT 3.295881594 63% 
KI67 3.178351861 77% 
K3W4Q8 3.176821273 78% 
MOT4 3.133896329 55% 
SRA1 3.128443865 53% 
MAVS 3.116232429 55% 
RM27 3.089410774 51% 
PYC 3.089339057 80% 
A0A0R4J0T5 3.068419193 59% 
NSMA3 3.052409218 55% 
E9PZ97 3.032865818 65% 
MFS10 3.029930613 60% 
RRS1 2.992391584 53% 
AT131 2.986363154 58% 
TFR1 2.950759968 77% 
BASI 2.938760399 77% 
RL39 2.85225458 53% 
E9PUQ5 2.840505581 51% 
AB17C 2.812938361 78% 
E9QP62 2.802208636 54% 
DNMT1 2.727523308 66% 
KAD4 2.724352103 69% 
DDAH1 2.710950923 50% 
NCBP3 2.708044334 51% 
A2AUM0 2.691828829 50% 
MIC26 2.682100351 72% 
GTR1 2.668670345 61% 
CBX5 2.662932355 62% 
E9PWG6 2.64845045 72% 
MYEF2 2.640070827 51% 
MSMO1 2.619052916 57% 
SMC2 2.589416922 66% 
SYNE3 2.523543649 63% 
DHB7 2.510119858 56% 
MCM5 2.508739148 66% 
Q3UNN4 2.461155731 63% 
NRM 2.449179585 59% 
TBA1A 2.445783927 51% 
BRI3B 2.442106192 56% 
SEC63 2.428361781 71% 
ERO1A 2.425634386 65% 
BCL7C 2.411474052 56% 
LRC59 2.385233562 76% 
TT21B 2.375570528 55% 
NCBP2 2.341750529 53% 
IL2RA 2.310505317 76% 
LRC8C 2.281477925 61% 
TERF2 2.273376489 64% 
S2539 2.260478731 57% 
K2013 2.237671604 51% 
RM17 2.225342186 57% 
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E9QAS5 2.224122917 58% 
A0JNY3 2.201726637 51% 
A2A5V4 2.201716211 50% 
NSDHL 2.193123487 77% 
E9PX68 2.101974524 57% 
E9QP00 2.081551819 51% 
VIME 2.073260383 82% 
PPIF 2.045078012 64% 
DDX27 2.025132612 58% 
AP2S1 2.017330939 64% 
Q9CZN7 2.008627512 81% 
MBB1A 1.952073224 75% 
F6ZBR8 1.944945527 52% 
ATIF1 1.844961515 51% 
GNAS1 1.828819526 57% 
A0A0R4J170 1.772732171 73% 
IMP3 1.755311086 58% 
A0A0R4J0V1 1.745982981 62% 
TNC18 1.744082202 60% 
ITIH4 1.720990902 69% 
GTR3 1.719255828 61% 
A0A0R4J0D3 1.715367511 70% 
Q8C2Q7 1.705611861 56% 
LAP2A 1.694158517 50% 
ABHGA 1.684692205 50% 
PGES2 1.674929385 65% 
SYAM 1.674713361 52% 
IIGP1 1.589790297 62% 
LAT 1.571947656 52% 
MOT1 1.543162215 57% 
FKBP8 1.530549418 78% 
CD47 1.521756522 57% 
TM9S4 1.511747048 71% 
4F2 1.50855694 54% 
GBG2 1.426500688 82% 
GAPR1 1.403211843 77% 
PYRD 1.393353099 59% 
ERG28 1.386334816 58% 
RSSA 1.370983006 52% 
FKBP2 1.341284766 57% 
PHB2 1.316208488 74% 
RPN1 1.307906372 78% 
SFXN1 1.240247886 79% 
ADT2 1.230661374 66% 
P5CS 1.222021762 72% 
FLOT1 1.215065514 51% 
SSRG 1.204912186 70% 
Q31093 1.20450616 52% 
PDIA6 1.200289106 80% 
ERP29 1.189546739 66% 
OAT 1.169299517 69% 
ENPL 1.163797268 72% 
CTL2 1.135686634 60% 
ICAM1 1.111363701 61% 
PHB 1.105551485 73% 
LS14A 1.101804273 54% 
SDF2L 1.08763238 70% 
Q3UJB0 1.081230351 54% 
SUV3 1.072920317 56% 
MYH7B 1.04837306 72% 
NOP2 1.047483349 53% 
RL27A 1.030620908 55% 
RBBP4 1.0130215 61% 
MTA2 1.009859995 54% 
E41L2 0.99525125 51% 
RL10A 0.967143477 69% 
J7NUP1 0.958626237 56% 
A0A1L1SUX8 0.933950976 87% 
THY1 0.899042313 61% 
LONM 0.896113946 51% 
PR40A 0.891082324 58% 
Q9D8L3 0.888433694 67% 
FUBP2 0.885628316 64% 
MFGM 0.879667225 64% 
PNKP 0.87918808 85% 
A0A0A0MQF6 0.860111589 60% 
RNH2B 0.850019537 58% 
IRGM1 0.833009637 79% 
ESYT1 0.811507111 73% 
RL19 0.799144763 75% 
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RUXF 0.794192962 52% 
Q3TCU5 0.786387113 53% 
SNRPA 0.780766765 58% 
URP2 0.723522629 51% 
F208B 0.723052921 58% 
VDAC1 0.668898776 59% 
G3UYV7 0.656685347 56% 
ROAA 0.647674179 52% 
VDAC2 0.620943323 54% 
GRP75 0.557654145 57% 
CATE -0.608240043 54% 
RAC2 -0.649188436 78% 
D39U1 -0.699734246 53% 
COR1A -0.710889411 68% 
CD5 -0.726835796 67% 
EFTU -0.729583272 66% 
PTCA -0.787351171 65% 
CHM1A -0.821679604 52% 
THIM -0.83078699 52% 
UBC9 -0.832849377 64% 
ACD10 -0.855542919 51% 
SODM -0.954900893 52% 
GIMA1 -0.981637575 60% 
ACO13 -1.002283757 55% 
LIMD2 -1.106030929 69% 
G3X9U9 -1.120982422 57% 
IVD -1.230495099 69% 
ACOT9 -1.234025867 64% 
ES1 -1.311787078 51% 
IL16 -1.335764945 66% 
ACTC -1.344187262 61% 
COX7C -1.35312901 65% 
CECR5 -1.405217941 54% 
ECI1 -1.470161359 67% 
ARHL2 -1.47219518 58% 
PRDX5 -1.54121843 65% 
FETUA -1.56103197 64% 
CYB -1.629090902 61% 
K1C17 -1.667139482 58% 
K1C16 -1.781354311 55% 
ACOT2 -1.866607248 87% 
EYA4 -1.941342071 63% 
NAA35 -1.987904367 57% 
TBC8B -1.99922149 63% 
K1C14 -2.011751053 56% 
E0CZ27 -2.03178395 72% 
K22E -2.045144758 58% 
MA2B2 -2.050546159 55% 
E9Q0F0 -2.075959586 55% 
K2C79 -2.167485783 81% 
ROCK2 -2.174853235 56% 
NEST -2.177505857 56% 
K1C10 -2.264287146 80% 
PDPR -2.291383666 56% 
F16B1 -2.292925895 52% 
K2C1B -2.440165523 76% 
HMGB1 -2.53477992 58% 
CCD66 -2.576701269 53% 
A2A513 -2.664352983 91% 
E9Q0G1 -2.778194168 55% 
Q9Z1R9 -2.897566049 85% 
A0A0R4J0J3 -3.268143068 50% 
HYEP -3.342961114 76% 
Q9CZP3 -3.401367187 65% 
E9QA45 -3.507008954 89% 
H2B2B -3.846890226 57% 
MIO -4.010402747 76% 
Q792Z1 -4.472107504 77%      
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E9PWW6 5.559155236 64% 
PIGT 4.832151703 60% 
A2CG76 4.683056553 55% 
CUL4A 4.218718279 52% 
A2A4U6 4.004331271 54% 
IL2RA 3.989840648 86% 
A0A0R4J0F6 3.927736011 56% 
M3K11 3.862699048 77% 
F8WIA1 3.842171432 52% 
PSF3 3.829572051 57% 
PIGT 3.821267208 60% 
BASI 3.747434177 74% 
G3UW40 3.682472314 54% 
KAD4 3.658885869 61% 
SUGP1 3.630801647 51% 
SLIT2 3.615743029 61% 
KIF15 3.611043066 69% 
Q3UMA3 3.602690664 52% 
GALE 3.573333406 77% 
PDCD5 3.546400758 51% 
D3Z5N2 3.524383792 79% 
IFI4 3.507845444 57% 
MSMO1 3.483693611 57% 
GNAS1 3.459294559 58% 
DNM3A 3.393564932 63% 
S2539 3.366041142 64% 
K3W4Q8 3.360816069 73% 
KI67 3.340960314 79% 
IIGP1 3.330678165 84% 
SBNO2 3.323354638 70% 
CD2 3.296968449 50% 
RNH2B 3.284702392 59% 
NDRG1 3.280034785 75% 
BOREA 3.274421675 53% 
DOPD 3.268777389 65% 
ATIF1 3.233359566 66% 
4EBP1 3.2003607 62% 
ERG28 3.158011445 66% 
PYC 3.151068223 84% 
Q9CQ43 3.142918632 78% 
VPS4A 3.136851637 50% 
CBX5 3.111914523 69% 
SMC2 3.109652269 64% 
PSMD8 3.103586189 81% 
SUH 3.09436734 55% 
Q9EQ08 3.09335696 61% 
TPIS 3.076976336 83% 
GALM 3.044242329 55% 
STMN1 3.036256437 80% 
E9Q1M6 3.027505613 62% 
GTR1 3.023694626 64% 
GPAA1 3.00142856 55% 
TFR1 2.983734914 76% 
TERF2 2.979699407 78% 
ALDOC 2.970230418 85% 
MESH1 2.960810877 51% 
Q3UKN6 2.95931301 61% 
DYR 2.957170294 80% 
A0A0R4J0V1 2.955900269 70% 
HYI 2.92141074 50% 
STA5A 2.907566911 59% 
TNC18 2.90099338 65% 
NAMPT 2.897522132 78% 
AACS 2.89308307 72% 
NDUA8 2.883069609 62% 
RT06 2.879233288 58% 
SHCBP 2.873829522 63% 
FPPS 2.871557255 80% 
BAIP2 2.867752465 61% 
FABP5 2.846191754 82% 
E9PYG6 2.83949123 64% 
E9QP00 2.81844582 58% 
CK074 2.813915429 65% 
E9Q718 2.805532954 51% 
MCM4 2.795949987 77% 
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IMPA1 2.779843837 50% 
J3QMA2 2.741028464 70% 
NXP20 2.723781165 67% 
FAS 2.719077107 79% 
SPA3F 2.718619946 78% 
E9Q496 2.71718032 70% 
E9PWG6 2.705015172 66% 
PLP2 2.704603759 88% 
SETD3 2.701306318 58% 
A0A0A0MQ90 2.698801123 52% 
TOP2A 2.690370738 50% 
CAPG 2.664927486 86% 
MCM5 2.650982754 91% 
Q99LB4 2.649193605 84% 
ERGI1 2.64735627 52% 
CATZ 2.639800205 50% 
SRSF9 2.617679294 54% 
A0A0U1RP59 2.601792295 61% 
PCNA 2.592876153 73% 
E9PYH2 2.588704044 78% 
IMPA2 2.586731817 70% 
PFKAP 2.573353772 57% 
CDK6 2.569498455 76% 
TNC18 2.558653751 71% 
F6UHR6 2.551821316 53% 
RL7L 2.5501486 71% 
A2BHP6 2.545877507 69% 
ESPL1 2.534847943 52% 
ITIH4 2.519288988 76% 
BRI3B 2.518654628 58% 
B2RPU8 2.494793056 51% 
HAUS1 2.493639948 64% 
MOT4 2.479640796 70% 
MCM2 2.47509484 75% 
MAVS 2.467043417 82% 
Q3UNN4 2.459755016 64% 
E9PZ97 2.459544987 68% 
SPA3G 2.449753779 78% 
TM9S4 2.446434989 67% 
PRI2 2.441787802 73% 
3BP1 2.437179528 52% 
IIGP1 2.433734268 65% 
CMTD1 2.433597794 56% 
E9PWG6 2.429462828 78% 
MCM6 2.417444737 75% 
RIR1 2.403678379 77% 
XYLT1 2.399761071 71% 
Q52KC3 2.393455024 72% 
RFC4 2.389911836 50% 
FKBP2 2.377922052 59% 
MCM7 2.374954349 75% 
LRC59 2.365011568 77% 
MCM3 2.364746749 77% 
E9Q8A3 2.36025079 60% 
PGK1 2.346306028 82% 
ERO1A 2.340809611 64% 
HAT1 2.337554928 67% 
MARK4 2.337224834 77% 
ARHG2 2.333715051 80% 
DMAP1 2.329111577 58% 
TBA1B 2.328380379 80% 
DCAF8 2.325847354 76% 
GALK1 2.302387039 78% 
CNDP2 2.299759994 84% 
Q8C605 2.290971047 80% 
E9PW39 2.290770924 61% 
SYVC 2.263121452 80% 
NSDHL 2.240879661 66% 
MA2B1 2.232547174 55% 
SERC 2.22582669 74% 
AB17C 2.224911281 91% 
OGFR 2.223176253 54% 
T2EA 2.215388461 73% 
Q9CZN7 2.212182356 78% 
CAC1H 2.201571585 51% 
RPB7 2.189047433 53% 
DPOLA 2.183557266 58% 
PA1B3 2.180860215 64% 
SNTB2 2.161517247 54% 
A6ZI44 2.154366575 79% 
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CHD6 2.147292027 56% 
TLK1 2.147093049 56% 
STAT2 2.1467769 64% 
XYLT1 2.130477264 70% 
VIME 2.130196516 81% 
GLYC 2.12924806 75% 
E41L2 2.126801181 70% 
PPP5 2.104629423 58% 
TBB5 2.089422699 86% 
ICAM1 2.088484151 75% 
ENDD1 2.082881302 66% 
PFKAL 2.078124351 64% 
RNH2B 2.074334519 54% 
PDCL3 2.064675767 51% 
VIME 2.061522961 83% 
MP2K1 2.058629765 53% 
A0A0R4J138 2.042460314 65% 
A0A0B4J1E7 2.029864194 58% 
NFAC2 2.02483718 82% 
ALDOA 2.023559372 81% 
RPAP1 2.022005589 61% 
RFC4 1.987279854 62% 
STML2 1.985355633 72% 
SND1 1.979233844 58% 
DHB7 1.971263535 71% 
GBG2 1.969401634 82% 
MIF 1.968522247 52% 
HEM6 1.962878898 73% 
CDK2 1.944907077 50% 
CHD4 1.935840861 52% 
KPYM 1.929475817 85% 
LDHA 1.912384368 72% 
A0A0R4J170 1.911242674 56% 
ADA 1.905315422 53% 
A1L3S7 1.899933358 62% 
OAT 1.892847691 73% 
PPIF 1.890645245 51% 
IMP3 1.859463566 51% 
Q9QXJ2 1.84545505 74% 
ARMX3 1.839322416 53% 
A0A0A0MQF6 1.837020016 73% 
PYR1 1.824300903 72% 
Q3UE92 1.823171388 52% 
TBB2B 1.821006703 77% 
STN1 1.809933447 69% 
PUR6 1.806052401 58% 
IPO5 1.78536942 67% 
ADH7 1.783634354 57% 
CRADD 1.775646277 67% 
4F2 1.758453166 78% 
G3P 1.753386046 77% 
D3Z7B5 1.721490095 59% 
PDIA6 1.710162624 78% 
ENPL 1.708465071 69% 
CA198 1.702921616 55% 
COX17 1.696419399 61% 
PGAM1 1.692989898 80% 
ROA1 1.692583453 61% 
MYH7B 1.6795756 70% 
SERA 1.669320065 82% 
EF1G 1.669011448 77% 
PSMG3 1.662425733 71% 
OGA 1.658560256 57% 
GRHPR 1.648207833 80% 
MBB1A 1.645840468 75% 
E9PUQ5 1.635799069 52% 
A0A0R4J1E2 1.61621308 78% 
MICA1 1.602330095 50% 
P5CS 1.599882899 75% 
MIF 1.597179865 87% 
Q564E2 1.589577008 84% 
PHB2 1.588524208 53% 
DHX36 1.572690282 54% 
ENOA 1.567309792 87% 
TT21B 1.549117885 53% 
E9QNP0 1.539566891 56% 
TRAF6 1.522846749 70% 
DHX29 1.519335041 50% 
PSB7 1.510012511 57% 
Q31093 1.498033381 70% 
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SYTC 1.497845411 66% 
PGAM5 1.496061672 54% 
SYMC 1.487068742 67% 
RNH2C 1.477285553 62% 
CCS 1.475447159 60% 
M3K12 1.45785279 74% 
RL23A 1.456132094 53% 
Q8C2Q7 1.455006766 59% 
RL26 1.446939715 68% 
UMPS 1.432962884 53% 
AB17C 1.430177199 54% 
MOT1 1.413603563 56% 
IMDH2 1.406692428 78% 
TBA1B 1.389955705 59% 
EF1B 1.389369287 80% 
IPYR 1.383526393 55% 
A0A0A0MQF6 1.371039936 55% 
IF5A1 1.362846451 79% 
SYEP 1.361720183 59% 
GAPR1 1.357117614 57% 
PTMA 1.354998578 76% 
DAD1 1.352988021 54% 
A0A0R4J0D3 1.351135828 59% 
ADT2 1.344678287 72% 
TBB5 1.344341977 55% 
THIO 1.338384161 81% 
EF1D 1.326206589 78% 
NOP2 1.318071783 54% 
RIPK3 1.316804421 50% 
RS29 1.316718226 56% 
IF4E 1.310838381 50% 
BROX 1.309723463 54% 
ZER1 1.287441456 70% 
ADT1 1.279918167 54% 
YBOX1 1.276349573 51% 
WDR3 1.26512848 51% 
LS14A 1.246971579 73% 
PA2G4 1.214684399 75% 
URP2 1.211433566 59% 
SSRG 1.197982492 52% 
RPN1 1.194014959 80% 
Q8C2Q7 1.192867278 57% 
HNRPQ 1.190828981 52% 
MIC26 1.184683507 54% 
SAP3 1.17806936 52% 
TBA1A 1.17655849 64% 
ERF1 1.169421755 55% 
HPRT 1.146563114 56% 
RL19 1.143070962 82% 
Q8C3V4 1.141692881 55% 
AATC 1.136687692 69% 
EF2 1.133266328 80% 
Q8BG13 1.128935928 54% 
FKBP8 1.099878377 66% 
E9PW43 1.096909626 57% 
STAT1 1.085843415 50% 
RL6 1.083052811 52% 
RL19 1.08191587 81% 
ITPA 1.081146549 51% 
ROAA 1.080610158 72% 
GRP78 1.0785641 75% 
SNRPA 1.074266366 77% 
S10AD 1.070294986 59% 
PGES2 1.064467865 56% 
RL27 1.062161512 58% 
CASP7 1.057652884 51% 
GPSM1 1.057065685 52% 
EF1A1 1.051480432 69% 
PHB 1.048392902 73% 
IF2A 1.047079248 50% 
UBA1 1.044998548 79% 
G6PI 1.041903443 76% 
LPXN 1.036876116 54% 
RL10A 1.029569179 71% 
RBBP4 1.028278181 52% 
HDAC1 1.018936187 59% 
PPIB 1.009237446 79% 
EEA1 0.996993844 50% 
DEK 0.988629714 65% 
GBP1 0.984194799 57% 
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RL14 0.98302194 59% 
CTL2 0.978788974 76% 
HTR5B 0.973973679 88% 
PTN6 0.971391346 62% 
RAB10 0.971179383 59% 
HNRH1 0.958551784 83% 
RFA3 0.956030258 56% 
TBB4B 0.953977622 68% 
RL8 0.939331155 51% 
Q3TCU5 0.93724761 66% 
SFXN1 0.92869476 80% 
RL27A 0.924006855 51% 
Q9Z1A1 0.922285588 63% 
AN32E 0.919597655 56% 
KRT85 0.91739029 54% 
MTA2 0.915037968 54% 
A0A0A6YX26 0.910082515 74% 
RAB8B 0.903000604 57% 
C1TM 0.895060187 53% 
TCPB 0.874490194 56% 
OSTC 0.874058775 53% 
RL7 0.864567996 60% 
HS90B 0.864227695 76% 
FUBP2 0.860930387 65% 
STING 0.859196742 56% 
PPIA 0.85869303 81% 
YIPF4 0.853214957 57% 
GDIB 0.844906766 66% 
RL13 0.844492705 57% 
SPEE 0.840533447 67% 
A0A1B0GTA4 0.832047561 58% 
RS25 0.829755529 67% 
AT1A1 0.82115059 54% 
A0A1L1SQA8 0.818715112 56% 
1433F 0.81605988 70% 
PNKP 0.815304654 77% 
RL27A 0.79728746 56% 
TKT 0.796464877 61% 
A2A547 0.780974565 80% 
TCPG 0.772720765 70% 
TCPD 0.767603764 83% 
RS27 0.761183195 61% 
CN37 0.749809186 52% 
PRPS1 0.740501349 57% 
UBP3 0.731093474 55% 
OST48 0.729405619 52% 
PR40A 0.717399317 51% 
Q6ZWZ7 0.704555893 51% 
PRDX1 0.703942427 59% 
HS90A 0.702117829 71% 
RL31 0.689031861 60% 
RL17 0.683684578 63% 
RS3A 0.679492804 52% 
RL35 0.674449786 52% 
F208B 0.672359051 56% 
RS14 0.668101312 55% 
Q9D8L3 0.65764416 59% 
1433E 0.657499632 54% 
RL10A 0.6498865 66% 
DNM1L 0.645518054 55% 
RL31 0.635978157 70% 
PCBP1 0.626722243 75% 
IRGM1 0.612352468 61% 
RS18 0.606782635 52% 
RL12 0.596279164 50% 
PCBP1 0.595370864 63% 
RS7 0.593101251 50% 
HNRPK 0.579491287 58% 
PSB4 0.576415746 74% 
Q6ZWZ4 0.576043999 50% 
VDAC2 0.574906435 79% 
UBCP1 0.549088285 54% 
RLA2 0.547959766 50% 
G3UYV7 0.540616148 68% 
CATC 0.537165283 57% 
NUCL 0.531891746 56% 
PSDE 0.53161895 59% 
FKB1A 0.517983025 58% 
U2AF2 0.506144811 57% 
RL29 0.481448909 57% 
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RLA0 0.464531573 69% 
RSSA 0.456147974 61% 
PNKP 0.398051591 55% 
HSP7C 0.387396585 52% 
RS28 0.335413777 54% 
KAPCB -0.470857914 55% 
ARP5L -0.550545379 53% 
ARC1B -0.564631198 65% 
SORCN -0.572122368 53% 
NDUA4 -0.590489965 59% 
ELMO1 -0.594409681 60% 
CD5 -0.638900794 63% 
NSF1C -0.660526197 62% 
CLCB -0.666952343 53% 
ANXA6 -0.691317171 64% 
HCD2 -0.701369887 78% 
BIN2 -0.712069363 54% 
Q3UDM0 -0.717330187 55% 
ASC -0.729686054 70% 
A0A0N4SVT1 -0.741054097 61% 
EYA4 -0.744997917 68% 
LASP1 -0.755690577 77% 
Q99N15 -0.768015251 53% 
ANX11 -0.777212561 64% 
A0A0N4SVQ1 -0.778366989 64% 
GSTP1 -0.784517523 69% 
Q924B0 -0.793717767 66% 
CAZA1 -0.799841036 60% 
BIEA -0.799958815 57% 
CCD66 -0.802007204 61% 
PTCA -0.807579386 56% 
INPP -0.809855844 68% 
PROF1 -0.811687843 78% 
UBC9 -0.822117613 54% 
CBX3 -0.834326117 73% 
UBC9 -0.84329792 64% 
GIMA4 -0.85554105 87% 
IF4A3 -0.872231438 69% 
LSM7 -0.891835471 66% 
MGDP1 -0.903836934 63% 
COR1A -0.91111261 77% 
NHP2 -0.914958865 51% 
CRLF3 -0.927646997 75% 
COF1 -0.94141141 54% 
SP100 -0.944815874 80% 
SAMH1 -0.94936271 78% 
RPR1B -0.956373236 80% 
TAGL2 -0.956977577 68% 
RAC2 -0.957107882 84% 
A0A0R4J195 -0.959440335 70% 
U2AF2 -0.962340629 61% 
IL16 -0.96793139 84% 
Q5RKN9 -0.993656526 54% 
MGN -1.003309619 59% 
K22E -1.0042561 51% 
A0A0A6YY34 -1.004623611 68% 
LAMP1 -1.008024769 52% 
CNN2 -1.008254104 51% 
GLRX1 -1.013137832 64% 
E9QMV2 -1.016496052 81% 
TRNT1 -1.036411946 50% 
K1671 -1.044370197 72% 
A2A513 -1.048432426 78% 
TPM3 -1.052414196 56% 
OPA1 -1.054233874 52% 
Q6GT24 -1.066243206 72% 
PRDX6 -1.073920222 50% 
ALDR -1.079451626 88% 
CAP1 -1.087472527 70% 
THIM -1.089823745 62% 
F8WGL3 -1.0922213 56% 
MOES -1.097251805 73% 
NH2L1 -1.109045467 78% 
H4 -1.114510167 71% 
Q91VB8 -1.1209302 64% 
A0A0R4J0J8 -1.127067758 57% 
PKHA1 -1.127865275 53% 
ANXA5 -1.141691596 79% 
NOP58 -1.146317373 53% 
ARHL2 -1.154401189 69% 
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NCK5L -1.156445447 66% 
THUM1 -1.162496586 62% 
GDPP1 -1.165136767 59% 
ADK -1.175762857 68% 
E9Q0F0 -1.190445254 51% 
RMXL1 -1.192946013 54% 
CATE -1.193534417 89% 
B2RUG9 -1.196912924 70% 
PDXK -1.199200137 52% 
D39U1 -1.200422659 59% 
FUBP1 -1.2076978 52% 
HBB2 -1.226541892 61% 
ROA2 -1.22733264 78% 
DCPS -1.246104259 75% 
PI42A -1.25004861 77% 
F193A -1.267376018 63% 
LDHB -1.289491892 78% 
HNRPD -1.30849955 68% 
Q6ZWQ9 -1.316611498 58% 
FBRL -1.323596698 62% 
S10AB -1.329855686 70% 
KBTBB -1.332604766 65% 
CO6A2 -1.343800204 55% 
ROA3 -1.364167377 79% 
COX7C -1.368479124 84% 
FETUA -1.386146982 68% 
CBX1 -1.397948782 60% 
CATE -1.407538019 81% 
LIMD2 -1.409976024 76% 
GDIR2 -1.415366181 71% 
B7FAU9 -1.474612825 85% 
ROA0 -1.479440772 60% 
IL16 -1.506103682 77% 
HNRPC -1.514502888 61% 
A2A6J4 -1.515731388 82% 
FLNA -1.524219641 82% 
COTL1 -1.525748345 71% 
SH3L3 -1.543965971 82% 
BAG5 -1.574801689 82% 
CBR1 -1.583023149 77% 
HPCL1 -1.616369907 82% 
LSP1 -1.628432214 85% 
RASF2 -1.664829713 79% 
PGM2 -1.667656052 72% 
BRX1 -1.679977502 54% 
MDHC -1.708506835 87% 
TMCC3 -1.743178097 51% 
A2AQN4 -1.749531203 53% 
TBC8B -1.751181055 59% 
THRB -1.798281139 52% 
ACD10 -1.829842923 54% 
NUF2 -1.860929641 57% 
K1C17 -1.91191341 58% 
K1C16 -1.917822773 90% 
DDAH1 -1.932109472 51% 
ACOT2 -1.942605378 78% 
Q9Z1R9 -1.948313756 85% 
RASK -1.970742154 56% 
PKHO2 -2.013592645 51% 
E9QJT5 -2.035008499 80% 
EYA4 -2.041675267 51% 
NUD16 -2.064480502 66% 
GSHR -2.10542411 66% 
K1C10 -2.112424327 86% 
SET1B -2.121980488 71% 
K22E -2.167944004 61% 
PI42A -2.173163563 61% 
SPT6H -2.252464196 80% 
MRCKB -2.254648796 52% 
E9QA45 -2.264238531 83% 
H12 -2.295020308 51% 
G3X8X3 -2.314798048 53% 
IF4A2 -2.362177239 82% 
DAAM2 -2.388110879 52% 
K2C1B -2.402019745 81% 
SQRD -2.419766151 58% 
A2A513 -2.426828568 95% 
K2C1 -2.456747494 78% 
ACYP1 -2.472075023 76% 
DHB11 -2.485943772 54% 
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E9Q0F0 -2.505614478 69% 
ACTN1 -2.528755871 83% 
K2C79 -2.545858794 87% 
Q9EQ08 -2.589184426 56% 
E9Q0A7 -2.607330026 55% 
NAA35 -2.637379099 60% 
D3YX85 -2.650315559 70% 
NEST -2.662024848 61% 
GBG5 -2.688484175 60% 
HDDC2 -2.717227558 65% 
HYEP -2.742116187 69% 
K1C14 -2.787940779 71% 
Q9Z1R9 -2.807432235 75% 
HMGB1 -2.819757201 64% 
CCZ1 -3.024920159 57% 
UBE3C -3.045184245 62% 
A0A0R4J0J3 -3.209759287 63% 
PAXB1 -3.358714664 53% 
PSMD8 -3.386751388 50% 
Q8BH78 -3.416332776 51% 
2A5A -3.513004252 66% 
FARP1 -3.517023663 52% 
NOG2 -3.758666749 52% 
UH1BL -3.761452963 55% 
E9QA45 -3.823835615 88% 
LMNB2 -3.881132184 55% 
MIO -4.058872946 79% 
K2C73 -4.200880488 74% 
RUSD2 -4.4907361 65% 
AP3M2 -4.535437702 57% 
D3Z6X7 -4.614218008 51% 
HINT2 -4.884016944 59% 
Q792Z1 -5.602066665 97% 
A2CG76 4.683056553 55% 
A2A4U6 4.004331271 54% 
IL2RA 3.989840648 86% 
A0A0R4J0F6 3.927736011 56% 
M3K11 3.862699048 77% 
F8WIA1 3.842171432 52% 
PIGT 3.821267208 60% 
BASI 3.747434177 74% 
KAD4 3.658885869 61% 
SUGP1 3.630801647 51% 
PDCD5 3.546400758 51% 
MSMO1 3.483693611 57% 
GNAS1 3.459294559 58% 
DNM3A 3.393564932 63% 
S2539 3.366041142 64% 
K3W4Q8 3.360816069 73% 
KI67 3.340960314 79% 
CD2 3.296968449 50% 
BOREA 3.274421675 53% 
ATIF1 3.233359566 66% 
ERG28 3.158011445 66% 
PYC 3.151068223 84% 
CBX5 3.111914523 69% 
SMC2 3.109652269 64% 
SUH 3.09436734 55% 
GTR1 3.023694626 64% 
GPAA1 3.00142856 55% 
TFR1 2.983734914 76% 
TERF2 2.979699407 78% 
Q3UKN6 2.95931301 61% 
A0A0R4J0V1 2.955900269 70% 
TNC18 2.90099338 65% 
NDUA8 2.883069609 62% 
RT06 2.879233288 58% 
E9QP00 2.81844582 58% 
CK074 2.813915429 65% 
IMPA1 2.779843837 50% 
NXP20 2.723781165 67% 
PLP2 2.704603759 88% 
TOP2A 2.690370738 50% 
ERGI1 2.64735627 52% 
SRSF9 2.617679294 54% 
A0A0U1RP59 2.601792295 61% 
F6UHR6 2.551821316 53% 
RL7L 2.5501486 71% 
ESPL1 2.534847943 52% 
ITIH4 2.519288988 76% 
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BRI3B 2.518654628 58% 
MOT4 2.479640796 70% 
MAVS 2.467043417 82% 
Q3UNN4 2.459755016 64% 
E9PZ97 2.459544987 68% 
TM9S4 2.446434989 67% 
IIGP1 2.433734268 65% 
CMTD1 2.433597794 56% 
E9PWG6 2.429462828 78% 
XYLT1 2.399761071 71% 
RFC4 2.389911836 50% 
FKBP2 2.377922052 59% 
LRC59 2.365011568 77% 
ERO1A 2.340809611 64% 
DMAP1 2.329111577 58% 
NSDHL 2.240879661 66% 
Q9CZN7 2.212182356 78% 
CAC1H 2.201571585 51% 
RPB7 2.189047433 53% 
SNTB2 2.161517247 54% 
CHD6 2.147292027 56% 
E41L2 2.126801181 70% 
ICAM1 2.088484151 75% 
ENDD1 2.082881302 66% 
RNH2B 2.074334519 54% 
VIME 2.061522961 83% 
STML2 1.985355633 72% 
SND1 1.979233844 58% 
DHB7 1.971263535 71% 
GBG2 1.969401634 82% 
MIF 1.968522247 52% 
CHD4 1.935840861 52% 
A0A0R4J170 1.911242674 56% 
A1L3S7 1.899933358 62% 
OAT 1.892847691 73% 
PPIF 1.890645245 51% 
IMP3 1.859463566 51% 
ADH7 1.783634354 57% 
4F2 1.758453166 78% 
PDIA6 1.710162624 78% 
ENPL 1.708465071 69% 
CA198 1.702921616 55% 
ROA1 1.692583453 61% 
MYH7B 1.6795756 70% 
MBB1A 1.645840468 75% 
E9PUQ5 1.635799069 52% 
P5CS 1.599882899 75% 
PHB2 1.588524208 53% 
Q31093 1.498033381 70% 
PGAM5 1.496061672 54% 
Q8C2Q7 1.455006766 59% 
AB17C 1.430177199 54% 
MOT1 1.413603563 56% 
TBA1B 1.389955705 59% 
A0A0A0MQF6 1.371039936 55% 
GAPR1 1.357117614 57% 
DAD1 1.352988021 54% 
A0A0R4J0D3 1.351135828 59% 
ADT2 1.344678287 72% 
TBB5 1.344341977 55% 
NOP2 1.318071783 54% 
ADT1 1.279918167 54% 
WDR3 1.26512848 51% 
LS14A 1.246971579 73% 
SSRG 1.197982492 52% 
RPN1 1.194014959 80% 
HNRPQ 1.190828981 52% 
MIC26 1.184683507 54% 
FKBP8 1.099878377 66% 
E9PW43 1.096909626 57% 
RL19 1.08191587 81% 
ROAA 1.080610158 72% 
GRP78 1.0785641 75% 
SNRPA 1.074266366 77% 
PGES2 1.064467865 56% 
RL27 1.062161512 58% 
PHB 1.048392902 73% 
RL10A 1.029569179 71% 
RBBP4 1.028278181 52% 
HDAC1 1.018936187 59% 
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PPIB 1.009237446 79% 
DEK 0.988629714 65% 
CTL2 0.978788974 76% 
HNRH1 0.958551784 83% 
Q3TCU5 0.93724761 66% 
SFXN1 0.92869476 80% 
MTA2 0.915037968 54% 
RAB8B 0.903000604 57% 
C1TM 0.895060187 53% 
OSTC 0.874058775 53% 
FUBP2 0.860930387 65% 
STING 0.859196742 56% 
YIPF4 0.853214957 57% 
AT1A1 0.82115059 54% 
PNKP 0.815304654 77% 
RL27A 0.79728746 56% 
CN37 0.749809186 52% 
UBP3 0.731093474 55% 
OST48 0.729405619 52% 
PR40A 0.717399317 51% 
RL31 0.689031861 60% 
F208B 0.672359051 56% 
Q9D8L3 0.65764416 59% 
IRGM1 0.612352468 61% 
PCBP1 0.595370864 63% 
HNRPK 0.579491287 58% 
VDAC2 0.574906435 79% 
U2AF2 0.506144811 57% 
NDUA4 -0.590489965 59% 
CD5 -0.638900794 63% 
HCD2 -0.701369887 78% 
Q99N15 -0.768015251 53% 
A0A0N4SVQ1 -0.778366989 64% 
PTCA -0.807579386 56% 
UBC9 -0.84329792 64% 
LAMP1 -1.008024769 52% 
THIM -1.089823745 62% 
CATE -1.193534417 89% 
B2RUG9 -1.196912924 70% 
D39U1 -1.200422659 59% 
Q6ZWQ9 -1.316611498 58% 
COX7C -1.368479124 84% 
LIMD2 -1.409976024 76% 
IL16 -1.506103682 77% 
TBC8B -1.751181055 59% 
ACD10 -1.829842923 54% 
K1C17 -1.91191341 58% 
K1C16 -1.917822773 90% 
ACOT2 -1.942605378 78% 
RASK -1.970742154 56% 
EYA4 -2.041675267 51% 
K1C10 -2.112424327 86% 
SET1B -2.121980488 71% 
K22E -2.167944004 61% 
PI42A -2.173163563 61% 
K2C1B -2.402019745 81% 
SQRD -2.419766151 58% 
A2A513 -2.426828568 95% 
K2C1 -2.456747494 78% 
DHB11 -2.485943772 54% 
E9Q0F0 -2.505614478 69% 
K2C79 -2.545858794 87% 
Q9EQ08 -2.589184426 56% 
E9Q0A7 -2.607330026 55% 
NAA35 -2.637379099 60% 
D3YX85 -2.650315559 70% 
NEST -2.662024848 61% 
GBG5 -2.688484175 60% 
HDDC2 -2.717227558 65% 
HYEP -2.742116187 69% 
K1C14 -2.787940779 71% 
Q9Z1R9 -2.807432235 75% 
HMGB1 -2.819757201 64% 
A0A0R4J0J3 -3.209759287 63% 
PSMD8 -3.386751388 50% 
Q8BH78 -3.416332776 51% 
FARP1 -3.517023663 52% 
UH1BL -3.761452963 55% 
E9QA45 -3.823835615 88% 
MIO -4.058872946 79% 
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K2C73 -4.200880488 74% 
AP3M2 -4.535437702 57% 
Q792Z1 -5.602066665 97%   
Table 12A. List of upregulated and downregulated proteins in iTregs vs Stim nTregs, sorted based on the 
fold-change and Confidence score ≥50%. Protein Fold-change Confidence score  
A2CG76 5.657989106 56% 
M3K11 4.509704489 76% 
DUS2L 4.14225154 63% 
NDRG2 4.067892127 66% 
A2A4U6 4.005840853 51% 
PYRD 3.926554798 52% 
E9Q921 3.905628453 59% 
PLP2 3.577217635 63% 
E9PVS1 3.475987236 57% 
GCSH 3.460801273 51% 
AT1B1 3.460268379 73% 
LS14A 3.340596745 66% 
RIPL1 3.331845328 50% 
PTH2 3.132438217 52% 
HSDL1 3.127337017 62% 
RM01 3.114133088 69% 
HEM6 2.896277154 59% 
E9Q9M1 2.85709485 54% 
RT33 2.856289003 59% 
SYAM 2.807181974 53% 
COR1C 2.777681764 52% 
NEP1 2.753260303 53% 
PDLI4 2.713160944 63% 
ARL1 2.694743401 60% 
A2AUM0 2.667574288 55% 
A0A0R4J1W7 2.635598641 58% 
E9Q1R5 2.591113778 57% 
Q3UMA3 2.537521504 58% 
HBB2 2.50627012 82% 
SNX27 2.465747009 54% 
XYLT1 2.427943035 60% 
ITIH4 2.369637137 75% 
H7BWX9 2.212874309 56% 
EXOC3 2.195117169 64% 
ENDD1 2.055316868 72% 
WASH1 2.046238744 55% 
BABA1 2.044312994 52% 
Q9EQ08 1.952920588 61% 
VAMP7 1.946837719 58% 
A0A0N4SVQ1 1.927118411 88% 
MAVS 1.918304864 76% 
UB2D1 1.881335457 51% 
CE162 1.814775525 64% 
NEST 1.811374492 74% 
RRAS 1.794195303 52% 
F7DEU6 1.793348831 52% 
HBB1 1.782801113 55% 
WDR37 1.701282608 51% 
SUV3 1.676663277 58% 
NAA35 1.676247159 64% 
NDUA4 1.674278579 84% 
HBA 1.620753196 57% 
SP110 1.615521212 81% 
FOLH1 1.559357666 77% 
RAB35 1.538967971 57% 
F8VPV0 1.515456878 68% 
A0A0R4J0V1 1.45737645 51% 
RNH2B 1.449446056 56% 
Q91VB8 1.448690555 54% 
CASP7 1.400496445 54% 
A2AP32 1.36643211 60% 
K1C17 1.359503912 57% 
K2C79 1.357875187 64% 
H32 1.311871776 61% 
MYH9 1.292172134 68% 
NDUB8 1.279772753 70% 
ODPX 1.275758488 66% 
321  
NDUA5 1.273114407 69% 
ML12B 1.271526643 78% 
CATC 1.259888432 62% 
NDUS7 1.2571113 70% 
MBRL 1.248397752 51% 
Q91VB8 1.243211965 51% 
CYH3 1.233364146 70% 
H4 1.226259047 52% 
CS012 1.206407294 82% 
CILP1 1.195248824 64% 
D3YX85 1.189041772 71% 
A2A513 1.18756759 63% 
AL3A1 1.145773572 79% 
SUN2 1.126600942 72% 
CHD9 1.117373767 68% 
UBCP1 1.057800534 70% 
ALBU 1.049935047 61% 
ECHB 1.049259836 79% 
COTL1 1.033433252 51% 
ADT2 1.022358684 68% 
PNKP 0.983430056 76% 
P85A 0.954164446 63% 
SRSF1 0.951079509 85% 
E9QA45 0.93853452 86% 
Q9DCC5 0.901269961 54% 
COX6C 0.901238868 58% 
IDHG1 0.900135772 62% 
DJC16 0.892247918 52% 
CX6B1 0.8876547 79% 
ALDR 0.878933723 78% 
SUOX 0.870261818 57% 
ATPO 0.860886629 65% 
A0A0A6YY34 0.859472753 78% 
ECHA 0.858119424 66% 
PHB2 0.856149692 67% 
TT39B 0.855707346 60% 
B7FAU9 0.814184712 64% 
THIL 0.813818443 51% 
PYRD 0.809476313 52% 
MIO 0.806192253 67% 
Q8C3V4 0.789784289 67% 
THIM 0.786348742 52% 
NDUB3 0.775349041 71% 
ADA10 0.752922619 54% 
NDUS3 0.748538153 85% 
STAT1 0.745990076 73% 
COR1C 0.735238075 59% 
CD47 0.731799738 53% 
NDUBB 0.726149384 50% 
FBXL8 0.725992309 54% 
ATP5L 0.718152104 51% 
F6QFD1 0.714715698 72% 
Q6PFB2 0.710464373 53% 
BAG5 0.678019468 65% 
IRGM1 0.673175571 70% 
INPP 0.671660412 53% 
PHB 0.670677363 71% 
PR40A 0.66950428 52% 
VIME 0.649926391 67% 
ATPA 0.641585681 54% 
Q99LB4 0.640830052 77% 
CN37 0.636946223 52% 
CAPG 0.624199188 60% 
SUMO1 0.622779553 52% 
ACON 0.621769615 53% 
Q31093 0.615682627 54% 
NDUV2 0.591516994 54% 
SUMO2 0.580639633 90% 
CX7A2 0.545158408 65% 
A2BIE1 0.530821116 57% 
DNPEP 0.521207988 53% 
GRAP2 0.513419007 57% 
ATPD 0.471001881 62% 
UH1BL 0.452031222 56% 
VDAC2 0.430430054 63% 
TNC18 0.422158575 59% 
D3Z6X7 -0.275591631 52% 
RS28 -0.312331185 67% 
A2A6J4 -0.333886045 50% 
GPSM1 -0.364854389 55% 
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RAC2 -0.364936305 63% 
NDKB -0.383120763 50% 
SERA -0.394649492 58% 
LASP1 -0.424552177 56% 
PYM1 -0.425801219 61% 
PROF1 -0.429147049 56% 
PEBP1 -0.429930692 71% 
PCBP1 -0.431425263 73% 
PSDE -0.433821968 60% 
RL31 -0.43945428 54% 
COR1A -0.44297623 73% 
OSTC -0.444386077 54% 
ARF1 -0.445214421 51% 
DNM1L -0.445980346 59% 
PSA3 -0.45258416 52% 
RSSA -0.452784663 71% 
A0A0A6YX26 -0.458164129 55% 
COPD -0.464171455 52% 
HSP7C -0.472771834 66% 
GIMA4 -0.48893402 68% 
GALE -0.491554274 61% 
RL31 -0.492490454 80% 
CBX5 -0.494227663 53% 
IMB1 -0.518859931 65% 
RS27 -0.519428679 58% 
Q9D8L3 -0.526091815 55% 
DDX5 -0.528915817 52% 
A0A1L1SQA8 -0.529029258 64% 
Q9CQF7 -0.530895119 56% 
ADH7 -0.531422602 53% 
NHRF1 -0.531432639 51% 
TM109 -0.539196937 62% 
CAC1H -0.540208906 74% 
SH3L1 -0.542024535 59% 
RINI -0.542998092 54% 
PABP1 -0.545263988 61% 
Q9Z1A1 -0.546320164 55% 
F208B -0.546330964 54% 
RLA0 -0.546458547 77% 
RL10A -0.547849831 64% 
RAB5A -0.548893103 50% 
SKP1 -0.548916364 59% 
GRHPR -0.549776309 74% 
TEX10 -0.551448659 55% 
RL27A -0.552095235 64% 
LRRF1 -0.556288561 56% 
A0A0A6YX26 -0.561687475 68% 
STIP1 -0.570366259 58% 
ACTG -0.571484421 70% 
EYA4 -0.572955285 63% 
RBX1 -0.574720781 51% 
THMS1 -0.577589186 52% 
RS3A -0.577625148 63% 
Q8BFQ1 -0.579630725 62% 
RL14 -0.584184048 64% 
SYTC -0.585195661 56% 
Q3U2G2 -0.585381568 72% 
PDIA3 -0.586011844 61% 
A0A1B0GSG5 -0.590234591 59% 
AIMP1 -0.59131329 63% 
HS90B -0.592805791 69% 
LRC47 -0.592955984 54% 
SRP14 -0.595183548 58% 
BCL10 -0.5957755 57% 
ARP3 -0.597094364 61% 
ARBK1 -0.59980922 59% 
CLIC1 -0.601378279 72% 
RLA2 -0.603592092 62% 
IST1 -0.60453529 56% 
TES -0.604866284 64% 
NUCL -0.605967316 69% 
LY9 -0.608765695 51% 
Q6ZWZ7 -0.61058827 60% 
COF1 -0.615651332 77% 
RL17 -0.616208346 70% 
IF1A -0.616701099 69% 
UB2L3 -0.616890281 63% 
Q91YS7 -0.616991017 51% 
PLSL -0.618190397 79% 
THADA -0.618289837 55% 
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IGSF8 -0.618601797 58% 
F7A8H6 -0.619015891 57% 
RL10A -0.619138213 64% 
CDK2 -0.620400764 76% 
RL17 -0.621325117 54% 
ELOB -0.623792322 53% 
G3X8R0 -0.626636319 58% 
CAPZB -0.627358205 75% 
HINT1 -0.629229862 71% 
HS90A -0.629554533 53% 
RUVB2 -0.634754435 56% 
IMDH2 -0.635863747 50% 
RL27A -0.639486587 69% 
CAB39 -0.640744027 62% 
WDR1 -0.642126633 51% 
RL35 -0.644770395 62% 
CLCB -0.64751973 56% 
PDC6I -0.6478963 67% 
BAIP2 -0.648283668 65% 
RUVB1 -0.649305483 76% 
GLRX1 -0.654636642 69% 
PFD2 -0.655957673 63% 
PTPRC -0.661490977 51% 
HNRPD -0.673618912 55% 
SAHH -0.674723684 72% 
CHM4B -0.683315722 61% 
RS25 -0.685878079 70% 
ITB2 -0.686032425 63% 
THIO -0.693809938 63% 
FAS -0.694085768 71% 
RL34 -0.69580973 72% 
SSRA -0.696024299 73% 
KBTBB -0.696572229 71% 
NAGK -0.69723095 55% 
ITAL -0.697550865 59% 
PTMA -0.700170227 56% 
SND1 -0.701821488 55% 
DHPR -0.703019135 71% 
SSU72 -0.70404831 70% 
RS20 -0.707340262 88% 
TPM4 -0.709718354 75% 
KAD2 -0.709909136 57% 
A0A1C7CYV0 -0.710269825 68% 
A0A1B0GTA4 -0.712791894 59% 
SNX6 -0.712898929 58% 
1433G -0.720347614 74% 
MIF -0.727398692 85% 
IF4G1 -0.732267177 77% 
ARC1B -0.732905424 84% 
GBLP -0.734039823 73% 
IF5 -0.740944197 71% 
SAP3 -0.751000506 67% 
G6PI -0.752007616 68% 
Q3TJ22 -0.752525277 56% 
RL4 -0.755736292 56% 
PKN1 -0.75736667 59% 
FKBP4 -0.759652567 53% 
NUCL -0.76058686 68% 
HA1D -0.76255854 78% 
FLOT1 -0.766614316 57% 
Q564E2 -0.772561477 71% 
ECHD1 -0.775885802 57% 
RLA1 -0.780759604 78% 
E9QAZ2 -0.78121233 50% 
ZER1 -0.782658854 86% 
SYG -0.782765896 67% 
6PGD -0.78782033 76% 
E9PW43 -0.789526888 62% 
SYSC -0.797984072 82% 
CYC -0.801320953 59% 
TCB1 -0.804109032 72% 
RAB2A -0.805456372 56% 
Q3UE92 -0.814886376 60% 
RS28 -0.817269249 53% 
PCNA -0.8230427 71% 
LANC1 -0.824427021 51% 
SERB -0.825239365 59% 
1433E -0.82756698 63% 
FKBP5 -0.8276963 63% 
UGPA -0.83133097 53% 
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GAPR1 -0.834927111 85% 
Z4YJT3 -0.835694064 54% 
LDHA -0.838035987 71% 
RL37A -0.839208766 59% 
PGP -0.840459284 56% 
A2APM5 -0.842048962 56% 
PPIB -0.842465586 51% 
TAGL2 -0.844516828 68% 
URP2 -0.844781463 79% 
M3K12 -0.845842731 63% 
SYYC -0.85137823 82% 
FXYD5 -0.856899011 52% 
ACTC -0.858333468 78% 
GBB2 -0.858984432 50% 
HPRT -0.859299361 53% 
SR140 -0.863493335 55% 
TCPQ -0.867847089 50% 
G3UYV7 -0.871456166 53% 
EXOC4 -0.872539541 53% 
PFKAM -0.872931711 59% 
PP1G -0.876932607 65% 
MVD1 -0.879433116 56% 
PAIRB -0.886823037 83% 
IF2G -0.889014446 75% 
NSDHL -0.891372017 52% 
ENOA -0.892003652 83% 
RS3 -0.906220052 54% 
PFKAL -0.90760953 78% 
CALX -0.909398202 53% 
PIN1 -0.909785692 54% 
SMYD5 -0.911940648 60% 
Q8C605 -0.921885286 77% 
EF1B -0.92200363 60% 
CD2 -0.925669425 83% 
GMFB -0.942273999 54% 
MARK4 -0.94392759 51% 
PGAM1 -0.945093052 61% 
GLU2B -0.953378083 56% 
HAUS1 -0.957128854 71% 
RLA2 -0.958415818 79% 
FKB1A -0.973418195 91% 
RSSA -0.97365636 61% 
GLU2B -0.977127985 52% 
SYAC -0.979640987 76% 
AEDO -0.996255392 53% 
PDIA3 -0.996726904 78% 
E9QA45 -0.998134649 78% 
S10AB -1.015138187 76% 
KCC4 -1.01561214 62% 
ALDOC -1.017960262 82% 
EP400 -1.022304838 55% 
RU1C -1.027610045 56% 
CORO7 -1.027847783 84% 
A0A0R4J0Z1 -1.035481646 67% 
FPPS -1.054271408 88% 
GALK1 -1.055480896 72% 
NDRG1 -1.05669919 96% 
KIF15 -1.059074097 74% 
PDIA4 -1.064455457 67% 
PSB6 -1.066383133 54% 
F7DEU6 -1.080333131 72% 
A0A087WR57 -1.085449633 67% 
HNRPM -1.08815051 64% 
GRP78 -1.101663232 80% 
LEG1 -1.107036128 71% 
GLGB -1.112720906 54% 
SERC -1.114576146 72% 
LRCH1 -1.117817428 65% 
ZFAN6 -1.120131526 52% 
PPCE -1.145191178 84% 
PGM1 -1.147275203 82% 
KPYM -1.149878496 82% 
HYOU1 -1.154015606 58% 
Q9Z1R9 -1.162291571 63% 
RS20 -1.167131196 71% 
TCOF -1.182444543 56% 
A0A0A0MQF6 -1.192087026 76% 
ERP44 -1.195326517 52% 
RL7A -1.196419172 73% 
RAD50 -1.196853691 54% 
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STRN4 -1.198396157 60% 
STS -1.211731742 53% 
KI13A -1.226718251 56% 
SDF2L -1.236848012 81% 
LDHA -1.244345608 51% 
PRDX5 -1.24742343 77% 
PFKAP -1.252421892 82% 
G3P -1.263757268 62% 
TXD12 -1.281562117 62% 
TT21B -1.288855879 69% 
RIPK3 -1.305234238 87% 
PDIA6 -1.32030456 81% 
TLK1 -1.321792855 69% 
PGK1 -1.329200545 77% 
CCS -1.342127574 73% 
NOP2 -1.343842007 64% 
A6ZI44 -1.35945162 83% 
E9PUA7 -1.359682024 63% 
SODC -1.370081696 62% 
G3X920 -1.37224243 54% 
CH10 -1.389566424 67% 
AATM -1.393070268 85% 
DHC24 -1.400358972 58% 
SPA3G -1.403353719 66% 
CD48 -1.403672351 58% 
ALKB5 -1.404268477 54% 
TXLNA -1.41680287 54% 
MDHM -1.418027854 77% 
ALDOA -1.421907306 86% 
VATF -1.430204492 51% 
DYST -1.436120684 55% 
EGLN1 -1.436960932 60% 
ENPL -1.448612715 78% 
ACLY -1.453117773 95% 
APOB -1.457038943 67% 
GAPR1 -1.463095218 53% 
A0A0B4J1E7 -1.47102055 72% 
SPA3F -1.476304176 88% 
MT2 -1.480386624 65% 
S10AD -1.48860292 58% 
ENPL -1.500172608 71% 
MOT4 -1.501815381 82% 
G3UZK1 -1.507009855 70% 
RS27A -1.520178599 54% 
A0A087WSR7 -1.523329165 55% 
BASI -1.525014471 72% 
HMGA1 -1.52669643 57% 
GRP78 -1.536138384 78% 
PACN2 -1.558201563 55% 
NUCB1 -1.56056157 61% 
CDK6 -1.563025965 76% 
CC137 -1.564090467 51% 
KPYM -1.564594298 72% 
KCRB -1.566737076 81% 
RHG22 -1.578408503 68% 
F6ZHD8 -1.588726336 67% 
IL2RA -1.597345775 69% 
SEC20 -1.617906244 64% 
COX7C -1.629280439 67% 
AB17C -1.630170069 91% 
G5E8E4 -1.656800895 77% 
PDIA1 -1.678518041 75% 
AB17C -1.681696409 81% 
GTR1 -1.683074089 77% 
HXK2 -1.685988105 76% 
K3W4Q8 -1.696090034 72% 
PDIA6 -1.71458761 85% 
SATB1 -1.719932023 81% 
PLCD1 -1.726917233 58% 
PRAF3 -1.738156175 72% 
SATB2 -1.781314873 85% 
H2AV -1.826444551 71% 
CASPC -1.854176448 52% 
CASP6 -1.867183968 56% 
SHOC2 -1.868214409 53% 
RBX1 -1.881239854 58% 
MT1 -1.886086913 74% 
E9Q718 -1.891678897 62% 
PDIA1 -1.915141515 75% 
D3YVZ9 -1.984119994 67% 
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ERO1A -2.00943444 79% 
MTMR2 -2.012766593 55% 
MIO -2.023700216 67% 
GNAS1 -2.040515325 58% 
NUSAP -2.044346518 52% 
XPOT -2.052410116 56% 
ERO1A -2.107882786 82% 
PLXA2 -2.108376518 66% 
FAAA -2.169981388 51% 
D3YXP6 -2.181594237 53% 
ANGP4 -2.217129801 61% 
F7AAP4 -2.220912727 68% 
ZN593 -2.251456661 60% 
TPIS -2.325213721 81% 
CEPT1 -2.350904385 60% 
H12 -2.355236798 53% 
GRIN3 -2.367632202 64% 
SCAM3 -2.37872277 51% 
KRT85 -2.38792522 67% 
NDRG2 -2.398247871 65% 
SPA3G -2.412715444 55% 
ANXA2 -2.430981498 84% 
SACS -2.446702163 52% 
SATB2 -2.470664621 55% 
NDST1 -2.533993197 56% 
HMCS1 -2.544196329 83% 
SDF2L -2.722122677 62% 
A0A140T8R5 -2.731680021 55% 
SC61G -2.731768844 79% 
PROS -2.767237838 60% 
GTR3 -2.779761605 61% 
CO4B -2.810133413 57% 
CS025 -2.847717997 67% 
PSMD8 -2.848313712 57% 
Q8CBB6 -2.870354834 84% 
DDX54 -2.887269522 64% 
H14 -2.905267883 78% 
H2A1K -2.953415335 69% 
H15 -2.967253795 75% 
E9Q9B0 -2.975441426 54% 
CSTN1 -3.01698865 56% 
A0A140T8R5 -3.044404268 53% 
NPAT -3.048176435 51% 
ASB6 -3.074628505 70% 
Q792Z1 -3.08881418 90% 
ITB3 -3.10493335 67% 
JUND -3.123777656 56% 
SMU1 -3.135291138 62% 
CHD9 -3.149055364 50% 
SSF1 -3.163700243 55% 
CS043 -3.165420134 60% 
NEK9 -3.167121902 60% 
GRAB -3.175869528 87% 
SBP1 -3.205841696 91% 
GRAB -3.221427098 77% 
KLC3 -3.290931043 54% 
GTR3 -3.374183916 88% 
CCD91 -3.389296045 52% 
CR1L -3.414490283 54% 
SF3B5 -3.460499755 52% 
ECM1 -3.511618282 77% 
CLP1L -3.550379187 57% 
UBE3C -3.571273246 65% 
H4 -3.587128446 81% 
Q8C253 -3.59067114 71% 
SMAG2 -3.608447137 52% 
F8WI14 -3.649687631 85% 
ATG3 -3.697168054 52% 
F8WI14 -3.712162613 92% 
FOLH1 -3.755971889 78% 
ECM1 -3.815754469 83% 
G3X920 -3.93081132 73% 
H13 -3.933487547 70% 
F6V6T4 -3.960380673 54% 
HPDL -4.781425397 57% 
B1ASU9 -6.288779263 67%   
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